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Abstract 
I 
Abstract 
 
With KRAS being one of the most frequently altered oncogenes in colorectal cancer 
(CRC), it is an obvious target for cancer therapy. However, despite enormous efforts 
over the past three decades to target mutated KRAS, not a single drug has made it to 
the clinic.  
To unravel vulnerabilities of KRAS-mutant CRC cells, a shRNA-based screen was 
performed in CaCo2 cells harboring conditional oncogenic KRASG12V. The custom-
designed shRNA library comprised 121 selected genes, which were previously 
identified to be strongly up- or downregulated in response to MEK inhibition. 
The screen as well as the subsequent validations showed that CaCo2 cells expressing 
KRASG12V were sensitive to the suppression of the DNA replication licensing factor 
Minichromosome Maintenance Complex Component 7 (MCM7), whereas KRASwt 
CaCo2 cells were largely resistant to MCM7 suppression. Similar results were obtained 
in an isogenic DLD-1 cell culture model. Knockdown of MCM7 in a KRAS-mutant 
background led to replication stress as indicated by increased nuclear RPA 
focalization. Further investigation showed a significant increase in mitotic cells after 
simultaneous MCM7 knockdown and KRASG12V expression. The increased percentage 
of mitotic cells coincided with strongly increased DNA damage in mitosis. Taken 
together, the accumulation of DNA damage in mitotic cells is due to replication stress 
that remained unresolved, which results in mitotic catastrophe and cell death.  
In summary, the data show a vulnerability of KRAS-mutant cells towards suppression 
of MCM7 and suggest that inhibiting DNA replication licensing might be a viable 
strategy to target KRAS-mutant cancers. 
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Zusammenfassung 
 
KRAS ist eines der am häufigsten mutierten Onkogene in Darmkrebspatienten. Dies 
macht es zu einem guten Ansatzpunkt für gezielte Krebstherapien. Trotz 
jahrzehntelanger Forschungsbemühungen hat sich jedoch keines der zur Inhibition des 
mutierten KRAS entwickelten Medikamente klinisch etablieren können. 
Um eventuelle Schwachstellen von KRAS mutierten Darmkrebszellen aufzudecken, 
wurde in der vorliegenden Studie ein shRNA basierter Screen in CaCo2 Zellen mit 
konditioneller KRASG12V Expression ausgeführt. Die maßangefertigte shRNA-Bibliothek 
umfasste 121 ausgewählte Gene, die zuvor nach MEK Inhibition als stark hoch- oder 
herunterreguliert identifiziert wurden. 
Der Screen sowie die Screen-Validierung zeigten, dass KRASG12V exprimierende CaCo2 
Zellen besonders sensitiv für den Knockdown des DNA 
Replikationslizensierungsfaktors Minichromosome Maintenance Complex 
Component 7 (MCM7) waren, wohingegen sich KRASwt CaCo2 Zellen als 
weitestgehend resistent gegenüber des MCM7 Knockdowns erwiesen. Ähnliche 
Ergebnisse wurden im isogenen DLD-1 Zellmodell erzielt. Des Weiteren hat der 
Knockdown von MCM7 spezifisch in KRAS mutierten Zellen zu erhöhtem 
Replikationsstress geführt, der durch gesteigerte nukleare RPA Fokalisierung 
nachgewiesen wurde. Weitere Untersuchungen haben außerdem eine signifikant 
erhöhte Anzahl an mitotischen Zellen nach gleichzeitigem MCM7 Knockdown und 
KRASG12V Expression ergeben. Diese Zunahme an mitotischen Zellen wurde zusätzlich 
von einer stark angestiegenen Anzahl an DNS Schäden in der Mitose begleitet. Das 
hohe Maß an DNS Schäden in der Mitose kann auf den gesteigerten Replikationsstress 
zurückgeführt werden, der ungelöst zu einer gestörten Segregation der Chromosomen 
in der Mitose führt. 
Zusammenfassend zeigen die Ergebnisse, dass KRAS mutierte Darmkrebszellen 
sensitiv auf den Knockdown von MCM7 sind. Demzufolge könnte die Inhibition von 
DNS Replikationslizensierung ein geeigneter Ansatz für die gezielte Therapie von KRAS 
mutierten Darmkrebs sein.  
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1. Introduction 
 
Life is only possible because cells can store and pass on information through encoded 
deoxyribonucleic acid (DNA). Its code is composed of four distinct letters, which are 
read and translated into the building blocks that make up all living organisms. To pass 
on this information, the code has to be faithfully copied in a process called DNA 
replication. This process is highly efficient and accurate, nevertheless, rare copying 
mistakes do occur. These errors are necessary in the long run since they are the basis 
for genetic diversity and therefore evolution. However, mistakes at the wrong position 
of the genetic code can alter the building blocks of a cell in a way that is detrimental 
for regulated growth. By losing the ability to regulate and control their growth, healthy 
cells can be transformed into malignant cancer cells.  
Since the basis of life and cancer are so closely linked, it is not surprising that cancer 
is considered to be an “ancient disease” (Faltas, 2011). The term “cancer” originates 
from the Greek physician Hippocrates (460-375 BC) as it reminded him of a crab or 
καρκίνος (karkinos) in Greek (Hajdu, 2011). The first descriptions of cancer, however, 
dates back even further to about 3,000 BC. The Edwin Smith Surgical Papyrus is the 
oldest document found to this date to mention cancer as a disease. It describes 
“bulging tumors” in the breast for which “there is no treatment” (Breasted, 1930; 
Donegang, 2006) (Figure 1).  
In the following 5,000 years, treatment of cancerous growths was largely limited to 
surgical removal. This was until the late 20th century when chemotherapy and radiation 
combined with surgery started to become the standard for cancer treatment 
(Sudhakar, 2009). Despite the fact that cancer treatments have improved, it is still one 
of the biggest burdens on health up to this day. According to estimations of the World 
Health Organization, cancer contributed to 27% of all deaths in Germany in 2015 and 
was next to cardiovascular diseases the second most common cause of death (World 
Health Organization, 2015). 
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Figure 1: Excerpt from the Edwin Smith Surgical Papyrus from ca 3,000 B.C. (A) Image 
of case 45 the original Edwin Smith Surgical Papyrus (Donegang, 2006). (B) 
Transcription and translation of the earliest description of tumors (Breasted, 1930). 
 
Cancer, with very few exceptions, is – as mentioned before - almost always caused by 
several separately occurring alterations to the DNA code, which either activate tumor-
driving oncogenes or disable tumor suppressors. These alterations are what 
differentiate malignant cells from healthy cells. Douglas Hanahan and Robert 
Weinberg summarized the properties of cancer cells in their famous paper “The 
hallmarks of cancer” in 2000. They concluded that most cancers acquire the following 
properties: self-sufficiency in growth signals, insensitivity to anti-growth signals, tissue 
invasion and metastasis, limitless replicative capacity, sustained angiogenesis, and 
the evasion from apoptosis. 11 years later, they further expanded upon these six 
hallmarks by adding four additional hallmarks: deregulating cellular energetics, 
avoiding immune destruction, genome instability and mutation, and tumor-promoting 
inflammation (Hanahan and Weinberg, 2000, 2011). Interestingly, KRAS is one single 
oncogene that can feed into several different hallmarks of cancer simultaneously, such 
as self-sufficiency in growth signals, insensitivity to anti-growth signals, sustained 
angiogenesis, and deregulating cellular energetics (Bryant et al., 2014; Matsuo et al., 
2009; Pylayeva-Gupta et al., 2011; Yang et al., 2013). 
Nonetheless, these differences of cancerous cells compared to healthy cells also open 
up opportunities for treatments. In this thesis, I will focus on how mutations in the 
KRAS gene can be exploited for cancer therapy. 
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1.1. Colorectal Cancer 
 
It is important to understand that cancer is not one single disease. One of the most 
common types of cancer is colorectal cancer (CRC). CRC is the second most frequent 
type of cancer in women after breast cancer and the third most common type in men 
after lung and prostate cancer. In total, there are about 1.4 million new cases and 
694,000 deaths reported worldwide each year (Ferlay et al., 2015). 
Colorectal cancers are in the clinical routine most commonly sub-classified in the 
following genetic and epigenetic groups: microsatellite instable (MSI), chromosome 
instable (CIN), and CpG island methylator phenotype (CIMP), as well as BRAF and 
KRAS mutant or wild-type (Jass, 2007). All of these classifications have been shown 
to have a prognostic value on patient survival (Phipps et al., 2015). A more recent and 
comprehensive attempt of subclassification proposed four sub-types of colorectal 
cancer that are defined by their distinct transcription profiles. The authors of the study 
concluded that colorectal cancer can be grouped into four types: MSI immune, 
canonical, metabolic, and mesenchymal. These groups also demonstrated prognostic 
value (Guinney et al., 2015). Those groups, however, do not overlap with the above 
mentioned genetic and epigenetic subtypes. Therefore, they can serve as a separate 
classifier rather than an extension of the former system. 
Treatment in CRC still relies heavily on conventional chemotherapy. The most common 
therapy regimens for metastatic CRC combine 5-fluorouracil (5-FU) and folinic acid 
with oxaliplatin or irinotecan (FOLFOX/FOLFIRI). Another common strategy is the 
combination of capecitabine (a 5-FU precursor) with oxaliplatin or irinotecan 
(CAPOX/CAPIRI). Both strategies result in an average overall survival of about 18 
months. In addition to conventional chemotherapy, more targeted therapies such as 
epidermal growth factor receptor (EGFR) and vascular endothelial growth factor 
(VEGF) inhibition have emerged in the recent years. Since then, the addition of targeted 
therapy has significantly improved overall survival of metastatic CRC patients to 22-29 
months (Ciombor and Berlin, 2014; Van Cutsem et al., 2014; Martini et al., 2017). A 
prerequisite for effective targeted EGFR inhibition in CRC is the lack of activating 
mutations in the RAS genes downstream of EGFR (Amado et al., 2008; Douillard et al., 
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2013). The RAS genes are, however, are mutated in about 50% of all CRC patients and 
are one of the most commonly mutated oncogenes in CRC next to the tumor 
suppressor genes APC (75%) and TP53 (53%) (The Cancer Genome Atlas, 2012). 
 
 
1.2. The Ras Pathway in Cancer 
 
RAS was one of the first oncogenes to be identified in the late 1970s (Malumbres and 
Barbacid, 2003). It was later discovered that there are three very homologous but 
distinct human RAS genes: Kirsten rat sarcoma viral oncogene homolog (KRAS), 
neuroblastoma RAS viral oncogene homolog (NRAS), and Harvey rat sarcoma viral 
oncogene homolog (HRAS). Additionally, KRAS has two splicing isoforms, namely 
KRAS4A and KRAS4B, of which the latter is the most prevalent variant (Hobbs et al., 
2016). The RAS proteins are small GTPases that cycle between its inactive and active 
state, which depends on the binding of GDP or GTP, respectively. Almost all RAS 
mutations are found in one of three hotspot locations on the gene (G12, G13, and Q61). 
Mutations at these sites prevent the hydrolysis of GTP to GDP and thereby leave RAS 
permanently in its active GTP bound state, which leads to a constitutive activation of 
a variety of downstream pathways (COSMIC v83; Forbes et al., 2017; Pylayeva-Gupta 
et al., 2011). Overall, the RAS genes are mutated in about 27% of all human cancers 
(Hobbs et al., 2016). Despite the fact that all RAS homologs are highly similar and feed 
into the same pathways, they seem to have distinct functions. For example, a complete 
Kras knockout in mice leads to the death of the mouse embryos during gestation 
(Johnson et al., 1997). Nras and Hras knockouts in mice, on the other hand, do not lead 
to changes in viability of the offspring (Esteban et al., 2001). Additionally, KRAS is by 
far the most commonly mutated homolog (85%) followed by NRAS (11%) and HRAS 
(4%) (Hobbs et al., 2016). Nevertheless, the exact differences of the RAS homologs on 
their downstream pathways and the following cellular effects are still a matter of 
investigation. 
The distinct importance of the three RAS homologs in different tissues is also well 
illustrated by the occurrence of mutations in different cancer entities. In pancreatic 
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ductal adenocarcinomas (PDAC) and colorectal cancer (CRC) KRAS is by far the most 
commonly mutated RAS homolog (PDAC: KRAS 90%, NRAS 0.3%, HRAS 0% - CRC: 
KRAS 42%, NRAS 9%, HRAS 0%) (Bailey et al., 2016; Cerami et al., 2012; The Cancer 
Genome Atlas, 2012). In melanoma, however, NRAS mutations (26%) play a far bigger 
role than KRAS (0%) or HRAS (0.8%) (Cancer Genome Atlas Network et al., 2015; 
Cerami et al., 2012). Figure 2 summarizes the occurrence of mutations for each RAS 
homolog across different cancer types. 
 
 
Figure 2: Mutation incidence of KRAS, NRAS, and HRAS across different cancer 
entities. Different cancer types show diverse mutation frequencies of the three RAS 
homologs. KRAS is the most frequently altered homolog. NRAS exhibits a high 
mutation rate specifically in multiple myeloma and melanoma. HRAS shows the 
highest mutation rate across the RAS homologs in bladder cancer and head and neck 
cancer (Bailey et al., 2016; Cancer Genome Atlas Network et al., 2015; Cerami et al., 
2012; Collisson et al., 2014; Getz et al., 2013; Lawrence et al., 2015; Lohr et al., 2014; 
The Cancer Genome Atlas, 2012; Weinstein et al., 2014). 
 
1. Introduction 
6 
1.2.1. RAS signaling 
 
In normal physiological conditions, RAS serves as a signal transducer of extracellular 
stimuli. It is activated through a wide variety of cell surface receptors such as receptor 
tyrosine kinases (RTKs) as well as G-protein-coupled-receptors (GPCRs). One of the 
most intensively studied pathways of RAS activation starts at the RTK epidermal 
growth factor receptor (EGFR). Upon ligand binding, EGFR dimerizes and auto-
phosphorylates itself. The phosphorylation creates a binding site for the SH2-domain 
of growth-factor-receptor-bound protein 2 (GRB2), which is bound to the guanine 
nucleotide exchange factor (GEF) son of sevenless (SOS). GEFs activate plasma 
membrane-associated RAS by facilitating the exchange of GDP to GTP (Downward, 
2003). RAS has a weak intrinsic GTPase activity, which means it can inactivate itself 
to a small degree. However, inactivation of RAS is mainly achieved through a number 
of GTPase activating proteins (GAPs), which promote the hydrolysis of RAS bound GTP 
to GDP. There are 14 known GAPs, e.g. neurofibromin or DAB2IP, which play a role in 
limiting the signal transduction through RAS (Maertens and Cichowski, 2014) (Figure 
3). 
 
Figure 3: EGFR driven activation of RAS. Upon EGF binding, EGFR can 
autophosphorylate itself, which facilitates GRB2 binding. GRB2 then recruits the GEF 
SOS, which activates RAS by facilitating the exchange of GDP to GTP of RAS (adapted 
from Downward, 2003). 
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The conformational change upon GTP binding of RAS allows binding and activation of 
its downstream targets in different effector pathways. One of the most well-known 
downstream pathways of RAS is the mitogen-activated protein kinase (MAPK) 
pathway. The immediate targets of RAS in the MAPK pathway are the RAF proteins 
(ARAF, BRAF, c-RAF1), which in turn phosphorylate mitogen-activated protein kinase 
kinases 1 and 2 (MEK1/2). Phosphorylated MEK1/2 can then activate extracellular 
signal-regulated kinases 1 and 2 (ERK1/2), which in turn targets a wide variety of 
kinases and transcription factors, e.g. ELK1, p90RSK, or c-JUN (Downward, 2003). The 
cellular responses of activated MAPK signaling are diverse. They include increased 
proliferation by stimulating cell cycle progression, interfering with DNA damage 
checkpoint signaling, preventing apoptosis, as well as several metabolic changes 
(Downward, 2003; Knauf et al., 2006; Pylayeva-Gupta et al., 2011). RAS also activates 
the phosphatidylinositol 3-kinase (PI3K) pathway that is known for its pro-survival 
signaling. GTP bound RAS can recruit PI3K to the membrane and activate it. PI3K 
indirectly activates AKT, which phosphorylates and inhibits several pro-apoptotic 
targets like BAD and FORKHEAD. Moreover, RAS influences vesicle transport and cell 
cycle progression through the ral guanine nucleotide dissociation stimulator (RALGDS) 
pathway and has been shown to contribute towards calcium signaling via the 
1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase ε (PLCε) pathway (Figure 
4) (Downward, 2003; Pylayeva-Gupta et al., 2011). 
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Figure 4: Downstream targets of RAS signaling. Active RAS can activate multiple 
different downstream pathways. Besides the most prominent MAPK and PI3K 
pathway, RAS also signals into the RALGDS and PLCε pathway (adapted from 
Downward, 2003; Neel et al., 2011). 
 
1.2.2. Targeting oncogenic RAS  
 
The significant role of mutant RAS in cancer renders it an obvious therapeutic target. 
This has, however, turned out to be remarkably challenging - so challenging that RAS 
has previously been coined to be “undruggable” (Cox et al., 2014). This chapter will 
summarize different strategies of targeting aberrant RAS signaling and explain why 
most of these approaches have not been successful so far (Figure 5). 
The most straightforward approach is to target the RAS protein itself directly. To be 
active, RAS has to bind GTP. Therefore, targeting the GTP binding pocket with a small-
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molecule antagonist, similar to kinase inhibitors, which target ATP binding pockets, 
seemed like an apparent strategy. The problem is that RAS has an affinity towards GTP 
in the picomolar range, which makes it virtually impossible to develop a GTP-
competitive inhibitor for RAS (Cox et al., 2014). Nevertheless, some studies have 
shown that it is possible to specifically target and inhibit the mutant KRASG12C variant. 
These inhibitors covalently bind the mutated cysteine in the GDP/GTP binding pocket 
of KRAS and thereby promote GDP instead of GTP binding, which inactivates mutant 
KRAS (Janes et al., 2018; Lim et al., 2014; Ostrem et al., 2013; Zeng et al., 2017). While 
these are promising results, they only address a rather rare mutation in KRAS. 
KRASG12C mutations make up only 3% in PDACs and 11% in CRCs of all KRAS mutations 
(Cox et al., 2014). Furthermore, the efficacy has yet to be shown in clinical trials. 
Other attempts focused on interfering with RAS localization. In addition to GTP binding, 
RAS has to be localized at the plasma membrane to be active. Initially, RAS is 
translated as an inactive, cytosolic protein. At its C-terminus, it has a CAAX site (C 
=cysteine, A = aliphatic amino acid, X = any amino acid), which directs a post-
translational farnesyl moiety to the cysteine via the farnesyltransferase (FTase). The 
farnesylation allows then for the membrane localization of the otherwise hydrophobic 
RAS protein (Ahearn et al., 2011). Therefore, inhibition of FTase activity was thought 
to prevent proper RAS localization and thus inhibit KRAS activity. Initial studies on 
FTase inhibitors showed promising results in HRAS driven tumors but subsequent 
clinical trials failed to demonstrate the efficacy of FTase inhibitors in KRAS mutated 
cancers (Papke and Der, 2017). The reason for the low efficacy is that KRAS and NRAS 
can - in contrast to HRAS - be alternatively prenylated via geranylgeranylation by the 
geranylgeranyltransferase (GGTase) in the presence of FTase inhibitors (Whyte et al., 
1997). More recently, two small-molecule inhibitors were described that prevent 
membrane association of KRAS through inhibition of phosphodiesterase δ (PDEδ). 
PDEδ shuttles prenylated KRAS to the Golgi or endosomes from where its transported 
to the plasma membrane. The PDEδ inhibitors have been shown to reduce RAS 
signaling and growth of RAS-mutated cancer cells. On the other hand, PDEδ inhibitors 
have a similarly high risk of off-target effects as FTase and GGTase inhibitors (Papke 
and Der, 2017; Papke et al., 2016; Zimmermann et al., 2013). It is estimated that over 
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100 proteins are prenylated by FTase and GGTase, many of which would also be 
affected by the inhibition of PDEδ (Lane and Beese, 2006). 
Since targeting RAS activity directly has been proven to be problematic, another 
approach is to target downstream effectors of RAS signaling. While RAS activates 
several downstream effector pathways, there is evidence that at least in some cancers 
such as CRC and lung cancer the RAF-MEK-ERK pathway might be the one with the 
greatest impact (Collisson et al., 2012; Papke and Der, 2017; Ryan et al., 2015). 
However, the results of MEK inhibition with trametinib and cobimetinib in clinical trials 
have been underwhelming. MEK inhibition abolishes an inhibitory feedback-loop via 
activated ERK through RAF. This results in a reactivation of the pathway despite MEK 
inhibition and thus would require administration of high MEK inhibitor doses that are 
not applicable in a clinical setting (Duncan et al., 2012; Papke and Der, 2017). A similar 
problem of paradoxical MAPK activation upon BRAF inhibition has recently been 
overcome with the development of RAF inhibitors that show efficacy in RAS-driven 
cancers and do not lead to a MAPK activation (Holderfield et al., 2014; Peng et al., 
2015; Zhang et al., 2015). However, another mechanism preventing MAPK signaling 
inhibition from efficiently preventing cancer cells growth is that cancer cells evade the 
treatment by activating PI3K signaling. Colorectal cancer cells have been shown to 
activate AKT upon MEK inhibition. This is mediated via a lack of a negative feedback 
from ERK to EGFR, which then, in turn, activates the PI3K pathway (Klinger et al., 2013; 
Prahallad et al., 2012). Unfortunately, blocking both pathways simultaneously has 
proven to be clinically not practicable mainly due to the high toxicity observed in 
clinical trials (Papke and Der, 2017). Recently, an inhibitor was published that was 
suggested to inhibit RAS signaling in several pathways simultaneously. Rigosertib acts 
as a RAS mimetic that binds and blocks the RAS-binding domain of several 
downstream effectors such as RAF, PI3K, and RALGDS (Athuluri-Divakar et al., 2016). 
Another study suggested, however, that the reduction in MAPK signaling by rigosertib 
was not due to inhibition of RAS-RAF interaction, but is rather an indirect effect of 
stress-induced JNK activity, followed by inhibition of RAF and SOS1 (Ritt et al., 2016). 
Rigosertib was also recently identified as a microtubule-destabilizing agent, which 
might hint towards rigosertib affecting a much broader spectrum of cellular processes, 
which raises the risk of unwanted side effects (Jost et al., 2017). 
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Figure 5: Strategies for drugging oncogenic RAS signaling. Several different 
strategies for targeting RAS signaling in cancer have been under investigation in the 
past decades. Next to the straightforward strategies of direct inhibition, inhibition of 
membrane association, and inhibition of downstream effectors, more indirect 
strategies are also under consideration. Namely, inhibition of the metabolism and 
inhibition of synthetic lethal interactors (adapted from Papke and Der, 2017). 
 
Among the many additional cellular downstream effects of mutant KRAS signaling are 
also metabolic changes. RAS shifts the cellular energy production machinery from 
oxidative phosphorylation towards glycolysis by upregulating hypoxia-inducible factor 
1α (HIF1α) via the MAPK and PI3K pathway. HIF1α leads to the elevated production of 
glucose transporter 1 (GLUT1) and thereby to increased glucose uptake (Blum et al., 
2005; Chen et al., 2001; Flier et al., 1987; Pylayeva-Gupta et al., 2011). Glycolysis is 
further promoted by RAS through upregulation of several glycolytic enzymes such as 
6-phosphofructo-1-kinase and lactate dehydrogenase (Chiaradonna et al., 2006; Kole 
et al., 1991; Pylayeva-Gupta et al., 2011). Moreover, mutant KRAS has also been shown 
to rewire the glutamine metabolism away from the TCA cycle towards the reduction of 
NADP+ to NADPH and the production of pyruvate (Gaglio et al., 2011; Papke and Der, 
2017; Son et al., 2013). To further fuel cancer cells, RAS also increases extracellular 
nutrient uptake by micropinocytosis and recycling of cell components through 
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autophagy. Several studies indicate that RAS driven cancer cells might rely on these 
two processes in order manage their metabolic needs (Commisso et al., 2013; Guo et 
al., 2011; Lock et al., 2011; White, 2013; Yang et al., 2011). Since the approach to target 
metabolic dependencies of KRAS-mutant cancers is relatively new, there have not been 
many clinical studies so far. However, some metabolic inhibitors are currently in 
clinical trials. The unspecific autophagy and micropinocytosis inhibitor chloroquine is 
currently in clinical trials for PDACs (clinicaltrials.gov, identifier: NCT01506973). 
Another inhibitor of the glutamine metabolism (CB-839) is also in several clinical trials 
(Cox et al., 2014; National Institutes of Health (NIH); Papke and Der, 2017). 
In summary, targeting mutant RAS in cancer still constitutes a major hurdle up to this 
day. The broad variety of downstream effects that mutant RAS elicits in cells is only 
one reason why targeting RAS has proven to be so difficult. The next chapter focuses 
on another strategy that might allow specific targeting of RAS-mutant cancer cells in 
a more indirect manner.  
 
1.2.3. Synthetic lethality 
 
Since KRAS has proven to be notoriously hard to be inhibited directly, indirect targeting 
strategies could be a more promising strategy. An approach to indirectly but 
specifically target oncogenic KRAS signaling is the concept of synthetic lethality. The 
term “synthetic lethality” was coined by Theodore Dobzhansky. He observed that in 
Drosophila melanogaster flies that inherited two different deleterious genes were non-
viable. In contrast, the parent generation harboring only one of these mutant genes 
was viable (Dobzhansky, 1946; Nijman, 2011). 
The most prominent example for a successful synthetic lethal therapy is the inhibition 
of poly (ADP-ribose) polymerase (PARP) in Breast Cancer 1/2 (BRCA1/2) defective 
cancers (Bryant et al., 2005; Farmer et al., 2005). BRCA1 and BRCA2 are tumor 
suppressors involved in homologous recombination (HR), which is in addition to non-
homologous end joining (NHEJ) one of the two major DNA double-strand break (DSB) 
repair mechanisms. PARP, on the other hand, facilitates DNA single-strand break (SSB) 
repair by binding SSBs and recruiting other DNA repair proteins to the site of DNA 
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damage. Inhibition of PARP by olaparib traps it on the DNA. The trapped PARP 
presents an obstacle for approaching DNA replication forks, which in turn cause 
replication fork stalling and eventually fork collapse. Collapsed forks can efficiently be 
repaired via HR, for which BRCA is required. Therefore, BRCA proficient cells survive 
the perturbation on PARP, whereas BRCA deficient cells accumulate non-repairable 
DNA damage and eventually die. In 2014, the PARP inhibitor olaparib was approved by 
the FDA for the treatment of BRCA mutated ovarian cancer (Dziadkowiec et al., 2016). 
Very recently, it was additionally approved for therapy of BCRA mutant breast cancers 
(U.S. Food & Drug Administration, 2018). 
The idea of using the synthetic lethality approach in KRAS-mutant cancers is very 
similar: While inhibition or depletion of some proteins is tolerable for normal, non-
transformed cells, KRAS mutated cells might heavily rely on the activity or presence of 
distinct proteins. Therefore, targeting a synthetic lethal interactor of mutant KRAS 
would specifically kill KRAS transformed cancer cells, while normal cells remain largely 
unaffected (Figure 6). 
 
Figure 6: The concept of synthetic lethality. The concept of targeting mutant RAS via 
synthetic lethal interactors relies on the idea that oncogenic RAS signaling creates 
specific dependencies on other proteins or pathways for the cell. While these synthetic 
lethal components are dispensable for RAS wild-type cells, RAS-mutant cells heavily 
rely on them. Thus, inhibition or depletion of synthetic lethal components is compatible 
with RAS wild-type cell’s survival but lethal for RAS-mutant cells. 
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RNAi or CRISPR/Cas9 based screens are the current state of the art methodology for 
identifying synthetic lethal interactors of RAS without prior knowledge or assumptions. 
Most screens knock down (RNAi screens) or knock out (CRISPR/Cas9 screens) a 
library of genes in a panel of RASmut and RASwt cells, in isogenic cell lines, or a 
combination of both. While there have been multiple attempts to identify synthetic 
lethal interactors of mutant RAS, there is only very little overlap in their identified 
synthetic lethal targets across most screens. Julian Downward reviewed and 
summarized the results from all RAS focused synthetic lethality screens in 2015. Table 
1 shows the summary of Julian Downward’s review and additionally other targets that 
have been identified since then (Downward, 2015). Although the individual genes 
identified do not show a big overlap between screens, two cellular processes dominate 
the collective results. For one, several components of the proteasome have been 
identified across different screens to be synthetic lethal with mutant RAS (Barbie et al., 
2009; Luo et al., 2009; Steckel et al., 2012). Independent studies, however, showed poor 
selectivity of proteasome targeting drugs towards cancer cells with mutated RAS 
(Barretina et al., 2012; Downward, 2015; Garnett et al., 2012). The other process 
commonly identified in screens is the regulation of the cell cycle (Costa-Cabral et al., 
2016; Luo et al., 2009; Sarthy et al., 2007; Steckel et al., 2012; Wang et al., 2016). The 
next chapter will thus focus on cell cycle regulation, DNA replication, and how RAS 
signaling influences those processes. 
 
Table 1: Summary of synthetic lethal targets derived from synthetic lethality screens 
targeting RAS (adapted and expanded from Downward, 2015). 
target(s) Cell culture model Screen setup Reference 
RAN, TPX1, 
SDC1 
H1299 NRASQ61K mutant human 
lung cancer cells 
~3,700 druggable genes, 
siRNA, multi-well cell death 
(Morgan-Lappe 
et al., 2007) 
Survivin DLD-1 KRASG13D isogenic colon 
cancer cell lines 
~4,000 druggable genes, 
siRNA, multi-well cell death 
(Sarthy et al., 
2007) 
PLK1, APC/C, 
proteasome 
DLD-1 and HCT116 KRASG13D 
isogenic colon cancer cell lines 
Whole-genome retroviral 
shRNA library, pooled 
proliferation screen microarray 
readout 
(Luo et al., 2009) 
STK33, AKT3, 
DGKZ 
Panel of 4 KRAS-mutant and 4 
wild-type pan-cancer cell lines, 
plus 2 normal cell lines 
~1,000 druggable genes, 
lentiviral shRNA, multi-well 
proliferation 
(Scholl et al., 
2009) 
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TBK1, PSKH2, 
PSMD14, 
PTCH2 
Human pan-cancer cell line 
panel 
~1,000 druggable genes, 
lentiviral shRNA, multi-well 
proliferation 
(Barbie et al., 
2009) 
WT1 Mouse lung cancer cells LKR10 
and LKR13 KrasG12D 
162 KRAS relevant genes, 
shRNA pooled screen in vivo, 
bead array readout 
(Vicent et al., 
2010) 
SNAI2 HCT116 isogenic colon cancer 
cell lines 
~2,500 druggable genes, 
retroviral shRNA pooled 
proliferation screen, 
microarray readout 
(Wang et al., 
2010) 
GATA2, CDC6, 
proteasome 
HCT116 isogenic colon cancer 
cells and pan-cancer 26 cell line 
panel 
~8,000 genes siRNA, multi-well 
cell proliferation and apoptosis 
(Kumar et al., 
2012; Steckel et 
al., 2012) 
TAK1 SW620G12V KRAS and SW837G12C 
KRAS human colon cancer cell 
lines 
Lentiviral shRNA screen with 
17 selected kinases, multi-well 
proliferation 
(Singh et al., 
2012) 
BCL-XL KRAS-mutant colon cancer cell 
lines HCT116 and SW620 
~1,200 druggable genes, 
shRNA, pooled NGS readout, 
synergistic death with MEK 
inhibitor 
(Corcoran et al., 
2013) 
Ctnnb1, Mllt6 HrasG12V–mutant mouse 
keratinocytes in vivo 
Whole-genome lentiviral 
shRNA library, pooled in vivo 
proliferation screen NGS 
readout 
(Beronja et al., 
2013) 
COPI coatomer KRAS plus LKB1-mutant lung 
cancer 17–cell line panel 
Whole-genome siRNA, multi-
well cell proliferation 
(Kim et al., 2013) 
ARHGEF2 Human pan-cancer 72–cell line 
panel 
Whole-genome lentiviral 
shRNA library, pooled 
proliferation screen NGS 
readout 
(Cullis et al., 
2014) 
CDK1 Isogenic LIM1215 colorectal 
cancer cell line and 26-cell line 
panel 
784 genes, multi-well 
proliferation 
(Costa-Cabral et 
al., 2016) 
combined 
PLK1 and 
ROCK inhibition 
Isogenic T29 ovarian surface 
epithelial cells +/- KRASG12V 
20 drugs in pairs (190 
combinations), multi-well 
proliferation 
(Wang et al., 
2016) 
XPO1 12 non-small-cell lung cancer 
cell lines 
genome-wide siRNA screen, 
multi-well proliferation 
(Kim et al., 2016) 
PREX1 (Rac 
pathway) 
14 human acute myeloid 
leukemia cell lines 
genome-wide viral CRISPR 
screen, pooled proliferation 
screen NGS readout 
(Wang et al., 
2017) 
Mitochondrial 
translation 
Isogenic HT116 and DLD-1 
colorectal cancer cell lines 
genome-wide lentiviral CRISPR 
screen, pooled proliferation 
screen NGS readout 
(Martin et al., 
2017) 
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1.3. Cell cycle, DNA replication, and stress 
 
All proliferating cells go through a tightly regulated series of events in their goal of 
faithful DNA replication and cell division called the cell cycle. The cell cycle can be 
subdivided into four different phases: G1, S, G2, M. The “G” in G1 and G2 stands for 
“gap” since these are the cell states between DNA synthesis (S) and mitotic cell 
division (M). Cells that have ceased to proliferate remain in a similar state as cells in 
G1 referred to as G0 (Schafer, 1998). The transitions between the cell cycle phases are 
controlled by cyclins and cyclin-dependent kinases (CDKs). There are four different 
CDKs (CDK1, CDK2, CDK4, and CDK6) and four classes of cyclins (cyclin A, B, D, and 
E). As their names suggest, the activity of CDKs relies on binding of cyclins, whose 
expression cycle between specific cell cycle phases (Malumbres and Barbacid, 2009). 
Interestingly, only the mitotic CDK1 seems to be essential for the mammalian cell 
cycle, whereas the interphase CDKs (CDK2, CDK4, and CDK6) are largely dispensable 
and merely lead to defects in some specialized cell types (Barrière et al., 2007; Berthet 
et al., 2003; Diril et al., 2012; Malumbres and Barbacid, 2009; Malumbres et al., 2004; 
Ortega et al., 2003; Santamaría et al., 2007; Tsutsui et al., 1999). For example, 
simultaneous knockout of CDK2 and CDK4 results in a normal embryogenesis in mice. 
However, they die shortly after birth due to cardiological complication. In contrast, if 
CDK2 is conditionally knocked out after birth in a CDK4-/- background, mice show no 
observable phenotype (Barrière et al., 2007). An additional layer of cell cycle control in 
response to DNA damage are the cell cycle checkpoints. They are mainly executed 
through the two checkpoint kinases CHK1 and CHK2. Canonically, CHK1 is activated 
by ATR upon replication stress and is required for a robust G2/M arrest. CHK2, on the 
other hand, is activated by ATM upon DNA damage such as DSB and is primarily 
implicated in the G1/S arrest. However, these activation schemes have been 
challenged, since ATM has been shown to be able to activate CHK1. In addition, ATM-
independent activations of CHK2 have been reported (Bartek and Lukas, 2003; Kastan 
and Bartek, 2004). Figure 7 shows a summary of the cell cycle regulation.  
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Figure 7: Regulation of the cell cycle. The different cell cycle phases are regulated by 
the expression of different cyclins and their binding to cyclin-dependent kinases 
(CDKs). Furthermore, several other regulators like the INK4-family and Kip/Cip-family 
proteins play a role in the G1/S transition, as well as WEE1, MYT1, and CDC25 in the 
G2/M transition (Malumbres and Barbacid, 2009). 
 
1.3.1. DNA replication licensing and initiation by the MCM complex 
 
The tight regulation of the cell cycle is a prerequisite for a complete and accurate 
duplication of the genome throughout the lifetime of each cell. One of the key players 
ensuring complete replication is the replicative helicase Minichromosome 
Maintenance protein complex (MCM). It is a hexameric complex, which consists of the 
six related proteins MCM2-7. To control DNA replication, the cell utilizes the MCM 
complex in a two-step process throughout the cell cycle (Deegan and Diffley, 2016). 
First, MCM is recruited as a double hexamer to the origins of replication in a process 
called DNA replication licensing (Evrin et al., 2009; Gambus et al., 2011; Remus et al., 
2009). To recruit MCM to the origins of replication, the origin recognition complex 
(ORC) first binds the origins of replication, which are spread throughout the genome. 
Then CDC6 can be recruited to the ORC. Recruitment of CDC6 creates a binding hub 
for CDT1, which is bound to the MCM complex and thereby recruits MCM to the origins 
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of replication. Upon binding of the first MCM complex, a second CDT1-MCM complex 
is recruited under involvement of a second CDC6 forming the pre-replication complex 
(pre-RC) (Figure 8) (Deegan and Diffley, 2016; Evrin et al., 2009; Gambus et al., 2011). 
To prevent re-replication of the same genomic areas, DNA licensing is strictly limited 
to late mitosis and G1. This is mainly accomplished by the expression of CDT1 inhibitor 
geminin from S-phase to mid of mitosis, thereby effectively preventing replication 
licensing during replicative states of the cell cycle (Klotz-Noack et al., 2012; Nishitani 
and Lygerou, 2002). 
 
Figure 8: Mechanism of replication origin loading. Loading of the MCM complex is a 
stepwise process. First ORC binds DNA at origins of replication and recruits CDC6. 
Then CDT1 can recruit the MCM complex to the ORC and CDC6 bound sites. To obtain 
the necessary MCM double-hexamer, two different CDC6 and CDT1 proteins are 
required to load the second MCM complex onto the DNA and thereby form the final 
pre-replication complex (pre-RC) (adapted from Deegan and Diffley, 2016). 
 
Upon S-phase entry, the pre-RC complex undergoes further modifications to initiate the 
second step: DNA replication. While the exact mechanism of DNA replication initiation 
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is not fully understood, it is clear that it is a multi-step process, of which the order of 
the steps is yet to be determined. Several replication factors have to bind and remodel 
the two MCM complexes. The two kinases cyclin-dependent kinase (CDK) and Dbf4-
dependent kinase CDC7 (DDK) play a crucial role in the remodeling of the MCM 
double-hexamer. DDK phosphorylates MCM, which promotes the recruitment of 
SLD3/7 and CDC45. CDK also phosphorylates SLD2 and SLD3. This facilitates the 
binding of SLD2/3 to DPB11, which subsequently leads to the recruitment of GINS to 
MCM. The recruitment of CDC45 and GINS to both MCM complexes creates the active 
CMG (CDC45-MCM-GINS) helicases and is essential for the assembly of the complete 
replisome later on (Deegan and Diffley, 2016; Heller et al., 2011; Yeeles et al., 2015). 
The segregation of the two CMG helicases and assembly of the complete replisome 
leads then to the start of two replication forks per origin in a process called origin firing 
(Deegan and Diffley, 2016; Gambus et al., 2006; Ilves et al., 2010; Moyer et al., 2006). 
Thereby, the two MCM complexes unwind the DNA in both directions and provide a 
single-stranded DNA template for the DNA polymerase (Bochman and Schwacha, 
2008, 2009) (Figure 9). As soon as two replication forks converge, MCM7 is 
polyubiquitinated by SCFDia2 (in yeast) which causes the subsequent CMG removal by 
Cdc48/p97 (Deegan and Diffley, 2016; Dewar et al., 2015; Labib et al., 2000; Maculins 
et al., 2015).  
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Figure 9: Assembly of the active helicase during replication origin firing. To initiate 
DNA replication cyclin-dependent kinase (CDK) and the Dbf4-dependent kinase CDC7 
(DDK) remodel the pre-RC, which facilitates the recruitment of GINS and CDC45 to the 
MCM complex. Thereby, the active replicative CGM helicase is formed. Subsequently, 
MCM10 and DNA polymerase ε are recruited to facilitate DNA replication (adapted 
from Deegan and Diffley, 2016). 
 
Interestingly, only a small fraction of the licensed origins (~10%) is used during 
unperturbed replication. The vast majority of licensed origins remain dormant during 
S phase and serve as a back-up to resolve perturbations such as stalled replication 
forks (Burkhart et al., 1995; Mahbubani et al., 1997; McIntosh and Blow, 2012; Wong et 
al., 2011). 
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Since the MCM complex plays a central role in DNA replication, it is also a crucial player 
in cancer cell proliferation. Several MCM subunits have been shown to be amplified in 
a variety of cancers including pancreatic cancer (MCM4 4-5%, MCM7 5-20%), breast 
cancer (MCM4 7%, MCM7 2.3%), and colorectal cancer (MCM4 4%, MCM7 2.3%) 
(Cerami et al., 2012; Ciriello et al., 2015; TCGA provisional; Witkiewicz et al., 2015). 
Additionally, MCM2 over-expression has been suggested to be a marker for the 
diagnosis of cervical cancer (Zheng, 2015). Additionally, MCM7 was proposed to be a 
prognostic marker for hepatocellular carcinoma (Qu et al., 2017) and prostate cancer 
(Padmanabhan et al., 2004; Ren et al., 2006).  
 
1.3.2. RAS and replication stress 
 
Oncogenes and their ability to drive abnormal proliferation are closely related to the 
regulation of DNA replication. The term replication stress is not well defined but can 
be understood as a collective term for perturbations of DNA replication that eventually 
lead to slowing or stalling of replication forks. A hallmark of replication stress are 
stretches of unreplicated, single-stranded DNA. The main source for this is double-
stranded DNA that is unwound by the MCM complex but because following DNA 
replication machinery is stalled, two unwound single strands of DNA are left behind 
(Zou et al., 2000). The RPA complex binds this single-stranded DNA and thereby serves 
as a sensor for replication stress (Zeman and Cimprich, 2014; Zou and Elledge, 2003). 
Expression of oncogenic RAS proteins has previously been implicated in causing 
replication stress (Hills and Diffley, 2014). A term that is commonly used to describe 
replication stress caused by oncogenes, such as RAS, is oncogene-induced genotoxic 
stress (Dietlein et al., 2015; Grabocka et al., 2014, 2015). It is an elegantly simple term 
that masks the complexity of the many distinct mechanisms by which mutated RAS 
can disturb DNA replication and cause replicative stress. 
For one, expression of mutant HRAS and NRAS have been reported to diminish the 
cellular nucleotide pool, whose depletion is a known cause of replication stress and 
genomic instability. The depletion is caused by RAS dependent downregulation of 
ribonucleotide reductase and thymidylate synthase - both crucial enzymes in the 
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nucleotide synthesis. Since a constant supply of nucleotides is essential for DNA 
synthesis, deoxyribose nucleoside triphosphate (dNTP) depletion can cause 
replication fork slowing or stalling (Aird et al., 2013; Bester et al., 2011; Mannava et al., 
2013; Zeman and Cimprich, 2014). 
RAS also targets the nucleotide pool via another mechanism: reactive oxygen species 
(ROS). It is well established that expression of oncogenic RAS increases cellular ROS 
levels (Irani et al., 1997; Lee et al., 1999; Ogrunc et al., 2014). While it seems to be clear 
that mutant RAS expression causes an increase in ROS, the source of ROS is still being 
discussed. Accumulation of ROS is assumed to be due to an upregulation of the 
mitochondrial NADPH oxidases NOX1 and NOX4 upon RAS expression (Mitsushita et 
al., 2004; Ogrunc et al., 2014; Weyemi et al., 2012). However, other results suggest that 
the ROS source is mitochondria independent (Maya-Mendoza et al., 2015). Increased 
cellular ROS levels indirectly impede replication fork progression by oxidating DNA and 
dNTPs, most prominently the oxidation of GTP to 8-oxo-dGTP, which perturbs 
replication fork progression (Rai et al., 2009).  
An increase in transcription has also been discussed as a cause for RAS driven 
replication stress. Transcription can cause interference with DNA replication when 
transcription machineries collide with oncoming replication forks. As one study 
showed, overexpression of RAS causes a global increase of transcription and leads to 
replication fork slowing, which could be partially rescued by inhibition of RNA 
transcription (Kotsantis et al., 2016). Additionally, nascent RNA can become a hurdle 
for DNA replication by incorrectly forming a three-stranded RNA/DNA-hybrid – a 
so-called R-loop (Zeman and Cimprich, 2014).  
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Figure 10: Sources of RAS-driven replication stress. Oncogenic RAS can cause 
replication stress via multiple mechanisms including deregulation of cell cycle 
checkpoints, dNTP depletion, generation of reactive oxygen species, R-loop formation 
via increased transcription, and increased replication origin firing.  
 
Overexpression of HRAS has also been shown to cause increased replication origin 
firing (Di Micco et al., 2006). As mentioned in the last chapter, dormant origins are 
needed as a fail-safe mechanism in the case of perturbations during DNA synthesis. 
Increased origin firing could lead to stalled replication forks that cannot be resolved 
due to the lack of remaining adjacent dormant origins. However, the exact mechanism 
of how mutant RAS promotes origin firing is not fully understood. 
Lastly, RAS has a well-established impact on the regulation of the cell cycle. RAS driven 
overexpression of cyclin D has been linked to triggering S-phase entry via 
retinoblastoma (Rb) phosphorylation (Figure 7) and thereby reduces the duration of 
the G1 phase (Filmus et al., 1994; Hitomi and Stacey, 1999; Liu et al., 1995). Since DNA 
replication licensing takes place primarily in G1, a shortened G1 phase can lead to an 
S-phase entry with an under-licensed genome and thereby cause replication stress. 
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Additionally, mutant RAS has been shown to interfere with the G2/M checkpoint and 
cause premature entry into mitosis (Grabocka et al., 2014; Knauf et al., 2006). 
In summary, RAS causes oncogene-induced replication stress via diverse mechanisms 
(Figure 10). The so-called “genotoxic stress” inflicted by RAS is probably the result of 
a combination of several of the factors discussed above. However, which of these 
mechanisms is most decisive and if this is cell type-dependent has yet to be 
determined.  
 
 
1.4. Aims and objectives 
 
Despite enormous efforts that have been undertaken to disrupt the RAS pathway since 
its discovery, no targeted therapy for RAS-mutant cancers has successfully made its 
way to the clinic, yet (Cox et al., 2014; Malumbres and Barbacid, 2003; Papke and Der, 
2017). Therefore, the purpose of this thesis is to identify novel synthetic lethal 
interactors with oncogenic KRAS in colorectal cancer cells. To find synthetic lethal 
interactions, a CaCo2 cell culture model with doxycycline (DOX) inducible expression 
of KRASG12V will first be characterized to assess its suitability as an isogenic KRAS cell 
culture model for further investigations. Next, the transgenic cell line will be used as a 
model system in an RNAi-based screen to identify genes that are essential for 
proliferation and survival with oncogenic KRAS signaling (+DOX) yet are dispensable 
in the absence of mutant KRAS (-DOX). To this end, the cells will be transfected with a 
custom designed short hairpin RNA (shRNA) library consisting of 625 shRNAs 
targeting 121 genes (Table A 1), which were previously shown to be highly regulated 
upon MEK inhibition (Jürchott et al., 2010). The screening results will then be verified 
using functional growth assays. Subsequently, the mechanism behind the synthetic 
lethal interaction of the most promising target will be further investigated.  
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2. Results 
2.1. Characterization of the KRASG12V inducible CaCo2 cell line 
 
CaCo2 cells with DOX-inducible KRASG12V were chosen as a model for cancer cells 
harboring oncogenic KRAS mutations. CaCo2 are colorectal cancer cells that retained 
their epithelial-like growth. A genetic characterization of CaCo2 was performed by 
Ahmed and colleagues in 2013, in which they described CaCo2 as microsatellite stable 
(MSS) and CIN+ (chromosomal instability). They are furthermore wild-type for KRAS 
and important downstream effectors such as BRAF, PIK3CA, and PTEN. They do, 
however, harbor a TP53E204X nonsense mutation (Ahmed et al., 2013). To test how 
efficiently KRASG12V expression could be induced in the CaCo2 model, doxycycline was 
added to the cells for 1-3 days and KRAS protein expression, as well as downstream 
activation of ERK1/2, was analyzed. In contrast to many conditional expression 
systems, induced KRASG12V expression in this CaCo2 model system remained at 
around two-fold compared to the endogenous KRAS expression instead of being highly 
overexpressed. Yet, expression of mutant KRASG12V at low levels led to a potent 
phosphorylation and activation of ERK1/2 (Figure 11). 
 
Figure 11: Doxycycline inducible KRASG12V expression level in CaCo2 cells over time. 
(A) Western blot of KRASG12V induced CaCo2 cells shows overexpression of KRAS and 
increased ERK1/2 phosphorylation after 1-3 days. Vinculin served as a loading control. 
(B) Quantification of total KRAS protein expression from 1-3 days. Mean fold change 
± SEM is shown (n=2-3).  
 
Since ectopic expression of RAS is often associated with reduced proliferation due to 
oncogene-induced senescence (Dimauro and David, 2010; Kilbey et al., 2008), the 
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growth of KRASG12V expressing CaCo2 cells was compared to cells with an empty 
vector control (vector) using live cell imaging. Interestingly, there was no difference in 
growth observed upon expression of oncogenic KRAS over the course of one week 
(Figure 12). 
Taken together, the CaCo2 cell culture model provided a suitable platform to 
investigate characteristics of mutant KRAS in an otherwise isogenic background. 
 
 
Figure 12: Representative growth curve of CaCo2 cells after KRASG12V induction. No 
difference in growth with or without KRASG12V expression was observed over a period 
of approx. one week. (n=6 technical replicates; error bars=SEM). 
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2.2. RNAi screen 
 
To identify new synthetic lethal interactors of oncogenic KRAS, an RNAi-based 
proliferation screen was performed over a total of 21 days. Figure 13 shows a 
schematic outline of the screen.  
 
 
Figure 13: Outline of the RNAi screen. CaCo2 cells with doxycycline-inducible 
KRASG12V expression were transduced with an shRNA library by retroviral transduction. 
After 3 days of selection, a control sample was taken. The remaining cells were split 
into two populations and KRASG12V expression was induced in one of the two 
populations. After each 14 and 21 days of culture, a sample was taken. Subsequently, 
the genomic DNA, which contained the respective shRNA cassette, was isolated and 
the integrated shRNA cassettes were PCR amplified. The amplified cassettes were 
then sequenced via massive parallel sequencing. 
 
First, CaCo2 cells harboring a doxycycline-inducible KRASG12V were transduced with a 
retroviral shRNA library targeting 121 genes, previously shown to be highly regulated 
upon MEK inhibition, using a retroviral transfection system. To avoid multiple 
transductions of a single cell, a transduction efficiency of less than 20% was aimed at. 
Three days after transduction the baseline control sample was taken and a 
transduction efficiency of 16.5% was observed (Figure 14). The cell population was 
then split into two populations and cultured with or without KRASG12V induction, 
respectively. After 14 and 21 more days of culture, the shRNA expressing cells 
(mCherry+) were sorted and a sample was taken from the -KRASG12V and the +KRASG12V 
populations. At the end of the screening period of 21 days, the amount of shRNA 
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expressing cells in the two populations had increased from 16.5% to 70.0% (-KRASG12V) 
and 77.6% (+KRASG12V), respectively (Figure 14). 
 
 
Figure 14: Fluorescence-activated cell sorting (FACS) of CaCo2 cells after 
transduction of the retroviral shRNA library. After 3 days of G418 selection, 16.5% of 
the cells constitutively expressed an shRNA (mCherry+). An arbitrary channel (FITC), 
which presents no further information, was used for the x-axis. After 21 days, 77.6% of 
KRASG12V induced cells and 70.0% of uninduced cells expressed an shRNA construct 
(mCherry+). To monitor the induction of KRASG12V, mTagBFP was used as a fluorescent 
reporter protein. Thus, cells exhibited an increased mTagBFP intensity upon KRASG12V 
induction.  
 
After that, genomic DNA of all samples was isolated and the stably integrated shRNA 
cassettes were amplified via PCR. The relative abundance of each shRNA in both 
populations was determined by massive parallel sequencing. As a measurement of 
sequencing quality, the reads per shRNA were compared across all samples including 
the input library. All samples showed a median read count of over 15,000 
reads/shRNA. In detail, the input library displayed 15,548 reads/shRNA and the control 
sample 17,084 reads/shRNA. The -KRASG12V samples exhibited medians of 
16,333 reads/shRNA after 14 days and 16,029 reads/shRNA after 21 days. The 
KRASG12V induced samples displayed medians of 15,529 reads/shRNA after 14 days 
and 15,838 reads/shRNA after 21 days. Overall, the distribution of the reads/shRNA 
were highly similar across all samples (Figure 15). 
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Processing of the raw sequencing data as well as quality control was performed by 
Dr. Bertram Klinger, Institute of Pathology, Charité and IRI Life Sciences, Humboldt-
University. 
 
Figure 15: Distributions of number of reads after massive parallel sequencing as an 
indicator for sequencing quality. (A) Histogram of the sequencing reads (log2) of all 
shRNA cassettes showed a highly similar distribution across all samples with a 
median of about 16,000 reads/shRNA. (B) The same data represented as boxplots 
showed comparable distributions of reads/shRNA across all samples (outliers 
excluded). 
 
2.2.1. RNAi screen results 
 
To identify potentially interesting targets from all screened shRNAs, the list of enriched 
and depleted shRNAs in both populations (+/- KRASG12V) compared to the control 
sample (Table A 2) was manually evaluated. shRNAs were picked for further 
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investigation if they showed a consistent difference in enrichment or depletion at both 
time points. Of all 625 shRNAs, 18 shRNAs showed a consistent change in abundance 
in a KRASG12V dependent manner after 14 and 21 days, namely XRCC6.828, ENO1.681, 
PPP2R5E.2031, MCM7.1879, WBP11.1135, ENO1.1440, MED8.561, DNAJC2.429, 
PPP1R15A.1494, HMGB3.628, FOXM1.2496, PPP2R5A.183, DNMT1.3991, ILF2.1851, 
PPP2R5B.1879, DAB2IP.2670, SPRY1.137, RASA4.3049. Therein, only one gene was 
targeted by two independent shRNAs (ENO1) (Table 2, Figure 16). All of these 18 
shRNAs that showed a consistent KRASG12V dependent change in abundance were 
selected for further validation. Interestingly, only four shRNAs showed a consistent 
suppression of more than two-fold across all samples and time points, suggesting 
KRASG12V independent lethality (ZNF207.1051, KLF10.1084, SRF.901, and ETV5.390) 
(Table A 2). One of these lethal targets (KLF10) was selected for further verification. 
In contrast, not a single shRNA in the screen showed an enrichment of more than two-
fold across both samples and time points. Table 2 summarizes the shRNAs that were 
selected for further validation including their respective log2 fold change +/- KRASG12V 
compared to the control sample. 
 
Table 2: List of selected shRNAs targeting 18 genes for further verification. Values 
indicate the log2 fold change of shRNA abundance compared to the control sample 
after massive parallel sequencing. (blue = depletion; red = enrichment). 
  14 days 21 days 
shRNA -KRASG12V  
+ 
KRASG12V 
- 
KRASG12V 
+ 
KRASG12V 
KLF10.1084 -1.61 -3.08 -2.04 -2.71 
XRCC6.828 -1.01 -1.64 -0.37 -2.39 
ENO1.681 -0.02 -1.72 -1.49 -2.15 
PPP2R5E.2031 0.28 -5.09 0.55 -1.66 
MCM7.1879 0.22 -1.07 0.06 -1.41 
WBP11.1135 -0.20 -0.91 -0.67 -1.22 
ENO1.1440 0.04 -1.5 0.12 -1.18 
MED8.561 0.17 -1.07 0.66 -1.13 
DNAJC2.429 -0.45 -0.89 -0.47 -1.13 
PPP1R15A.1494 0.17 -0.80 0.59 -1.03 
HMGB3.628 -0.13 -0.62 0.07 -0.89 
FOXM1.2496 -0.19 -0.85 -0.39 -0.67 
PPP2R5A.183 1.04 -3.62 0.92 -0.60 
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DNMT1.3991 -0.66 -1.10 -0.11 -0.52 
ILF2.1851 -2.15 0.49 -2.29 -0.49 
PPP2R5B.1879 -0.38 0.35 -1.58 -0.41 
DAB2IP.2670 0.28 -0.61 0.82 -0.27 
SPRY1.137 0.09 -0.46 0.66 -0.15 
RASA4.3049 -1.55 -0.46 -1.31 -0.07 
 
 
 
Figure 16: Ranked shRNAs or RNAi screen after 14 and 21 days. All shRNAs were 
ranked according to their change in abundance compared to the control sample and 
plotted according to their rank and log2 fold-change. Selected shRNAs for further 
verification are annotated and marked in blue. 
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2.2.2. Target validation 
 
To validate the results obtained from the RNAi screen, all selected shRNAs (Table 2) 
were cloned into a doxycycline-inducible expression vector (p425, Table 15). For eight 
targets, one to two additional independent shRNAs were introduced. Furthermore, a 
scrambled shRNA (scrbl) was used as a control. The DOX-inducible knockdown 
constructs were then transduced into CaCo2 cells with either DOX-inducible KRASG12V 
or an empty vector control via a retroviral delivery system. To investigate the effect of 
each shRNA on cell growth, the transduced cells were plated at low density and 
cultured for 10–13 days with or without doxycycline addition. Subsequently, the 
colonies were stained with methylene blue and their confluency was assessed using 
CellProfiler v2.2.0 (http://cellprofiler.org/) (Carpenter et al., 2006) (Figure 17 A). The 
outcome of the screen validation is depicted in Figure 17B. Half of the 18 investigated 
genes did not lead to any substantial alteration in growth upon knockdown (DAB2IP, 
DNMT1, FOXM1, XRCC6, HMBG3, PPP1R15A, PPP2R5B, PPP2R5E, and RASA4). 
KLF10.1084, which was identified in the screen to be essential independently of 
KRASG12V, did not show any lethality upon closer investigation. In contrast, the shRNA 
targeting MED8 caused strong lethality in the control cells as well as the KRASG12V 
expressing cells. Knockdown of only four genes showed a similar pattern as predicted 
by the screen (MCM7, DNAJC2, PPP2R5A, and SPRY1). SPRY1.137 caused a KRASG12V 
specific growth reduction of about 28%, however, it also led to a noticeable growth 
reduction in the control cells. DNAJC2.428 and PPP2R5A.1879 lead to a KRASG12V 
specific decrease in growth of about 37% and 40%, respectively. The highest degree of 
synthetic lethality was observed with the knockdown of MCM7. MCM7.1879 and 
MCM7.sh3 led to a reduction in growth in KRASG12V expressing cells of about 57% and 
59%, respectively. MCM7.1534v had a lesser impact but still surpassed all other genes 
in validation with about 46% KRASG12V specific growth reduction. 
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Figure 17: Validation of selected shRNAs by clonogenic assays. (A) Representative 
clonogenic assays of CaCo2 cells with knockdown of selected genes from the RNAi 
screen. (B) Quantification of the clonogenic assays cells after knockdown of 
respective targets. Only shRNAs against MCM7 showed a consistent growth reduction 
in a KRASG12V dependent manner. Mean relative confluency in % ± SEM is shown 
(n= 2-4). Student’s t-test (unpaired); * = p < 0.05; ** = p < 0.01. 
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2.3. MCM7 suppression is synthetic lethal with mutant KRAS 
 
The screen validation results clearly identified MCM7 as the most promising candidate 
from the shRNA screen as a synthetic lethal interactor of mutant KRAS signaling. 
Therefore, MCM7 was chosen to be the focus of all further investigations. 
 
2.3.1. Knockdown efficiencies of shRNAs targeting MCM7 
 
First, the knockdown efficiency of the shRNAs targeting MCM7 was examined by 
western blot. MCM7.1879 and MCM7.sh3 led to an efficient knockdown of MCM7 in 
cells expressing KRASG12V or an empty vector, whereas MCM7.1534v exhibited a less 
effective knockdown of MCM7 (Figure 18). This is in line with the previous result that 
showed a lower degree of synthetic lethality with MCM7.1534v than MCM7.1879 and 
MCM7.sh3 (Figure 17).  
 
Figure 18: Knockdown efficiency of three different shRNAs against MCM7 in CaCo2 
cells detected by western blot analysis after 1-5 or 1-7 days. MCM7.1879 and 
MCM7.sh3 led to a strong knockdown of MCM7, whereas MCM7.1534v showed a less 
efficient knockdown potential. Vinculin served as a loading control. 
 
Since MCM7 is part of the MCM complex, which is in its functional state bound to DNA, 
the knockdown efficiency of MCM7.sh3 was additionally examined on chromatin level. 
MCM7 was efficiently suppressed in the soluble and chromatin-bound fraction after 
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the knockdown. Furthermore, MCM2, another MCM subunit, was only depleted in the 
chromatin fraction but not in the soluble fraction (Figure 19A). This was additionally 
visualized after an in situ chromatin fractionation of adherent cells and subsequent 
immunofluorescence straining that showed specific depletion of chromatin-bound 
MCM2 after seven days of MCM7 knockdown (Figure 19B).  
 
 
Figure 19: Knockdown efficiency of MCM7.sh3 in CaCo2 cells on chromatin level. 
(A) Western blot of the soluble (including soluble nuclear proteins) and chromatin-
bound cell fraction after two and seven days of MCM7 knockdown. PCNA served as a 
loading control for soluble and chromatin-bound protein. β-tubulin served as a loading 
control which is only present in the soluble fraction. (B) Immunofluorescence of in situ 
chromatin fractionation of adherent cells shows efficient suppression of chromatin-
bound MCM2 (red) after seven days of MCM7 knockdown in CaCo2 cells. DAPI (blue) 
was used as nuclear counter-staining. Scale bar = 20 µm. 
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2.3.2. Suppression of MCM7 reduces growth in KRASG12V expressing CaCo2 cells 
in 3D culture conditions 
 
A hallmark of RAS-transformed cells is anchorage-independent growth (Kang and 
Krauss, 1996). To test the KRASG12V dependent growth inhibition of MCM7 suppression 
in 3D growth conditions, cells were seeded in soft agar and cultured for 5 weeks until 
visible colonies had formed. CaCo2 cells, which lack any MAPK activating mutations, 
showed an inherently low anchorage-independent growth capacity. Expression of 
oncogenic KRAS increased colony formation efficiency of CaCo2 cells about five-fold 
compared to the vector control. While the knockdown of MCM7 had no impact on 
colony formation in cells expressing the vector control, CaCo2 cells expressing 
KRASG12V showed a marked reduction of colonies (Figure 20). 
 
Figure 20: Soft agar assay of CaCo2 cells after MCM7 knockdown. (A) Representative 
soft agar assays after KRASG12V expression and MCM7 knockdown. (B) Quantification 
of soft agar assays. KRASG12V expression increased colony formation in CaCo2 cells 
about five-fold. MCM7 knockdown had no detectable effect on cells expressing a 
vector control, whereas cells expressing additionally KRASG12V showed significantly 
reduced colony formation. Mean fold change of colonies formed after five weeks of 
culture is shown ± SEM (n = 3 per group). Student’s t-test (unpaired); 
NS = not significant; *** = p < 0.001. 
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2.3.3. MCM7 knockdown causes apoptosis in KRASG12V expressing CaCo2 cells 
 
To assess whether the observed growth reduction is solely due to reduced cell growth 
or is accompanied with increased cell death, the presence of cleaved poly(ADP ribose) 
polymerase (clPARP) and cleaved Caspase 3 as indicators for apoptosis was 
investigated. Cells with reduced MCM7 levels alone showed only modest cleavage of 
PARP and caspase 3. In contrast, MCM7 suppression in KRASG12V expressing cells led 
to a pronounced increase in clPARP (Figure 21) and in cleaved caspase 3+ cells to 
around 10% (Figure 22).  
 
 
Figure 21: Western blot of CaCo2 cells assessing cleaved PARP expression after 
1-7 days of MCM7 knockdown. Cleaved PARP was specifically enriched after 5 and 7 
days after KRASG12V and MCM7.sh3 induction. Vinculin served as a loading control.  
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Figure 22: Flow cytometry analysis of cleaved Caspase 3 (clCaspase 3).  
(A) Representative plot of cleaved caspase+ cells assessed via flow cytometry after 
induction of KRASG12V and knockdown of MCM7. (B) Cells co-expressing KRASG12V and 
MCM7.sh3 showed a significantly higher increase of apoptosis than cells expressing 
MCM7.sh3 alone. Mean percentage of clCaspase 3+ cells ± SEM is shown (n = 4 per 
group). Student’s t-test (unpaired); *** = p < 0.001; **** = p < 0.0001. 
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2.3.4. MCM7 suppression is lethal in other colorectal cancer cell lines 
 
So far, all experiments have focused on CaCo2 cells as a model for mutant KRAS 
expression, yet it was unclear whether KRAS sensitizes other colorectal cancer cell 
lines to MCM7 suppression, as well. Therefore, DLD-1 cells (KRASwt/G13D) were 
compared to an isogenic derivative cell line lacking the mutated KRAS allele (KRASwt/-) 
(Shirasawa et al., 1993). MCM7.sh3 induction in both cell lines resulted in a specific 
knockdown of MCM7 in the soluble as well as the chromatin fraction. Similar to CaCo2 
cells, MCM2 followed the MCM7 depletion only in the chromatin fraction. After seven 
days of MCM7.sh3 induction, MCM7 levels increased again in DLD-1 (KRASwt/G13D) 
cells and to a lesser extent in DLD-1 (KRASwt/-) cells (Figure 23) probably due to the 
selective pressure exerted by MCM7.sh3 induction. In colony formation assays, both 
cell lines showed decreased growth upon MCM7 suppression. However, DLD-1 cells 
that harbor the mutant KRAS allele were, in fact, more sensitive to reduced MCM7 
levels than the KRAS wild-type cell line. DLD-1 (KRASwt/-) cells displayed a confluence 
of about 39% after 10 days of MCM7 knockdown, whereas the parental KRAS-mutant 
cell line exhibited a final confluence of only approx. 20% (Figure 24).  
 
 
Figure 23: Knockdown efficiency of MCM7.sh3 in DLD-1 cells on chromatin level. 
Western blot of the soluble and chromatin-bound cell fraction after two and seven days 
of doxycycline induction showed efficient MCM7 knockdown in both DLD-1 cell lines. 
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PCNA served as a loading control for soluble and chromatin-bound protein. GAPDH 
served as a loading control that is only present in the soluble fraction. 
 
Figure 24: Quantification of clonogenic assays in DLD-1 (KRAS(wt/-) and 
DLD-1 (KRASwt/G13D) after MCM7 knockdown. Both cell lines are sensitive to MCM7 
suppression, but DLD-1 cells lacking mutated KRAS showed decreased sensitivity to 
the MCM7 knockdown. Mean relative confluency ± SEM is shown (n = 3 per group). 
Student’s t-test (unpaired); * = p < 0.05; **** = p < 0.0001. 
 
Next, the impact of MCM7 knockdown in additional, non-isogenic colorectal cancer 
cell lines was investigated. All of these cell lines harbor either KRAS or BRAF 
mutations, leading to constitutive MAPK signaling. The cell lines were transduced with 
a control shRNA (scrbl) or an MCM7 targeting shRNA (MCM7.sh3) and evaluated in 
long-term growth assays after testing the knockdown efficiency via qPCR. Induction 
of MCM7.sh3 led to a similarly efficient knockdown in SW480 (KRASG12V), HT-29 
(BRAFV600E), and WiDr (BRAFV600E) cells with about 20% remaining MCM7 mRNA 
expression. MCM7 expression in HCT-8 (KRASG13D) remained at about 39% (Figure 25). 
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Figure 25: mRNA expression of SW480, HCT-8, HT-29, and WiDr cells three days after 
induction of MCM7.sh3. Knockdown of MCM7 caused an efficient suppression of 
MCM7 expression in all four cell lines after 3 days of doxycycline induction. Mean fold 
change normalized to scrbl control ± SD is shown (n = 2-3 technical replicates per 
group). 
 
Next, the effect of MCM7 suppression on cell growth was assessed. In all cell lines, a 
significant growth reduction was observed upon MCM7 knockdown (Figure 26). 
Similarly, MCM7 suppression in anchorage-independent growth assays resulted in a 
reduction of colonies for both KRAS mutated cell lines, DLD-1 and SW480 (Figure 27). 
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Figure 26: Quantification of clonogenic assays in SW480 (KRASG12V), HCT-8 
(KRASG13D), HT-29 (BRAFV600E), WiDr (BRAFV600E). All cell lines showed decreased 
growth after doxycycline induction of MCM7.sh3 compared to the control shRNA 
(scrbl). Mean relative confluency ± SEM is shown (n = 3 per group). Student’s t-test 
(unpaired); * = p < 0.05; *** = p < 0.001.  
 
 
Figure 27: Quantification of colony formation in soft agar assays in KRAS mutated 
DLD-1 and SW480 cells. Both DLD-1 and SW480 cells showed a significant decrease 
in colony formation after three weeks of MCM7 knockdown in soft agar assays. Mean 
fold change of colonies ± SEM is shown (n = 6 per group). Student’s t-test (unpaired); 
** = p < 0.01; **** = p < 0.0001. 
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Krenoula Hani Fouad Salib contributed to obtaining the results shown in Figure 23, 
Figure 25, and Figure 26 in the framework of a laboratory rotation of the Master’s 
program Molecular Medicine (https://molecular-medicine.charite.de/) at the Charité –
Universitätsmedizin Berlin. 
 
 
2.4. Mutant KRAS causes replicative stress in cells with low MCM7 levels 
 
From the results obtained so far, it was clear that MCM7 suppression led to decreased 
cell growth in colorectal cancer cells and mutant KRAS additionally sensitized cells to 
the knockdown of MCM7. The following experiments focused on the underlying 
molecular mechanism responsible for the role of oncogenic KRAS in sensitizing 
colorectal cancer cells to MCM7 suppression. 
 
2.4.1. KRAS-mutant cells show increased formation of RPA foci after MCM7 
knockdown 
 
The MCM complex is the key component of the replicative helicase and therefore a 
major player in DNA replication (Deegan and Diffley, 2016). Additionally, mutant RAS 
expression has been shown to influence DNA replication and to be a trigger for 
replication stress (reviewed in 1.3.2 RAS and replication stress). To investigate the 
impact of mutant KRAS expression in the context of MCM7 suppression on replication 
stress, replication protein A (RPA) focalization was assessed. RPA specifically binds 
single-stranded DNA (ssDNA), which is abundantly present in stalled replication forks. 
Therefore, the resulting nuclear RPA focalization can be used as a reliable cellular 
marker of replication stress (Zeman and Cimprich, 2014; Zou and Elledge, 2003).  
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Figure 28: RPA focalization after KRASG12V expression and MCM7 knockdown in 
CaCo2 cells. (A) Representative immunofluorescence images after 7 days of 
doxycycline induction showed RPA2 foci formation in CaCo2 cells after simultaneous 
KRASG12V expression and MCM7 knockdown. Scale bar = 10µm. (B) Quantification of 
nuclei with 5 or more RPA2 foci showed a significant increase of RPA2 focalization 
only when KRASG12V and MCM7.sh3 were co-expressed in CaCo2 cells. After 4 and 7 
days, ~26% and ~40% of cells exhibited 5 or more RPA2 foci, respectively. Mean 
percentage of cells with ≥5 RPA2 foci ± SEM is shown (n = 3 per group). At least 50 
cells per experiment were counted. Student’s t-test (unpaired); * = p < 0.05, ** = p < 
0.01. 
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Expression of KRASG12V and knockdown of MCM7 was induced in CaCo2 cells for 4 
and 7 days and the RPA subunit RPA2 was visualized using immunofluorescence. 
Neither KRASG12V expression nor MCM7 suppression alone led to a significant change 
in number of cells exhibiting RPA foci. However, knockdown of MCM7 in KRAS-mutant 
CaCo2 cells caused a substantial increase of cells exhibiting RPA foci to approx. 26% 
after 4 days of induction and approx. 40% after 7 days (Figure 28). Additionally, western 
blot analysis showed RPA2 phosphorylation at T21 exclusively upon MCM7 
suppression in KRASG12V expressing cells, confirming the previous observation (Figure 
29). Similarly, increased RPA foci formation was observed in KRAS-mutant DLD-1 and 
SW480 cells upon MCM7 suppression (Figure 30). Interestingly, RPA foci co-localized 
well with 53BP1 nuclear bodies (Figure 31). 
 
 
Figure 29: Western blot analysis of RPA2(T21) phosphorylation in CaCo2 cells after 
KRASG12V expression and MCM7 knockdown. RPA2 was specifically phosphorylated 
at the T21 site in KRASG12V expressing CaCo2 cells after MCM7 knockdown. Tubulin 
served as a loading control. Western blot was performed by Birgit Schaefer, medical 
technical assistant, Institute of Pathology, Charité. 
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Figure 30: Quantification of RPA focalization in DLD-1 and SW480 cells. The 
quantification of immunofluorescence images revealed an increase of cells with RPA 
foci after 4 days of MCM7 knockdown. Mean percentage of cells with ≥5 RPA 
foci ± SEM is shown (n = 3 per group). At least 50 cells per experiment were counted. 
Student’s t-test (unpaired); * = p < 0.05; ** = p < 0.01. 
 
 
Figure 31: Immunofluorescence of RPA2 and 53BP1 in CaCo2 cells after 
simultaneous KRASG12V and MCM7.sh3 expression.  RPA foci showed co-localization 
with 53BP1 nuclear bodies in CaCo2 cells after 7 days of KRASG12V induction and 
MCM7 knockdown. Scale bar = 10 µm. 
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2.4.2. Mutant KRAS confers resistance to CDC7 inhibition 
 
The source of mutant KRAS inflicted replication stress in the background of low 
replication licensing is still elusive. Previously, expression of oncogenic RAS has been 
linked to replication stress due to an increase in replication origin firing (Hills and 
Diffley, 2014; Di Micco et al., 2006). Aberrant origin firing can deplete dormant origins 
that function as a fail-safe mechanism to recover stalled replication forks (Burkhart et 
al., 1995; Mahbubani et al., 1997; McIntosh and Blow, 2012; Wong et al., 2011). 
Therefore, the influence of mutant KRAS on the pharmacological inhibition of origin 
firing was investigated. CDC7 is one of the kinases that initiate origin firing via 
phosphorylation and subsequent remodeling of the MCM complex (Deegan and 
Diffley, 2016; Heller et al., 2011). Thus, the link between oncogenic KRAS and origin 
firing in colorectal cancer cells, the effect of the CDC7 inhibitor PHA 767491 on growth 
in KRAS-mutant and KRAS wild-type cells was assessed. Indeed, a decrease in 
phosphorylation of MCM2 at serine 40, an indicator for CDC7 activity and origin firing 
(Montagnoli et al., 2006, 2008), was observed upon 24 h of CDC7 inhibition with 10 µM 
PHA 767491 (Figure 32). CaCo2 cells expressing mutant KRASG12V showed a slightly 
increased resistance to CDC7 inhibition, as indicated by a shift in IC50 of PHA 767491 
from 0.576 µM (95% CI: 0.467 µM-0.710 µM) to 0.851 µM 
(95% CI: 0.662 µM-1.095 µM). An even more pronounced shift was observed in DLD-1 
cells with KRASG13D compared to the isogenic cells harboring only a KRAS wild-type 
allele from 1.406 µM (95% CI: 1.140 µM to 1.735 µM) to 3.086 µM (95% CI: 2.777 µM 
to 3.431 µM) (Figure 32, Figure 33). 
 
Figure 32: Western blot of pMCM2 (S40) as an indicator for origin firing after 
CDC7 inhibition  CaCo2 cells showed decreased phosphorylation of MCM2 at 
serine 40 after 24 h of pharmacological CDC7 inhibition with 10 µM PHA 767491. 
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The 0.5 µM and 2.5 µM concentrations did not cause an observable change in 
MCM2 phosphorylation after 24 h. GAPDH served as a loading control. 
 
Figure 33: IC50 determination of KRASmut and KRASwt cells to the CDC7 inhibitor 
PHA 767491. (A,B) CaCo2 cells exhibited a slight shift in IC50 from 0.576 µM 
(95% CI: 0.467 µM - 0.710 µM) to 0.851 µM (95% CI: 0.662 µM - 1.095 µM) upon 
KRASG12V expression. R²vector=0.9675; R²KRAS(G12V)= 0.9574 (C,D) DLD-1 cells 
harboring KRASG13D were substantially more resistance to CDC7 inhibition 
exhibiting an IC50 of 1.406 µM (95% CI: 1.140 µM - 1.735 µM) compared to the 
KRASwt DLD-1 cells with an IC50 of 3.086 µM (95% CI: 2.777 µM - 3.431 µM). 
R²KRAS(wt/-)=0,9267; R²KRAS(G13D/wt)=0.9662. Mean relative confluency ± SEM is shown 
(n = 3-4 per group). Nonlinear regression - extra sum-of-squares F test (A, C). Mean 
IC50 ± SEM is shown (n = 4). Student’s t-test (unpaired) (B, D); * = p < 0.05; 
** = p < 0.01; **** = p < 0.0001.  
 
2.4.3. MCM7 knockdown causes checkpoint activation 
 
Consistent with the observed replicative stress, increased CHK1 activation was 
detected specifically in CaCo2 cells with simultaneous KRASG12V expression and 
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MCM7 knockdown. In contrast, CHK2 was activated after MCM7 suppression 
independently of KRASG12V expression (Figure 34). 
 
Figure 34: Western blot analysis of pCHK1(S345) and pCHK2(T68). CHK1 is 
specifically activated after 7 days of KRASG12V and MCM7.sh3 co-expression. CHK2 is 
activated after 5 days of MCM7 knockdown, independently of KRASG12V expression. 
Vinculin served as a loading control. 
 
 
2.5. Knockdown of MCM7 leads to a shift in cell cycle distribution 
 
Activation of the checkpoint kinases CHK1 and CHK2 can trigger a delay in cell cycle 
progression until the cause of their activation is resolved (Bartek and Lukas, 2003). 
Therefore, cell cycle distributions were analyzed in CaCo2 cells after MCM7 
knockdown in a KRAS wild-type and mutant background. 
 
2.5.1. Cells accumulate in G2/M phase after MCM7 suppression independently of 
mutant KRAS expression 
 
To assess the impact of MCM7 and KRASG12V induced replication stress on the cell 
cycle distribution, CaCo2 cells were analyzed after 7 days of MCM7 knockdown with 
or without KRASG12V expression and 30 minutes of BrdU incorporation by flow 
cytometry. CaCo2 cells did not arrest in G1 after MCM7 knockdown, despite decreased 
DNA replication licensing, as indicated by the loss of chromatin-bound MCM7 and 
MCM2 (Figure 19). In contrast, the cells accumulated in G2/M after MCM7 knockdown. 
2. Results 
50 
This was seen independently of KRASG12V expression. KRASG12V expression itself had 
no major impact on the cell cycle distribution. A slight increase in G1 as observed after 
KRASG12V expression. However, this might be the consequence of slight differences in 
initial plating densities that resulted in a higher confluency in KRASG12V expressing cells 
and thus in a higher G1 population due to increased cell-cell contact inhibition. (Figure 
35). 
 
 
Figure 35: Analysis of cell cycle distributions in CaCo2 cells after 7 days of KRASG12V 
and MCM7.sh3 expression. BrdU was added to the cells 30 min before they were 
harvested and stained with propidium iodide (PI) and an anti BrdU-AF488 antibody. (A) 
Representative plot of cell cycle distributions in CaCo2 cells after KRASG12V expression 
and MCM7 knockdown. (B) Flow cytometry analysis revealed increased persistence of 
CaCo2 cells with low levels of MCM7 in G2/M phase independently of KRASG12V seven 
days after induction. (n=2 per group). 
 
2.5.2. KRAS-mutant cells accumulate specifically in mitosis after MCM7 
knockdown 
 
To differentiate between G2 and M phase arrest, CaCo2 cells were stained for 
phospho-Histone H3 (pHH3), which is specifically phosphorylated at serine 10 in 
mitosis (Hans and Dimitrov, 2001). Analysis of immunofluorescence images showed 
that KRASG12V expression or knockdown of MCM7 alone did not change the number of 
cells in mitosis after 7 days of induction. This indicates that cells halt in G2 after MCM7 
suppression but still enter mitosis eventually, albeit with some delay. Remarkably, cells 
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co-expressing KRASG12V and MCM7.sh3 show a robust increase of cells in mitosis 
from approximately 5% to 11% (Figure 36).  
 
Figure 36: Fluorescence microscopy analysis of pHH3(S10) positive CaCo2 cells 
after 7 days of KRASG12V expression and MCM7 knockdown. (A) Representative 
immunofluorescence images of CaCo2 cells stained for phospho-Histone H3 (pHH3) 
after 7 days of induction. Scale bar = 40 µm. (B) Quantification of pHH3+ stained cells 
revealed that about 5% of all cells stained positive for pHH3 after 7 days of doxycycline 
addition except cells co-expressing KRASG12V and MCM7.sh3, which exhibited an 
increase of mitotic cells to over 11%. Mean percentage of pHH3+ cells ± SEM is shown 
(n = 4 per group). At least 200 cells were counted per experiment. Student’s t-test 
(unpaired); *** = p < 0.001. 
 
Comparable results were obtained in an independent experiment after measuring 
pHH3+ cells via flow cytometry. Again, CaCo2 cells showed the highest increase in 
pHH3+ cells after simultaneous KRASG12V expression and MCM7 knockdown (Figure 
37). However, the flow cytometry analysis showed a more pronounced increase in 
pHH3 positive cells after MCM7 knockdown in the absence of KRASG12V. The reason 
for the slight differences between immunofluorescence and flow cytometry 
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experiments is not entirely clear, however, it might be due to not further known 
technical discrepancies between the two experimental procedures.  
 
Figure 37: Flow cytometry analysis of pHH3(S10) positive CaCo2 cells after 7 days of 
KRASG12V and MCM7.sh3 expression. A higher fraction of mitotic cells was observed 
after MCM7 knockdown, which was further increased after additional KRASG12V 
expression. Mean percentage of pHH3+ cells ± SEM is shown (n = 2 per group). Flow 
cytometry was performed by Kathleen Klotz-Noack, Institute of Pathology, Charité.  
 
 
2.6. KRAS-mutant cells are driven into mitotic catastrophe after MCM7 
suppression 
2.6.1. KRAS-mutant cells enter mitosis with damaged DNA 
 
Premature entry into mitosis in the presence of DNA damage due to the lack of a 
functional G2/M checkpoint is a hallmark of mitotic catastrophe (Castedo et al., 2004; 
Vakifahmetoglu et al., 2008). Thus, the hypothesis that mitotic catastrophe is the 
underlying mechanism of oncogenic KRAS dependent cell death in MCM7 depleted 
cells was assessed. To test this, KRASG12V expression and MCM7 knockdown were 
induced in CaCo2 cells for 7 days before the cells were stained for pHH3 (S10) and 
phospho-H2AX at Ser139 (γH2AX). Cells with either KRASG12V expression or MCM7 
suppression alone showed no significant increase of γH2AX foci in mitosis. However, 
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a striking 61% of cells with simultaneous KRASG12V expression and MCM7 knockdown 
exhibited DNA damage in mitosis (Figure 38).  
 
 
Figure 38: Fluorescence microscopy analysis of DNA damage (γH2AX+) during 
mitosis (pHH3+) in CaC2 cells after KRASG12V and MCM7.sh3 expression. (A) 
Representative immunofluorescence images of phospho-Histone H3 (pHH3) and 
γH2AX stained CaCo2 cells after 7 days of doxycycline induction. (B) Quantification of 
γH2AX foci in pHH3+ CaCo2 cells. KRASG12V or MCM7.sh3 expression alone did not 
significantly change the number of mitotic cells with 5 or more γH2AX foci. Co-
expression of KRASG12V and MCM7.sh3 caused an increase of mitotic γH2AX+ cells to 
about 61%. At least 86 cells per group were counted through the course of 5 
independent experiments. Fisher’s exact test; **** = p < 0.0001. 
 
The increased DNA damage during mitosis observed in cells simultaneously 
expressing KRASG12V and MCM7.sh3 was confirmed in an independent flow cytometry 
experiment. About 13.5% of KRAS-mutant cells showed high γH2AX levels during 
mitosis after MCM7 knockdown, whereas cells with MCM7 knockdown alone 
remained at low levels of γH2AX+ cells during mitosis (Figure 39). Again, the 
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fluorescence microscopy experiment and the flow cytometry experiment showed 
slightly different outcomes. The fluorescence microscopy experiment showed DNA 
damage in about 61% of all mitotic cells, whereas only about 14% of cells were γH2AX 
positive in the flow cytometry experiment. This difference can be explained by the 
different sensitivities of the two assays. While single sites of DNA damage are visible 
in fluorescence microscopy (each γH2AX focus is a site of DNA damage), high levels 
of DNA damage are required to display a cell as γH2AX positive in flow cytometry. 
Therefore, the absolute numbers of γH2AX positive cells in mitosis were lower in the 
flow cytometry experiment, however, the relative proportions between samples were 
similar in both experiments. 
 
 
Figure 39: Flow cytometry analysis of γH2AX+/pHH3+ CaCo2 cells. CaCo2 cells 
showed a pronounced increase of γH2AX+ cells in mitosis specifically after 
simultaneous expression of KRASG12V and knockdown of MCM7 for 7 days. Mean 
percentage of γH2AX+ cells (gated on pHH3+ cells) ± SEM is shown (n = 2 per group). 
Flow cytometry was performed by Kathleen Klotz Noack, Institute of Pathology, 
Charité. 
 
As a consequence of DNA damage in mitosis and the resulting mitotic catastrophe, 
random distributions of condensed chromosomes throughout the cell (Figure 40) and 
massive chromosomal aberrations during mitosis (Figure 41) were frequently 
observed after simultaneous KRASG12V expression and MCM7 knockdown.  
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Figure 40: Analysis of aberrant chromosome alignments during mitosis.  
Immunofluorescence imaging (A) and subsequent quantification (B). CaCo2 cells 
showed an increased number of cells with DNA damage and randomly distributed 
chromosomes throughout the cell during mitosis after 7 days of KRASG12V expression 
and MCM7 knockdown. Arrows indicate misaligned chromosomes. Scale bar = 10 µm. 
Fisher’s exact test; * = p < 0.05; **** = p < 0.0001. 
 
Figure 41: Immunofluorescence of massively aberrated chromosomes during mitosis 
after 7 days of KRASG12V expression and MCM7 knockdown. CaCo2 cells expression 
KRASG12V and MCM7.sh3 simultaneously for 7 days exhibit in part massive 
chromosomal aberrations and DNA damage during mitosis. Scale bar = 10 µm. 
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2.6.1. The influence of KRASG12V on the G2/M checkpoint 
 
The results so far showed that KRAS-mutant cells display an increased mitotic cell 
population as well as DNA damage in mitosis after MCM7 suppression. It was 
previously suggested that oncogenic RAS might promote the G2/M transition via 
ERK1/2 and p90RSK and therefore might be able to push cells with unreplicated DNA 
in mitosis (Grabocka et al., 2014; Knauf et al., 2006). To assess the impact of 
oncogenic KRAS in the G2/M transition after MCM7 suppression, several downstream 
targets of p90RSK that are linked to the regulation of mitotic entry were analyzed, 
including CHK1, CDC25B/C, and MYT1, as indicators for functional G2 arrest. The 
output of all analyzed proteins converges in the mitotic kinase CDK1. The active CDK1-
cyclin B complex phosphorylates numerous targets involved in chromosome 
condensation, spindle assembly, and nuclear membrane breakdown among other 
processes that lead to mitotic entry. Its activity can be inhibited by phosphorylation at 
Thr14 and Tyr15 via WEE1 and MYT1 (Booher et al., 1997; Mueller et al., 1995; Nigg, 
2001). The hypothetical molecular connecting KRAS and the G2/M transition is 
summarized in Figure 42. 
 
Figure 42: Hypothetical molecular impact of oncogenic KRAS on the G2/M transition. 
Mutant KRAS causes activation of p90RSK via its downstream targets ERK1/2 
(Grabocka et al., 2014; Knauf et al., 2006). p90RSK inhibits MYT1 by phosphorylation 
and thus prevents MYT1 from inhibiting CDK1, thereby triggering entry into mitosis 
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(Palmer et al., 1998). Additionally, p90RSK can also phosphorylate CHK1 at the 
inhibitory site S280. Without CHK1 activity upon DNA damage, the phosphatase CDC25 
remains active and removes inhibitory phosphorylations from CDK1, allowing cells to 
proceed into mitosis (Donzelli and Draetta, 2003; Ray-David et al., 2013). 
 
No changes in the activity of the ERK1/2 downstream target p90RSK, as measured by 
the phosphorylation at T359/S363, were observed upon KRASG12V expression or MCM7 
knockdown. Similarly, the inhibitory phosphorylation site serine 280 in CHK1 showed 
no increase after KRASG12V or MCM7.sh3 induction (Figure 43A). The CDK1 activating 
phosphatases CDC25B and CDC25C also showed no change in activation after neither 
after KRASG12V expression nor after MCM7 knockdown (Figure 43B). In contrast, MYT1 
was hyperphosphorylated after knockdown of MCM7. This hyperphosphorylation was 
highest after simultaneous MCM7 knockdown and KRASG12V expression. KRASG12V 
expression alone did not induce increased MYT1 phosphorylation. However, the 
inhibitory phosphorylation of MYT1 did not result in changes in CDK1 phosphorylation 
(Figure 43C). 
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Figure 43: Analysis of G2/M checkpoint transition protein activation by western blot.  
CaCo2 cells were induced for 3, 5, and 7 days and then analyzed by western blot. (A) 
Phosphorylation of pRSK90 did not increase after 3, 5, or 7 days of doxycycline 
induction at the activating sites T359 and S363 in any of the samples. Similarly, CHK1 
showed no increased inhibition by phosphorylation at S280. (B) The phosphatases 
CDC25B and CDC25C also exhibited no change in phosphorylation at S323 or S216, 
respectively. (C) MYT1 was hyperphosphorylated after MCM7 suppression. This was 
more prominent after simultaneous KRASG12V expression. No change in the inhibitory 
phosphorylation at Y15 of CDK1 was observed. Vinculin and β-tubulin served as 
loading controls. Western blot was performed by Birgit Schaefer, medical technical 
assistant, Institute of Pathology, Charité. 
 
To test the dynamics of CDK1 phosphorylation, the cells were treated with hydroxyurea 
to elicit inhibition of CDK1. However, despite the efficient reduction of MYT1 
hyperphosphorylation upon hydroxyurea treatment, no increased CDK1 
phosphorylation at Y15 was observed (Figure 44). 
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Figure 44: Western blot analysis of MYT1 and CDK1 phosphorylation after treatment 
with hydroxyurea. CaCo2 cells were induced with doxycycline for 3 days and treated 
with 0.25-2 mM hydroxyurea for 4 hours. Hyperphosphorylation of MYT1 was 
decreased after treatment with hydroxyurea. pCDK1(Y15) remained unchanged upon 
hydroxyurea treatment. Vinculin served as a loading control. Western blot was 
performed by Birgit Schaefer, medical technical assistant, Institute of Pathology, 
Charité. 
 
 
2.7. Mutated KRAS confers increased sensitivity towards perturbation of 
replication fork progression 
 
Currently, there are no pharmacological inhibitors of DNA replication licensing 
available. However, DNA replication as a process is a major target in cancer therapy. 
To assess whether KRAS-mutant cells are also sensitive to pharmacological 
perturbations of DNA replication progression, CaCo2 cells were exposed to 
hydroxyurea and oxaliplatin, which both lead to perturbations in DNA synthesis through 
different mechanisms. Hydroxyurea depletes the dNTP pool by inhibiting the 
ribonucleotide reductase and thereby prevents the incorporation of nucleotides during 
DNA replication, which leads to stalled replication forks (Singh and Xu, 2016; Yarbro, 
1992). Oxaliplatin, on the other hand, inhibits replication by generating DNA inter- and 
intra-strand crosslinks (Alcindor and Beauger, 2011). Indeed, increased sensitivity of 
CaCo2 cells to hydroxyurea and oxaliplatin was observed when KRASG12V was 
expressed. KRASG12V expression in CaCo2 cells caused a shift in the IC50 of 
hydroxyurea from 207.3 µM (95% CI: 192.7 µM-223.0 µM) to 154.7 µM 
(95% CI: 142.1 µM-168.4 µM) upon KRASG12V induction. Likewise, KRASG12V expression 
resulted in a shift in oxaliplatin IC50 from 0.157 µM (95% CI: 0.1342 µM-0.1826 µM) to 
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0.076 µM (95% CI: 0.066 µM-0.088 µM) (Figure 45). These results suggest that mutant 
KRAS expression can indeed sensitize cells to perturbations of DNA replication. 
 
Figure 45: Perturbations of replication fork progression by hydroxyurea and 
oxaliplatin in CaCo2 cells. Hydroxyurea and oxaliplatin showed increased efficacy in 
KRAS-mutant CaCo2 cells. KRAS induction caused a shift in IC50 from 207.3 µM to 
154.7 µM with hydroxyurea (R²vector=0.9379; R²KRAS(G12V)=0.9257) (A,B) and 0.157 µM to 
0.076 µM with oxaliplatin (R²vector=0.9123; R²KRAS(G12V)=0.9155) (C,D). Mean relative 
confluency ± SEM is shown (n = 3-5 per group). Nonlinear regression - extra sum-of-
squares F test; Mean IC50 ± SEM is shown (n = 3). Student’s t-test (unpaired) (B,D); 
** = p < 0.01; *** = p < 0.001; **** = p < 0.0001.  
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3. Discussion 
 
KRAS is one of the most commonly mutated oncogenes in human cancers. Therefore, 
specific inhibition of oncogenic KRAS signaling would be an obvious choice for 
targeted cancer therapy. However, through the past decades, it has become clear that 
this is agonizingly difficult to achieve. Despite enormous efforts to specifically target 
KRAS mutant cells in cancer therapy, no sustainable treatment targeting KRAS directly 
has made its way to the clinic up to this date (Cox et al., 2014; Papke and Der, 2017). 
For a while, KRAS has even been coined “undruggable” (Cox et al., 2014). Figure 5 
summarizes the different strategies of targeting oncogenic KRAS in cancer that have 
been explored so far. One of the approaches to target mutant KRAS is the concept of 
synthetic lethality (Figure 6). By inhibiting synthetic lethal interactors, cells with a 
specific alteration such as KRAS mutations can be targeted indirectly. This approach 
has been proven to be successful in BRCA-deficient ovarian cancers and breast 
cancers and thus the PARP inhibitor olaparib was approved by the FDA for the 
treatment of BRCA-deficient ovarian and breast cancer (Dziadkowiec et al., 2016; U.S. 
Food & Drug Administration, 2018).  
To identify synthetic lethal interactors of oncogenic KRAS, I performed an RNAi screen 
in an isogenic CaCo2 cell culture model targeting genes, which have been previously 
found to be highly regulated upon MEK inhibition (Jürchott et al., 2010). I demonstrated 
that KRAS mutated colorectal cancer cells specifically rely on high MCM7 levels and 
its suppression is synthetically lethal with KRAS mutated cells. 
 
 
3.1. Lethality of MCM7 knockdown in KRAS-mutant cancer cell lines 
 
The synthetic lethality of MCM7 suppression in KRAS-mutant CaCo2 cells was 
predicted by one shRNA that was specifically depleted in the KRASG12V induced 
samples after 14 and 21 days in the RNAi screen (Table 2, Figure 16). Subsequent 
validation with two additional and independent shRNAs confirmed the sensitivity of 
KRASG12V expressing CaCo2 cells to the knockdown of MCM7 (Figure 17, Figure 20). 
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This indicates that the observed synthetic lethality is the result of a specific MCM7 
suppression and not due to off-target effects. Additionally, it is worth noting that the 
strength of synthetic lethality correlated with the knockdown efficiency of the 
respective shRNAs. While the shRNAs MCM7.1879 and MCM7.sh3 showed a high 
knockdown efficiency and high synthetic lethality with KRASG12V, MCM7.1534v 
exhibited a lower potency of MCM7 suppression and KRASG12V specific growth 
reduction. Thus, MCM7 was confirmed to act in a synthetic lethal manner with 
KRASG12V in CaCo2 cells with three independent shRNAs (Figure 17, Figure 18). 
Importantly, overall MCM7 suppression led to a simultaneous depletion of chromatin-
bound MCM2, but not of soluble MCM2 (Figure 19). This suggests that the knockdown 
was specific for MCM7 but the suppression of MCM7 expression led to a disruption of 
proper MCM complex formation or recruitment to the DNA as it was previously 
described (Ibarra et al., 2008). Therefore, by suppressing MCM7 expression, the entire 
origin licensing process could be targeted. 
The specific growth reduction in KRASG12V expressing CaCo2 cells after MCM7 
suppression could at least partially be attributed to the induction of apoptosis as it was 
shown by the increased presence of cleaved PARP and cleaved caspase 3 (Figure 21, 
Figure 22). Nevertheless, a slight increase of apoptotic cells was also observed in 
CaCo2 cells that expressed MCM7.sh3 in the absence of KRASG12V, suggesting a mild 
toxicity of MCM7 suppression in the parental CaCo2 cells. However, decreased 
proliferation or non-apoptotic cell death mechanisms cannot be excluded to play an 
additional role in the observed overall growth reduction in KRASG12V expressing cells 
after MCM7 suppression. 
The synthetic lethality could additionally be verified in an isogenic DLD-1 cell culture 
model. In contrast to KRAS wild-type CaCo2 cells, DLD-1 cells harbor an endogenous 
KRASG13D mutation (Ahmed et al., 2013). Indeed, the parental DLD-1 (KRASwt/G13D) cells 
were more sensitive to MCM7 suppression than their derivative KRAS wild-type DLD-1 
(KRASwt/-), confirming the observations made in the CaCo2 cell culture model (Figure 
17, Figure 24). However, in contrast to the CaCo2 model, DLD-1 cells without oncogenic 
KRAS showed a marked growth reduction after MCM7 knockdown. The reason for this 
sensitivity is not clear. It is possible that the DLD-1 KRASG13D knockout clone has 
adapted in a way that phenocopies the lacking oncogenic KRAS signal. This is further 
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supported by increased endogenous activation of ERK1/2 in DLD-1 (KRASwt/-) 
compared to DLD-1 (KRASwt/G13D) cells (not shown, data courtesy of Sylvia Ispasanie, 
Institute of Pathology, Charité). In addition, DLD-1 cells might exhibit higher 
endogenous replication stress, which requires higher levels of DNA replication 
licensing. 
Lastly, a panel of four non-isogenic colorectal cancer cell lines showed a sensitivity to 
MCM7 suppression (Figure 26). Interestingly, not only the KRAS-mutant cell lines 
SW480 and HCT-8, but also the KRAS wild-type HT-29 and WiDr cells were sensitive to 
the knockdown of MCM7. Both HT-29 and WiDr harbor a BRAFV600E mutation that leads 
to constitutive activation of the MAPK pathway (Ahmed et al., 2013; Davies et al., 2002) 
and might function as a substitute for the sensitizing KRAS mutation. This would 
indicate a central role of MAPK signaling, which was however not further investigated. 
In summary, the presented data showed that KRAS mutations sensitize colorectal 
cancer cells to decreased replication licensing via the suppression of the replication 
factor MCM7. Additionally, colorectal cancer cells with constitutive MAPK activity via 
BRAFV600E mutations exhibited a strong sensitivity to the knockdown of MCM7. 
 
 
3.2. KRAS and replication stress 
 
The major distinctive phenotype induced in KRASmut cells after MCM7 knockdown was 
the presence of RPA foci, which is considered to be a hallmark of replication stress 
(Zeman and Cimprich, 2014; Zou and Elledge, 2003; Zou et al., 2000). KRASG12V 
expressing CaCo2 cells showed a drastic increase in replication stress as indicated by 
nuclear RPA2 focalization and phosphorylation (Figure 28, Figure 29). Consistent with 
the observed replicative stress, increased CHK1 activation was specifically detected 
in cells with simultaneous KRASG12V expression and MCM7 knockdown (Figure 34). 
Additionally, an increase of RPA2 focalization upon MCM7 knockdown was observed 
in the KRAS-mutant cell lines DLD-1 and SW480 (Figure 30). As mentioned in 1.3.2 RAS 
and replication stress, RPA binds single-stranded DNA, which is abundantly present in 
stalled replication forks. Stalled replication forks and unreplicated DNA are a hallmark 
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of replication stress, which renders RPA focalization a robust marker for replication 
stress (Zeman and Cimprich, 2014; Zou and Elledge, 2003; Zou et al., 2000).  
Interestingly, KRASG12V expression alone did not cause any observable replication 
stress in CaCo2 cells (Figure 28, Figure 29). This finding is in strong contrast to 
previous publications, which show that oncogenic RAS expression alone causes 
replication stress (reviewed in 1.3.2 RAS and replication stress). Di Micco and 
colleagues, for example, showed that expression of oncogenic HRASG12V expression 
in normal human fibroblasts leads to a marked increase of RPA foci formation (Di 
Micco et al., 2006). However, the authors worked with a strong overexpression of 
mutant HRAS, which is not considered to reflect physiological conditions. While 
amplifications (~0.5-1.6% of patients) and upregulation of gene expression (~5-7% of 
patients) of the RAS homologs do occur in colorectal cancer patients, most patients 
show unaltered expression levels of RAS compared to a reference population (Cerami 
et al., 2012; Muzny et al., 2012). Therefore, high RAS overexpression could result in 
observations that do not reflect normal cancer biology. Nevertheless, nine publications 
cited in 1.3.2 RAS and replication stress that showed replication stress upon 
oncogenic RAS expression used cell culture models with high RAS overexpression 
(Aird et al., 2013; Kotsantis et al., 2016; Lee et al., 1999; Mannava et al., 2013; Maya-
Mendoza et al., 2015; Di Micco et al., 2006; Mitsushita et al., 2004; Ogrunc et al., 2014; 
Weyemi et al., 2012). Only Irani and colleagues used a cell culture model with ectopic 
HRAS expression close to endogenous levels (Irani et al., 1997). Four publications did 
not indicate the respective RAS expression levels (Filmus et al., 1994; Hitomi and 
Stacey, 1999; Knauf et al., 2006; Liu et al., 1995). This begs the question: Does 
oncogenic KRAS expression at physiological levels actually result in enough 
replication stress to disturb cell proliferation and survival? Ectopic oncogenic RAS 
expression is commonly attributed to cause oncogene-induced senescence due to 
increased replication stress (Dimauro and David, 2010). Expression of KRASG12V at low 
levels in CaCo2 cells, however, had no observable effect on cell growth as well as on 
replication stress. Only in combination with knockdown of MCM7, a pronounced 
increase in replication stress was detected (Figure 11, Figure 12, Figure 28, Figure 29). 
This suggests that oncogenic KRAS expression at low levels alone is not sufficient to 
cause detectable replication stress. However, oncogenic KRAS expression can 
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sensitize cells towards additional perturbations of replication in the form of decreased 
origin licensing. Furthermore, knockdown of MCM7 alone did not lead to an increase 
of RPA focalization in CaCo2 cells. This result is consistent with previous findings, 
which showed that MCM2-7 levels can be decreased several-fold in human cancer 
cells (U2OS and HeLa) without major effects on replication (Ge et al., 2007; Ibarra et 
al., 2008). The strong reduction of MCM2-7 levels is probably possible because about 
90% of licensed origins remain dormant during unperturbed replication and are only 
activated upon nearby fork stalling to resume DNA replication (Burkhart et al., 1995; 
Mahbubani et al., 1997; McIntosh and Blow, 2012; Wong et al., 2011). Therefore, 
decreased origin licensing can be compatible with cell proliferation in the absence of 
additional replication stress such as oncogene-induced origin firing.  
How KRASG12V expression causes this additional replication stress that sensitizes cells 
to MCM7 suppression is not entirely clear. Oncogenic HRASG12V expression has 
previously been shown to cause decreased distance between active replicons – a sign 
for increased origin firing (Hills and Diffley, 2014; Di Micco et al., 2006). This finding is 
substantiated by the increased resistance of KRAS-mutant cells to inhibition of origin 
firing with the CDC7 inhibitor PHA 767491 (Figure 33). Moreover, pharmacological 
inhibition of origin firing with PHA 767491 could partially counteract the KRASG12V 
dependent lethality of CaCo2 cells after MCM7 knockdown (Figure A 1). Therefore, it 
is plausible that KRASG12V expression triggers origin firing, which additionally to the 
MCM7 knockdown further reduces the presence of dormant origins. As a 
consequence, KRAS-mutant cells would have an increased dependency on high levels 
of DNA replication licensing components. Still, the exact mechanism by which RAS 
increases origin firing is not yet clear. One possibility is that RAS directly regulates 
origin firing by modulating CHK1 activity via p90RSK. Since CHK1 controls dormant 
origin firing, RAS driven inhibition of CHK1 could lead to increased origin firing (Blow 
et al., 2011; Ge and Blow, 2010; Ray-David et al., 2013). However, no indications for this 
could be detected in CaCo2 cells by western blot analysis (Figure 43). Another 
possibility is the RAS-dependent upregulation of cyclins and CDKs that promote origin 
firing (Hills and Diffley, 2014). Finally, increased origin firing by RAS could merely be 
an indirect effect. It is possible that excessive dormant origin firing is due to increased 
replicative stress caused by RAS-dependent dNTP depletion (Aird et al., 2013; Bester 
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et al., 2011; Mannava et al., 2013), ROS accumulation (Irani et al., 1997; Lee et al., 1999; 
Ogrunc et al., 2014), and increased transcription (Kotsantis et al., 2016). These 
processes could trigger additional firing of dormant origins. 
In summary, mutant KRAS expression is likely to cause replication stress. However, 
the extent of this stress is probably low when oncogenic KRAS is expressed at 
physiological levels. Nevertheless, the mild replication stress caused by mutant KRAS 
can sensitize cells towards decreased replication origin licensing as seen with the 
suppression of MCM7 expression. 
 
 
3.3. KRAS, MCM7 knockdown, and their influence on the cell cycle 
 
Depletion of DNA replication licensing factors such as ORC, CDC6, or CDT1, or MCM2-7 
itself prevents full licensing of DNA replication origins. It was previously reported that 
inhibition of DNA replication origin licensing leads to the activation of the licensing 
checkpoint in G1. Activation of this checkpoint prevents cells from entering S-phase 
with an under-licensed genome, which would render cells susceptible to replication 
stress due to the reduction of dormant origins (Feng et al., 2003; Machida et al., 2005; 
McIntosh and Blow, 2012; Shreeram et al., 2002). Conversely, decreasing origin 
licensing in CaCo2 cells by knockdown of MCM7 did not lead to an accumulation in 
G1, indicating that the licensing checkpoint is not being activated in CaCo2 cells. 
Instead of a G1 arrest, CaCo2 cells accumulated in G2/M following MCM7 knockdown 
independently of KRASG12V expression (Figure 35). It was previously suggested that 
the tumor suppressor p53 is required for a sufficient G1 arrest as a response to the 
licensing checkpoint (Nevis et al., 2009). CaCo2 cells, as well as the majority of 
colorectal cancers, harbor TP53 alterations that render it p53-deficient (Ahmed et al., 
2013; The Cancer Genome Atlas, 2012). This can explain why CaCo2 cells lack a 
functional licensing checkpoint. The observed cell cycle delay in G2/M is also in line 
with previous findings by Ibarra and colleagues, who showed an accumulation in G2/M 
in cancer cell lines after MCM2 and MCM3 knockdown (Ibarra et al., 2008). The G2/M 
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checkpoint activation is likely the result of DNA damage caused by stalled and 
unresolved replication forks in the absence of p53. 
While there was no difference in the G2/M accumulation after MCM7 suppression in 
KRAS wild-type or KRAS-mutant CaCo2 cells, KRASG12V expressing cells showed a 
marked increase in the number of mitotic cells (Figure 36, Figure 37). This might 
suggest that oncogenic KRAS can deregulate the G2/M checkpoint and drive cells into 
mitosis. Mutant KRAS and HRAS signaling have previously been shown to overwrite 
the G2/M checkpoint by activating p90RSK via ERK (Grabocka et al., 2014; Knauf et al., 
2006). p90RSK can phosphorylate CHK1 at its inhibitory site S280 and thereby 
prevents DNA damage-induced inhibition of CDC25. Active CDC25, in turn, activates 
the mitotic kinase CDK1 by dephosphorylation and initiates mitosis (Donzelli and 
Draetta, 2003; Ray-David et al., 2013). Additionally, p90RSK has been shown to regulate 
mitotic entry through MYT1 inhibition, which is an inhibitory kinase of CDK1 (Palmer et 
al., 1998). Thus, oncogenic KRAS might shift the CDC25/MYT1 balance towards 
mitosis promoting CDC25 and away from MYT1, thereby overwriting the G2/M 
checkpoint (Figure 42).  
However, western blot analysis of p90RSK(T359/S363), CHK1(S280), CDC25B(S323), 
CDC25C(S216), as well as CDK1(Y15) showed no marked difference in their respective 
activation status in a KRASG12V dependent manner. Only MYT1 exhibited strong 
hyperphosphorylation upon simultaneous KRASG12V expression and MCM7 
knockdown. Yet, this signal was not noticeably transduced to CDK1 (Figure 43). The 
increased hyperphosphorylation of MYT1 is also not necessarily proof of increased 
G2/M transition signaling since MYT1 is inhibited by hyperphosphorylation throughout 
mitosis (Booher et al., 1997; Chow and Poon, 2013) and CaCo2 cells showed an 
increased mitotic population after KRASG12V expression and MCM7 knockdown (Figure 
36, Figure 37). Thus, increased MYT1 hyperphosphorylation could be solely due to an 
increased number of mitotic cells.  
To test whether the inhibitory phosphorylation of CDK1 can be detected by western 
blot at all in CaCo2 cells, the cells were exposed to different concentrations of 
hydroxyurea, which has been shown to elicit CDK1 phosphorylation at Y15 (Chow and 
Poon, 2013). While MYT1 efficiently lost its hyperphosphorylation at all tested 
hydroxyurea concentrations, inhibition of CDK1 could not be detected (Figure 44). This 
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indicates that changes in CDK1 activity might be below the detection limit of western 
blot assays in asynchronous CaCo2 cells. On the other hand, it cannot be ruled out 
entirely that the reason no change in CDK1 inhibition was observed is that CaCo2 cells 
are possibly deficient in the G2/M checkpoint control regulation in general. This, 
however, is unlikely to fully explain why no CDK1 inhibition could be detected since a 
consistent accumulation of cells in G2/M was observed after MCM7 knockdown that 
could not completely be attributed to cells in mitosis (Figure 35, Figure 36). Also, 
results from RNA sequencing data derived from CaCo2 KRASG12V cells showed a 
two-fold upregulation of the CDK1 interaction partner cyclin B3. The binding of 
cyclin B3 to CDK1 is required for CDK1 activity. Therefore, increased cyclin B3 levels 
could promote the transition from G2 to M in a KRAS dependent manner (not shown, 
data courtesy of Sylvia Ispasanie, Institute of Pathology, Charité). Similar observations 
have been made by Knauf and colleagues, who showed that oncogenic HRAS causes 
an upregulation of cyclin B1 that lead to an accelerated G2/M transition (Knauf et al., 
2006).  
While the role of oncogenic KRAS in the G2/M transition is not fully understood, it is 
clear that KRASG12V expressing cells could enter mitosis despite the presence of DNA 
perturbations. Cells that were depleted for MCM7 and expressed KRASG12V 
simultaneously displayed an increased number of mitotic cells and exhibited DNA 
damage in mitosis as marked by γH2AX foci accumulation (Figure 36, Figure 37, Figure 
38, Figure 39). The high ratio of mitotic cells with DNA damage was not observed in 
cells with only MCM7 suppression or only KRASG12V expression (Figure 38, Figure 39). 
The DNA perturbations in mitotic KRAS-mutant cells after MCM7 knockdown were 
likely derived from increased levels of unresolved replication stress (Figure 28, Figure 
29).  
In summary, knockdown of MCM7 caused a shift in the cell cycle from G1 to G2/M 
independent of oncogenic KRAS expression. Published data suggest that oncogenic 
RAS signaling can accelerate the G2/M transition. From the data presented here, 
however, it is not entirely clear to which extend oncogenic KRAS signaling contributes 
to the G2/M transition in the presence of replication stress. Therefore, further 
experiments are required to fully elucidate the connections between mutant KRAS and 
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the G2/M checkpoint. Still, it is clear that KRASG12V expressing cells specifically 
exhibited a mitotic delay and DNA damage during mitosis. 
 
 
3.4. Mechanism of KRAS-mutant cell’s sensitivity to MCM7 suppression 
 
During my work, I showed that KRAS-mutant cells are specifically susceptible to MCM7 
suppression. The mechanism behind this sensitivity is that KRAS-mutant cells showed 
higher levels of replication stress after MCM7 suppression, which resulted in 
unreplicated DNA (Figure 28, Figure 30). Unreplicated DNA cannot be resolved through 
conventional replication once there are no dormant origins remaining to resolve sites 
of stalled replication forks as origins cannot be re-licensed in G2 (Klotz-Noack et al., 
2012; Nishitani and Lygerou, 2002). Homologous recombination has been suggested 
as a possible mechanism to rescue stalled replication forks and complete DNA 
replication in G2 (Michel et al., 2001). However, when cells fail to resolve stretches of 
unreplicated DNA before entering mitosis, they become prone to mitotic catastrophe 
(Aarts et al., 2012; O’Connor, 2015). This was specifically observed in cells expressing 
KRASG12V after MCM7 knockdown as marked by the presence of γH2AX foci in mitotic 
cells (Figure 38, Figure 39). Additionally, KRASG12V expressing cells showed the highest 
proportion of cells with randomly distributed chromosomes throughout the cell and 
massive chromosomal aberrations during mitosis (Figure 40, Figure 41), which is 
characteristic for mitotic catastrophe (Vakifahmetoglu et al., 2008). In conclusion, my 
work provides evidence that even low levels of oncogenic KRAS expression sensitize 
colorectal cancer cells to inhibition of DNA replication origin licensing via the 
suppression of the replication factor MCM7. Mechanistically, KRAS-mutant cells – in 
comparison to KRAS wild-type cells - displayed higher levels of unreplicated DNA after 
MCM7 knockdown that could not be resolved before entering mitosis. The presence 
of unreplicated DNA in mitosis led to a strongly perturbed mitosis, resulting in mitotic 
catastrophe followed by cell death. The mechanism behind the synthetic lethality of 
MCM7 suppression with mutant KRAS cancer cells is summarized in Figure 46. 
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Figure 46: Mechanism of synthetic lethality of mutant KRAS and MCM7 suppression. 
Knockdown of MCM7 in KRAS-mutant cells causes excessive replication stress, which 
results in unreplicated DNA. The presence of unreplicated DNA in mitosis leads then 
to mitotic catastrophe and cell death. 
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There are three potential outcomes of mitotic catastrophe: cell death by either 
apoptosis or necrosis, senescence, and survival with aneuploidy or polyploidy. Cells 
can either succumb without completing mitosis or die a mitotic death. This can happen 
in a directed apoptotic death or in undirected necrosis. In contrast, cells can complete 
mitosis after mitotic catastrophe and become senescent or die in the following G1 
phase. However, cells can potentially also continue to proliferate with aneuploid or 
polyploid nuclei (Figure 47) (Vitale et al., 2011).  
 
 
Figure 47: Potential cell fates after mitotic catastrophe. (A) Unperturbed cells 
progress normally through all cell cycle phases. Cells with perturbations during mitosis 
exhibit a mitotic arrest followed by mitotic catastrophe. There are three main 
outcomes of mitotic catastrophe: Cells can (B1) fail to exit mitosis and therefore die 
directly in mitosis, (B2) exit mitosis and die in the following G1 phase, (B3) become 
senescent in G1 after mitotic exit, (B4) or continue proliferating as aneuploid or 
polyploid cells (adapted from Vitale et al., 2011).  
 
There is evidence that some cells completed mitosis despite the presence of 
unreplicated DNA since co-localization of RPA foci and 53BP1 nuclear bodies were 
observed (Figure 31). 53BP1 has been implicated in the repair of under-replicated DNA 
after mitosis, suggesting increased transmission of unreplicated DNA through cell 
division (Lukas et al., 2011; Moreno et al., 2016). This can then result in apoptosis or 
senescence as mentioned above (Figure 47). Even though senescence following 
mitotic catastrophe cannot be excluded entirely, it is probably not the main mechanism 
of growth reduction. Senescent cells would be expected to accumulate in G1 after 
mitotic catastrophe (Vakifahmetoglu et al., 2008), however, there was no significant 
increase in the G1 cell cycle population observed (Figure 35). Additionally, cells could 
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be equally well synchronized in mitosis with nocodazole independent of KRASG12V 
expression or MCM7 knockdown, which indicates that most cells still show an active 
cell cycle (Figure A 2). On the other hand, only about 10% of KRASG12V and MCM7.sh3 
co-expressing cells exhibited an induction of the apoptosis marker cleaved caspase 3 
(Figure 22). Additional necrotic cell death could explain the strong KRASG12V dependent 
growth reduction after MCM7 knockdown. Therefore, it is likely that KRASG12V and 
MCM7.sh3 co-expressing cells died from a combination of necrosis and apoptosis due 
to mitotic catastrophe. 
 
 
3.5. Limitations 
3.5.1. RNAi screen 
 
The RNAi screen performed far below expectations and the raw results obtained from 
it should be regarded with caution. From 121 genes, only one gene (ENO1) showed a 
KRASG12V specific effect on cell proliferation with two independent shRNAs at both day 
14 and day 21 in the screen (Table A 2). Despite this, a KRASG12V specific lethality could 
not be validated for ENO1 in long-term growth assays. In fact, out of the 19 genes that 
were selected for further validation, only MCM7 could be verified with more than one 
shRNA to cause a KRASG12V specific effect on cell growth (due to the low level of 
synthetic lethality with KRASG12V found in DNAJC2, PPP2R5A, and SPRY1 with one 
shRNA, no further shRNAs were tested) (Figure 17). Interestingly, although 
suppression of MCM7 was successfully identified to be synthetic lethal with mutant 
KRAS, only one out of the five shRNAs in the RNAi screen showed KRASG12V specific 
lethality (Table A 2).  
There are multiple reasons for the poor performance of the shRNA screen: First, CaCo2 
cells that were used is the screen are not an ideal cell line for proliferation screens. 
CaCo2 cells are rather slowly proliferating cells with a doubling time of over 30 h 
(inferred from live cell imaging growth curves). Therefore, specific and detectable 
depletion of shRNAs during the selection period might remain below thresholds even 
after 21 days. Additionally, CaCo2 cells have retained a solid epithelial phenotype with 
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strong cell-cell adhesion. This makes it difficult to obtain single cell suspensions when 
passaging the cells during the screen. Both of these attributes hamper efficient 
selection in a proliferation screen. In retrospect, the faster proliferating DLD-1 cells 
might have been a more promising choice as an isogenic KRAS-mutant cell culture 
model and should be considered for future screening attempts.  
Another culprit is the shRNA technology. Testing of several shRNAs targeting a single 
gene by Kathleen Klotz-Noack (Institute of Pathology, Charité) revealed that on 
average only three out of five shRNAs produced a knockdown of more than 50% of the 
target gene expression levels (data not shown). Additionally, the knockdown efficiency 
can vary vastly between different shRNAs. Therefore, shRNAs with merely a mild 
knockdown might not elicit a functionally relevant effect in the cell. An alternative to 
shRNA screens are CRISPR/Cas screens. CRISPR is a technology that allows a fast 
and specific knockout of genes of interest, which ideally results in a complete loss of 
function of the gene. Knockdown of genes with shRNAs, on the other hand, causes 
merely a decrease in the abundance of a gene product. Therefore, even an efficient 
knockdown of a gene product that functions at low abundances might not be sufficient 
to effectively block its function. A systematic comparison of shRNA and CRISPR 
screens by Evers and colleagues showed that CRISPR knockout screens outperform 
shRNA screens in several aspects. The CRISPR knockout screens showed a lower 
variability between separate screens and less off-target effects than shRNA screens. 
This resulted in overall decreased noise in CRISPR screens (Evers et al., 2016). 
Therefore, CRISPR screens might produce more reliable results in screens in the 
future.  
Nevertheless, shRNA screens clearly have some merit. MCM7 would not have been 
identified if a CRISPR screen had been employed instead of an RNAi screen. The MCM 
complex is essential for proliferation. In a CRISPR screen that strived to identify 
essential genes in the human genome, constructs against all MCM2-7 components 
were found to be strongly depleted (Wang et al., 2015). Since shRNAs merely reduce 
the abundance of a gene product, some residual activity remains. In the case of MCM2-
7, this residual protein amount is enough for proliferation in otherwise unperturbed 
cells (Ge et al., 2007; Ibarra et al., 2008). 
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In conclusion, for future screening endeavors, it is recommended to change the cell 
culture model to a more suitable cell line that exhibits a higher proliferation rate and 
has a lower cell-cell adhesion. Additionally, CRISPR knockout screens should be 
preferred over RNAi screens for more reliable results, even with the disadvantages of 
missing subtle quantitative effects. 
 
3.5.2. Targeting DNA replication licensing in cancer therapy 
 
This work demonstrated that KRAS-mutant cancer cells are susceptible to decreased 
DNA replication licensing in cell culture models. Therefore, the next step is to 
theoretically assess if targeting DNA replication licensing could be a viable strategy in 
cancer therapy.  
A major drawback of inhibiting DNA replication licensing in therapy is that only 
proliferating cells are targeted, similar to other conventional chemotherapies like 
oxaliplatin or irinotecan. Only proliferating cells require DNA replication licensing. In 
fact, cells in a quiescent G0 phase downregulate replication licensing factors such as 
CDC6 and MCM2-7 (Song et al., 2013). Quiescent cancer stem cells can reside in 
tumors in a senescence-like G0 cell cycle phase and possess the ability to re-enter the 
cell cycle (Chen et al., 2016). Therefore, quiescent cells would be entirely unaffected 
by the treatment and could allow the tumor to re-emerge after treatment as it is 
observed in many other therapeutic approaches (Housman et al., 2014).  
Another concern is cells that slip through perturbed mitosis and manage to stay viable 
as aneuploid cells after decreased replication licensing induced chromosomal 
instability (CIN). CIN is associated with aneuploidy in cancer and is linked to drug 
resistance and an overall poor patient outcome (McGranahan et al., 2012). This is 
probably due to the fact that chromosomally aberrated tumors exhibit increased 
intra-tumor heterogeneity and therefore an evolutionary advantage of having more 
chromosomes and thereby a higher chance of functionally beneficial mutations 
(McGranahan et al., 2012). Therefore, any treatment that drives cancer cells into 
mitotic catastrophe might show promising results in short-term, however, could 
potentially have detrimental effects in the long run. 
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Additionally, it is difficult to estimate the potential toxicity of decreased replication 
licensing compared to standard chemotherapy since the sensitivity of MCM7 
suppression was only tested in cancer cell lines and no healthy cell lines in this study. 
Considering that DNA replication licensing is an essential process in all proliferating 
cells, targeting replication licensing might not come entirely without adverse effects. 
Nonetheless, previous data suggests it might be a viable approach with low toxicity. 
For example, while mice with decreased replication origin licensing due to MCM2 level 
reduction are cancer-prone (Pruitt et al., 2007), patients with Meier-Gorline Syndrome, 
which is caused by mutations in proteins required for replication licensing, show a 
primordial dwarfism phenotype but no higher cancer incidence rate. They also do not 
show severely health compromising symptoms (Bicknell et al., 2011; Bongers et al., 
2001; Klingseisen and Jackson, 2011). Furthermore, MCM2-7 levels can be decreased 
several-fold in human cells without major effects on replication (Ge et al., 2007; Ibarra 
et al., 2008). This is most likely due to the fact that most origins stay dormant, only a 
small fraction of the licensed origins (~10%) is used during unperturbed replication. 
This might suggest a low toxicity of a potential therapy targeting replication licensing 
for normal cells. Additionally, the presence of the licensing checkpoint might prevent 
healthy cells from entering S-phase before the genome is fully licensed (Feng et al., 
2003). This could avert healthy cells from experiencing replication stress caused by 
inhibition of origin licensing. However, further investigations are necessary to draw a 
definitive conclusion about potential toxicities. 
 
 
3.6. Outlook 
 
While there are no direct replication licensing inhibitors available at the time of writing, 
there are efforts being made to develop inhibitors of DNA replication licensing. 
Currently, there are nanobodies in development in the Stephen Bell lab (Massachusetts 
Institute of Technology, USA) that inhibit loading of the replicative helicase onto the 
origins of replication (according to a personal conversation with Lorraine De Jesús 
Kim, Massachusetts Institute of Technology, USA). It will be interesting to further 
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investigate our findings in clinically relevant models with a small molecule inhibitor of 
replication licensing. 
Additionally, this work indicates that oncogenic KRAS can sensitize cells to agents that 
interfere with DNA replication such as hydroxyurea and oxaliplatin (Figure 45). 
Therefore, eliciting replication stress by additional means than decreased origin 
licensing might also be a viable approach to specifically target KRAS-mutant cancer 
cells. That notion is further strengthened by previous studies that came to similar 
results (Lin et al., 2014; Steckel et al., 2012).  
On the contrary, inhibiting origin firing might result in a low efficacy in KRAS-mutant 
cancers as increased resistance to CDC7 inhibition was shown in KRAS-mutant cells 
(Figure 33). This is probably because mutant KRAS results in aberrant origin firing as 
it has been reported for HRASG12V expressing cells (Di Micco et al., 2006). This could 
explain why mutant KRAS can rescue cells from CDC7 inhibition. At the time of writing, 
Cancer Research UK and Millennium Pharmaceuticals, Inc. are recruiting patients for 
phase I clinical trials to test the CDC7 inhibitor LY3143921 and TAK-931, respectively, 
in a variety of solid tumors including highly KRAS mutated cancers such as colorectal 
cancer, pancreatic cancer and lung cancer (clinicaltrials.gov, identifiers: 
NCT03096054, NCT02699749). According to the results presented here, patients with 
KRAS mutated tumors might show lower treatment efficacy. To better interpret the 
results of the study, it could be helpful to stratify patient groups in KRAS wild-type and 
mutant patients. 
In conclusion, the data collected during this work is unlikely to be directly translated 
into a cure for KRAS-mutant colorectal cancer patients. However, it sheds more light 
on the mechanism how mutant KRAS sensitizes cancer cells to additional replication 
stress. Hopefully, these insights will provide a valuable foundation for future studies 
to further elucidate how KRAS influences DNA replication and how these properties 
can be exploited in cancer therapy. 
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4.1. Materials 
4.1.1. Consumables 
Table 3: Consumables 
Product Manufacturer # 
0.45 µm syringe filters Sarstedt 83.1826 
96 Well PCR plate, colorless, "Fast" Type Biozym 710888 
Adhesive Clear qPCR Seals, Sheets Biozym 600238 
Amersham Protran 0.2 NC GE Healthcare 10600001 
Cell Scraper 2-Posit. Blade 25 Sarstedt 83.1830 
CellTrics 30 µm, sterile Sysmex Partec 
GmbH 
04-004-2325 
CryoPure Tube 1.8 ml Sarstedt 72.379 
Falcon® 100 mm Cell Culture Dish Corning 353003 
Falcon® 12 Well Clear Flat Bottom plates Corning 353043 
Falcon® 15 ml Conical Centrifuge Tubes Corning 352097 
Falcon® 150 mm Cell Culture Dish Corning 353025 
Falcon® 175cm² Rectangular Straight Neck Cell 
Culture Flask with Vented Cap 
Corning 353118 
Falcon® 25cm² Rectangular Canted Neck Cell 
Culture Flask with Vented Cap 
Corning 353108 
Falcon® 50 ml Conical Centrifuge Tubes Corning 352098 
Falcon® 5mL Round Bottom Polystyrene Test Tube Corning 352054 
Falcon® 6 Well Clear Flat Bottom plates Corning 353046 
Falcon® 75cm² Rectangular Canted Neck Cell 
Culture Flask with Vented Cap 
Corning 353136 
Falcon® 96 Well Clear Flat Bottom plates Corning 353072 
Falcon® Polystyrene Serological Pipets (5 ml, 10 ml, 
25 ml) 
Corning 357543, 357551, 
357525 
Microscope cover glasses VWR 631-1578 
Microscopy slides R. Langenbrinck 03-0004 
Pasteur pipettes Brand GmbH 7477 20 
Phase Lock Gel light tubes 5 Prime  2302800 
Pipette Filter Tips Biosphere (10 µl, 100 µl, 300 µl, 
1000 µl, 1250 µl) 
Sarstedt 70.1116.210, 
70.760.212, 
70.765.210, 
70.762.211 
SafeSeal 0.5 ml PCR tubes Sarstedt 72.704 
SafeSeal 1.5 ml reaction tubes Sarstedt 72.706 
SafeSeal 2.0 ml reaction tubes Sarstedt 72.695.500 
Whatman® cellulose papers GE Healthcare 3030-931 
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Table 4: Commercial kits 
Product Manufacturer # 
Amplitaq Gold Applied Biosystems N8080241 
GoTaq qPCR Master Mix Promega A6002 
High-Capacity cDNA ReverseTranscription Kit Roche 4368814 
Phusion High-Fidelity DNA Polymerase Thermo Fisher F-553L 
Pierce BCA protein assay kit Thermo Fisher 23225 
QIAGEN Plasmid Maxi Kit QIAGEN 12163 
QIAGEN Plasmid Midi kit QIAGEN 12145 
QIAGEN Plasmid Mini kit QIAGEN 12125 
QIAquick gel extraction kit QIAGEN 28704 
QIAquick PCR Purification kit QIAGEN 28104 
RNase-free DNase Set QIAGEN 79254 
RNeasy Mini kit QIAGEN 74104 
 
4.1.2. Devices 
Table 5: Devices 
Product Manufacturer 
8-Channel Multipipet 300 μl Xplorer Eppendorf 
Agarose gel chamber Bio-Rad 
ASPIRE Laboratory Aspirator Accuris 
Balance BP toploader 2100S Sartorius 
Balance RC210P Sartorius 
BD Accuri C6 flow cytometer BD Biosciences 
Bioruptor Diagenode 
Camera Lumix DMC-TZ3 Panasonic 
Camera Nexus 5X LG 
Centrifuge 5415C Eppendorf 
Centrifuge 5417R Eppendorf 
Centrifuge 5810 Eppendorf 
Centrifuge 8510R Eppendorf 
Centrifuge Avanti J-25 Beckman 
Clean Bench LaminAir HBB2448 Heraeus 
Clean Bench Maxisafe 2020 Thermo Fisher 
Clean Bench NU-437-600E NuAire 
Electrophoresis power supply EPS 200 Amersham parmacia biotech 
Electrophoresis power supply EPS 301 Amersham parmacia biotech 
Electrophoresis power supply PowerPac 300 Bio-Rad 
FACSAria II BD Biosciences 
FluorChem M System Protein Simple 
Incubator B6120 microbiological Heraeus 
Incubator Heracell 240i Heraeus 
IncuCyte Zoom Essen BioScience 
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Magnetic Stirrers RCT basic IKA 
Microscope TCS SPE confocal system Leica 
Microskope Axiovert 40 CFL Zeiss 
Microwave M1913 Samsung 
Mini-PROTEAN Tetra Cell Bio-Rad 
Miscellaneous glasware Duran 
Neubauer Improved cell counting chamber Carl Roth 
Odyssey Infrared System 9120 LI-COR 
PCR cycler T Gradient Biometra 
PCR cycler T1 Thermocycler Biometra 
PerfectBlue Semi-Dry Electroblotter Peqlab 
pH-meter CG 840 Schott 
PIPETBOY INTEGRA Biosciences 
Plate reader Synergy 2 BioTek 
Research pipette 0.1-2.5 µl Eppendorf 
Research pipette 0.5-10 µl Eppendorf 
Research pipette 2-20 µl Eppendorf 
Research pipette 10-100 µl Eppendorf 
Research pipette 100-1000 µl Eppendorf 
Rocking Platform Duomax 1030 Heidolph 
Rocking Platform STR9 Stuart scientific 
Roller 6 IKA 
Roller SRT6D Stuart scientific 
Shaking Incubator Type 3031 GFL  
StepOnePlus Real-Time PCR System Applied Biosystems 
Thermocell Cooling & Heating Block Biozym Scientific 
Thermomixer 5436 Eppendorf 
Transiluminator Bioview UST-20M-8R Biostep 
Vortex mixer MSI Minishaker IKA 
Vortex mixer REAX 2000 Heidolph 
Water Bath 1004 GFL 
Water Bath 61569 Köttermann 
Water purification system Classic ELGA 
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4.1.3. Chemicals, drugs, and enzymes 
Table 6: Chemicals 
Product Manufacturer # 
2-Mercaptoethanol (C2H6OS) Applichem A1108,0250 
Agarose Serva 11404.07 
Albumin bovine (BSA) Serva 11926.03 
Ammonium persulfate (APS) Merck 1.01200.1000 
Bacto Agar BD Bioscience  214010 
Bacto Tryptone BD Bioscience  211705 
Bacto Yeast Extract BD Bioscience  212750 
Bromodeoxyuridine (BrdU) Sigma-Aldrich B5002  
Bromphenol Blue Sigma-Aldrich B-6896 
Calcium chloride (CaCl2) Merck 1.02382.0500 
cOmplete Protease Inhibitor Cocktail Tablets Roche 11697498001 
DAPI (4',6-diamidino-2-phenylindole) Sigma-Aldrich D9542 
Dimethyl sulfoxide (DMSO) Applichem A3672,0050 
Disodium hydrogen phosphate (Na2HPO2) Merck 1.06559.0500 
Dithiothreitol (DTT) Biomol 04010.25 
Ethanol (CH3CH2OH) J.T. Baker 2606 
Ethidium bromide Sigma-Aldrich E1510 
Ethylenediaminetetraacetic acid (EDTA) Invitrogen 15576-028 
Formalin solution, neutral buffered, 10% Sigma-Aldrich HT501128 
GelRed Biotium 41001 
Glycerol Merck 1.04093.1000 
Glycin Merck 1.04169.1000 
HEPES Sigma-Aldrich H3375-100G 
Hydrogen chloride (HCl) Merck HC825345 
Isopropanol Merck 8.18766.1000 
Magnesium chloride Merck 1.05833.8250 
Methanol (CH3OH) J.T. Baker 8045 
Methylene blue Applichem A4261 
Noble Agar BD Bioscience  214220 
Nonfat dried milk powder Applichem A0830 
NP-40, 10 % solution Merck 492018 
Paraformaldehyde (PFA) Merck 1.04005.1000 
Pellet Paint Co-Precipitant Novagen  69049 
Phenol Sigma-Aldrich P4557 
PhosSTOP Phosphatase Inhibitor Cocktail Tablets Roche 4906845001 
Poly-L-lysine Sigma-Aldrich P9155  
Polyoxyethylene sorbitan monolaurate (Tween-20) DAKO S1966 
Potassium chloride (KCl) Merck 1.04936 
Potassium dihydrogen phosphate (H2KO4P) Merck 1.04873.1000 
Propidium iodide Sigma-Aldrich P4170 
Sodium acetate (CH3COONa) Merck 1.06267.0500 
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Sodium chloride (NaCl) Merck 567440-1KG 
Sodium deoxycholate Sigma-Aldrich D5670-5G 
Sodium dodecyl sulfate (SDS) Serva 20765.03 
Sodium hydroxide (NaOH) Applichem 141687.1211 
Sodium phosphate (NaH2PO4) Merck 6345.1000 
TEMED (N,N,N’,N’-tetramethylethane-1,2-diamine) Sigma-Aldrich T-9281 
Tris-Base Merck 1.08382.0500 
Triton X-100 Sigma-Aldrich T8532-500ml 
UltraPure™ Agarose Invitrogen 16500500 
 
Table 7: Enzymes 
Product Manufacturer # 
Alkaline Phosphatase, Calf Intestinal (CIP) New England Biolabs M0290S 
EcoRI New England Biolabs R0101S 
Proteinase K Ambion AM2546 
RNase, DNase-free Roche 11119915001  
T4 DNA Ligase New England Biolabs M0202S 
XhoI New England Biolabs R0146S 
 
Table 8: Drugs 
Product Manufacturer # 
5-Fluorouracil  Sigma-Aldrich F6627  
Ampicilin Sigma-Aldrich A9518-5G 
Blasticidin Applichem A3784,0025 
Doxycycline Applichem A2951,0025 
Etoposide Sigma-Aldrich E1383  
Geneticindisulfat (G418) Roth CP11.3 
Hydroxyurea Sigma-Aldrich H8627  
Hygromycin B Roche 10843555001 
Nocodazole Sigma-Aldrich M1404 
Oxaliplatin Sigma-Aldrich O9512  
PHA 767491 Sigma-Aldrich PZ0178  
Puromycin dihydrochloride Sigma-Aldrich P8833  
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4.1.4. Buffers, solutions, and media 
Table 9: Commercial buffers, solutions, and media 
Product Manufacturer # 
1 kb DNA ladder New England Biolabs N3232L 
100 bp DNA ladder New England Biolabs N3231L 
10x DMEM Sigma-Aldrich D2429 
10x DPBS Gibco 14200-067 
10x RPMI-1640  Sigma-Aldrich R1145 
6 x DNA loading dye Thermo Fisher R0611 
Amersham ECL Western Blotting Detection Reagent GE Healthcare RPN2235 
D-(+)-Glucose solution Sigma G8769 
DMEM Lonza BE12-707F 
Fetal calve serum (FCS) PAN Biotech P30-1506 
Lot No. 
P130902 
M-PER Mammalian Protein Extraction Reagent  Thermo Scientific 78501 
NEBuffer 3.1 New England Biolabs B7203S 
Odyssey Blocking Buffer LI-COR Bioscience P/N 927 
PageRuler™ Prestained Protein Ladder Thermo Fisher 26616 
Penicillin/Streptomycin Biochrom A 2212 
Polybrene Merck Millipore TR-1003 
Rotiphorese Gel 30 Roth 3029 
RPMI 1640 Biochrom FG1385 
Sodium Bicarbonate 7.5% Biochrom L 1713 
Sodium Pyruvate Gibco 11360070 
SuperSignal™ West Femto Maximum Sensitivity Substrate Thermo Fisher 34095 
TrypLE Express Gibco 12604-013 
Ultraglutamine 1 Lonza BE17-605E/U1 
VECTASHIELD HardSet Antifade Mounting Medium Vector Laboratories H-1400 
 
Table 10: Self-made solutions 
Solution Recipe 
Running buffer (1x) 5.02 g Tris-base, 15 g Glycine, 1 g SDS, add H2O to 1,000 ml 
Blotting buffer (1x) 5.812 g Tris-base, 2.932 g Glycine, 1.876 ml 20% SDS, 
200 ml Methanol, add H2O to 1,000 ml 
Separation gel (8%) 4.6 ml H2O, 2.5 ml 1.5 M Tris-HCl pH=8.6, 100 µl 10% SDS, 
2.7 ml 30% Acrylamide, 100 µl 10% APS, 6 µl TEMED 
Separation gel (10%) 4 ml H2O, 2.5 ml 1.5 M Tris-HCl pH=8.6, 100 µl 10% SDS, 
3.33 ml 30% Acrylamide, 100 µl 10% APS, 4 µl TEMED 
Separation gel (12%) 3.33 ml H2O, 2.5 ml 1.5 M Tris-HCl pH=8.6, 100 µl 10% SDS, 
4 ml 30% Acrylamide, 100 µl 10% APS, 4 µl TEMED 
Stacking gel (2%) 3.05 ml H2O, 1.25 ml 0.5 M Tris-HCl pH=6.8, 50 µl 10% SDS, 
0.665 ml 30% Acrylamide, 25 µl 10% APS, 5 µl TEMED 
1x LB medium 10 g BactoTM Tryptone, 5 g Bacto Yeast Extract, 10 g NaCl, pH 
7.5, add H2O to 1,000 ml 
1x LB agar 15 g Bacto Agar per 1 l H2O 
50x Tris-acetate EDTA buffer 
(TAE) 
242 g Tris-Base, 57.1 ml Glacial acetic acid, 18.6 g EDTA, 
pH=7.5 - 7.8, add 1 l H2O 
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Phosphate buffered saline 
(PBS) 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 
pH=7.4 
Tris-buffered saline (TBS) 50 mM Tris-base, 150 mM NaCl, pH=7.6 
RIPA 50 mM Tris-HCI pH=7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 
0.5% Na-deoxycholate 
CSK buffer 10 mM Hepes pH=7.4, 300 mM Sucrose, 100 mM NaCl, 3 mM 
MgCl2, 0.5% Triton X-100 
PO4 solution  70 mM Na2HPO4, 70 mM NaH2PO4 
2x HBS 41.96 mM Hepes, 273.78 mM NaCl, pH=7.15 
6x SDS-sample-buffer 300 mM Tris-HCl pH=6.8, 600 mM DTT, 12% SDS, 60% Glycerol, 
0.6% w/v Bromophenol blue 
DNA extraction buffer 10 mM Tris-HCl pH=8.0, 150 mM NaCl, 10 mM EDTA 
 
4.1.5. Antibodies 
Table 11: Primary antibodies 
Antibody target Manufacturer # dilution 
WB 
dilution 
IF 
dilution 
FACS 
53BP1 Biomol Bethyl  A300-272A-
M 
  1:100   
BrdU BD Bioscience  #347580     1:50 
pCDC25B (S323) Sigma SAB4503810 1:200     
pCDC25C (S216) CST 4901 1:1,000     
CDK1 CST 3652 1:1,000     
pCDK1 (Y15) CST 9111 1:1,000     
CHK1 Santa Cruz sc-8408 1:200     
pCHK1 (S280) Abcam ab92630 1:2,500     
pCHK1 (S345) CST 2341 1:1,000     
pCHK2 (T68) CST 2661 1:2,000     
Cleaved Caspase 3 
(Asp175) Alexa Fluor® 647 
Conjugate 
CST 9602     1:50 
cleaved PARP CST 9541 1:1,000     
pERK1/2 CST 4370 1:2,000     
γH2AX Millipore  05-636   1:100 1:250 
γH2AX CST 9718   1:200   
GAPDH Invitrogen AM4300 1:10,000     
pHH3 (Ser10) CST 9701   1:200   
pHH3 (Ser10) 
(PE Conjugate) 
CST 5764     1:50 
KRAS OriGene TA801672 1:2,000     
MCM2 BD 610701 1:2,000 1:50   
pMCM2 Abcam ab133243 1:1,000   
MCM7 Santa Cruz sc-9966 1:200     
PCNA Santa Cruz sc-56 1:200     
p-p90RSK (T359/S363) CST 9344 1:1,000     
RPA2 Abcam ab2175 1:500 1:300   
pRPA2 (Thr21) Abcam ab61065 1:500     
β-Tubulin CST 2146 1:1,000     
Vinculin CST 4650 1:1,000     
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Table 12: Secondary antibodies 
Antibody target Manufacturer # dilution 
WB 
dilution 
IF 
dilution 
FACS 
α-mouse Alexa Fluor 488 Invitrogen  A-21204   1:400 1:1,000 
α-mouse Alexa Fluor 568 Invitrogen  A-11031   1:400   
α-mouse Alexa Fluor 647  Invitrogen A-21237   1:400   
α-mouse HRP-linked CST 7076 1:2,000   
α-mouse IRDye 680RD LI-COR 925-68070 1:10,000   
α-mouse IRDye 800CW  LI-COR 925-32210 1:10,000   
α-rabbit Alexa Fluor 488 Invitrogen  A-11008   1:400   
α-rabbit Alexa Fluor 568 Invitrogen  A-11036   1:400   
α-rabbit HRP-linked CST 7074 1:2,000   
α-rabbit IRDye 680RD LI-COR 925-68071 1:10,000   
α-rabbit IRDye 800CW LI-COR 925-32211 1:10,000   
 
4.1.6. Cell lines 
Table 13: Human cell lines and culture conditions 
cell line authentic-
cation 
medium additions Hygro-
mycin 
Puro-
mycin 
G418 Blasti-
cidin 
CaCo2 
(ATCC) 
13 Feb 
2018, CLS 
GmbH 
DMEM 10% FCS, 
1% Pen/Strep, 
1% Ultraglutamine 
solution 
250 µg/
ml  
5.0 µg/ml 1250 
µg/ml 
--- 
HT29 
(ATCC) 
11 Nov 
2018, CLS 
GmbH 
DMEM 10% FCS, 
1% Pen/Strep, 
1% Ultraglutamine 
solution 
--- 1.0 µg/ml 1000 
µg/ml 
--- 
WiDr 
(provided by 
Prof. 
Reinhold 
Schäfer) 
29 May 
2015, CLS 
GmbH 
DMEM 10% FCS, 
1% Pen/Strep, 
1% Ultraglutamine 
solution 
--- 1.0 µg/ml 1000 
µg/ml 
--- 
SW480 
(ATCC) 
13 Feb 
2018, CLS 
GmbH 
DMEM 10% FCS, 
1% Pen/Strep, 
1% Ultraglutamine 
solution 
--- 5.0 µg/ml 1250 
µg/ml 
--- 
HCT8 
(ATCC) 
12 Apr 
2016, CLS 
GmbH 
DMEM 10% FCS, 
1% Pen/Strep, 
1% Ultraglutamine 
solution, 
4g/L glucose 
--- 5.0 µg/ml 1250 
µg/ml 
--- 
DLD-1 
(KRASwt/G13D) 
(Horizon 
Discovery) 
May 2016, 
freshly 
purchased 
RPMI 10% FCS, 
1% Pen/Strep 
--- 2.5 µg/ml 1250 
µg/ml 
--- 
DLD-1 
(KRASwt/-) 
(Horizon 
Discovery) 
May 2016, 
freshly 
purchased 
RPMI 10% FCS, 
1% Pen/Strep 
--- 2.5 µg/ml 1250 
µg/ml 
--- 
PlatE 
(HEK293T) 
(provided by 
Prof. 
Johannes 
Zuber, IMP) 
--- DMEM 10% FCS, 
1% Pen/Strep, 
1% Ultraglutamine 
solution, 
4g/L glucose 
--- 1.0 µg/ml --- 10 µg/ml 
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Table 14: Bacteria 
cell line: medium manufacturer # 
E. coli (OneShot) Stabl3 LB Invitrogen C737303 
 
4.1.7. Plasmids 
Table 15: Plasmids used to generate transgenic cell lines 
Plasmid provided by Gene/shRNA Resistance Fluorescen
t marker 
TRE3G_KRAS_IRES_TagBF
P_SV40polyA 
Dr. Kathleen 
Klotz-Noack 
KRASG12V Hygromycin BFP 
TRE3G_IRES_TagBFP_SV4
0polyA 
Dr. Kathleen 
Klotz-Noack 
--- Hygromycin BFP 
gagpol Prof. Johannes 
Zuber, IMP 
viral group antigens 
and reverse 
transcriptase 
--- --- 
00419_pRRL-SFFV-rtTA3-
IRES-EcoRec-PGK-Puro 
(pRRL-RIEP) 
Prof. Johannes 
Zuber, IMP 
SLC7A1  
(M. musculus)/ 
reverse tetracycline-
controlled 
transactivator 3 
Puromycin --- 
00409_LMN.miRE.mCherry
.shX 
Dr. Kathleen 
Klotz-Noack 
shRNA library G418 mCherry 
(p425) 00425_pSIN-
TRE3G-turboGFP-miRE-
Ren.713-PGK-Neo 
Prof. Johannes 
Zuber, IMP 
Renilla.713 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-scrbl-PGK-
Neo 
derived from 
p425 
scrbl control shRNA G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
MCM7.1879-PGK-Neo 
derived from 
p425 
MCM7.1879 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
MCM7.1534v-PGK-Neo 
derived from 
p425 
MCM7.1534v G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
MCM7.sh3-PGK-Neo 
derived from 
p425 
MCM7.sh3 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
DAB2IP.2670-PGK-Neo 
derived from 
p425 
DAB2IP.2670 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
DAB2IP.468-PGK-Neo 
derived from 
p425 
DAB2IP.468 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
DNMT1.3205v-PGK-Neo 
derived from 
p425 
DNMT1.3205v G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
DNMT1.3991-PGK-Neo 
derived from 
p425 
DNMT1.3991 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
FOXM1.1812v-PGK-Neo 
derived from 
p425 
FOXM1.1812v G418 TurboGFP 
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00425_pSIN-TRE3G-
turboGFP-miRE-
FOXM1.2496-PGK-Neo 
derived from 
p425 
FOXM1.2496 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
XRCC6.190v-PGK-Neo 
derived from 
p425 
XRCC6.190v G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
XRCC6.828-PGK-Neo 
derived from 
p425 
XRCC6.828 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
DNAJC2.428-PGK-Neo 
derived from 
p425 
DNAJC2.428 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-ENO1.681-
PGK-Neo 
derived from 
p425 
ENO1.681 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
ENO1.1440-PGK-Neo 
derived from 
p425 
ENO1.1440 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
HMBG3.628-PGK-Neo 
derived from 
p425 
HMBG3.628 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-ILF2.1851-
PGK-Neo 
derived from 
p425 
ILF2.1851 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
KLF10.1084-PGK-Neo 
derived from 
p425 
KLF10.1084 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
KLF1.1822v-PGK-Neo 
derived from 
p425 
KLF1.1822v G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
MED8.561-PGK-Neo 
derived from 
p425 
MED8.561 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
PPP1R15A.1494-PGK-Neo 
derived from 
p425 
PPP1R15A.1494 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
PPP1R15A.49v-PGK-Neo 
derived from 
p425 
PPP1R15A.49v G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
PPP2R5A.183-PGK-Neo 
derived from 
p425 
PPP2R5A.183 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
PPP2R5B.1879-PGK-Neo 
derived from 
p425 
PPP2R5B.1879 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
PPP2R5E.2031-PGK-Neo 
derived from 
p425 
PPP2R5E.2031 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
RASA4.3049-PGK-Neo 
derived from 
p425 
RASA4.3049 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
SPRY1.137-PGK-Neo 
derived from 
p425 
SPRY1.137 G418 TurboGFP 
00425_pSIN-TRE3G-
turboGFP-miRE-
WBP11.1135-PGK-Neo 
derived from 
p425 
WBP11.1135 G418 TurboGFP 
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4.1.8. shRNAs 
Table 16: shRNAs used for target validation of the RNAi screen 
Name Guide 97mere sequence 
scrbl TATTCATCTGAGCATCTTCG
CA 
TGCTGTTGACAGTGAGCGAGCGAAGATGC
TCAGATGAATATAGTGAAGCCACAGATGTA
TATTCATCTGAGCATCTTCGCATGCCTACT
GCCTCGGA 
MCM7.1879 TTTGACATCTCCATTAGCCT
GA 
TGCTGTTGACAGTGAGCGCCAGGCTAATG
GAGATGTCAAATAGTGAAGCCACAGATGTA
TTTGACATCTCCATTAGCCTGATGCCTACT
GCCTCGGA 
MCM7.1534v TAGGTCATTGTCTCGGTCGG
GC 
TGCTGTTGACAGTGAGCGACCCGACCGAG
ACAATGACCTATAGTGAAGCCACAGATGTA
TAGGTCATTGTCTCGGTCGGGCTGCCTACT
GCCTCGGA 
MCM7.sh3 TTTTCGTAGAAATCCTCCTC
TG 
TGCTGTTGACAGTGAGCGAAGAGGAGGAT
TTCTACGAAAATAGTGAAGCCACAGATGTA
TTTTCGTAGAAATCCTCCTCTGTGCCTACT
GCCTCGGA 
DAB2IP.468 TTCTTCTTGTCGGTCTCCCG
GT 
TGCTGTTGACAGTGAGCGCCCGGGAGACC
GACAAGAAGAATAGTGAAGCCACAGATGT
ATTCTTCTTGTCGGTCTCCCGGTTGCCTAC
TGCCTCGGA 
DAB2IP.2670 TCGTCTTCTAACAACTGCGC
GT 
TGCTGTTGACAGTGAGCGCCGCGCAGTTGT
TAGAAGACGATAGTGAAGCCACAGATGTAT
CGTCTTCTAACAACTGCGCGTTGCCTACTG
CCTCGGA 
DNMT1.3991 TTGAAGGAGACAAAGTTCCT
GA 
TGCTGTTGACAGTGAGCGCCAGGAACTTTG
TCTCCTTCAATAGTGAAGCCACAGATGTAT
TGAAGGAGACAAAGTTCCTGATGCCTACTG
CCTCGGA 
DNMT1.3205v TTTGATGTCAGTCTCATTGG
GC 
TGCTGTTGACAGTGAGCGACCCAATGAGA
CTGACATCAAATAGTGAAGCCACAGATGTA
TTTGATGTCAGTCTCATTGGGCTGCCTACT
GCCTCGGA 
FOXM1.2496 TAGCTCAGGAATAAACTGGG
AC 
TGCTGTTGACAGTGAGCGATCCCAGTTTAT
TCCTGAGCTATAGTGAAGCCACAGATGTAT
AGCTCAGGAATAAACTGGGACTGCCTACTG
CCTCGGA 
FOXM1.1812v TTGAATCACAAGCATTTCCG
AG 
TGCTGTTGACAGTGAGCGATCGGAAATGCT
TGTGATTCAATAGTGAAGCCACAGATGTAT
TGAATCACAAGCATTTCCGAGTGCCTACTG
CCTCGGA 
XRCC6.828 TTAACCTGCTGAGTGCTCGC
TT 
TGCTGTTGACAGTGAGCGCAGCGAGCACT
CAGCAGGTTAATAGTGAAGCCACAGATGTA
TTAACCTGCTGAGTGCTCGCTTTGCCTACT
GCCTCGGA 
XRCC6.190v TGAGTGAGTAGTCAGATCCG
TG 
TGCTGTTGACAGTGAGCGAACGGATCTGAC
TACTCACTCATAGTGAAGCCACAGATGTAT
GAGTGAGTAGTCAGATCCGTGTGCCTACTG
CCTCGGA 
DNAJC2.428 TTCATCTTCTGATTCCTCGG
AT 
TGCTGTTGACAGTGAGCGCTCCGAGGAATC
AGAAGATGAATAGTGAAGCCACAGATGTAT
TCATCTTCTGATTCCTCGGATTGCCTACTG
CCTCGGA 
ENO1.681 TCTTCGATAGACACCACTGG
GT 
TGCTGTTGACAGTGAGCGCCCCAGTGGTGT
CTATCGAAGATAGTGAAGCCACAGATGTAT
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CTTCGATAGACACCACTGGGTTGCCTACTG
CCTCGGA 
ENO1.1440 TTTGAGCACAAAACCACCGG
GG 
TGCTGTTGACAGTGAGCGACCCGGTGGTTT
TGTGCTCAAATAGTGAAGCCACAGATGTAT
TTGAGCACAAAACCACCGGGGTGCCTACT
GCCTCGGA 
HMGB3.628 TTCATCTTCCTCTTCCACCT
TT 
TGCTGTTGACAGTGAGCGCAAGGTGGAAG
AGGAAGATGAATAGTGAAGCCACAGATGT
ATTCATCTTCCTCTTCCACCTTTTGCCTACT
GCCTCGGA 
ILF2.1851 TGATATTCTAGTTTACTCTG
GT 
TGCTGTTGACAGTGAGCGCCCAGAGTAAA
CTAGAATATCATAGTGAAGCCACAGATGTA
TGATATTCTAGTTTACTCTGGTTGCCTACT
GCCTCGGA 
KLF10.1084 TATGTCTTGCCACATCCTGG
GT 
TGCTGTTGACAGTGAGCGCCCCAGGATGT
GGCAAGACATATAGTGAAGCCACAGATGT
ATATGTCTTGCCACATCCTGGGTTGCCTAC
TGCCTCGGA 
KLF10.1822v TACATCTCCATGTCTGTACC
GT 
TGCTGTTGACAGTGAGCGCCGGTACAGAC
ATGGAGATGTATAGTGAAGCCACAGATGTA
TACATCTCCATGTCTGTACCGTTGCCTACT
GCCTCGGA 
MED8.561 TTAAAGGTCTGCTTGTTCGG
CC 
TGCTGTTGACAGTGAGCGAGCCGAACAAG
CAGACCTTTAATAGTGAAGCCACAGATGTA
TTAAAGGTCTGCTTGTTCGGCCTGCCTACT
GCCTCGGA 
PPP1R15A.1494 TTCTCTTTCATCCTCGGCTG
AT 
TGCTGTTGACAGTGAGCGCTCAGCCGAGG
ATGAAAGAGAATAGTGAAGCCACAGATGT
ATTCTCTTTCATCCTCGGCTGATTGCCTAC
TGCCTCGGA 
PPP1R15A.49v TTGCATAAGATCAACAACTG
GG 
TGCTGTTGACAGTGAGCGACCAGTTGTTGA
TCTTATGCAATAGTGAAGCCACAGATGTAT
TGCATAAGATCAACAACTGGGTGCCTACTG
CCTCGGA 
PPP2R5A.183 TACTATATCAGAATACGCTG
AT 
TGCTGTTGACAGTGAGCGCTCAGCGTATTC
TGATATAGTATAGTGAAGCCACAGATGTAT
ACTATATCAGAATACGCTGATTGCCTACTG
CCTCGGA 
PPP2R5B.1879 TTGAGCACATTGTAGATCAG
TG 
TGCTGTTGACAGTGAGCGAACTGATCTACA
ATGTGCTCAATAGTGAAGCCACAGATGTAT
TGAGCACATTGTAGATCAGTGTGCCTACTG
CCTCGGA 
PPP2R5E.2031 TTCTACTACATAAACGTGTG
AC 
TGCTGTTGACAGTGAGCGATCACACGTTTA
TGTAGTAGAATAGTGAAGCCACAGATGTAT
TCTACTACATAAACGTGTGACTGCCTACTG
CCTCGGA 
SPRY1.137 TCATAGTCTAATCTCTGACG
GC 
TGCTGTTGACAGTGAGCGACCGTCAGAGAT
TAGACTATGATAGTGAAGCCACAGATGTAT
CATAGTCTAATCTCTGACGGCTGCCTACTG
CCTCGGA 
RASA4.3049 TTTGAGGAGAGAACAGCTGG
TT 
TGCTGTTGACAGTGAGCGCACCAGCTGTTC
TCTCCTCAAATAGTGAAGCCACAGATGTAT
TTGAGGAGAGAACAGCTGGTTTGCCTACTG
CCTCGGA 
WBP11.1135 TTGAAGAGGAGTCAGTTCCT
TC 
TGCTGTTGACAGTGAGCGAAAGGAACTGA
CTCCTCTTCAATAGTGAAGCCACAGATGTA
TTGAAGAGGAGTCAGTTCCTTCTGCCTACT
GCCTCGGA 
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4.1.9. Primer 
Table 17: Primer 
Name Sequence (5' - 3') 
p5 SOLEXA adapter AATGATACGGCGACCACCGATGGATGTGGAATGTGTGCGAGG 
p7loop_AAGC CAAGCAGAAGACGGCATACGAAAGCTAGTGAAGCCACAGATGT 
p7loop_AGAC CAAGCAGAAGACGGCATACGAAGACTAGTGAAGCCACAGATGT 
p7loop_CAAC CAAGCAGAAGACGGCATACGACAACTAGTGAAGCCACAGATGT 
p7loop_CGAA  CAAGCAGAAGACGGCATACGACGAATAGTGAAGCCACAGATGT 
p7loop_GAGT  CAAGCAGAAGACGGCATACGAGAGTTAGTGAAGCCACAGATGT 
p7loop_GGAT  CAAGCAGAAGACGGCATACGAGGATTAGTGAAGCCACAGATGT 
MCM7 qPCR fwd GTTTGACCTCCTCTGGCTGA 
MCM7 qPCR rev AGAGGTTCAAACTGGGAGGG 
UBE2D2 fwd ATGGCGCTGAAGAGGATTC 
UBE2D2 rev CTTGCCAGTGGAACAAGTCA 
ZUB-SEQ-SH TGTTTGAATGAGGCTTCAGTAC 
mirE-XhoI TACAATACTCGAGAAGGTATATTGCTGTTGACAGTGAGCG 
mirE-EcoRI TTAGATGAATTCTAGCCCCTTGAAGTCCGAGGCAGTAGGCA 
 
4.1.10. Software 
Table 18: Software and databases 
Name Version Company/Institute License Website 
ApE 2.0.47 M. Wayne Davis Freeware 
 
BD CSampler 
C6 software 
1.0.264
.21 
BD Bioscience Charité 
 
cBio Portal 1.11.3 Center for Molecular 
Oncology,  
Memorial Sloan 
Kettering Cancer Center 
--- http://www.cbioportal.org/  
CellProfiler 2.2.0 Broad Institute Freeware 
 
ClinicalTrials.
gov 
Januar
y 2018 
National Institutes of 
Health (NIH) 
--- http://www.clinicaltrials.gov/  
COSMIC v83 Wellcome Sanger 
Institute 
--- https://cancer.sanger.ac.uk/cos
mic  
FlowJo v10.2 FlowJo Freeware 
 
Gen5 2.04 BioTek Charité 
 
GraphPad 
Prism 
6.07 GraphPad Software Charité 
 
Illustrator CS6 Adobe Charité 
 
Image Studio 3.1 LI-COR Bioscience Charité 
 
ImageJ 1.48v NIH Freeware 
 
IncuCyte 
Zoom 
2016B Essen BioScience Charité 
 
LAS AF 1.0 Leica Microsystems Charité 
 
Mendeley 
Desktop 
1.17.11 Mendeley Freeware 
 
Microsoft 
Excel 
2016 Microsoft Charité 
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Microsoft 
Word 
2016 Microsoft Charité 
 
Photoshop CS6 Adobe Charité 
 
R 3.2.1 The R Foundation for 
Statistical Computing 
Freeware 
 
R Studio 1.0.44 Rstudio Freeware 
 
SnapGene 
viewer 
4.0.2 GSL Biotech Freeware 
 
StepOne 
Software 
2.3 Applied Biosystems Charité 
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4.2. Methods 
4.2.1. Cell culture 
 
Cell lines were cultured in their respective medium with antibiotic selection as 
indicated in Table 13: Human cell lines and culture conditions with 10% fetal calf serum 
and 1% Penicillin/Streptomycin at 37°C and 5% CO2. Transgene expression was 
induced with 2 µg/ml of doxycycline immediately after seeding the cells (if indicated). 
For drug treatment experiments, transgene expression was induced immediately after 
seeding and drugs were added one night after seeding the cells. Long-term storage of 
all cells was achieved by resuspending the cells in their respective medium and 
10% DMSO without selection antibiotics and freezing them in liquid nitrogen. 
 
4.2.2. Retrovirus production and transduction 
 
Twenty µg of the target plasmid and 7.5 µg of gag plasmid (encoding gag and pol) 
were diluted in a total of 440 µl H2O and incubated at 37 °C for 5 h while shaking. Plat-
E cells were seeded at a confluency of 4x106 cells in a 10 cm dish in 9 ml medium and 
cultured for at least 4 h. When cells were approx. 75% confluent, 10 µl PO4 solution 
was added to 0.5 ml 2x HBS. Then, 60 µl 2 M CaCl2 was mixed with the DNA solution 
and added dropwise to the 2x HBS-PO4 solution while gently shaking. The mixture was 
incubated for 1 min at room temperature and then distributed dropwise onto the cells. 
20 h after the transfection the medium was exchanged and reduced to 5 ml per plate. 
The virus-containing supernatant was harvested 34 h after transfection. At this point, 
the supernatant could be stored for up to two weeks at 4 °C. The virus-containing 
supernatant was then diluted 1:1 with medium and polybrene was added in a dilution 
of 1:1,200 to the final volume before the mixture was added to cell lines (previously 
transduced with a lentivirus containing an ecotropic receptor) for 24 h. 
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4.2.3. RNAi screen 
4.2.3.1. Library transduction and proliferation screen. 
 
CaCo2 cells with doxycycline-inducible KRASG12V were transfected by retroviral 
transduction with a custom-designed shRNA library containing 625 shRNAs against 
121 different targets (Table A 1; purchased from CustomArray Inc. and prepared by 
Kathleen Klotz-Noack, Institute of Pathology, Charité) with less than 20% transduction 
efficiency to predominantly integrate a single shRNA construct per cell. This was 
achieved by diluting the retrovirus library 1:7. Three days after transfection and G418 
selection, a fraction of cells was sorted for mCherry+ cells (shRNA+) using a 
FACSAria II and frozen down as the baseline control. The remaining cells were split in 
half and cultured in the presence or absence of doxycycline for 14 and 21 more days, 
respectively, before the two fractions were sorted for mCherry+ cells and frozen down. 
Before cell sorting, the cell populations were filtered through a 30 µm cell filter. The 
shRNA representation was kept over 1,000x at any given time.  
 
4.2.3.2. Phenol extraction and precipitation of genomic DNA 
 
To isolate the genomic DNA, the sorted cell pellets were resuspended in 400 µl DNA 
extraction buffer. Then, 4 µl 10% SDS and 4 µl proteinase K (20 mg/ml stock) were 
added to the samples. After each addition, the samples were vortexed. Next, the 
samples were incubated at 55 °C in a shaker (800 rpm) for 16.5 h overnight. On the 
next day, the samples were mixed with 400 µl phenol, transferred to PhaseLock tubes, 
and centrifuged at maximum speed for 8 min. The DNA containing aqueous solution 
was transferred to a fresh tube while leaving 30 µl of the aqueous fraction in the tube 
to avoid contamination with the phenol soluble fraction. The phenol extraction was 
repeated two more times while adjusting for the phenol volumes according to the 
current volume of the aqueous fraction. To precipitate the genomic DNA, 31 µl 3 M 
Sodium acetate pH=5.2 (
1
10
 the volume of the aqueous solution), 930 µl 96% ethanol (3 
volumes of the aqueous solution), and 1 µl Pellet Paint Co-Precipitant were added and 
mixed. The DNA was then left to precipitate at -20 °C overnight. On the next day, the 
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DNA samples were centrifuged at maximum speed at 4 °C for 30 min. The resulting 
DNA pellet was then washed with 200 µl 70% ethanol and centrifuged for 5 min at 4 °C. 
The supernatant was discarded and the DNA pellet was air dried for 5 min at 55 °C 
before it was resuspended in 40 µl elution buffer (EB, provided in QIAGEN Plasmid Mini 
Kit). To facilitate resuspension, the DNA solution was incubated for 1.5 h at 55 °C while 
shaking at 800 rpm. The final DNA concentrations across all samples were then 
equilibrated to 0.5 µg/µl. 
 
4.2.3.3. Barcoding and Solexa sequencing sample preparation 
 
Samples were PCR amplified and barcoded (adapter primers: p5 SOLEXA adapter, 
p7loop_XYXY [XYXY = barcoding nucleotides]) according to PCR conditions shown in 
Table 19 and Table 20. To prevent amplification artifacts, each sample was amplified 
in 10 separate reactions and the resulting PCR products were mixed. 
 
Table 19: PCR mix for shRNA cassette amplification and barcoding 
Template DNA 0.5 µg/µl 1.0 µl 
H2O 36.5 µl 
10x PCR buffer 5.0 µl 
MgCl2 3.0 µl 
dNTPs (2 mM each) 1.0 µl 
p7loop_XYXY (fwd) 10 µM 1.5 µl 
p5 SOLEXA adapter (rev) 10 
µM 
1.5 µl 
Amplitaq Gold 0.5 µl 
total 50.0 µl 
 
Table 20: PCR cycling conditions for shRNA cassette amplification and barcoding 
Initial denaturation 95 °C 10 min  
Denaturation 95 °C 30 s  
Primer annealing 52 °C 45 s 33x 
Extension 72 °C 60 s  
Final Extension 72 °C 7 min  
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To purify the amplified DNA, one round of Phenol extraction was performed as 
described in 4.2.3.2 Phenol extraction and precipitation of genomic DNA. The DNA 
pellet was resuspended in 30 µl elution buffer (EB, provided in QIAGEN Plasmid Mini 
Kit) and was run through a 2% agarose gel. The correct band at 345 bp was excised 
and purified using a QIAGEN QIAquick gel extraction kit according to the 
manufacturer’s instructions with following adjustments: samples were incubated for 
10 min after addition of 1 volume isopropanol to increase precipitation, the optional 
washing step with QG buffer was skipped, samples were washed a second time with 
0.5 ml PE buffer, and the DNA was eluted in 30 µl EB after 15 min of incubation at 
ambient temperature. The isolated DNA was then diluted to obtain a concentration of 
100 nM (~22.77 ng/µl for 345 bp) per sample. The abundance of each shRNA was 
assessed by deep sequencing and compared to baseline control. Deep sequencing 
was performed on the Illumina HiSeq 2500 platform by the sequencing unit of the 
Campus Science Support Facilities (CSF), which was renamed to Vienna BioCenter 
Core Facilities GmbH (VBCF) in 2015. Mapping of the raw reads was performed by Dr. 
Bertram Klinger, Institute of Pathology, Charité and IRI Life Sciences, Humboldt 
University. Briefly, BAM files were converted into FASTQ files using BEDtools2 v2.2.3 
(Quinlan and Hall, 2010). Counts were created by perfectly matching inverted reverse 
complement sequences for hairpin and barcode using the processAmplicon function 
of edgeR v3.8.6 (Robinson et al., 2010). Samples were normalized by scaling the total 
count of each sample to the average total count of all samples. All processing steps 
following FASTQ file generation were conducted in R v3.2.1. 
 
4.2.4. Growth assays 
4.2.4.1. Long-term growth assays 
 
Approximately 5x103-1x104 cells/well were seeded in 6 well plates and cultured with 
or without 2 µg/ml doxycycline or additional drugs as indicated in 2 ml medium. Culture 
medium was changed after approximately six days or every three to four days if the 
cells were treated with other drugs than doxycycline. After 10-13 days, cells were fixed 
and stained with 0.2% methylene blue in 50% methanol for 20 min before washing the 
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plates by submerging them in ambient temperature tap water. The final confluency 
was quantified using a custom pipeline in CellProfiler (Carpenter et al., 2006). Results 
were normalized to each respective control (no doxycycline or no drug). 
 
4.2.4.2. Soft agar assays 
 
105 CaCo2 cells or 103 SW480/DLD-1 cells were suspended in one part 37°C warm 2x 
DMEM (CaCo2, SW480) or 2x RPMI-1640 (DLD-1) with their respective selection 
antibiotic and mixed with one part 42°C warm 0.4% Noble Agar in T25 flasks. After 
thorough mixing, the flasks were set on ice for 30 min and subsequently incubated at 
37 °C and 5% CO2 for 3 weeks (SW480, DLD-1) or 5 weeks (CaCo2). All cell lines were 
induced with 2 µg/ml doxycycline at the time of seeding. The number of colonies was 
quantified using a custom pipeline in CellProfiler (Carpenter et al., 2006). 
 
4.2.5. Protein expression analysis 
4.2.5.1. Protein isolation and quantification 
 
Cell lines were seeded at low confluency on 10 cm plates and doxycycline was added 
at different times according to desired end points. All cell lines in a given experiment 
were harvested at the same time. For whole cell extracts, cell pellets were lysed using 
M-PER buffer with PhosSTOP and cOmplete protease inhibitor cocktail for 10 min on 
ice. For chromatin fractionation, the cell pellets were first lysed in CSK buffer 
(+PhosSTOP and cOmplete) for 15 min on ice before centrifuging the samples at 5,000 
g at 4°C for 5 min. The supernatant containing the soluble protein fraction was 
collected and snap frozen in liquid nitrogen. The pellets were washed twice with CSK 
buffer and again snap frozen in liquid nitrogen. After rethawing, the pellets were lysed 
in RIPA buffer (+PhosSTOP and cOmplete) for 10 min on ice. Next, the lysate was 
sonicated twice for 10 min with on/off intervals of 30 s using a Bioruptor before 
centrifuging the lysate at about 20,000 g for 10 min and collecting the supernatant 
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containing the chromatin-bound fraction. Protein concentrations were quantified using 
BCA protein quantification kit according to the manufacturer’s instructions.  
 
4.2.5.2. SDS-PAGE and western blot 
 
Proteins were mixed with 6x SDS sample buffer and boiled for 10 min at 95 °C while 
shaking. After cooling the samples on ice, they were separated by SDS-PAGE using a 
2% stacking gel and 8%, 10%, or 12% separation gel in a Mini-PROTEAN Tetra Handcast 
Systems (Bio-Rad). The gels were run at a voltage of 68 V for 20 min followed by about 
2 h at 110 V. To transfer the protein samples to a nitrocellulose membrane, a semi-dry 
western blot was performed at a current of 0.8 to 1.2 mA/cm² of membrane area 
(about 100 mA per membrane) for 1-1.5 h. The membranes were then blocked with 5% 
milk powder in TBS + 0.1% Tween20 (TBS-T) (blocking buffer) for 1 h at ambient 
temperature. Next, the membranes were rinsed once with TBS-T and incubated with a 
primary antibody in blocking buffer at 4 °C overnight. On the next day, the membranes 
were washed twice with TBS-T before a secondary antibody in blocking buffer was 
added and incubated for 1 h at ambient temperature. The respective antibody dilutions 
are listed in Table 11: Primary antibodies and Table 12: Secondary antibodies. After 
that, the membranes were rinsed with TBS-T and then washed three times with TBS-T 
for 10 min each. Next, the membranes were washed once with TBS, before they were 
analyzed using a LI-COR Odyssey Infrared System 9120 or a Protein Simple FluorChem 
M System. Western blots were quantified using ImageJ 1.48v. 
 
4.2.6. cDNA synthesis and quantitative polymerase chain reaction (qPCR) 
 
Cells were seeded in 6 well plates and induced for two days with doxycycline before 
RNA was collected using a QIAGEN RNeasy Mini kit according to the manufacturer's 
protocol.  
The collected RNA was transcribed to cDNA using the High-Capacity cDNA 
ReverseTranscription Kit. First, 1 µl of anchored-oligo(dT)18 primer and random 
4. Materials and Methods 
97 
hexamer primer each was added to 1 µg RNA in 9.4 µl RNase free H2O and incubated 
at 65 °C for 10 min. Next, 8.6 µl master mix (4 µl buffer, 0.5 µl RNase inhibitor, 
2 µl dNTPs, 1 µl DTT, and 1.1 µl reverse transcriptase) were added to the RNA/primer 
mix. The cDNA synthesis was carried out using the following conditions: 10 min at 
29 °C, 60 min at 48 °C, and 5 min at 85 °C. 
Quantitative PCR (qPCR) was performed using the Promega GoTaq qPCR Master Mix. 
First, the transcribed cDNA was diluted 1:100 in nuclease-free H2O. Then 1 µl of diluted 
cDNA was added to 7.5 µl SybrGreen Master Mix and 5.5 µl nuclease-free H2O. The 
total 14 µl were pipetted on a 96-well PCR plate, before adding 1 µl of the primer mix 
to reach a final primer concentration of 333 nM per primer. All samples were run as 
technical triplicates. The qPCR was run on an Applied Biosystems StepOnePlus Real-
Time PCR System using the cycle conditions in Table 21. 
 
Table 21: qPCR cycling conditions  
Initial denaturation 95 °C 2 min  
Denaturation 95 °C 15 s  
Primer annealing 60 °C 30 s 40x 
 
The Ct values (threshold cycle value) were normalized to the values of the endogenous 
control UBE2D2 (∆Ct values). Next, the ∆Ct values were normalized to the control 
sample (∆∆Ct values). 
 
4.2.7. Cell cycle analysis 
 
Cells were seeded at low confluency and induced with 2 µg/ml doxycycline for 7 days. 
Prior to harvesting, the cells were treated with 20 µM BrdU for 30 min. Afterwards, cells 
were trypsinized, washed twice with PBS and fixed with ice-cold 70% ethanol. Next, 
cells were washed with 1 ml washing buffer (1 % BSA, 0.2 % Triton X-100 in PBS) twice 
and denatured in 2 M HCl + 0.2% Triton-X for 30 min at ambient temperature under 
gentle agitation. Thereafter, cells were washed twice with washing buffer and blocked 
with blocking buffer (5% BSA, 0.2% Triton X-100 in PBS) for 1 h at ambient temperature 
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under gentle agitation. The blocking buffer was replaced with anti-BrdU antibody in 
blocking buffer and incubated for 1 h at ambient temperature under gentle agitation. 
Cells were then washed twice with washing buffer and incubated with anti-mouse 
Alexa Fluor 488 in blocking buffer under gentle agitation. Lastly, cells were washed 
with washing buffer and stained with PI staining solution (50 µg/ml Propidium iodide, 
50 µg/ml RNase, 0.1% Triton X-100 in PBS) for 10-20 min at ambient temperature. 
Samples were analyzed with the BD Accuri™ C6 flow cytometer. Data were analyzed 
with FlowJo v10. 
 
4.2.8. Cleaved Caspase 3 flow cytometry analysis 
 
Cells were cultured in 10 cm plates for 3 days with 2 µg/ml doxycycline. Cells were 
then split and cultured for 4 more days with doxycycline for a total of 7 days. Floating 
and adherent cells were collected and fixed in 1 ml 2% formaldehyde for 10 min at 
ambient temperature before chilling the fixed cells for 1 min on ice. Next, the cells were 
washed with 1 ml PBS and permeabilized in ice-cold 90% methanol on ice for 30 min, 
before storing the cells for up to several weeks at -20 °C. Subsequently, the fixed cells 
were washed twice with incubation buffer (0.5% BSA in PBS) and stained for 1 h with 
an anti-Cleaved Caspase-3 Alexa Fluor® 647 antibody at ambient temperature. Next, 
the cells were washed with 500 µl incubation buffer, resuspended in 200 µl PBS, and 
analyzed with the BD Accuri™ C6 flow cytometer. Data were analyzed with FlowJo v10. 
 
4.2.9. pHH3 and γH2AX flow cytometry analysis 
 
All steps until the addition of the first antibody were performed identically to 
4.2.8 Cleaved Caspase 3 flow cytometry analysis. The cells were then incubated in 
100 µl γH2AX antibody solution (Millipore, 05-636, 1:250 in incubation buffer [0.5% BSA 
in PBS]) at ambient temperature for 1 h. Then, the cells were washed with 500 µl 
incubation buffer by centrifugation before they were incubated with 100 µl anti-mouse 
antibody conjugated to Alexa Fluor 488 in incubation buffer at ambient temperature 
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for 1 h. This was followed by three washing steps in 500 µl incubation buffer, and one 
blocking step for 15-30 min in incubation buffer. After centrifugation, the cells were 
incubated in an 1:50 pHH3-PE in incubation buffer at ambient temperature for 1 h. 
Finally, the cells were washed with 500 µl incubation buffer, centrifuged, resuspended 
in 200 µl PBS, and analyzed with the BD Accuri™ C6 flow cytometer. Data were 
analyzed with FlowJo v10. 
 
4.2.10. Immunofluorescence and confocal microscopy  
 
Cells were seeded and induced with doxycycline 4 days prior fixation on poly-L-lysine 
coated coverslips. For the 7-day time point, cells were pre-induced 3 days before 
seeding. On the day of the staining, cells were washed once with PBS and fixed with 
3% PFA in PBS + 0.1% Triton-X100 for 10 min. (In case of the in situ chromatin 
fractionation of adherent cells for the MCM2 staining, cells were, prior to fixation, 
incubated in ice-cold CSK buffer for 15 min and then washed 2x with CSK buffer and 
1x with PBS.) The fixation buffer was washed off 3x briefly and 2x for 5 min with PBS. 
Next, the cells were permeabilized with 0.3% Triton-X100 in PBS for 2 min before 
washing the cells again 3x briefly and 2x for 5 min with PBS. The cells were 
subsequently incubated in blocking buffer (3% BSA in PBS + 0.1% Tween-20) for 1 h 
before washing them briefly 2x with PBS-T (PBS + 0.1% Tween-20). Next, the cells were 
incubated with the primary antibody in blocking buffer for 1 h, washed 3x for 5 min with 
PBS-T, incubated in the secondary antibody in blocking buffer for 1 h, and washed 
again 3x for 5 min with PBS-T. To visualize DNA, the cells were incubated in 2 µg/ml 
DAPI (in PBS) for 15 min and washed 2x with dH2O. The coverslips were air dried and 
mounted on microscope slides in VECTASHIELD HardSet Mounting Medium and 
stored at 4 °C. All steps were carried out at ambient temperature. Images were taken 
with a Leica TCS SPE confocal system. Image analysis was performed using ImageJ 
(https://imagej.nih.gov/ij/) after projecting the maximum intensity of each z-stack into 
a single image. The “Find Maxima…” tool was used to quantify the number of RPA2 
and γH2AX foci per cell. 
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4.2.11. Nocodazole cell cycle synchronization and release 
 
Cells were seeded on 10 cm dishes and induced with doxycycline for 3 days before 
they were treated with 1 µM nocodazole for 21 h. The cells were then washed three 
times with PBS and 10 ml fresh medium was added. The cells were then harvested by 
trypsinization after 0-8 h in 1 h intervals and washed two times with PBS before fixing 
the cells with ice-cold 70% ethanol. For FACS analysis, the cells were washed twice 
with 1 ml washing buffer (1% BSA, 0.2% Triton X-100 in PBS) and stained for their DNA 
content in 350 µl PI staining solution (50 µg/ml propidium iodide, 50 µg/ml RNase, 
0.1% Triton X-100 in PBS) for 30 min before they were analyzed with the BD Accuri™ 
C6 flow cytometer. Data were analyzed with FlowJo v10. 
 
4.2.12. Knockdown construct cloning and bacterial transformation 
 
97mere DNA oligos containing the shRNA sequence were purchased from Integrated 
DNA Technologies. Johannes Zuber, IMP (Vienna), kindly provided the shRNA 
sequences, which were generated using a proprietary algorithm (Fellmann et al., 2011). 
First, the oligos were PCR amplified with mirE-XhoI and mirE-EcoRI primers to extend 
the sequence for XhoI and EcoRI restriction recognition sites. PCR conditions are listed 
in Table 22 and Table 23. The PCR product was then purified using a QIAquick PCR 
Purification kit according to the manufacturer’s instructions.  
 
Table 22: PCR mix for primer extension of 97mere oligos 
Template DNA (0.1 ng/µl) 1.0 µl 
H2O 29.5 µl 
5X Phusion HF reaction buffer 10.0 µl 
MgCl2 3.0 µl 
dNTPs (10 mM) 1.0 µl 
mirE-XhoI (fwd) 10 mM 2.5 µl 
mirE-EcoRI (rev) 10 mM 2.5 µl 
Phusion DNA Polymerase 0.5 µl 
total 50.0 µl 
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Table 23: PCR cycling conditions for primer extension of 97mere oligos 
Initial denaturation 98 °C 2 min  
Denaturation 98 °C 15 s  
Primer annealing 54 °C 30 s 33x 
Extension 72 °C 25 s  
Final Extension 72 °C 5 min  
 
One µg of the purified PCR product, as well as 2.3 µg of the backbone plasmid p425, 
were then digested with EcoRI and XhoI in NEBuffer 3.1 digestion buffer for 4 h at 
37 °C. The resulting 5’ and 3’ ends of the backbone vector were additionally 
dephosphorylated by adding 1 µl of calf intestinal alkaline phosphatase (CIP) to the 
reaction for 1 h at 37 °C. The digestion of the backbone and insert DNA was next 
separated on a 2% agarose gel and the 131 bp band of the insert as well as the 7,721 
bp band of the backbone were excised and purified using a QIAquick gel extraction kit 
according to the manufacturer’s instructions. Next, the ligation was set up at an insert 
to backbone ratio of 3:1. The ligation reaction was performed using the T4 DNA ligase 
at 15 °C for 16 h before the ligase was inactivated at 65 °C for 10 min. 
To amplify the ligated plasmid, OneShot Stbl3 Escherichia coli were transformed via 
heat shock transformation. First, 50 µl of E. coli suspension was incubated in a 1.5 ml 
reaction tube on ice for 15 min. Next, 5 µl ligation product (~26 ng DNA) were mixed 
with the bacteria suspension by gently flicking the tube. The DNA/bacteria mix was 
then incubated for additional 5 min on ice before applying a heat shocking at 42 °C in 
a water bath for 60 s. The reaction tube was then incubated on ice for 2 min before 
plating the bacteria suspension on a pre-warmed LB agar plate. The LB agar plate 
contained 100 µg/ml ampicillin for the selection of successfully transformed bacteria. 
The plates were incubated at 37 °C overnight. Successfully transformed bacteria 
formed colonies, which were further expanded in LB medium in a shaking incubator at 
37 °C overnight. Plasmid DNA was then isolated using a QIAGEN Plasmid Midi kit. The 
plasmid was then Sanger sequenced by Eurofins Genomics using the ZUB-SEQ-SH 
sequencing primer to assure the sequence was correctly amplified and ligated.  
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4.2.13. Statistical analysis 
 
Unpaired, two-sided Student’s t-tests, Fisher’s exact test, and nonlinear regressions 
were performed using GraphPad Prism 6. To assess statistically significant 
differences in drug sensitivity, the drug concentrations were first transformed on a 
log10 scale. All data points were then normalized in a way that the smallest and highest 
value in each data set represents 0% and 100%, respectively. On these data, a nonlinear 
regression was performed using the corresponding “log(inhibitor) vs. normalized 
response -- Variable slope” setting. The curves were compared using the extra sum-of-
squares F test. Alternatively, the IC50 values of every single replicate were calculated 
individually and subsequently compared via an unpaired, two-sided Student’s t-test. 
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Abbreviations 
2D two-dimensional 
3D three-dimensional 
53BP1 p53-Binding Protein 1 
5-FU 5-fluorouracil  
AF Alexa Fluor™ 
AKT AKT Serine/Threonine Kinase 
APC  Adenomatosis Polyposis Coli Tumor Suppressor 
ATM  Ataxia Telangiectasia Mutated 
ATP Adenosine triphosphate 
ATR Ataxia Telangiectasia And Rad3-Related Protein 
BAD BCL2 Associated Agonist Of Cell Death 
BC before Christ 
bp base pair 
BRCA Breast Cancer 
BrdU  Bromodeoxyuridine 
CDC25 Cell Division Cycle 25 
CDC45 Cell Division Cycle 45 
CDC6 Cell Division Cycle 6 
CDC7 Cell division cycle 7-related protein kinase 
CDK Cyclin-dependent kinase 
CDK1 Cyclin-dependent kinase 1 
CDK2 Cyclin-dependent kinase 2 
CDK4 Cyclin-dependent kinase 4 
CDK6 Cyclin-dependent kinase 6 
cDNA complementary DNA 
CDT1 Chromatin Licensing And DNA Replication Factor 1 
CHK1 Checkpoint Kinase 1 
CHK2 Checkpoint Kinase 2 
CI confidence interval 
CIMP CpG island methylator phenotype  
CIN chromosome instability  
c-JUN Jun proto-oncogene 
clCaspase 3 cleaved Caspase 3 
clPARP cleaved poly(ADP ribose) polymerase 
CMG CDC45-MCM-GINS 
COSMIC  Catalogue of Somatic Mutations in Cancer 
CRC colorectal cancer  
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
CSK Cytoskeletal (buffer) 
DAB2IP DAB2 Interacting Protein 
DAPI 4',6-diamidino-2-phenylindole 
DDK Dbf4-dependent kinase 
DNA deoxyribonucleic acid  
DNA Pol. DNA polymerase 
DNAJC2 DnaJ Heat Shock Protein Family (Hsp40) Member C2 
DNMT1 DNA (cytosine-5)-methyltransferase 1 
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dNTP deoxyribose nucleoside triphosphate  
DOX Doxycycline 
DSB DNA double-strand break  
dsDNA double-stranded DNA 
E2F E2F Transcription Factor 
EGF epidermal growth factor 
EGFR epidermal growth factor receptor  
ELK1 ETS Transcription Factor 
ENO1 Enolase 1 
ERK extracellular signal-regulated kinase 
FACS Fluorescence-activated cell sorting  
FDA  United States Food and Drug Administration 
FITC Fluorescein isothiocyanate 
FOXM1 Forkhead box protein M1 
FTase farnesyltransferase  
GAP GTPase activating protein 
GDP Guanosine diphosphate 
GEF guanine nucleotide exchange factor 
GGTase geranylgeranyltransferase  
GINS DNA Replication Complex GINS 
GLUT1 glucose transporter 1  
GPCR G-protein-coupled-receptors  
GRB2  growth-factor-receptor-bound protein 2 
GSK3 Glycogen Synthase Kinase 3 
GTP  Guanosine triphosphate 
HIF1α hypoxia-inducible factor 1α 
HMGB3 High mobility group protein B3 
HR homologous recombination  
HRAS Harvey rat sarcoma viral oncogene homolog 
IC50 half maximal inhibitory concentration 
ILF2 Interleukin enhancer binding factor 2 
JNK  c-Jun N-terminal kinase 
KLF10 Krueppel-like factor 10 
KRAS Kirsten rat sarcoma viral oncogene homolog 
MAPK Mitogen-activated protein kinase  
MCM Minichromosome Maintenance protein complex 
MCM2 Minichromosome Maintenance Complex Component 2 
MCM7 Minichromosome Maintenance Complex Component 7 
MED8 Mediator of RNA polymerase II transcription subunit 8 
MEK mitogen-activated protein kinase kinase 
MSI microsatellite instability  
mut mutant 
NADP+/NADPH Nicotinamide adenine dinucleotide phosphate 
NHEJ non-homologous end joining  
NOX1 NADPH Oxidase 1 
NOX4 NADPH Oxidase 4 
NRAS neuroblastoma RAS viral oncogene homolog  
NS not significant 
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ORC origin recognition complex  
p90RSK p90 ribosomal s6 kinase 
PARP poly (ADP-ribose) polymerase  
PCNA Proliferating Cell Nuclear Antigen 
PCR Polymerase chain reaction 
PDAC Pancreatic ductal adenocarcinoma 
PDEδ phosphodiesterase δ 
Pen/Strep Penicillin/Streptomycin 
PI3K Phosphatidylinositol 3-kinase 
PKC Protein Kinase C 
PLCε 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase ε 
PLD Phospholipase D 
PPP1R15A Protein phosphatase 1 regulatory subunit 15A 
PPP2R5A Protein Phosphatase 2 Regulatory Subunit B'Alpha 
PPP2R5B Protein Phosphatase 2 Regulatory Subunit B'Beta 
PPP2R5E Protein Phosphatase 2 Regulatory Subunit B'Epsilon 
pre-RC pre-replication complex 
PTEN Phosphatase And Tensin Homolog 
qPCR quantitative polymerase chain reaction 
RAF rat fibrosarcoma 
RAL RAS Like Proto-Oncogene 
RALGDS Ral guanine nucleotide dissociation stimulator 
RAS rat sarcoma 
RASA4 RAS P21 Protein Activator 4 
Rb Retinoblastoma 
RIPA Radioimmunoprecipitation assay (buffer) 
RNA ribonucleic acid 
RNAi RNA interference 
ROS reactive oxygen species  
RPA replication protein A 
RTK receptor tyrosine kinase 
scrbl scrambled shRNA 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
shRNA short hairpin RNA  
SOS son of sevenless 
SPRY1 Sprouty RTK Signaling Antagonist 1 
SSB single-strand break 
ssDNA single-stranded DNA 
TCA cycle tricarboxylic acid cycle 
TP53 Tumor Protein P53 
VEGFR vascular endothelial growth factor receptor 
WBP11 WW Domain Binding Protein 11 
wt wild-type 
XRCC6 X-ray repair cross-complementing protein 6 
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Appendix 
Table A 1: shRNAs contained in shRNA library 
Gene shRNA name Guide 97mer 
DUSP4 DUSP4.1283 TTAAGCATAATTATTCATCTGT TGCTGTTGACAGTGAGCGCCAGATGAATAAT
TATGCTTAATAGTGAAGCCACAGATGTATTA
AGCATAATTATTCATCTGTTGCCTACTGCCT
CGGA 
DUSP4 DUSP4.31 TTTTAGAACAGAATTCTGGGTA TGCTGTTGACAGTGAGCGCACCCAGAATTCT
GTTCTAAAATAGTGAAGCCACAGATGTATTT
TAGAACAGAATTCTGGGTATGCCTACTGCCT
CGGA 
DUSP4 DUSP4.1193 TACAACAACGACAACAAAGGGA TGCTGTTGACAGTGAGCGCCCCTTTGTTGTC
GTTGTTGTATAGTGAAGCCACAGATGTATAC
AACAACGACAACAAAGGGATGCCTACTGCC
TCGGA 
DUSP4 DUSP4.1545 TTAAAAAGCAATTCAAACCTAA TGCTGTTGACAGTGAGCGCTAGGTTTGAATT
GCTTTTTAATAGTGAAGCCACAGATGTATTA
AAAAGCAATTCAAACCTAATGCCTACTGCCT
CGGA 
DUSP4 DUSP4.2934 TATTTCTAGAGGAAGCAGGGAG TGCTGTTGACAGTGAGCGATCCCTGCTTCCT
CTAGAAATATAGTGAAGCCACAGATGTATAT
TTCTAGAGGAAGCAGGGAGTGCCTACTGCC
TCGGA 
DUSP6 DUSP6.1299 TTGTCTAGTACAGACAGCTGGT TGCTGTTGACAGTGAGCGCCCAGCTGTCTGT
ACTAGACAATAGTGAAGCCACAGATGTATTG
TCTAGTACAGACAGCTGGTTGCCTACTGCCT
CGGA 
DUSP6 DUSP6.1902 TTAGTGATAATAGTGTCCGTAA TGCTGTTGACAGTGAGCGCTACGGACACTAT
TATCACTAATAGTGAAGCCACAGATGTATTA
GTGATAATAGTGTCCGTAATGCCTACTGCCT
CGGA 
DUSP6 DUSP6.1330 TTAGTATTAACCAATTCCGCAC TGCTGTTGACAGTGAGCGATGCGGAATTGG
TTAATACTAATAGTGAAGCCACAGATGTATT
AGTATTAACCAATTCCGCACTGCCTACTGCC
TCGGA 
DUSP6 DUSP6.1382 TATCTATACAGCATGTCCTGTT TGCTGTTGACAGTGAGCGCACAGGACATGC
TGTATAGATATAGTGAAGCCACAGATGTATA
TCTATACAGCATGTCCTGTTTGCCTACTGCC
TCGGA 
DUSP6 DUSP6.2099 TATACTGTTTAGCACAGCTGAA TGCTGTTGACAGTGAGCGCTCAGCTGTGCTA
AACAGTATATAGTGAAGCCACAGATGTATAT
ACTGTTTAGCACAGCTGAATGCCTACTGCCT
CGGA 
ELK1 ELK1.447 TTGTAGACGAACTTCTGGCCGC TGCTGTTGACAGTGAGCGACGGCCAGAAGT
TCGTCTACAATAGTGAAGCCACAGATGTATT
GTAGACGAACTTCTGGCCGCTGCCTACTGCC
TCGGA 
ELK1 ELK1.1078 TAACTCTTCTACTCACATCCAA TGCTGTTGACAGTGAGCGCTGGATGTGAGT
AGAAGAGTTATAGTGAAGCCACAGATGTATA
ACTCTTCTACTCACATCCAATGCCTACTGCC
TCGGA 
ELK1 ELK1.408 TTCTTGTCATAGTAGTACCGCA TGCTGTTGACAGTGAGCGCGCGGTACTACTA
TGACAAGAATAGTGAAGCCACAGATGTATTC
TTGTCATAGTAGTACCGCATGCCTACTGCCT
CGGA 
ELK1 ELK1.1708 TTGCCTAGAATAGAGACAGGAC TGCTGTTGACAGTGAGCGATCCTGTCTCTAT
TCTAGGCAATAGTGAAGCCACAGATGTATTG
CCTAGAATAGAGACAGGACTGCCTACTGCC
TCGGA 
ELK1 ELK1.1488 TATAGGAAGAGATGACTCCCTC TGCTGTTGACAGTGAGCGAAGGGAGTCATC
TCTTCCTATATAGTGAAGCCACAGATGTATA
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TAGGAAGAGATGACTCCCTCTGCCTACTGCC
TCGGA 
MAPK1 MAPK1.1316 TTTAAGATCTGTATCCTGGCTG TGCTGTTGACAGTGAGCGAAGCCAGGATAC
AGATCTTAAATAGTGAAGCCACAGATGTATT
TAAGATCTGTATCCTGGCTGTGCCTACTGCC
TCGGA 
MAPK1 MAPK1.1233 TCCATGTCGAACTTGAATGGTG TGCTGTTGACAGTGAGCGAACCATTCAAGTT
CGACATGGATAGTGAAGCCACAGATGTATC
CATGTCGAACTTGAATGGTGTGCCTACTGCC
TCGGA 
MAPK1 MAPK1.1121 TGAATGTCAACATTTTGTCCAA TGCTGTTGACAGTGAGCGCTGGACAAAATGT
TGACATTCATAGTGAAGCCACAGATGTATGA
ATGTCAACATTTTGTCCAATGCCTACTGCCT
CGGA 
MAPK1 MAPK1.528 TTCATTTGCTCGATGGTTGGTG TGCTGTTGACAGTGAGCGAACCAACCATCG
AGCAAATGAATAGTGAAGCCACAGATGTATT
CATTTGCTCGATGGTTGGTGTGCCTACTGCC
TCGGA 
MAPK1 MAPK1.537 TATACATCTTTCATTTGCTCGA TGCTGTTGACAGTGAGCGCCGAGCAAATGA
AAGATGTATATAGTGAAGCCACAGATGTATA
TACATCTTTCATTTGCTCGATGCCTACTGCC
TCGGA 
MAPK3 MAPK3.1741 TATATTTATATATTAGACGGGT TGCTGTTGACAGTGAGCGCCCCGTCTAATAT
ATAAATATATAGTGAAGCCACAGATGTATAT
ATTTATATATTAGACGGGTTGCCTACTGCCT
CGGA 
MAPK3 MAPK3.1200 TTTTCTAACAGTCTGGCGGGAG TGCTGTTGACAGTGAGCGATCCCGCCAGAC
TGTTAGAAAATAGTGAAGCCACAGATGTATT
TTCTAACAGTCTGGCGGGAGTGCCTACTGCC
TCGGA 
MAPK3 MAPK3.912 TAAAGGTTAACATCCGGTCCAG TGCTGTTGACAGTGAGCGATGGACCGGATG
TTAACCTTTATAGTGAAGCCACAGATGTATA
AAGGTTAACATCCGGTCCAGTGCCTACTGCC
TCGGA 
MAPK3 MAPK3.751 TTGGAGTTCAGCATGATCTCTG TGCTGTTGACAGTGAGCGAAGAGATCATGCT
GAACTCCAATAGTGAAGCCACAGATGTATTG
GAGTTCAGCATGATCTCTGTGCCTACTGCCT
CGGA 
MAPK3 MAPK3.616 TTGATGAGCAGGTTGGAGGGCT TGCTGTTGACAGTGAGCGCGCCCTCCAACCT
GCTCATCAATAGTGAAGCCACAGATGTATTG
ATGAGCAGGTTGGAGGGCTTGCCTACTGCC
TCGGA 
SRF SRF.2720 TTTGTTTTCACTTCGTCTCCTC TGCTGTTGACAGTGAGCGAAGGAGACGAAG
TGAAAACAAATAGTGAAGCCACAGATGTATT
TGTTTTCACTTCGTCTCCTCTGCCTACTGCC
TCGGA 
SRF SRF.901 TCCATCTTGATCTTCACGCGGC TGCTGTTGACAGTGAGCGACCGCGTGAAGA
TCAAGATGGATAGTGAAGCCACAGATGTATC
CATCTTGATCTTCACGCGGCTGCCTACTGCC
TCGGA 
SRF SRF.85 TAAAGAGATACAATGTTTCCTT TGCTGTTGACAGTGAGCGCAGGAAACATTGT
ATCTCTTTATAGTGAAGCCACAGATGTATAA
AGAGATACAATGTTTCCTTTGCCTACTGCCT
CGGA 
SRF SRF.3603 TTCACCTAATCACAGAAGCCAG TGCTGTTGACAGTGAGCGATGGCTTCTGTGA
TTAGGTGAATAGTGAAGCCACAGATGTATTC
ACCTAATCACAGAAGCCAGTGCCTACTGCCT
CGGA 
SRF SRF.1868 TGAAACAGGGATCTGCACTGTC TGCTGTTGACAGTGAGCGAACAGTGCAGAT
CCCTGTTTCATAGTGAAGCCACAGATGTATG
AAACAGGGATCTGCACTGTCTGCCTACTGCC
TCGGA 
AATF AATF.1732 TTTTGCTTCGTAACTTCTGGAT TGCTGTTGACAGTGAGCGCTCCAGAAGTTAC
GAAGCAAAATAGTGAAGCCACAGATGTATTT
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TGCTTCGTAACTTCTGGATTGCCTACTGCCT
CGGA 
AATF AATF.1150 TAGATATCTAGTGTCTGGGTAC TGCTGTTGACAGTGAGCGATACCCAGACACT
AGATATCTATAGTGAAGCCACAGATGTATAG
ATATCTAGTGTCTGGGTACTGCCTACTGCCT
CGGA 
AATF AATF.968 TTTTGTAGTTTGATCCTTCCTT TGCTGTTGACAGTGAGCGCAGGAAGGATCA
AACTACAAAATAGTGAAGCCACAGATGTATT
TTGTAGTTTGATCCTTCCTTTGCCTACTGCC
TCGGA 
AATF AATF.1152 TACTAGATATCTAGTGTCTGGG TGCTGTTGACAGTGAGCGACCAGACACTAG
ATATCTAGTATAGTGAAGCCACAGATGTATA
CTAGATATCTAGTGTCTGGGTGCCTACTGCC
TCGGA 
AATF AATF.1223 TTCTTCTCTTCTACCAGCTCAT TGCTGTTGACAGTGAGCGCTGAGCTGGTAG
AAGAGAAGAATAGTGAAGCCACAGATGTAT
TCTTCTCTTCTACCAGCTCATTGCCTACTGC
CTCGGA 
ANKRD5
7 
ANKRD57.224
6 
TTGCATTTCAACTTTGATCTGA TGCTGTTGACAGTGAGCGCCAGATCAAAGTT
GAAATGCAATAGTGAAGCCACAGATGTATTG
CATTTCAACTTTGATCTGATGCCTACTGCCT
CGGA 
ANKRD5
7 
ANKRD57.297
4 
TTAAATATAGAAATAGTCCCAT TGCTGTTGACAGTGAGCGCTGGGACTATTTC
TATATTTAATAGTGAAGCCACAGATGTATTA
AATATAGAAATAGTCCCATTGCCTACTGCCT
CGGA 
ANKRD5
7 
ANKRD57.366
7 
TTTTGAGACAGAGTCTCCGTTG TGCTGTTGACAGTGAGCGAAACGGAGACTC
TGTCTCAAAATAGTGAAGCCACAGATGTATT
TTGAGACAGAGTCTCCGTTGTGCCTACTGCC
TCGGA 
AREG AREG.517 TTAACTACCTGTTCAACTCTGA TGCTGTTGACAGTGAGCGCCAGAGTTGAAC
AGGTAGTTAATAGTGAAGCCACAGATGTATT
AACTACCTGTTCAACTCTGATGCCTACTGCC
TCGGA 
AREG AREG.677 TATATATTTGCATTCTCCGTGA TGCTGTTGACAGTGAGCGCCACGGAGAATG
CAAATATATATAGTGAAGCCACAGATGTATA
TATATTTGCATTCTCCGTGATGCCTACTGCC
TCGGA 
AREG AREG.868 TTGTCTTCTAAGCTGGACTGTA TGCTGTTGACAGTGAGCGCACAGTCCAGCTT
AGAAGACAATAGTGAAGCCACAGATGTATT
GTCTTCTAAGCTGGACTGTATGCCTACTGCC
TCGGA 
AREG AREG.850 TGTAATAACAGCAACAGCTGTG TGCTGTTGACAGTGAGCGAACAGCTGTTGCT
GTTATTACATAGTGAAGCCACAGATGTATGT
AATAACAGCAACAGCTGTGTGCCTACTGCCT
CGGA 
AREG AREG.460 TTCGTTATCATACTCTTCTGAG TGCTGTTGACAGTGAGCGATCAGAAGAGTAT
GATAACGAATAGTGAAGCCACAGATGTATTC
GTTATCATACTCTTCTGAGTGCCTACTGCCT
CGGA 
ARNTL2 ARNTL2.1018 TTGTCTTTCTTACTGTTCCTTT TGCTGTTGACAGTGAGCGCAAGGAACAGTA
AGAAAGACAATAGTGAAGCCACAGATGTAT
TGTCTTTCTTACTGTTCCTTTTGCCTACTGC
CTCGGA 
ARNTL2 ARNTL2.674 TTGTCCAGTCAAACTAGCCTGA TGCTGTTGACAGTGAGCGCCAGGCTAGTTTG
ACTGGACAATAGTGAAGCCACAGATGTATTG
TCCAGTCAAACTAGCCTGATGCCTACTGCCT
CGGA 
ARNTL2 ARNTL2.111 TAGCTGTTGGTCTTGTCCCTGG TGCTGTTGACAGTGAGCGACAGGGACAAGA
CCAACAGCTATAGTGAAGCCACAGATGTATA
GCTGTTGGTCTTGTCCCTGGTGCCTACTGCC
TCGGA 
ARNTL2 ARNTL2.2192 TATGTAAGTAGTATTCTTGGTT TGCTGTTGACAGTGAGCGCACCAAGAATACT
ACTTACATATAGTGAAGCCACAGATGTATAT
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GTAAGTAGTATTCTTGGTTTGCCTACTGCCT
CGGA 
ARNTL2 ARNTL2.3342 TTTTGTTTTATTACCTTTGGTT TGCTGTTGACAGTGAGCGCACCAAAGGTAA
TAAAACAAAATAGTGAAGCCACAGATGTATT
TTGTTTTATTACCTTTGGTTTGCCTACTGCC
TCGGA 
ATAD2 ATAD2.1342 TTGCATTGGATCAACATCGGCA TGCTGTTGACAGTGAGCGCGCCGATGTTGAT
CCAATGCAATAGTGAAGCCACAGATGTATTG
CATTGGATCAACATCGGCATGCCTACTGCCT
CGGA 
ATAD2 ATAD2.569 TAATCCTACAACTTCGACGCAC TGCTGTTGACAGTGAGCGATGCGTCGAAGTT
GTAGGATTATAGTGAAGCCACAGATGTATAA
TCCTACAACTTCGACGCACTGCCTACTGCCT
CGGA 
ATAD2 ATAD2.1599 TACTTAGACAATCAGCACCTTT TGCTGTTGACAGTGAGCGCAAGGTGCTGATT
GTCTAAGTATAGTGAAGCCACAGATGTATAC
TTAGACAATCAGCACCTTTTGCCTACTGCCT
CGGA 
ATAD2 ATAD2.4380 TACTATTTTAATCTTTTCCTTA TGCTGTTGACAGTGAGCGCAAGGAAAAGAT
TAAAATAGTATAGTGAAGCCACAGATGTATA
CTATTTTAATCTTTTCCTTATGCCTACTGCCT
CGGA 
ATAD2 ATAD2.3499 TTTATCACCAACAAGAGTGGAA TGCTGTTGACAGTGAGCGCTCCACTCTTGTT
GGTGATAAATAGTGAAGCCACAGATGTATTT
ATCACCAACAAGAGTGGAATGCCTACTGCCT
CGGA 
BARD1 BARD1.548 TTTAATTGAATTCTTCTTGTTT TGCTGTTGACAGTGAGCGCAACAAGAAGAA
TTCAATTAAATAGTGAAGCCACAGATGTATT
TAATTGAATTCTTCTTGTTTTGCCTACTGCC
TCGGA 
BARD1 BARD1.1690 TATATTAACAGCATTTCTGGAG TGCTGTTGACAGTGAGCGATCCAGAAATGCT
GTTAATATATAGTGAAGCCACAGATGTATAT
ATTAACAGCATTTCTGGAGTGCCTACTGCCT
CGGA 
BARD1 BARD1.543 TTGAATTCTTCTTGTTTCCTGC TGCTGTTGACAGTGAGCGACAGGAAACAAG
AAGAATTCAATAGTGAAGCCACAGATGTATT
GAATTCTTCTTGTTTCCTGCTGCCTACTGCC
TCGGA 
BARD1 BARD1.582 TATCTGACTTTCTTACTTCGAG TGCTGTTGACAGTGAGCGATCGAAGTAAGA
AAGTCAGATATAGTGAAGCCACAGATGTATA
TCTGACTTTCTTACTTCGAGTGCCTACTGCC
TCGGA 
BARD1 BARD1.1647 TTGACTATATCCACATGCCCAT TGCTGTTGACAGTGAGCGCTGGGCATGTGG
ATATAGTCAATAGTGAAGCCACAGATGTATT
GACTATATCCACATGCCCATTGCCTACTGCC
TCGGA 
BAZ1A BAZ1A.1434 TTTATTAGCAACATTGTCCTCT TGCTGTTGACAGTGAGCGCGAGGACAATGT
TGCTAATAAATAGTGAAGCCACAGATGTATT
TATTAGCAACATTGTCCTCTTGCCTACTGCC
TCGGA 
BAZ1A BAZ1A.5651 TAAACTTGGACTTAATACCTGC TGCTGTTGACAGTGAGCGACAGGTATTAAGT
CCAAGTTTATAGTGAAGCCACAGATGTATAA
ACTTGGACTTAATACCTGCTGCCTACTGCCT
CGGA 
BAZ1A BAZ1A.4264 TAACTTGTGGTCTTCCTCGTTT TGCTGTTGACAGTGAGCGCAACGAGGAAGA
CCACAAGTTATAGTGAAGCCACAGATGTATA
ACTTGTGGTCTTCCTCGTTTTGCCTACTGCC
TCGGA 
BAZ1A BAZ1A.5297 TATCTTTCCTACATTCTCCTGA TGCTGTTGACAGTGAGCGCCAGGAGAATGT
AGGAAAGATATAGTGAAGCCACAGATGTAT
ATCTTTCCTACATTCTCCTGATGCCTACTGC
CTCGGA 
BAZ1A BAZ1A.4218 TTGAGAGTCATCTTCATCTTGT TGCTGTTGACAGTGAGCGCCAAGATGAAGA
TGACTCTCAATAGTGAAGCCACAGATGTATT
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GAGAGTCATCTTCATCTTGTTGCCTACTGCC
TCGGA 
BAZ1B BAZ1B.5150 TAAACATTTAAATTCTTCCTGC TGCTGTTGACAGTGAGCGACAGGAAGAATTT
AAATGTTTATAGTGAAGCCACAGATGTATAA
ACATTTAAATTCTTCCTGCTGCCTACTGCCT
CGGA 
BAZ1B BAZ1B.3381 TTGACTTTCTCTTATTCCCTGA TGCTGTTGACAGTGAGCGCCAGGGAATAAG
AGAAAGTCAATAGTGAAGCCACAGATGTATT
GACTTTCTCTTATTCCCTGATGCCTACTGCC
TCGGA 
BAZ1B BAZ1B.2041 TTTCTTTCTCTCTTCGTTCTTT TGCTGTTGACAGTGAGCGCAAGAACGAAGA
GAGAAAGAAATAGTGAAGCCACAGATGTAT
TTCTTTCTCTCTTCGTTCTTTTGCCTACTGCC
TCGGA 
BAZ1B BAZ1B.2230 TAATAGGATACTGAGCATCTGG TGCTGTTGACAGTGAGCGACAGATGCTCAGT
ATCCTATTATAGTGAAGCCACAGATGTATAA
TAGGATACTGAGCATCTGGTGCCTACTGCCT
CGGA 
BAZ1B BAZ1B.3695 TTTTCTTCTCTTTTGCTTGGGA TGCTGTTGACAGTGAGCGCCCCAAGCAAAA
GAGAAGAAAATAGTGAAGCCACAGATGTAT
TTTCTTCTCTTTTGCTTGGGATGCCTACTGC
CTCGGA 
BRCA1 BRCA1.656 TTCAGTATTTGTTACATCCGTC TGCTGTTGACAGTGAGCGAACGGATGTAAC
AAATACTGAATAGTGAAGCCACAGATGTATT
CAGTATTTGTTACATCCGTCTGCCTACTGCC
TCGGA 
BRCA1 BRCA1.2561 TAAACTTAGGGAAACCAGCTAT TGCTGTTGACAGTGAGCGCTAGCTGGTTTCC
CTAAGTTTATAGTGAAGCCACAGATGTATAA
ACTTAGGGAAACCAGCTATTGCCTACTGCCT
CGGA 
BRCA1 BRCA1.1108 TTTTACTGGTAGAACTATCTGC TGCTGTTGACAGTGAGCGACAGATAGTTCTA
CCAGTAAAATAGTGAAGCCACAGATGTATTT
TACTGGTAGAACTATCTGCTGCCTACTGCCT
CGGA 
BRCA1 BRCA1.37 TTTTGTACTTCTTCAACGCGAA TGCTGTTGACAGTGAGCGCTCGCGTTGAAG
AAGTACAAAATAGTGAAGCCACAGATGTATT
TTGTACTTCTTCAACGCGAATGCCTACTGCC
TCGGA 
BRCA1 BRCA1.190 TAAATCTCGTACTTTCTTGTAG TGCTGTTGACAGTGAGCGATACAAGAAAGT
ACGAGATTTATAGTGAAGCCACAGATGTATA
AATCTCGTACTTTCTTGTAGTGCCTACTGCC
TCGGA 
CBFB CBFB.3057 TAAACAAACAAACACACAGTAT TGCTGTTGACAGTGAGCGCTACTGTGTGTTT
GTTTGTTTATAGTGAAGCCACAGATGTATAA
ACAAACAAACACACAGTATTGCCTACTGCCT
CGGA 
CBFB CBFB.2451 TAACAATTTAAACACACTCCTT TGCTGTTGACAGTGAGCGCAGGAGTGTGTTT
AAATTGTTATAGTGAAGCCACAGATGTATAA
CAATTTAAACACACTCCTTTGCCTACTGCCT
CGGA 
CBFB CBFB.507 TCTAAGTCGACATACTCTCGGC TGCTGTTGACAGTGAGCGACCGAGAGTATG
TCGACTTAGATAGTGAAGCCACAGATGTATC
TAAGTCGACATACTCTCGGCTGCCTACTGCC
TCGGA 
CBFB CBFB.665 TTGTGCTAATGCATCCTCCTGC TGCTGTTGACAGTGAGCGACAGGAGGATGC
ATTAGCACAATAGTGAAGCCACAGATGTATT
GTGCTAATGCATCCTCCTGCTGCCTACTGCC
TCGGA 
CBFB CBFB.2457 AACAATTTAAACACACTCCTTT TGCTGTTGACAGTGAGCGCAAGGAGTGTGT
TTAAATTGTTTAGTGAAGCCACAGATGTAAA
CAATTTAAACACACTCCTTTTGCCTACTGCC
TCGGA 
CBX3 CBX3.1941 TTTAATGAGACAATTGACCCTA TGCTGTTGACAGTGAGCGCAGGGTCAATTGT
CTCATTAAATAGTGAAGCCACAGATGTATTT
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AATGAGACAATTGACCCTATGCCTACTGCCT
CGGA 
CBX3 CBX3.560 TTATTGAGCTTCATCTTCTGGA TGCTGTTGACAGTGAGCGCCCAGAAGATGA
AGCTCAATAATAGTGAAGCCACAGATGTATT
ATTGAGCTTCATCTTCTGGATGCCTACTGCC
TCGGA 
CBX3 CBX3.1278 TTGTCTAGTTTCCTCATCTGGA TGCTGTTGACAGTGAGCGCCCAGATGAGGA
AACTAGACAATAGTGAAGCCACAGATGTATT
GTCTAGTTTCCTCATCTGGATGCCTACTGCC
TCGGA 
CBX3 CBX3.1081 TTATCTCTTATTTTGCTTGGAA TGCTGTTGACAGTGAGCGCTCCAAGCAAAAT
AAGAGATAATAGTGAAGCCACAGATGTATTA
TCTCTTATTTTGCTTGGAATGCCTACTGCCT
CGGA 
CBX3 CBX3.628 TAAATCAAAATCTAAGACCCAA TGCTGTTGACAGTGAGCGCTGGGTCTTAGAT
TTTGATTTATAGTGAAGCCACAGATGTATAA
ATCAAAATCTAAGACCCAATGCCTACTGCCT
CGGA 
CHAF1A CHAF1A.1387 TTCTCTTCTTCTCTTAACCGTT TGCTGTTGACAGTGAGCGCACGGTTAAGAG
AAGAAGAGAATAGTGAAGCCACAGATGTAT
TCTCTTCTTCTCTTAACCGTTTGCCTACTGC
CTCGGA 
CHAF1A CHAF1A.3082 TAGAACTCTGCACACTTTGGGG TGCTGTTGACAGTGAGCGACCCAAAGTGTG
CAGAGTTCTATAGTGAAGCCACAGATGTATA
GAACTCTGCACACTTTGGGGTGCCTACTGCC
TCGGA 
CHAF1A CHAF1A.182 TTGTATTAACTTCTTAACTGGA TGCTGTTGACAGTGAGCGCCCAGTTAAGAA
GTTAATACAATAGTGAAGCCACAGATGTATT
GTATTAACTTCTTAACTGGATGCCTACTGCC
TCGGA 
CHAF1A CHAF1A.1374 TAACCGTTTCTCTTCTTCCTTT TGCTGTTGACAGTGAGCGCAAGGAAGAAGA
GAAACGGTTATAGTGAAGCCACAGATGTATA
ACCGTTTCTCTTCTTCCTTTTGCCTACTGCC
TCGGA 
CHAF1A CHAF1A.3031 TTACACAGGAATTGAGTCGGTT TGCTGTTGACAGTGAGCGCACCGACTCAATT
CCTGTGTAATAGTGAAGCCACAGATGTATTA
CACAGGAATTGAGTCGGTTTGCCTACTGCCT
CGGA 
CTNNBL
1 
CTNNBL1.388 TTGTCTGGAAACTTAATCCGCA TGCTGTTGACAGTGAGCGCGCGGATTAAGTT
TCCAGACAATAGTGAAGCCACAGATGTATTG
TCTGGAAACTTAATCCGCATGCCTACTGCCT
CGGA 
CTNNBL
1 
CTNNBL1.961 TTAAACACGGATAACTGCTGAA TGCTGTTGACAGTGAGCGCTCAGCAGTTATC
CGTGTTTAATAGTGAAGCCACAGATGTATTA
AACACGGATAACTGCTGAATGCCTACTGCCT
CGGA 
CTNNBL
1 
CTNNBL1.182
8 
TTGTGTAGAAACTGATCCTGGG TGCTGTTGACAGTGAGCGACCAGGATCAGTT
TCTACACAATAGTGAAGCCACAGATGTATTG
TGTAGAAACTGATCCTGGGTGCCTACTGCCT
CGGA 
CTNNBL
1 
CTNNBL1.165
3 
TTTTGATGGAGCTTCCTCGCAT TGCTGTTGACAGTGAGCGCTGCGAGGAAGC
TCCATCAAAATAGTGAAGCCACAGATGTATT
TTGATGGAGCTTCCTCGCATTGCCTACTGCC
TCGGA 
CTNNBL
1 
CTNNBL1.149
5 
TTGTCGATGATCTCTCCTCGCC TGCTGTTGACAGTGAGCGAGCGAGGAGAGA
TCATCGACAATAGTGAAGCCACAGATGTATT
GTCGATGATCTCTCCTCGCCTGCCTACTGCC
TCGGA 
DAB2IP DAB2IP.2670 TCGTCTTCTAACAACTGCGCGT TGCTGTTGACAGTGAGCGCCGCGCAGTTGTT
AGAAGACGATAGTGAAGCCACAGATGTATC
GTCTTCTAACAACTGCGCGTTGCCTACTGCC
TCGGA 
DAB2IP DAB2IP.468 TTCTTCTTGTCGGTCTCCCGGT TGCTGTTGACAGTGAGCGCCCGGGAGACCG
ACAAGAAGAATAGTGAAGCCACAGATGTAT
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TCTTCTTGTCGGTCTCCCGGTTGCCTACTGC
CTCGGA 
DAB2IP DAB2IP.2316 TTTTCAGTCAGTGACATCTGTC TGCTGTTGACAGTGAGCGAACAGATGTCACT
GACTGAAAATAGTGAAGCCACAGATGTATTT
TCAGTCAGTGACATCTGTCTGCCTACTGCCT
CGGA 
DAB2IP DAB2IP.411 TTGTGGAACTCGAAGTGCTCGC TGCTGTTGACAGTGAGCGACGAGCACTTCG
AGTTCCACAATAGTGAAGCCACAGATGTATT
GTGGAACTCGAAGTGCTCGCTGCCTACTGC
CTCGGA 
DAB2IP DAB2IP.957 TACAGCGCTTTGATGAACTCAC TGCTGTTGACAGTGAGCGATGAGTTCATCAA
AGCGCTGTATAGTGAAGCCACAGATGTATAC
AGCGCTTTGATGAACTCACTGCCTACTGCCT
CGGA 
DDX54 DDX54.301 TTCTTCTTCTTCTTGTTCTGGG TGCTGTTGACAGTGAGCGACCAGAACAAGA
AGAAGAAGAATAGTGAAGCCACAGATGTAT
TCTTCTTCTTCTTGTTCTGGGTGCCTACTGC
CTCGGA 
DDX54 DDX54.421 TTGCCATCCAAGATCACCGGGA TGCTGTTGACAGTGAGCGCCCCGGTGATCTT
GGATGGCAATAGTGAAGCCACAGATGTATT
GCCATCCAAGATCACCGGGATGCCTACTGC
CTCGGA 
DDX54 DDX54.2274 TAATCTTCTTCTTGTCTTCCTG TGCTGTTGACAGTGAGCGAAGGAAGACAAG
AAGAAGATTATAGTGAAGCCACAGATGTATA
ATCTTCTTCTTGTCTTCCTGTGCCTACTGCC
TCGGA 
DDX54 DDX54.1756 TTGATCTCAAAGATAGTCGCCC TGCTGTTGACAGTGAGCGAGGCGACTATCTT
TGAGATCAATAGTGAAGCCACAGATGTATTG
ATCTCAAAGATAGTCGCCCTGCCTACTGCCT
CGGA 
DDX54 DDX54.2269 TTCTTCTTGTCTTCCTGTCCTG TGCTGTTGACAGTGAGCGAAGGACAGGAAG
ACAAGAAGAATAGTGAAGCCACAGATGTAT
TCTTCTTGTCTTCCTGTCCTGTGCCTACTGC
CTCGGA 
DEK DEK.2225 TTAGTCATAATCGTGAAGCTGG TGCTGTTGACAGTGAGCGACAGCTTCACGAT
TATGACTAATAGTGAAGCCACAGATGTATTA
GTCATAATCGTGAAGCTGGTGCCTACTGCCT
CGGA 
DEK DEK.398 TAGATTTCTAAGTTCATCGGTT TGCTGTTGACAGTGAGCGCACCGATGAACTT
AGAAATCTATAGTGAAGCCACAGATGTATAG
ATTTCTAAGTTCATCGGTTTGCCTACTGCCT
CGGA 
DEK DEK.448 TTAATGAGGACACAGTGCCTGG TGCTGTTGACAGTGAGCGACAGGCACTGTG
TCCTCATTAATAGTGAAGCCACAGATGTATT
AATGAGGACACAGTGCCTGGTGCCTACTGC
CTCGGA 
DEK DEK.508 TTTTATATTGGACACTTCCTTT TGCTGTTGACAGTGAGCGCAAGGAAGTGTC
CAATATAAAATAGTGAAGCCACAGATGTATT
TTATATTGGACACTTCCTTTTGCCTACTGCC
TCGGA 
DEK DEK.829 TTTCTTTATCTTCATCATCTGA TGCTGTTGACAGTGAGCGCCAGATGATGAA
GATAAAGAAATAGTGAAGCCACAGATGTATT
TCTTTATCTTCATCATCTGATGCCTACTGCC
TCGGA 
DNAJC2 DNAJC2.1165 TTCTTTAGCTTCTTGCTCCTTC TGCTGTTGACAGTGAGCGAAAGGAGCAAGA
AGCTAAAGAATAGTGAAGCCACAGATGTATT
CTTTAGCTTCTTGCTCCTTCTGCCTACTGCC
TCGGA 
DNAJC2 DNAJC2.1455 TAATTGTAGATCATCTTCTGAC TGCTGTTGACAGTGAGCGATCAGAAGATGAT
CTACAATTATAGTGAAGCCACAGATGTATAA
TTGTAGATCATCTTCTGACTGCCTACTGCCT
CGGA 
DNAJC2 DNAJC2.1157 TTAGCTTCTTGCTCCTTCCGTT TGCTGTTGACAGTGAGCGCACGGAAGGAGC
AAGAAGCTAATAGTGAAGCCACAGATGTATT
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AGCTTCTTGCTCCTTCCGTTTGCCTACTGCC
TCGGA 
DNAJC2 DNAJC2.429 TTCATCTTCTGATTCCTCGGAT TGCTGTTGACAGTGAGCGCTCCGAGGAATC
AGAAGATGAATAGTGAAGCCACAGATGTATT
CATCTTCTGATTCCTCGGATTGCCTACTGCC
TCGGA 
DNAJC2 DNAJC2.1466 TTAGTAATTGTAGATCATCTTC TGCTGTTGACAGTGAGCGAAAGATGATCTAC
AATTACTAATAGTGAAGCCACAGATGTATTA
GTAATTGTAGATCATCTTCTGCCTACTGCCT
CGGA 
DNMT1 DNMT1.884 TTCATCTCTTTCTTCTTCCTTT TGCTGTTGACAGTGAGCGCAAGGAAGAAGA
AAGAGATGAATAGTGAAGCCACAGATGTATT
CATCTCTTTCTTCTTCCTTTTGCCTACTGCCT
CGGA 
DNMT1 DNMT1.3991 TTGAAGGAGACAAAGTTCCTGA TGCTGTTGACAGTGAGCGCCAGGAACTTTGT
CTCCTTCAATAGTGAAGCCACAGATGTATTG
AAGGAGACAAAGTTCCTGATGCCTACTGCCT
CGGA 
DNMT1 DNMT1.3205 TTTGATGTCAGTCTCATTGGGC TGCTGTTGACAGTGAGCGACCCAATGAGAC
TGACATCAAATAGTGAAGCCACAGATGTATT
TGATGTCAGTCTCATTGGGCTGCCTACTGCC
TCGGA 
DNMT1 DNMT1.2410 TTATAGTAACTCTTCTTCCCAT TGCTGTTGACAGTGAGCGCTGGGAAGAAGA
GTTACTATAATAGTGAAGCCACAGATGTATT
ATAGTAACTCTTCTTCCCATTGCCTACTGCC
TCGGA 
DNMT1 DNMT1.2839 TTGAACTTGTTGTCCTCTGTTG TGCTGTTGACAGTGAGCGAAACAGAGGACA
ACAAGTTCAATAGTGAAGCCACAGATGTATT
GAACTTGTTGTCCTCTGTTGTGCCTACTGCC
TCGGA 
DR1 DR1.1454 ATTGATATTATACTGAACCTTA TGCTGTTGACAGTGAGCGCAAGGTTCAGTAT
AATATCAATTAGTGAAGCCACAGATGTAATT
GATATTATACTGAACCTTATGCCTACTGCCT
CGGA 
DR1 DR1.1779 TAAACAAGTATATTGATCTGAG TGCTGTTGACAGTGAGCGATCAGATCAATAT
ACTTGTTTATAGTGAAGCCACAGATGTATAA
ACAAGTATATTGATCTGAGTGCCTACTGCCT
CGGA 
DR1 DR1.2938 TTAACTTATCGTTCTAGACTAG TGCTGTTGACAGTGAGCGATAGTCTAGAACG
ATAAGTTAATAGTGAAGCCACAGATGTATTA
ACTTATCGTTCTAGACTAGTGCCTACTGCCT
CGGA 
DR1 DR1.2574 TATCTTAAGTGACTTTTCCTTT TGCTGTTGACAGTGAGCGCAAGGAAAAGTC
ACTTAAGATATAGTGAAGCCACAGATGTATA
TCTTAAGTGACTTTTCCTTTTGCCTACTGCC
TCGGA 
DR1 DR1.766 TTTATTGATAGCAGCTCTGGGG TGCTGTTGACAGTGAGCGACCCAGAGCTGC
TATCAATAAATAGTGAAGCCACAGATGTATT
TATTGATAGCAGCTCTGGGGTGCCTACTGCC
TCGGA 
EGR1 EGR1.2823 TTTTGTTTTCTTACATTCTGGA TGCTGTTGACAGTGAGCGCCCAGAATGTAA
GAAAACAAAATAGTGAAGCCACAGATGTATT
TTGTTTTCTTACATTCTGGATGCCTACTGCC
TCGGA 
EGR1 EGR1.2815 TCTTACATTCTGGAGAACCGAA TGCTGTTGACAGTGAGCGCTCGGTTCTCCAG
AATGTAAGATAGTGAAGCCACAGATGTATCT
TACATTCTGGAGAACCGAATGCCTACTGCCT
CGGA 
EGR1 EGR1.2822 TTTGTTTTCTTACATTCTGGAG TGCTGTTGACAGTGAGCGATCCAGAATGTAA
GAAAACAAATAGTGAAGCCACAGATGTATTT
GTTTTCTTACATTCTGGAGTGCCTACTGCCT
CGGA 
EGR1 EGR1.2946 TAACATACAAAAATCGCCGCCT TGCTGTTGACAGTGAGCGCGGCGGCGATTTT
TGTATGTTATAGTGAAGCCACAGATGTATAA
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CATACAAAAATCGCCGCCTTGCCTACTGCCT
CGGA 
EGR1 EGR1.2525 TAACGGAACAACACTCTGACAC TGCTGTTGACAGTGAGCGATGTCAGAGTGTT
GTTCCGTTATAGTGAAGCCACAGATGTATAA
CGGAACAACACTCTGACACTGCCTACTGCCT
CGGA 
ENO1 ENO1.261 TTGATGACATTGAACGCCGGGA TGCTGTTGACAGTGAGCGCCCCGGCGTTCA
ATGTCATCAATAGTGAAGCCACAGATGTATT
GATGACATTGAACGCCGGGATGCCTACTGC
CTCGGA 
ENO1 ENO1.1440 TTTGAGCACAAAACCACCGGGG TGCTGTTGACAGTGAGCGACCCGGTGGTTTT
GTGCTCAAATAGTGAAGCCACAGATGTATTT
GAGCACAAAACCACCGGGGTGCCTACTGCC
TCGGA 
ENO1 ENO1.1437 TTTTGAGCACAAAACCACCGGG TGCTGTTGACAGTGAGCGACCGGTGGTTTTG
TGCTCAAAATAGTGAAGCCACAGATGTATTT
TGAGCACAAAACCACCGGGTGCCTACTGCC
TCGGA 
ENO1 ENO1.1441 TTTATTTTGAGCACAAAACCAC TGCTGTTGACAGTGAGCGATGGTTTTGTGCT
CAAAATAAATAGTGAAGCCACAGATGTATTT
ATTTTGAGCACAAAACCACTGCCTACTGCCT
CGGA 
ENO1 ENO1.681 TCTTCGATAGACACCACTGGGT TGCTGTTGACAGTGAGCGCCCCAGTGGTGT
CTATCGAAGATAGTGAAGCCACAGATGTATC
TTCGATAGACACCACTGGGTTGCCTACTGCC
TCGGA 
EREG EREG.1324 TAGATGAGTGACTAGTACCTGT TGCTGTTGACAGTGAGCGCCAGGTACTAGTC
ACTCATCTATAGTGAAGCCACAGATGTATAG
ATGAGTGACTAGTACCTGTTGCCTACTGCCT
CGGA 
EREG EREG.1188 TAGTGTTTAACACAGGACCTAT TGCTGTTGACAGTGAGCGCTAGGTCCTGTGT
TAAACACTATAGTGAAGCCACAGATGTATAG
TGTTTAACACAGGACCTATTGCCTACTGCCT
CGGA 
EREG EREG.3002 TAACCTATTCACATCCTCCTGT TGCTGTTGACAGTGAGCGCCAGGAGGATGT
GAATAGGTTATAGTGAAGCCACAGATGTATA
ACCTATTCACATCCTCCTGTTGCCTACTGCC
TCGGA 
EREG EREG.3718 TTATAGAACTTAATATTCCTGG TGCTGTTGACAGTGAGCGACAGGAATATTAA
GTTCTATAATAGTGAAGCCACAGATGTATTA
TAGAACTTAATATTCCTGGTGCCTACTGCCT
CGGA 
EREG EREG.993 TTGCTAACAATTCTTGAGCTAT TGCTGTTGACAGTGAGCGCTAGCTCAAGAAT
TGTTAGCAATAGTGAAGCCACAGATGTATTG
CTAACAATTCTTGAGCTATTGCCTACTGCCT
CGGA 
ESPL1 ESPL1.267 TAGCTTAGCAGTCAGCTGCTGG TGCTGTTGACAGTGAGCGACAGCAGCTGAC
TGCTAAGCTATAGTGAAGCCACAGATGTATA
GCTTAGCAGTCAGCTGCTGGTGCCTACTGCC
TCGGA 
ESPL1 ESPL1.1362 TACAACTGTCCACTAGTTGGGT TGCTGTTGACAGTGAGCGCCCCAACTAGTG
GACAGTTGTATAGTGAAGCCACAGATGTATA
CAACTGTCCACTAGTTGGGTTGCCTACTGCC
TCGGA 
ESPL1 ESPL1.1897 TCACAGATGATGTTGAAGCGTT TGCTGTTGACAGTGAGCGCACGCTTCAACAT
CATCTGTGATAGTGAAGCCACAGATGTATCA
CAGATGATGTTGAAGCGTTTGCCTACTGCCT
CGGA 
ESPL1 ESPL1.1771 TTTAGCTGTAGCTCCTTGTCTC TGCTGTTGACAGTGAGCGAAGACAAGGAGC
TACAGCTAAATAGTGAAGCCACAGATGTATT
TAGCTGTAGCTCCTTGTCTCTGCCTACTGCC
TCGGA 
ESPL1 ESPL1.2669 TTGACTTCGAAGCAGATCACAG TGCTGTTGACAGTGAGCGATGTGATCTGCTT
CGAAGTCAATAGTGAAGCCACAGATGTATTG
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ACTTCGAAGCAGATCACAGTGCCTACTGCCT
CGGA 
ETV4 ETV4.686 TTCATTTATATGTACACAGGGC TGCTGTTGACAGTGAGCGACCCTGTGTACAT
ATAAATGAATAGTGAAGCCACAGATGTATTC
ATTTATATGTACACAGGGCTGCCTACTGCCT
CGGA 
ETV4 ETV4.380 TAATAGTATCGGAGCGAGCGGC TGCTGTTGACAGTGAGCGACCGCTCGCTCC
GATACTATTATAGTGAAGCCACAGATGTATA
ATAGTATCGGAGCGAGCGGCTGCCTACTGC
CTCGGA 
ETV4 ETV4.806 TTTCCTTCCCAATGACTCCGGT TGCTGTTGACAGTGAGCGCCCGGAGTCATT
GGGAAGGAAATAGTGAAGCCACAGATGTAT
TTCCTTCCCAATGACTCCGGTTGCCTACTGC
CTCGGA 
ETV4 ETV4.385 TCTCATAATAGTATCGGAGCGA TGCTGTTGACAGTGAGCGCCGCTCCGATACT
ATTATGAGATAGTGAAGCCACAGATGTATCT
CATAATAGTATCGGAGCGATGCCTACTGCCT
CGGA 
ETV4 ETV4.816 TTTCTCCACTTTTCCTTCCCAA TGCTGTTGACAGTGAGCGCTGGGAAGGAAA
AGTGGAGAAATAGTGAAGCCACAGATGTAT
TTCTCCACTTTTCCTTCCCAATGCCTACTGC
CTCGGA 
ETV5 ETV5.390 TTGAAGTTGACTGAGATCCTGA TGCTGTTGACAGTGAGCGCCAGGATCTCAGT
CAACTTCAATAGTGAAGCCACAGATGTATTG
AAGTTGACTGAGATCCTGATGCCTACTGCCT
CGGA 
ETV5 ETV5.3563 TTTGATTAGAGTACAATGCTAA TGCTGTTGACAGTGAGCGCTAGCATTGTACT
CTAATCAAATAGTGAAGCCACAGATGTATTT
GATTAGAGTACAATGCTAATGCCTACTGCCT
CGGA 
ETV5 ETV5.2355 TATGATTTTGAGAACCACGGAG TGCTGTTGACAGTGAGCGATCCGTGGTTCTC
AAAATCATATAGTGAAGCCACAGATGTATAT
GATTTTGAGAACCACGGAGTGCCTACTGCCT
CGGA 
ETV5 ETV5.3085 TTACCTGTCAGTATCACACGTA TGCTGTTGACAGTGAGCGCACGTGTGATACT
GACAGGTAATAGTGAAGCCACAGATGTATTA
CCTGTCAGTATCACACGTATGCCTACTGCCT
CGGA 
ETV5 ETV5.2130 TAGTAGTCCATGATCGATGCAG TGCTGTTGACAGTGAGCGATGCATCGATCAT
GGACTACTATAGTGAAGCCACAGATGTATAG
TAGTCCATGATCGATGCAGTGCCTACTGCCT
CGGA 
EZH2 EZH2.292 TTCAATGAAAGTACCATCCTGA TGCTGTTGACAGTGAGCGCCAGGATGGTAC
TTTCATTGAATAGTGAAGCCACAGATGTATT
CAATGAAAGTACCATCCTGATGCCTACTGCC
TCGGA 
EZH2 EZH2.578 TTTCCTTTAGTTCTTCTGCTGT TGCTGTTGACAGTGAGCGCCAGCAGAAGAA
CTAAAGGAAATAGTGAAGCCACAGATGTATT
TCCTTTAGTTCTTCTGCTGTTGCCTACTGCC
TCGGA 
EZH2 EZH2.1100 TTTATTGGTGTTTGACACCGAG TGCTGTTGACAGTGAGCGATCGGTGTCAAAC
ACCAATAAATAGTGAAGCCACAGATGTATTT
ATTGGTGTTTGACACCGAGTGCCTACTGCCT
CGGA 
EZH2 EZH2.1112 TTTGGCTTCATCTTTATTGGTG TGCTGTTGACAGTGAGCGAACCAATAAAGAT
GAAGCCAAATAGTGAAGCCACAGATGTATTT
GGCTTCATCTTTATTGGTGTGCCTACTGCCT
CGGA 
EZH2 EZH2.1700 TATTTATCATACACTTTCCCTC TGCTGTTGACAGTGAGCGAAGGGAAAGTGT
ATGATAAATATAGTGAAGCCACAGATGTATA
TTTATCATACACTTTCCCTCTGCCTACTGCC
TCGGA 
FOS FOS.1690 TTAATTCCAATAATGAACCCAA TGCTGTTGACAGTGAGCGCTGGGTTCATTAT
TGGAATTAATAGTGAAGCCACAGATGTATTA
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ATTCCAATAATGAACCCAATGCCTACTGCCT
CGGA 
FOS FOS.1804 TTTTCTTAGTATAATATTGGTC TGCTGTTGACAGTGAGCGAACCAATATTATA
CTAAGAAAATAGTGAAGCCACAGATGTATTT
TCTTAGTATAATATTGGTCTGCCTACTGCCT
CGGA 
FOS FOS.1894 TAACATTACAATGAACATTGAT TGCTGTTGACAGTGAGCGCTCAATGTTCATT
GTAATGTTATAGTGAAGCCACAGATGTATAA
CATTACAATGAACATTGATTGCCTACTGCCT
CGGA 
FOS FOS.2115 TTTTATTGACAATGTCTTGGAA TGCTGTTGACAGTGAGCGCTCCAAGACATTG
TCAATAAAATAGTGAAGCCACAGATGTATTT
TATTGACAATGTCTTGGAATGCCTACTGCCT
CGGA 
FOS FOS.703 TCTAGTTGGTCTGTCTCCGCTT TGCTGTTGACAGTGAGCGCAGCGGAGACAG
ACCAACTAGATAGTGAAGCCACAGATGTATC
TAGTTGGTCTGTCTCCGCTTTGCCTACTGCC
TCGGA 
FOSL1 FOSL1.1280 TAAGGATCTACAAAGTCTCTGG TGCTGTTGACAGTGAGCGACAGAGACTTTGT
AGATCCTTATAGTGAAGCCACAGATGTATAA
GGATCTACAAAGTCTCTGGTGCCTACTGCCT
CGGA 
FOSL1 FOSL1.90 TATGAATGAAAAGTTCTCGGGC TGCTGTTGACAGTGAGCGACCCGAGAACTTT
TCATTCATATAGTGAAGCCACAGATGTATAT
GAATGAAAAGTTCTCGGGCTGCCTACTGCCT
CGGA 
FOSL1 FOSL1.1634 TTTTATTCCATTTTGGTAGGTT TGCTGTTGACAGTGAGCGCACCTACCAAAAT
GGAATAAAATAGTGAAGCCACAGATGTATTT
TATTCCATTTTGGTAGGTTTGCCTACTGCCT
CGGA 
FOSL1 FOSL1.91 TTATGAATGAAAAGTTCTCGGG TGCTGTTGACAGTGAGCGACCGAGAACTTTT
CATTCATAATAGTGAAGCCACAGATGTATTA
TGAATGAAAAGTTCTCGGGTGCCTACTGCCT
CGGA 
FOSL1 FOSL1.1405 TGAGTTAGTGTTCTAGGTGGGT TGCTGTTGACAGTGAGCGCCCCACCTAGAA
CACTAACTCATAGTGAAGCCACAGATGTATG
AGTTAGTGTTCTAGGTGGGTTGCCTACTGCC
TCGGA 
FOXM1 FOXM1.1812 TTGAATCACAAGCATTTCCGAG TGCTGTTGACAGTGAGCGATCGGAAATGCTT
GTGATTCAATAGTGAAGCCACAGATGTATTG
AATCACAAGCATTTCCGAGTGCCTACTGCCT
CGGA 
FOXM1 FOXM1.725 TCTAGGAAGATTCACATCCCTA TGCTGTTGACAGTGAGCGCAGGGATGTGAA
TCTTCCTAGATAGTGAAGCCACAGATGTATC
TAGGAAGATTCACATCCCTATGCCTACTGCC
TCGGA 
FOXM1 FOXM1.1277 TTGATGGTCATGTTCCGGCGGA TGCTGTTGACAGTGAGCGCCCGCCGGAACA
TGACCATCAATAGTGAAGCCACAGATGTATT
GATGGTCATGTTCCGGCGGATGCCTACTGCC
TCGGA 
FOXM1 FOXM1.2496 TAGCTCAGGAATAAACTGGGAC TGCTGTTGACAGTGAGCGATCCCAGTTTATT
CCTGAGCTATAGTGAAGCCACAGATGTATAG
CTCAGGAATAAACTGGGACTGCCTACTGCCT
CGGA 
FOXM1 FOXM1.463 TGGTTAATAATCTTGATCCCAG TGCTGTTGACAGTGAGCGATGGGATCAAGA
TTATTAACCATAGTGAAGCCACAGATGTATG
GTTAATAATCTTGATCCCAGTGCCTACTGCC
TCGGA 
FUBP1 FUBP1.2714 TATAGCAGCAGTACAGGTCTGA TGCTGTTGACAGTGAGCGCCAGACCTGTACT
GCTGCTATATAGTGAAGCCACAGATGTATAT
AGCAGCAGTACAGGTCTGATGCCTACTGCCT
CGGA 
FUBP1 FUBP1.1846 TTTCTTGTAGTACTCTTCCCAA TGCTGTTGACAGTGAGCGCTGGGAAGAGTA
CTACAAGAAATAGTGAAGCCACAGATGTATT
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TCTTGTAGTACTCTTCCCAATGCCTACTGCC
TCGGA 
FUBP1 FUBP1.521 TTAACATACAGGACCTTTCTGG TGCTGTTGACAGTGAGCGACAGAAAGGTCC
TGTATGTTAATAGTGAAGCCACAGATGTATT
AACATACAGGACCTTTCTGGTGCCTACTGCC
TCGGA 
FUBP1 FUBP1.236 TTGAATTCAGTGATGTCCCTGC TGCTGTTGACAGTGAGCGACAGGGACATCA
CTGAATTCAATAGTGAAGCCACAGATGTATT
GAATTCAGTGATGTCCCTGCTGCCTACTGCC
TCGGA 
FUBP1 FUBP1.1932 TTGTCTATAATACTCAGCCCAG TGCTGTTGACAGTGAGCGATGGGCTGAGTA
TTATAGACAATAGTGAAGCCACAGATGTATT
GTCTATAATACTCAGCCCAGTGCCTACTGCC
TCGGA 
FUS FUS.212 ATAACCACTGTAACTCTGCTGT TGCTGTTGACAGTGAGCGCCAGCAGAGTTA
CAGTGGTTATTAGTGAAGCCACAGATGTAAT
AACCACTGTAACTCTGCTGTTGCCTACTGCC
TCGGA 
FUS FUS.2807 TTGAGAGGAAAGCACTTCCCAA TGCTGTTGACAGTGAGCGCTGGGAAGTGCTT
TCCTCTCAATAGTGAAGCCACAGATGTATTG
AGAGGAAAGCACTTCCCAATGCCTACTGCCT
CGGA 
FUS FUS.960 TTGTTGTCTGAATTATCCTGTT TGCTGTTGACAGTGAGCGCACAGGATAATTC
AGACAACAATAGTGAAGCCACAGATGTATT
GTTGTCTGAATTATCCTGTTTGCCTACTGCC
TCGGA 
FUS FUS.1050 TTGTTTGTCTTAATAATACCAA TGCTGTTGACAGTGAGCGCTGGTATTATTAA
GACAAACAATAGTGAAGCCACAGATGTATT
GTTTGTCTTAATAATACCAATGCCTACTGCC
TCGGA 
FUS FUS.1028 TCTGCTTGAAGTAATCAGCCAC TGCTGTTGACAGTGAGCGATGGCTGATTACT
TCAAGCAGATAGTGAAGCCACAGATGTATCT
GCTTGAAGTAATCAGCCACTGCCTACTGCCT
CGGA 
HMGA1 HMGA1.211 TTTTGCTTCCCTTTGGTCGGCC TGCTGTTGACAGTGAGCGAGCCGACCAAAG
GGAAGCAAAATAGTGAAGCCACAGATGTAT
TTTGCTTCCCTTTGGTCGGCCTGCCTACTGC
CTCGGA 
HMGA1 HMGA1.155 TCCTTGAATTCCTCGAGCGGAG TGCTGTTGACAGTGAGCGATCCGCTCGAGG
AATTCAAGGATAGTGAAGCCACAGATGTATC
CTTGAATTCCTCGAGCGGAGTGCCTACTGCC
TCGGA 
HMGA1 HMGA1.40 TCATCTTCCCTTCTCTAAGGAG TGCTGTTGACAGTGAGCGATCCTTAGAGAAG
GGAAGATGATAGTGAAGCCACAGATGTATC
ATCTTCCCTTCTCTAAGGAGTGCCTACTGCC
TCGGA 
HMGA1 HMGA1.1061 TATGTACTCAGATCCCAGGCGG TGCTGTTGACAGTGAGCGACGCCTGGGATC
TGAGTACATATAGTGAAGCCACAGATGTATA
TGTACTCAGATCCCAGGCGGTGCCTACTGCC
TCGGA 
HMGA1 HMGA1.1391 TGAGGATGAACATTTGGCGCTG TGCTGTTGACAGTGAGCGAAGCGCCAAATG
TTCATCCTCATAGTGAAGCCACAGATGTATG
AGGATGAACATTTGGCGCTGTGCCTACTGCC
TCGGA 
HMGB1 HMGB1.2309 TTAACTAGTATTTAAAACCTCT TGCTGTTGACAGTGAGCGCGAGGTTTTAAAT
ACTAGTTAATAGTGAAGCCACAGATGTATTA
ACTAGTATTTAAAACCTCTTGCCTACTGCCT
CGGA 
HMGB1 HMGB1.2683 TACAGTAGAAACTTCCATCTAA TGCTGTTGACAGTGAGCGCTAGATGGAAGTT
TCTACTGTATAGTGAAGCCACAGATGTATAC
AGTAGAAACTTCCATCTAATGCCTACTGCCT
CGGA 
HMGB1 HMGB1.1726 TTGTATTTTAAGCTCACGCTTT TGCTGTTGACAGTGAGCGCAAGCGTGAGCT
TAAAATACAATAGTGAAGCCACAGATGTATT
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GTATTTTAAGCTCACGCTTTTGCCTACTGCC
TCGGA 
HMGB1 HMGB1.1534 TTGAGTAGATTGATTACTCTTC TGCTGTTGACAGTGAGCGAAAGAGTAATCA
ATCTACTCAATAGTGAAGCCACAGATGTATT
GAGTAGATTGATTACTCTTCTGCCTACTGCC
TCGGA 
HMGB1 HMGB1.2936 TTAGACATCCAACTTCTAGGGG TGCTGTTGACAGTGAGCGACCCTAGAAGTTG
GATGTCTAATAGTGAAGCCACAGATGTATTA
GACATCCAACTTCTAGGGGTGCCTACTGCCT
CGGA 
HMGB2 HMGB2.635 TTATTCTTCATCTTCATCCTCT TGCTGTTGACAGTGAGCGCGAGGATGAAGA
TGAAGAATAATAGTGAAGCCACAGATGTATT
ATTCTTCATCTTCATCCTCTTGCCTACTGCC
TCGGA 
HMGB2 HMGB2.1295 TTAGCTAATAAACAGAAACGTC TGCTGTTGACAGTGAGCGAACGTTTCTGTTT
ATTAGCTAATAGTGAAGCCACAGATGTATTA
GCTAATAAACAGAAACGTCTGCCTACTGCCT
CGGA 
HMGB2 HMGB2.102 TTCTTCTTGTGCTCTTCCCGGC TGCTGTTGACAGTGAGCGACCGGGAAGAGC
ACAAGAAGAATAGTGAAGCCACAGATGTAT
TCTTCTTGTGCTCTTCCCGGCTGCCTACTGC
CTCGGA 
HMGB2 HMGB2.952 TTACTATTGATACTAATTCCTA TGCTGTTGACAGTGAGCGCAGGAATTAGTAT
CAATAGTAATAGTGAAGCCACAGATGTATTA
CTATTGATACTAATTCCTATGCCTACTGCCT
CGGA 
HMGB2 HMGB2.849 TCTAACTGTATGAGTAGCCCAT TGCTGTTGACAGTGAGCGCTGGGCTACTCAT
ACAGTTAGATAGTGAAGCCACAGATGTATCT
AACTGTATGAGTAGCCCATTGCCTACTGCCT
CGGA 
HMGB3 HMGB3.2264 TTAACATTGAACATCAATCTAC TGCTGTTGACAGTGAGCGATAGATTGATGTT
CAATGTTAATAGTGAAGCCACAGATGTATTA
ACATTGAACATCAATCTACTGCCTACTGCCT
CGGA 
HMGB3 HMGB3.1909 TTTGACACACCATACACTCTGA TGCTGTTGACAGTGAGCGCCAGAGTGTATG
GTGTGTCAAATAGTGAAGCCACAGATGTATT
TGACACACCATACACTCTGATGCCTACTGCC
TCGGA 
HMGB3 HMGB3.628 TTCATCTTCCTCTTCCACCTTT TGCTGTTGACAGTGAGCGCAAGGTGGAAGA
GGAAGATGAATAGTGAAGCCACAGATGTAT
TCATCTTCCTCTTCCACCTTTTGCCTACTGC
CTCGGA 
HMGB3 HMGB3.1249 TACAGAAACAAGACAACCTGAA TGCTGTTGACAGTGAGCGCTCAGGTTGTCTT
GTTTCTGTATAGTGAAGCCACAGATGTATAC
AGAAACAAGACAACCTGAATGCCTACTGCC
TCGGA 
HMGB3 HMGB3.2531 TAATAGCACAAAAACACTCCTG TGCTGTTGACAGTGAGCGAAGGAGTGTTTTT
GTGCTATTATAGTGAAGCCACAGATGTATAA
TAGCACAAAAACACTCCTGTGCCTACTGCCT
CGGA 
HNRNPA
B 
HNRNPAB.124
3 
TTAAATAAGATGCACATGGGAC TGCTGTTGACAGTGAGCGATCCCATGTGCAT
CTTATTTAATAGTGAAGCCACAGATGTATTA
AATAAGATGCACATGGGACTGCCTACTGCCT
CGGA 
HNRNPA
B 
HNRNPAB.608 TCTTTGAACAGGATAAACCCAA TGCTGTTGACAGTGAGCGCTGGGTTTATCCT
GTTCAAAGATAGTGAAGCCACAGATGTATCT
TTGAACAGGATAAACCCAATGCCTACTGCCT
CGGA 
HNRNPA
B 
HNRNPAB.829 TTTTGTTCAACTTTGGATCCAT TGCTGTTGACAGTGAGCGCTGGATCCAAAGT
TGAACAAAATAGTGAAGCCACAGATGTATTT
TGTTCAACTTTGGATCCATTGCCTACTGCCT
CGGA 
HNRNPA
B 
HNRNPAB.157
5 
TTACAATACATTAGATTCCCAA TGCTGTTGACAGTGAGCGCTGGGAATCTAAT
GTATTGTAATAGTGAAGCCACAGATGTATTA
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CAATACATTAGATTCCCAATGCCTACTGCCT
CGGA 
HNRNPA
B 
HNRNPAB.106
3 
TTGTACTACCGAATTCCTCGAG TGCTGTTGACAGTGAGCGATCGAGGAATTC
GGTAGTACAATAGTGAAGCCACAGATGTATT
GTACTACCGAATTCCTCGAGTGCCTACTGCC
TCGGA 
HNRNPD HNRNPD.1275 TTGAACTGCTATTAGCAGGTGG TGCTGTTGACAGTGAGCGACACCTGCTAATA
GCAGTTCAATAGTGAAGCCACAGATGTATTG
AACTGCTATTAGCAGGTGGTGCCTACTGCCT
CGGA 
HNRNPD HNRNPD.2045 TATATTTCTTTAATCCTCCCTC TGCTGTTGACAGTGAGCGAAGGGAGGATTA
AAGAAATATATAGTGAAGCCACAGATGTATA
TATTTCTTTAATCCTCCCTCTGCCTACTGCC
TCGGA 
HNRNPD HNRNPD.774 TTAGGATCAATCACCTTCCCAT TGCTGTTGACAGTGAGCGCTGGGAAGGTGA
TTGATCCTAATAGTGAAGCCACAGATGTATT
AGGATCAATCACCTTCCCATTGCCTACTGCC
TCGGA 
HNRNPD HNRNPD.988 TTCCATTATCTTCTTCACTGGT TGCTGTTGACAGTGAGCGCCCAGTGAAGAA
GATAATGGAATAGTGAAGCCACAGATGTATT
CCATTATCTTCTTCACTGGTTGCCTACTGCC
TCGGA 
HNRNPD HNRNPD.1060 TTGCTGATATTGTTCCTTCGAC TGCTGTTGACAGTGAGCGATCGAAGGAACA
ATATCAGCAATAGTGAAGCCACAGATGTATT
GCTGATATTGTTCCTTCGACTGCCTACTGCC
TCGGA 
HNRNPR HNRNPR.2400 TTTAAAAACACAGTTAACCTAC TGCTGTTGACAGTGAGCGATAGGTTAACTGT
GTTTTTAAATAGTGAAGCCACAGATGTATTT
AAAAACACAGTTAACCTACTGCCTACTGCCT
CGGA 
HNRNPR HNRNPR.777 TTCTTTAGTCTTATTCTTCGGA TGCTGTTGACAGTGAGCGCCCGAAGAATAA
GACTAAAGAATAGTGAAGCCACAGATGTATT
CTTTAGTCTTATTCTTCGGATGCCTACTGCC
TCGGA 
HNRNPR HNRNPR.1892 TACTTGTCTACTTCCACTGTTG TGCTGTTGACAGTGAGCGAAACAGTGGAAG
TAGACAAGTATAGTGAAGCCACAGATGTATA
CTTGTCTACTTCCACTGTTGTGCCTACTGCC
TCGGA 
HNRNPR HNRNPR.1919 TTACTTGTCTACTTCCACTGTT TGCTGTTGACAGTGAGCGCACAGTGGAAGT
AGACAAGTAATAGTGAAGCCACAGATGTATT
ACTTGTCTACTTCCACTGTTTGCCTACTGCC
TCGGA 
HNRNPR HNRNPR.510 TTTGCCTACAAATACCTCCGTT TGCTGTTGACAGTGAGCGCACGGAGGTATTT
GTAGGCAAATAGTGAAGCCACAGATGTATTT
GCCTACAAATACCTCCGTTTGCCTACTGCCT
CGGA 
IL17RD IL17RD.5166 TTTTGAAGGACAGTCTTCCTGC TGCTGTTGACAGTGAGCGACAGGAAGACTG
TCCTTCAAAATAGTGAAGCCACAGATGTATT
TTGAAGGACAGTCTTCCTGCTGCCTACTGCC
TCGGA 
IL17RD IL17RD.4714 TAACCTATCTACACAAGCCTTT TGCTGTTGACAGTGAGCGCAAGGCTTGTGTA
GATAGGTTATAGTGAAGCCACAGATGTATAA
CCTATCTACACAAGCCTTTTGCCTACTGCCT
CGGA 
IL17RD IL17RD.660 TTTACAAGCTAGATTGTCCGGC TGCTGTTGACAGTGAGCGACCGGACAATCT
AGCTTGTAAATAGTGAAGCCACAGATGTATT
TACAAGCTAGATTGTCCGGCTGCCTACTGCC
TCGGA 
IL17RD IL17RD.1052 TTTTCTTGTTGCTTCTTGCGGC TGCTGTTGACAGTGAGCGACCGCAAGAAGC
AACAAGAAAATAGTGAAGCCACAGATGTATT
TTCTTGTTGCTTCTTGCGGCTGCCTACTGCC
TCGGA 
IL17RD IL17RD.493 TTTGAAGCTACTGTTGAGCTGC TGCTGTTGACAGTGAGCGACAGCTCAACAG
TAGCTTCAAATAGTGAAGCCACAGATGTATT
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TGAAGCTACTGTTGAGCTGCTGCCTACTGCC
TCGGA 
ILF2 ILF2.527 TAAAACTTCAGAAGGATCCTGT TGCTGTTGACAGTGAGCGCCAGGATCCTTCT
GAAGTTTTATAGTGAAGCCACAGATGTATAA
AACTTCAGAAGGATCCTGTTGCCTACTGCCT
CGGA 
ILF2 ILF2.45 TAGCAGACAACTGAAGAGGCGT TGCTGTTGACAGTGAGCGCCGCCTCTTCAGT
TGTCTGCTATAGTGAAGCCACAGATGTATAG
CAGACAACTGAAGAGGCGTTGCCTACTGCC
TCGGA 
ILF2 ILF2.1584 TTTCACAACATTTCAACAGCAA TGCTGTTGACAGTGAGCGCTGCTGTTGAAAT
GTTGTGAAATAGTGAAGCCACAGATGTATTT
CACAACATTTCAACAGCAATGCCTACTGCCT
CGGA 
ILF2 ILF2.1851 TGATATTCTAGTTTACTCTGGT TGCTGTTGACAGTGAGCGCCCAGAGTAAAC
TAGAATATCATAGTGAAGCCACAGATGTATG
ATATTCTAGTTTACTCTGGTTGCCTACTGCC
TCGGA 
ILF2 ILF2.785 TCTGATGAGAACTTTAACTGTG TGCTGTTGACAGTGAGCGAACAGTTAAAGTT
CTCATCAGATAGTGAAGCCACAGATGTATCT
GATGAGAACTTTAACTGTGTGCCTACTGCCT
CGGA 
ILF3 ILF3.2024 TTTTGTTGGAACCAGCACCTTG TGCTGTTGACAGTGAGCGAAAGGTGCTGGT
TCCAACAAAATAGTGAAGCCACAGATGTATT
TTGTTGGAACCAGCACCTTGTGCCTACTGCC
TCGGA 
ILF3 ILF3.1480 TTTCTTCTGAATCTTCTTCTTC TGCTGTTGACAGTGAGCGAAAGAAGAAGAT
TCAGAAGAAATAGTGAAGCCACAGATGTATT
TCTTCTGAATCTTCTTCTTCTGCCTACTGCC
TCGGA 
ILF3 ILF3.724 TTCTGTTACAGCAGCAAGCTGG TGCTGTTGACAGTGAGCGACAGCTTGCTGCT
GTAACAGAATAGTGAAGCCACAGATGTATTC
TGTTACAGCAGCAAGCTGGTGCCTACTGCCT
CGGA 
ILF3 ILF3.299 TTACTTCTTCTGTAGTGTCTGG TGCTGTTGACAGTGAGCGACAGACACTACA
GAAGAAGTAATAGTGAAGCCACAGATGTATT
ACTTCTTCTGTAGTGTCTGGTGCCTACTGCC
TCGGA 
ILF3 ILF3.534 TTCTTTACTGTCGTCCTCTGGG TGCTGTTGACAGTGAGCGACCAGAGGACGA
CAGTAAAGAATAGTGAAGCCACAGATGTATT
CTTTACTGTCGTCCTCTGGGTGCCTACTGCC
TCGGA 
IQGAP1 IQGAP1.7193 TTAACATGAACAAATGACCTTT TGCTGTTGACAGTGAGCGCAAGGTCATTTGT
TCATGTTAATAGTGAAGCCACAGATGTATTA
ACATGAACAAATGACCTTTTGCCTACTGCCT
CGGA 
IQGAP1 IQGAP1.622 TTCTTCTGTGAAGTCAACCTTT TGCTGTTGACAGTGAGCGCAAGGTTGACTTC
ACAGAAGAATAGTGAAGCCACAGATGTATT
CTTCTGTGAAGTCAACCTTTTGCCTACTGCC
TCGGA 
IQGAP1 IQGAP1.5499 TAACATGACATTTTAGTTGTGT TGCTGTTGACAGTGAGCGCCACAACTAAAAT
GTCATGTTATAGTGAAGCCACAGATGTATAA
CATGACATTTTAGTTGTGTTGCCTACTGCCT
CGGA 
IQGAP1 IQGAP1.4793 TTTCATGTAGTCTTGCTGCTGT TGCTGTTGACAGTGAGCGCCAGCAGCAAGA
CTACATGAAATAGTGAAGCCACAGATGTATT
TCATGTAGTCTTGCTGCTGTTGCCTACTGCC
TCGGA 
IQGAP1 IQGAP1.3207 TTGAATCTGATCTACCTTCGAC TGCTGTTGACAGTGAGCGATCGAAGGTAGA
TCAGATTCAATAGTGAAGCCACAGATGTATT
GAATCTGATCTACCTTCGACTGCCTACTGCC
TCGGA 
JUNB JUNB.308 TAGCTGTGTATGAGTCGTCGTG TGCTGTTGACAGTGAGCGAACGACGACTCA
TACACAGCTATAGTGAAGCCACAGATGTATA
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GCTGTGTATGAGTCGTCGTGTGCCTACTGCC
TCGGA 
JUNB JUNB.273 TCCATTTTAGTGCACATCCGGG TGCTGTTGACAGTGAGCGACCGGATGTGCA
CTAAAATGGATAGTGAAGCCACAGATGTATC
CATTTTAGTGCACATCCGGGTGCCTACTGCC
TCGGA 
JUNB JUNB.1535 TATGAATCGAGTCTGTTTCCAG TGCTGTTGACAGTGAGCGATGGAAACAGAC
TCGATTCATATAGTGAAGCCACAGATGTATA
TGAATCGAGTCTGTTTCCAGTGCCTACTGCC
TCGGA 
JUNB JUNB.363 TTCAGGAGTTTGTAGTCGTGTA TGCTGTTGACAGTGAGCGCACACGACTACA
AACTCCTGAATAGTGAAGCCACAGATGTATT
CAGGAGTTTGTAGTCGTGTATGCCTACTGCC
TCGGA 
JUNB JUNB.1241 TGACCTTCTGTTTGAGCTGGGC TGCTGTTGACAGTGAGCGACCCAGCTCAAA
CAGAAGGTCATAGTGAAGCCACAGATGTAT
GACCTTCTGTTTGAGCTGGGCTGCCTACTGC
CTCGGA 
KLF10 KLF10.622 TTGCTTTCTCATCAACATCTGC TGCTGTTGACAGTGAGCGACAGATGTTGATG
AGAAAGCAATAGTGAAGCCACAGATGTATT
GCTTTCTCATCAACATCTGCTGCCTACTGCC
TCGGA 
KLF10 KLF10.1350 TAGCTTGCTCACTTCCATCTGC TGCTGTTGACAGTGAGCGACAGATGGAAGT
GAGCAAGCTATAGTGAAGCCACAGATGTAT
AGCTTGCTCACTTCCATCTGCTGCCTACTGC
CTCGGA 
KLF10 KLF10.1822 TACATCTCCATGTCTGTACCGT TGCTGTTGACAGTGAGCGCCGGTACAGACA
TGGAGATGTATAGTGAAGCCACAGATGTATA
CATCTCCATGTCTGTACCGTTGCCTACTGCC
TCGGA 
KLF10 KLF10.1084 TATGTCTTGCCACATCCTGGGT TGCTGTTGACAGTGAGCGCCCCAGGATGTG
GCAAGACATATAGTGAAGCCACAGATGTAT
ATGTCTTGCCACATCCTGGGTTGCCTACTGC
CTCGGA 
KLF10 KLF10.1413 TTCTGACTCTTCACTTTCCGGT TGCTGTTGACAGTGAGCGCCCGGAAAGTGA
AGAGTCAGAATAGTGAAGCCACAGATGTATT
CTGACTCTTCACTTTCCGGTTGCCTACTGCC
TCGGA 
LRRFIP1 LRRFIP1.595 TCTTTTGTCATCTTGGTAGGAC TGCTGTTGACAGTGAGCGATCCTACCAAGAT
GACAAAAGATAGTGAAGCCACAGATGTATC
TTTTGTCATCTTGGTAGGACTGCCTACTGCC
TCGGA 
LRRFIP1 LRRFIP1.259 TATTTCTCTTCAACTTCTGCTA TGCTGTTGACAGTGAGCGCAGCAGAAGTTG
AAGAGAAATATAGTGAAGCCACAGATGTAT
ATTTCTCTTCAACTTCTGCTATGCCTACTGC
CTCGGA 
LRRFIP1 LRRFIP1.445 TGAAATTGCAGTATACTGTGGG TGCTGTTGACAGTGAGCGACCACAGTATACT
GCAATTTCATAGTGAAGCCACAGATGTATGA
AATTGCAGTATACTGTGGGTGCCTACTGCCT
CGGA 
LRRFIP1 LRRFIP1.592 TTTGTCATCTTGGTAGGACCTT TGCTGTTGACAGTGAGCGCAGGTCCTACCA
AGATGACAAATAGTGAAGCCACAGATGTATT
TGTCATCTTGGTAGGACCTTTGCCTACTGCC
TCGGA 
LRRFIP1 LRRFIP1.262 TTATATTTCTCTTCAACTTCTG TGCTGTTGACAGTGAGCGAAGAAGTTGAAG
AGAAATATAATAGTGAAGCCACAGATGTATT
ATATTTCTCTTCAACTTCTGTGCCTACTGCC
TCGGA 
MAFF MAFF.970 TTTCACTAGTCTTCCCACCCAC TGCTGTTGACAGTGAGCGATGGGTGGGAAG
ACTAGTGAAATAGTGAAGCCACAGATGTATT
TCACTAGTCTTCCCACCCACTGCCTACTGCC
TCGGA 
MAFF MAFF.1993 TAAATAAATTCTAGGAGCCGGG TGCTGTTGACAGTGAGCGACCGGCTCCTAG
AATTTATTTATAGTGAAGCCACAGATGTATA
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AATAAATTCTAGGAGCCGGGTGCCTACTGCC
TCGGA 
MAFF MAFF.708 TAAACTTTCAGCCAAGGGCGAT TGCTGTTGACAGTGAGCGCTCGCCCTTGGCT
GAAAGTTTATAGTGAAGCCACAGATGTATAA
ACTTTCAGCCAAGGGCGATTGCCTACTGCCT
CGGA 
MAFF MAFF.2 TCGCTTGATCGAATTCCTCGAG TGCTGTTGACAGTGAGCGATCGAGGAATTC
GATCAAGCGATAGTGAAGCCACAGATGTAT
CGCTTGATCGAATTCCTCGAGTGCCTACTGC
CTCGGA 
MAFF MAFF.839 TAGCTTTGAATCCTGGGAGGGT TGCTGTTGACAGTGAGCGCCCCTCCCAGGA
TTCAAAGCTATAGTGAAGCCACAGATGTATA
GCTTTGAATCCTGGGAGGGTTGCCTACTGCC
TCGGA 
MCM2 MCM2.715 TTCTCTTTGCACATGTCGCTGA TGCTGTTGACAGTGAGCGCCAGCGACATGT
GCAAAGAGAATAGTGAAGCCACAGATGTAT
TCTCTTTGCACATGTCGCTGATGCCTACTGC
CTCGGA 
MCM2 MCM2.1397 TACAGCAACCTTGTTGTCCTTC TGCTGTTGACAGTGAGCGAAAGGACAACAA
GGTTGCTGTATAGTGAAGCCACAGATGTATA
CAGCAACCTTGTTGTCCTTCTGCCTACTGCC
TCGGA 
MCM2 MCM2.1017 TACTTGACCATGCTGAGCTGGG TGCTGTTGACAGTGAGCGACCAGCTCAGCA
TGGTCAAGTATAGTGAAGCCACAGATGTATA
CTTGACCATGCTGAGCTGGGTGCCTACTGCC
TCGGA 
MCM2 MCM2.1427 TCATCTTCACATCTTCATCGGT TGCTGTTGACAGTGAGCGCCCGATGAAGAT
GTGAAGATGATAGTGAAGCCACAGATGTAT
CATCTTCACATCTTCATCGGTTGCCTACTGC
CTCGGA 
MCM2 MCM2.1302 TAGTTGTTGTGATAGATGCCAG TGCTGTTGACAGTGAGCGATGGCATCTATCA
CAACAACTATAGTGAAGCCACAGATGTATAG
TTGTTGTGATAGATGCCAGTGCCTACTGCCT
CGGA 
MCM3 MCM3.246 TTCACATTGACAATCAGCCGGT TGCTGTTGACAGTGAGCGCCCGGCTGATTGT
CAATGTGAATAGTGAAGCCACAGATGTATTC
ACATTGACAATCAGCCGGTTGCCTACTGCCT
CGGA 
MCM3 MCM3.957 TTACTGAACTTCTTGATCTTGG TGCTGTTGACAGTGAGCGACAAGATCAAGA
AGTTCAGTAATAGTGAAGCCACAGATGTATT
ACTGAACTTCTTGATCTTGGTGCCTACTGCC
TCGGA 
MCM3 MCM3.958 TTTACTGAACTTCTTGATCTTG TGCTGTTGACAGTGAGCGAAAGATCAAGAA
GTTCAGTAAATAGTGAAGCCACAGATGTATT
TACTGAACTTCTTGATCTTGTGCCTACTGCC
TCGGA 
MCM3 MCM3.2977 TTTCTTGACCTGCATGACGTGC TGCTGTTGACAGTGAGCGACACGTCATGCA
GGTCAAGAAATAGTGAAGCCACAGATGTATT
TCTTGACCTGCATGACGTGCTGCCTACTGCC
TCGGA 
MCM3 MCM3.3080 TAAGTTTATTCAACATCTCGGA TGCTGTTGACAGTGAGCGCCCGAGATGTTG
AATAAACTTATAGTGAAGCCACAGATGTATA
AGTTTATTCAACATCTCGGATGCCTACTGCC
TCGGA 
MCM4 MCM4.216 TTATCGAGGAACAAACTTGGAA TGCTGTTGACAGTGAGCGCTCCAAGTTTGTT
CCTCGATAATAGTGAAGCCACAGATGTATTA
TCGAGGAACAAACTTGGAATGCCTACTGCCT
CGGA 
MCM4 MCM4.3163 TTTTGAGACAGTCTCACTCTAT TGCTGTTGACAGTGAGCGCTAGAGTGAGAC
TGTCTCAAAATAGTGAAGCCACAGATGTATT
TTGAGACAGTCTCACTCTATTGCCTACTGCC
TCGGA 
MCM4 MCM4.86 TAGGTTTCCATGTTGATTCGGG TGCTGTTGACAGTGAGCGACCGAATCAACAT
GGAAACCTATAGTGAAGCCACAGATGTATA
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GGTTTCCATGTTGATTCGGGTGCCTACTGCC
TCGGA 
MCM4 MCM4.1641 TATTCTTAGTCTTCAATGCGTT TGCTGTTGACAGTGAGCGCACGCATTGAAG
ACTAAGAATATAGTGAAGCCACAGATGTATA
TTCTTAGTCTTCAATGCGTTTGCCTACTGCC
TCGGA 
MCM4 MCM4.217 TTTATCGAGGAACAAACTTGGA TGCTGTTGACAGTGAGCGCCCAAGTTTGTTC
CTCGATAAATAGTGAAGCCACAGATGTATTT
ATCGAGGAACAAACTTGGATGCCTACTGCCT
CGGA 
MCM5 MCM5.2528 TTTACCTGAACACACCGTGGCT TGCTGTTGACAGTGAGCGCGCCACGGTGTG
TTCAGGTAAATAGTGAAGCCACAGATGTATT
TACCTGAACACACCGTGGCTTGCCTACTGCC
TCGGA 
MCM5 MCM5.2529 TTTTACCTGAACACACCGTGGC TGCTGTTGACAGTGAGCGACCACGGTGTGTT
CAGGTAAAATAGTGAAGCCACAGATGTATTT
TACCTGAACACACCGTGGCTGCCTACTGCCT
CGGA 
MCM5 MCM5.1636 TTGACGATGAAGATCATGTCGA TGCTGTTGACAGTGAGCGCCGACATGATCTT
CATCGTCAATAGTGAAGCCACAGATGTATTG
ACGATGAAGATCATGTCGATGCCTACTGCCT
CGGA 
MCM5 MCM5.240 TGTATTTGAAGGTGAAGCCCGT TGCTGTTGACAGTGAGCGCCGGGCTTCACCT
TCAAATACATAGTGAAGCCACAGATGTATGT
ATTTGAAGGTGAAGCCCGTTGCCTACTGCCT
CGGA 
MCM5 MCM5.343 TTGTACAAGTAGTCGGCCAGGT TGCTGTTGACAGTGAGCGCCCTGGCCGACT
ACTTGTACAATAGTGAAGCCACAGATGTATT
GTACAAGTAGTCGGCCAGGTTGCCTACTGC
CTCGGA 
MCM6 MCM6.1479 ATGAATAGCAACTTGATCCCGC TGCTGTTGACAGTGAGCGACGGGATCAAGT
TGCTATTCATTAGTGAAGCCACAGATGTAAT
GAATAGCAACTTGATCCCGCTGCCTACTGCC
TCGGA 
MCM6 MCM6.2172 TTGATTTATGTCTTCATTGTAG TGCTGTTGACAGTGAGCGATACAATGAAGA
CATAAATCAATAGTGAAGCCACAGATGTATT
GATTTATGTCTTCATTGTAGTGCCTACTGCC
TCGGA 
MCM6 MCM6.2798 TTTGGTTCCAACTTCACTGGGA TGCTGTTGACAGTGAGCGCCCCAGTGAAGTT
GGAACCAAATAGTGAAGCCACAGATGTATTT
GGTTCCAACTTCACTGGGATGCCTACTGCCT
CGGA 
MCM6 MCM6.2096 TTGATCTAGATTGACATCAGGT TGCTGTTGACAGTGAGCGCCCTGATGTCAAT
CTAGATCAATAGTGAAGCCACAGATGTATTG
ATCTAGATTGACATCAGGTTGCCTACTGCCT
CGGA 
MCM6 MCM6.2807 TTACACATGAAAACAAAGGTAT TGCTGTTGACAGTGAGCGCTACCTTTGTTTT
CATGTGTAATAGTGAAGCCACAGATGTATTA
CACATGAAAACAAAGGTATTGCCTACTGCCT
CGGA 
MCM7 MCM7.1879 TTTGACATCTCCATTAGCCTGA TGCTGTTGACAGTGAGCGCCAGGCTAATGG
AGATGTCAAATAGTGAAGCCACAGATGTATT
TGACATCTCCATTAGCCTGATGCCTACTGCC
TCGGA 
MCM7 MCM7.897 TTGTTCATCTTCACAATCCGAT TGCTGTTGACAGTGAGCGCTCGGATTGTGAA
GATGAACAATAGTGAAGCCACAGATGTATTG
TTCATCTTCACAATCCGATTGCCTACTGCCT
CGGA 
MCM7 MCM7.8 TTGTAAGAACTTCTTAACCTTT TGCTGTTGACAGTGAGCGCAAGGTTAAGAA
GTTCTTACAATAGTGAAGCCACAGATGTATT
GTAAGAACTTCTTAACCTTTTGCCTACTGCC
TCGGA 
MCM7 MCM7.60 TACTTGAACTGCTTCTTCCCGA TGCTGTTGACAGTGAGCGCCGGGAAGAAGC
AGTTCAAGTATAGTGAAGCCACAGATGTATA
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CTTGAACTGCTTCTTCCCGATGCCTACTGCC
TCGGA 
MCM7 MCM7.674 TTCTTGCATCTTCATCTCCTGG TGCTGTTGACAGTGAGCGACAGGAGATGAA
GATGCAAGAATAGTGAAGCCACAGATGTATT
CTTGCATCTTCATCTCCTGGTGCCTACTGCC
TCGGA 
MED8 MED8.2 TTTTCCAGTCGAATTCCTCGAG TGCTGTTGACAGTGAGCGATCGAGGAATTC
GACTGGAAAATAGTGAAGCCACAGATGTATT
TTCCAGTCGAATTCCTCGAGTGCCTACTGCC
TCGGA 
MED8 MED8.561 TTAAAGGTCTGCTTGTTCGGCC TGCTGTTGACAGTGAGCGAGCCGAACAAGC
AGACCTTTAATAGTGAAGCCACAGATGTATT
AAAGGTCTGCTTGTTCGGCCTGCCTACTGCC
TCGGA 
MED8 MED8.222 TTGTTCAGAGTGTTCAGCTGTC TGCTGTTGACAGTGAGCGAACAGCTGAACA
CTCTGAACAATAGTGAAGCCACAGATGTATT
GTTCAGAGTGTTCAGCTGTCTGCCTACTGCC
TCGGA 
MED8 MED8.405 TTCTCCTGTTCTTCCACTTCAG TGCTGTTGACAGTGAGCGATGAAGTGGAAG
AACAGGAGAATAGTGAAGCCACAGATGTAT
TCTCCTGTTCTTCCACTTCAGTGCCTACTGC
CTCGGA 
MED8 MED8.474 TTATTCAAGCTCTGGATCTGCT TGCTGTTGACAGTGAGCGCGCAGATCCAGA
GCTTGAATAATAGTGAAGCCACAGATGTATT
ATTCAAGCTCTGGATCTGCTTGCCTACTGCC
TCGGA 
MYBL2 MYBL2.2073 TTCTTTGATACCTGACAGGGTG TGCTGTTGACAGTGAGCGAACCCTGTCAGGT
ATCAAAGAATAGTGAAGCCACAGATGTATTC
TTTGATACCTGACAGGGTGTGCCTACTGCCT
CGGA 
MYBL2 MYBL2.2234 TTCTCCTGCATGAAAAGCTGGT TGCTGTTGACAGTGAGCGCCCAGCTTTTCAT
GCAGGAGAATAGTGAAGCCACAGATGTATT
CTCCTGCATGAAAAGCTGGTTGCCTACTGCC
TCGGA 
MYBL2 MYBL2.1874 TCGATGATGAGTTCGATGCCAG TGCTGTTGACAGTGAGCGATGGCATCGAACT
CATCATCGATAGTGAAGCCACAGATGTATCG
ATGATGAGTTCGATGCCAGTGCCTACTGCCT
CGGA 
MYBL2 MYBL2.875 TTGGTCAGAAGACTTCCCTGGC TGCTGTTGACAGTGAGCGACCAGGGAAGTC
TTCTGACCAATAGTGAAGCCACAGATGTATT
GGTCAGAAGACTTCCCTGGCTGCCTACTGCC
TCGGA 
MYBL2 MYBL2.1535 TTAACAGGTGTGCTCTTGGGCG TGCTGTTGACAGTGAGCGAGCCCAAGAGCA
CACCTGTTAATAGTGAAGCCACAGATGTATT
AACAGGTGTGCTCTTGGGCGTGCCTACTGCC
TCGGA 
NAP1L4 NAP1L4.362 TATGTGAGCACATCTCACCTGA TGCTGTTGACAGTGAGCGCCAGGTGAGATG
TGCTCACATATAGTGAAGCCACAGATGTATA
TGTGAGCACATCTCACCTGATGCCTACTGCC
TCGGA 
NAP1L4 NAP1L4.2472 TAGAATATTCTAACTATTCTGT TGCTGTTGACAGTGAGCGCCAGAATAGTTAG
AATATTCTATAGTGAAGCCACAGATGTATAG
AATATTCTAACTATTCTGTTGCCTACTGCCT
CGGA 
NAP1L4 NAP1L4.740 TAACACAAAAGACATAGGCTGT TGCTGTTGACAGTGAGCGCCAGCCTATGTCT
TTTGTGTTATAGTGAAGCCACAGATGTATAA
CACAAAAGACATAGGCTGTTGCCTACTGCCT
CGGA 
NAP1L4 NAP1L4.909 TTGACAGTAACATTCTTTCCTT TGCTGTTGACAGTGAGCGCAGGAAAGAATG
TTACTGTCAATAGTGAAGCCACAGATGTATT
GACAGTAACATTCTTTCCTTTGCCTACTGCC
TCGGA 
NAP1L4 NAP1L4.885 TTCCAGTCAATAGTACACCCGT TGCTGTTGACAGTGAGCGCCGGGTGTACTAT
TGACTGGAATAGTGAAGCCACAGATGTATTC
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CAGTCAATAGTACACCCGTTGCCTACTGCCT
CGGA 
NF1 NF1.898 TATATCATGAACATCAACATTG TGCTGTTGACAGTGAGCGAAATGTTGATGTT
CATGATATATAGTGAAGCCACAGATGTATAT
ATCATGAACATCAACATTGTGCCTACTGCCT
CGGA 
NF1 NF1.898 TATATCATGAACATCAACATTG TGCTGTTGACAGTGAGCGAAATGTTGATGTT
CATGATATATAGTGAAGCCACAGATGTATAT
ATCATGAACATCAACATTGTGCCTACTGCCT
CGGA 
NF1 NF1.1588 TAGAAGGTGAATTCTGAGCCAG TGCTGTTGACAGTGAGCGATGGCTCAGAATT
CACCTTCTATAGTGAAGCCACAGATGTATAG
AAGGTGAATTCTGAGCCAGTGCCTACTGCCT
CGGA 
NF1 NF1.1588 TAGAAGGTGAATTCTGAGCCAG TGCTGTTGACAGTGAGCGATGGCTCAGAATT
CACCTTCTATAGTGAAGCCACAGATGTATAG
AAGGTGAATTCTGAGCCAGTGCCTACTGCCT
CGGA 
NF1 NF1.561 TAAAATAGTAGTGAGGCCGCTT TGCTGTTGACAGTGAGCGCAGCGGCCTCAC
TACTATTTTATAGTGAAGCCACAGATGTATA
AAATAGTAGTGAGGCCGCTTTGCCTACTGCC
TCGGA 
NF1 NF1.561 TAAAATAGTAGTGAGGCCGCTT TGCTGTTGACAGTGAGCGCAGCGGCCTCAC
TACTATTTTATAGTGAAGCCACAGATGTATA
AAATAGTAGTGAGGCCGCTTTGCCTACTGCC
TCGGA 
NF1 NF1.1785 TTCTTTAAATGTAAGACTCGGT TGCTGTTGACAGTGAGCGCCCGAGTCTTACA
TTTAAAGAATAGTGAAGCCACAGATGTATTC
TTTAAATGTAAGACTCGGTTGCCTACTGCCT
CGGA 
NF1 NF1.1785 TTCTTTAAATGTAAGACTCGGT TGCTGTTGACAGTGAGCGCCCGAGTCTTACA
TTTAAAGAATAGTGAAGCCACAGATGTATTC
TTTAAATGTAAGACTCGGTTGCCTACTGCCT
CGGA 
NF1 NF1.1361 TTACACAGTTTGACACAGGCAA TGCTGTTGACAGTGAGCGCTGCCTGTGTCAA
ACTGTGTAATAGTGAAGCCACAGATGTATTA
CACAGTTTGACACAGGCAATGCCTACTGCCT
CGGA 
NF1 NF1.1361 TTACACAGTTTGACACAGGCAA TGCTGTTGACAGTGAGCGCTGCCTGTGTCAA
ACTGTGTAATAGTGAAGCCACAGATGTATTA
CACAGTTTGACACAGGCAATGCCTACTGCCT
CGGA 
NFE2L3 NFE2L3.943 TTCATCATCATCATTCTGCTGA TGCTGTTGACAGTGAGCGCCAGCAGAATGA
TGATGATGAATAGTGAAGCCACAGATGTATT
CATCATCATCATTCTGCTGATGCCTACTGCC
TCGGA 
NFE2L3 NFE2L3.1541 TATTATTGTGACTTGAATCTAA TGCTGTTGACAGTGAGCGCTAGATTCAAGTC
ACAATAATATAGTGAAGCCACAGATGTATAT
TATTGTGACTTGAATCTAATGCCTACTGCCT
CGGA 
NFE2L3 NFE2L3.3599 TACTCTACACTGTAGCTCCTAT TGCTGTTGACAGTGAGCGCTAGGAGCTACA
GTGTAGAGTATAGTGAAGCCACAGATGTATA
CTCTACACTGTAGCTCCTATTGCCTACTGCC
TCGGA 
NFE2L3 NFE2L3.350 TAAAGATCTAGGTCTACGCGGA TGCTGTTGACAGTGAGCGCCCGCGTAGACC
TAGATCTTTATAGTGAAGCCACAGATGTATA
AAGATCTAGGTCTACGCGGATGCCTACTGCC
TCGGA 
NFE2L3 NFE2L3.1962 TAATATCTACTTAACATGCTAT TGCTGTTGACAGTGAGCGCTAGCATGTTAAG
TAGATATTATAGTGAAGCCACAGATGTATAA
TATCTACTTAACATGCTATTGCCTACTGCCT
CGGA 
NFKB1 NFKB1.1378 TTGTCTATGAACATCTGTGGGG TGCTGTTGACAGTGAGCGACCCACAGATGTT
CATAGACAATAGTGAAGCCACAGATGTATTG
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TCTATGAACATCTGTGGGGTGCCTACTGCCT
CGGA 
NFKB1 NFKB1.2926 TTCTAGTAACTTATACAGCTGC TGCTGTTGACAGTGAGCGACAGCTGTATAAG
TTACTAGAATAGTGAAGCCACAGATGTATTC
TAGTAACTTATACAGCTGCTGCCTACTGCCT
CGGA 
NFKB1 NFKB1.3703 TTTAATGACAATAGGAACGTAG TGCTGTTGACAGTGAGCGATACGTTCCTATT
GTCATTAAATAGTGAAGCCACAGATGTATTT
AATGACAATAGGAACGTAGTGCCTACTGCCT
CGGA 
NFKB1 NFKB1.2920 TAACTTATACAGCTGCAGCTTC TGCTGTTGACAGTGAGCGAAAGCTGCAGCT
GTATAAGTTATAGTGAAGCCACAGATGTATA
ACTTATACAGCTGCAGCTTCTGCCTACTGCC
TCGGA 
NFKB1 NFKB1.2367 TTGTGCTTGAGTAAGATACTGA TGCTGTTGACAGTGAGCGCCAGTATCTTACT
CAAGCACAATAGTGAAGCCACAGATGTATT
GTGCTTGAGTAAGATACTGATGCCTACTGCC
TCGGA 
PA2G4 PA2G4.706 TTCCTTGAGAATATAATCCTGG TGCTGTTGACAGTGAGCGACAGGATTATATT
CTCAAGGAATAGTGAAGCCACAGATGTATTC
CTTGAGAATATAATCCTGGTGCCTACTGCCT
CGGA 
PA2G4 PA2G4.994 TTCTCCATCGATGACATGCTGC TGCTGTTGACAGTGAGCGACAGCATGTCATC
GATGGAGAATAGTGAAGCCACAGATGTATT
CTCCATCGATGACATGCTGCTGCCTACTGCC
TCGGA 
PA2G4 PA2G4.1492 TTCGACTTGCAGAACTCTGGAG TGCTGTTGACAGTGAGCGATCCAGAGTTCTG
CAAGTCGAATAGTGAAGCCACAGATGTATTC
GACTTGCAGAACTCTGGAGTGCCTACTGCCT
CGGA 
PA2G4 PA2G4.1812 TCATTTAAAGTAGTCTTCCGTG TGCTGTTGACAGTGAGCGAACGGAAGACTA
CTTTAAATGATAGTGAAGCCACAGATGTATC
ATTTAAAGTAGTCTTCCGTGTGCCTACTGCC
TCGGA 
PA2G4 PA2G4.1809 TTTAAAGTAGTCTTCCGTGGTT TGCTGTTGACAGTGAGCGCACCACGGAAGA
CTACTTTAAATAGTGAAGCCACAGATGTATT
TAAAGTAGTCTTCCGTGGTTTGCCTACTGCC
TCGGA 
PHTF2 PHTF2.323 TTACTTGTAACCACCACCGGAA TGCTGTTGACAGTGAGCGCTCCGGTGGTGG
TTACAAGTAATAGTGAAGCCACAGATGTATT
ACTTGTAACCACCACCGGAATGCCTACTGCC
TCGGA 
PHTF2 PHTF2.269 TACAACTCGAACAATTCCCTTT TGCTGTTGACAGTGAGCGCAAGGGAATTGTT
CGAGTTGTATAGTGAAGCCACAGATGTATAC
AACTCGAACAATTCCCTTTTGCCTACTGCCT
CGGA 
PHTF2 PHTF2.808 TTGTATTCCATCTTCACCGCTT TGCTGTTGACAGTGAGCGCAGCGGTGAAGA
TGGAATACAATAGTGAAGCCACAGATGTATT
GTATTCCATCTTCACCGCTTTGCCTACTGCC
TCGGA 
PHTF2 PHTF2.993 TTCTATTCCGAAGAACACCTTC TGCTGTTGACAGTGAGCGAAAGGTGTTCTTC
GGAATAGAATAGTGAAGCCACAGATGTATTC
TATTCCGAAGAACACCTTCTGCCTACTGCCT
CGGA 
PHTF2 PHTF2.714 TATCAATTGAATTCTTTGCTTT TGCTGTTGACAGTGAGCGCAAGCAAAGAAT
TCAATTGATATAGTGAAGCCACAGATGTATA
TCAATTGAATTCTTTGCTTTTGCCTACTGCC
TCGGA 
PMEPA1 PMEPA1.4210 TTAACTTGAACAGAGCTTGGGA TGCTGTTGACAGTGAGCGCCCCAAGCTCTGT
TCAAGTTAATAGTGAAGCCACAGATGTATTA
ACTTGAACAGAGCTTGGGATGCCTACTGCCT
CGGA 
PMEPA1 PMEPA1.3541 TAACGTGACAACTACCATCTAG TGCTGTTGACAGTGAGCGATAGATGGTAGTT
GTCACGTTATAGTGAAGCCACAGATGTATAA
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CGTGACAACTACCATCTAGTGCCTACTGCCT
CGGA 
PMEPA1 PMEPA1.4018 TTTTCTTTCCTTATCGACGGGA TGCTGTTGACAGTGAGCGCCCCGTCGATAA
GGAAAGAAAATAGTGAAGCCACAGATGTAT
TTTCTTTCCTTATCGACGGGATGCCTACTGC
CTCGGA 
PMEPA1 PMEPA1.2011 TTAAGTGAGAATTGATCCGTGA TGCTGTTGACAGTGAGCGCCACGGATCAATT
CTCACTTAATAGTGAAGCCACAGATGTATTA
AGTGAGAATTGATCCGTGATGCCTACTGCCT
CGGA 
PMEPA1 PMEPA1.2873 TTAATCATCTTTACAAGTGCGT TGCTGTTGACAGTGAGCGCCGCACTTGTAAA
GATGATTAATAGTGAAGCCACAGATGTATTA
ATCATCTTTACAAGTGCGTTGCCTACTGCCT
CGGA 
PML PML.1271 TTGAACTCGTCGAAGCCATCGG TGCTGTTGACAGTGAGCGACGATGGCTTCG
ACGAGTTCAATAGTGAAGCCACAGATGTATT
GAACTCGTCGAAGCCATCGGTGCCTACTGC
CTCGGA 
PML PML.105 TTTAGATCTTGGAGTGCGTGAA TGCTGTTGACAGTGAGCGCTCACGCACTCCA
AGATCTAAATAGTGAAGCCACAGATGTATTT
AGATCTTGGAGTGCGTGAATGCCTACTGCCT
CGGA 
PML PML.109 TCGGTTTAGATCTTGGAGTGCG TGCTGTTGACAGTGAGCGAGCACTCCAAGA
TCTAAACCGATAGTGAAGCCACAGATGTATC
GGTTTAGATCTTGGAGTGCGTGCCTACTGCC
TCGGA 
PML PML.1148 TAGCACTTCATCCTCTGCACCA TGCTGTTGACAGTGAGCGCGGTGCAGAGGA
TGAAGTGCTATAGTGAAGCCACAGATGTATA
GCACTTCATCCTCTGCACCATGCCTACTGCC
TCGGA 
PML PML.111 TCTCGGTTTAGATCTTGGAGTG TGCTGTTGACAGTGAGCGAACTCCAAGATCT
AAACCGAGATAGTGAAGCCACAGATGTATC
TCGGTTTAGATCTTGGAGTGTGCCTACTGCC
TCGGA 
PNN PNN.401 TTTAACATCATCATCCTCCGGG TGCTGTTGACAGTGAGCGACCGGAGGATGA
TGATGTTAAATAGTGAAGCCACAGATGTATT
TAACATCATCATCCTCCGGGTGCCTACTGCC
TCGGA 
PNN PNN.1071 TATTTCTACATCATTGTGCTGA TGCTGTTGACAGTGAGCGCCAGCACAATGA
TGTAGAAATATAGTGAAGCCACAGATGTATA
TTTCTACATCATTGTGCTGATGCCTACTGCC
TCGGA 
PNN PNN.2904 TACTGTTTAGTTATCTACCGAA TGCTGTTGACAGTGAGCGCTCGGTAGATAAC
TAAACAGTATAGTGAAGCCACAGATGTATAC
TGTTTAGTTATCTACCGAATGCCTACTGCCT
CGGA 
PNN PNN.2847 TTAGATTAAAATAACAAGGGAG TGCTGTTGACAGTGAGCGATCCCTTGTTATT
TTAATCTAATAGTGAAGCCACAGATGTATTA
GATTAAAATAACAAGGGAGTGCCTACTGCCT
CGGA 
PNN PNN.400 TTAACATCATCATCCTCCGGGT TGCTGTTGACAGTGAGCGCCCCGGAGGATG
ATGATGTTAATAGTGAAGCCACAGATGTATT
AACATCATCATCCTCCGGGTTGCCTACTGCC
TCGGA 
POLR1E POLR1E.1199 TTGGCTATCTCCATCATCCTTT TGCTGTTGACAGTGAGCGCAAGGATGATGG
AGATAGCCAATAGTGAAGCCACAGATGTATT
GGCTATCTCCATCATCCTTTTGCCTACTGCC
TCGGA 
POLR1E POLR1E.501 TTCAATACAAGAATCCATCTTT TGCTGTTGACAGTGAGCGCAAGATGGATTCT
TGTATTGAATAGTGAAGCCACAGATGTATTC
AATACAAGAATCCATCTTTTGCCTACTGCCT
CGGA 
POLR1E POLR1E.815 TTCAGTATTTCTTCTGACGTGA TGCTGTTGACAGTGAGCGCCACGTCAGAAG
AAATACTGAATAGTGAAGCCACAGATGTATT
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CAGTATTTCTTCTGACGTGATGCCTACTGCC
TCGGA 
POLR1E POLR1E.1264 TTGTGATCTTCTTCACTGCCGG TGCTGTTGACAGTGAGCGACGGCAGTGAAG
AAGATCACAATAGTGAAGCCACAGATGTATT
GTGATCTTCTTCACTGCCGGTGCCTACTGCC
TCGGA 
POLR1E POLR1E.467 TTTGGTCTGACTCTCTAGCGCC TGCTGTTGACAGTGAGCGAGCGCTAGAGAG
TCAGACCAAATAGTGAAGCCACAGATGTATT
TGGTCTGACTCTCTAGCGCCTGCCTACTGCC
TCGGA 
POLR2F POLR2F.1308 TCTGACTTAATGTAACACCTGG TGCTGTTGACAGTGAGCGACAGGTGTTACAT
TAAGTCAGATAGTGAAGCCACAGATGTATCT
GACTTAATGTAACACCTGGTGCCTACTGCCT
CGGA 
POLR2F POLR2F.1300 TAATGTAACACCTGGAACCCAG TGCTGTTGACAGTGAGCGATGGGTTCCAGGT
GTTACATTATAGTGAAGCCACAGATGTATAA
TGTAACACCTGGAACCCAGTGCCTACTGCCT
CGGA 
POLR2F POLR2F.112 TTGTCTGACATGACACCCTCGC TGCTGTTGACAGTGAGCGACGAGGGTGTCA
TGTCAGACAATAGTGAAGCCACAGATGTATT
GTCTGACATGACACCCTCGCTGCCTACTGCC
TCGGA 
POLR2F POLR2F.181 TTCTCCAAGTCATCTAGCCCTT TGCTGTTGACAGTGAGCGCAGGGCTAGATG
ACTTGGAGAATAGTGAAGCCACAGATGTATT
CTCCAAGTCATCTAGCCCTTTGCCTACTGCC
TCGGA 
POLR2F POLR2F.1305 TGACTTAATGTAACACCTGGAA TGCTGTTGACAGTGAGCGCTCCAGGTGTTAC
ATTAAGTCATAGTGAAGCCACAGATGTATGA
CTTAATGTAACACCTGGAATGCCTACTGCCT
CGGA 
POLR3K POLR3K.166 TTCAGTTTTGGGTACTTCCGAT TGCTGTTGACAGTGAGCGCTCGGAAGTACC
CAAAACTGAATAGTGAAGCCACAGATGTATT
CAGTTTTGGGTACTTCCGATTGCCTACTGCC
TCGGA 
POLR3K POLR3K.726 TAACAGTTAAATATTTAGGGAC TGCTGTTGACAGTGAGCGATCCCTAAATATT
TAACTGTTATAGTGAAGCCACAGATGTATAA
CAGTTAAATATTTAGGGACTGCCTACTGCCT
CGGA 
POLR3K POLR3K.313 TTGTAGAAGGTGGTCATCGGCT TGCTGTTGACAGTGAGCGCGCCGATGACCA
CCTTCTACAATAGTGAAGCCACAGATGTATT
GTAGAAGGTGGTCATCGGCTTGCCTACTGCC
TCGGA 
POLR3K POLR3K.676 TATTTAAGAGTGTTGATTGGGA TGCTGTTGACAGTGAGCGCCCCAATCAACA
CTCTTAAATATAGTGAAGCCACAGATGTATA
TTTAAGAGTGTTGATTGGGATGCCTACTGCC
TCGGA 
POLR3K POLR3K.151 TTCCGATTTGTTACCTTGCGGG TGCTGTTGACAGTGAGCGACCGCAAGGTAA
CAAATCGGAATAGTGAAGCCACAGATGTATT
CCGATTTGTTACCTTGCGGGTGCCTACTGCC
TCGGA 
PPP1R1
5A 
PPP1R15A.49 TTGCATAAGATCAACAACTGGG TGCTGTTGACAGTGAGCGACCAGTTGTTGAT
CTTATGCAATAGTGAAGCCACAGATGTATTG
CATAAGATCAACAACTGGGTGCCTACTGCCT
CGGA 
PPP1R1
5A 
PPP1R15A.96
3 
TTCTGTTCTTTTATCCTCCGTG TGCTGTTGACAGTGAGCGAACGGAGGATAA
AAGAACAGAATAGTGAAGCCACAGATGTAT
TCTGTTCTTTTATCCTCCGTGTGCCTACTGC
CTCGGA 
PPP1R1
5A 
PPP1R15A.14
94 
TTCTCTTTCATCCTCGGCTGAT TGCTGTTGACAGTGAGCGCTCAGCCGAGGA
TGAAAGAGAATAGTGAAGCCACAGATGTATT
CTCTTTCATCCTCGGCTGATTGCCTACTGCC
TCGGA 
PPP1R1
5A 
PPP1R15A.23
44 
TTTATTCCTTATATAAACCCAC TGCTGTTGACAGTGAGCGATGGGTTTATATA
AGGAATAAATAGTGAAGCCACAGATGTATTT
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ATTCCTTATATAAACCCACTGCCTACTGCCT
CGGA 
PPP1R1
5A 
PPP1R15A.96
4 
TTTCTGTTCTTTTATCCTCCGT TGCTGTTGACAGTGAGCGCCGGAGGATAAA
AGAACAGAAATAGTGAAGCCACAGATGTAT
TTCTGTTCTTTTATCCTCCGTTGCCTACTGC
CTCGGA 
PPP2R5
A 
PPP2R5A.694 TACAACACAATATGCTAGCTGA TGCTGTTGACAGTGAGCGCCAGCTAGCATAT
TGTGTTGTATAGTGAAGCCACAGATGTATAC
AACACAATATGCTAGCTGATGCCTACTGCCT
CGGA 
PPP2R5
A 
PPP2R5A.49 AAACAGTATACAACACTGCTGC TGCTGTTGACAGTGAGCGACAGCAGTGTTGT
ATACTGTTTTAGTGAAGCCACAGATGTAAAA
CAGTATACAACACTGCTGCTGCCTACTGCCT
CGGA 
PPP2R5
A 
PPP2R5A.730 TTAGTGTTGTATCTTTCTCCAG TGCTGTTGACAGTGAGCGATGGAGAAAGAT
ACAACACTAATAGTGAAGCCACAGATGTATT
AGTGTTGTATCTTTCTCCAGTGCCTACTGCC
TCGGA 
PPP2R5
A 
PPP2R5A.96 TTCTTTGCTCTTCAAGTCTGAA TGCTGTTGACAGTGAGCGCTCAGACTTGAAG
AGCAAAGAATAGTGAAGCCACAGATGTATT
CTTTGCTCTTCAAGTCTGAATGCCTACTGCC
TCGGA 
PPP2R5
A 
PPP2R5A.183 TACTATATCAGAATACGCTGAT TGCTGTTGACAGTGAGCGCTCAGCGTATTCT
GATATAGTATAGTGAAGCCACAGATGTATAC
TATATCAGAATACGCTGATTGCCTACTGCCT
CGGA 
PPP2R5
B 
PPP2R5B.118
1 
TTTTGATCCACATATCTCTTGG TGCTGTTGACAGTGAGCGACAAGAGATATGT
GGATCAAAATAGTGAAGCCACAGATGTATTT
TGATCCACATATCTCTTGGTGCCTACTGCCT
CGGA 
PPP2R5
B 
PPP2R5B.273
3 
TTTTCTTGAATTTCTCTCTTTA TGCTGTTGACAGTGAGCGCAAAGAGAGAAA
TTCAAGAAAATAGTGAAGCCACAGATGTATT
TTCTTGAATTTCTCTCTTTATGCCTACTGCCT
CGGA 
PPP2R5
B 
PPP2R5B.134
2 
TCGAATTCATAGATGAACCGGA TGCTGTTGACAGTGAGCGCCCGGTTCATCTA
TGAATTCGATAGTGAAGCCACAGATGTATCG
AATTCATAGATGAACCGGATGCCTACTGCCT
CGGA 
PPP2R5
B 
PPP2R5B.117
8 
TTGATCCACATATCTCTTGGCC TGCTGTTGACAGTGAGCGAGCCAAGAGATA
TGTGGATCAATAGTGAAGCCACAGATGTATT
GATCCACATATCTCTTGGCCTGCCTACTGCC
TCGGA 
PPP2R5
B 
PPP2R5B.187
9 
TTGAGCACATTGTAGATCAGTG TGCTGTTGACAGTGAGCGAACTGATCTACAA
TGTGCTCAATAGTGAAGCCACAGATGTATTG
AGCACATTGTAGATCAGTGTGCCTACTGCCT
CGGA 
PPP2R5
C 
PPP2R5C.120
8 
TAGATTTTCTATTTTAACCCAT TGCTGTTGACAGTGAGCGCTGGGTTAAAATA
GAAAATCTATAGTGAAGCCACAGATGTATAG
ATTTTCTATTTTAACCCATTGCCTACTGCCT
CGGA 
PPP2R5
C 
PPP2R5C.118 TTTCACTTAAAGCAGCTCGTTT TGCTGTTGACAGTGAGCGCAACGAGCTGCTT
TAAGTGAAATAGTGAAGCCACAGATGTATTT
CACTTAAAGCAGCTCGTTTTGCCTACTGCCT
CGGA 
PPP2R5
C 
PPP2R5C.115
9 
TTCTCTTTTAGTTTCTCTGCTT TGCTGTTGACAGTGAGCGCAGCAGAGAAAC
TAAAAGAGAATAGTGAAGCCACAGATGTATT
CTCTTTTAGTTTCTCTGCTTTGCCTACTGCC
TCGGA 
PPP2R5
C 
PPP2R5C.631 TTGTGCTCTTCTTTTAGTGGTA TGCTGTTGACAGTGAGCGCACCACTAAAAG
AAGAGCACAATAGTGAAGCCACAGATGTAT
TGTGCTCTTCTTTTAGTGGTATGCCTACTGC
CTCGGA 
PPP2R5
C 
PPP2R5C.362 TATATTAGGTTGGAAATCTGGA TGCTGTTGACAGTGAGCGCCCAGATTTCCAA
CCTAATATATAGTGAAGCCACAGATGTATAT
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ATTAGGTTGGAAATCTGGATGCCTACTGCCT
CGGA 
PPP2R5E PPP2R5E.679 TAAACTGTGAGGAACTTTGCGA TGCTGTTGACAGTGAGCGCCGCAAAGTTCCT
CACAGTTTATAGTGAAGCCACAGATGTATAA
ACTGTGAGGAACTTTGCGATGCCTACTGCCT
CGGA 
PPP2R5E PPP2R5E.268
3 
TAAACTGATGCATGAATCCGAT TGCTGTTGACAGTGAGCGCTCGGATTCATGC
ATCAGTTTATAGTGAAGCCACAGATGTATAA
ACTGATGCATGAATCCGATTGCCTACTGCCT
CGGA 
PPP2R5E PPP2R5E.124
0 
TATTGTTAATCTGTTTTCGGAT TGCTGTTGACAGTGAGCGCTCCGAAAACAG
ATTAACAATATAGTGAAGCCACAGATGTATA
TTGTTAATCTGTTTTCGGATTGCCTACTGCC
TCGGA 
PPP2R5E PPP2R5E.126
9 
TTCTGTTTCATAAACAAACCTT TGCTGTTGACAGTGAGCGCAGGTTTGTTTAT
GAAACAGAATAGTGAAGCCACAGATGTATT
CTGTTTCATAAACAAACCTTTGCCTACTGCC
TCGGA 
PPP2R5E PPP2R5E.203
1 
TTCTACTACATAAACGTGTGAC TGCTGTTGACAGTGAGCGATCACACGTTTAT
GTAGTAGAATAGTGAAGCCACAGATGTATTC
TACTACATAAACGTGTGACTGCCTACTGCCT
CGGA 
PTTG1 PTTG1.670 TACAAATACACACAAACTCTGA TGCTGTTGACAGTGAGCGCCAGAGTTTGTGT
GTATTTGTATAGTGAAGCCACAGATGTATAC
AAATACACACAAACTCTGATGCCTACTGCCT
CGGA 
PTTG1 PTTG1.327 TTTGCTTTAACAGTCTTCTCAG TGCTGTTGACAGTGAGCGATGAGAAGACTG
TTAAAGCAAATAGTGAAGCCACAGATGTATT
TGCTTTAACAGTCTTCTCAGTGCCTACTGCC
TCGGA 
PTTG1 PTTG1.18 TATTGCAGGTCTTAACAGCCGC TGCTGTTGACAGTGAGCGACGGCTGTTAAG
ACCTGCAATATAGTGAAGCCACAGATGTATA
TTGCAGGTCTTAACAGCCGCTGCCTACTGCC
TCGGA 
PTTG1 PTTG1.236 TAGCTCTGTTGACAGTTCCCAA TGCTGTTGACAGTGAGCGCTGGGAACTGTC
AACAGAGCTATAGTGAAGCCACAGATGTAT
AGCTCTGTTGACAGTTCCCAATGCCTACTGC
CTCGGA 
PTTG1 PTTG1.7 TTAACAGCCGCATTCATCTGAG TGCTGTTGACAGTGAGCGATCAGATGAATGC
GGCTGTTAATAGTGAAGCCACAGATGTATTA
ACAGCCGCATTCATCTGAGTGCCTACTGCCT
CGGA 
RASA1 RASA1.1954 TTATCTTTAAAATAGAGTCTTT TGCTGTTGACAGTGAGCGCAAGACTCTATTT
TAAAGATAATAGTGAAGCCACAGATGTATTA
TCTTTAAAATAGAGTCTTTTGCCTACTGCCT
CGGA 
RASA1 RASA1.1954 TTATCTTTAAAATAGAGTCTTT TGCTGTTGACAGTGAGCGCAAGACTCTATTT
TAAAGATAATAGTGAAGCCACAGATGTATTA
TCTTTAAAATAGAGTCTTTTGCCTACTGCCT
CGGA 
RASA1 RASA1.396 TAGAATAGCTCGTACACGCCTT TGCTGTTGACAGTGAGCGCAGGCGTGTACG
AGCTATTCTATAGTGAAGCCACAGATGTATA
GAATAGCTCGTACACGCCTTTGCCTACTGCC
TCGGA 
RASA1 RASA1.396 TAGAATAGCTCGTACACGCCTT TGCTGTTGACAGTGAGCGCAGGCGTGTACG
AGCTATTCTATAGTGAAGCCACAGATGTATA
GAATAGCTCGTACACGCCTTTGCCTACTGCC
TCGGA 
RASA1 RASA1.573 TTCATGTGGATCTTCTTCCCGG TGCTGTTGACAGTGAGCGACGGGAAGAAGA
TCCACATGAATAGTGAAGCCACAGATGTATT
CATGTGGATCTTCTTCCCGGTGCCTACTGCC
TCGGA 
RASA1 RASA1.573 TTCATGTGGATCTTCTTCCCGG TGCTGTTGACAGTGAGCGACGGGAAGAAGA
TCCACATGAATAGTGAAGCCACAGATGTATT
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CATGTGGATCTTCTTCCCGGTGCCTACTGCC
TCGGA 
RASA1 RASA1.2153 TAAATATATCTCAATGTCGGTG TGCTGTTGACAGTGAGCGAACCGACATTGA
GATATATTTATAGTGAAGCCACAGATGTATA
AATATATCTCAATGTCGGTGTGCCTACTGCC
TCGGA 
RASA1 RASA1.2153 TAAATATATCTCAATGTCGGTG TGCTGTTGACAGTGAGCGAACCGACATTGA
GATATATTTATAGTGAAGCCACAGATGTATA
AATATATCTCAATGTCGGTGTGCCTACTGCC
TCGGA 
RASA1 RASA1.3593 TAAAACTATACAGTTGAACTAA TGCTGTTGACAGTGAGCGCTAGTTCAACTGT
ATAGTTTTATAGTGAAGCCACAGATGTATAA
AACTATACAGTTGAACTAATGCCTACTGCCT
CGGA 
RASA1 RASA1.3593 TAAAACTATACAGTTGAACTAA TGCTGTTGACAGTGAGCGCTAGTTCAACTGT
ATAGTTTTATAGTGAAGCCACAGATGTATAA
AACTATACAGTTGAACTAATGCCTACTGCCT
CGGA 
RASA2 RASA2.1380 TTGTATTGAATAACTTGTCTAC TGCTGTTGACAGTGAGCGATAGACAAGTTAT
TCAATACAATAGTGAAGCCACAGATGTATTG
TATTGAATAACTTGTCTACTGCCTACTGCCT
CGGA 
RASA2 RASA2.1380 TTGTATTGAATAACTTGTCTAC TGCTGTTGACAGTGAGCGATAGACAAGTTAT
TCAATACAATAGTGAAGCCACAGATGTATTG
TATTGAATAACTTGTCTACTGCCTACTGCCT
CGGA 
RASA2 RASA2.1884 TTGTTAAGCAGAACCATCGTTT TGCTGTTGACAGTGAGCGCAACGATGGTTCT
GCTTAACAATAGTGAAGCCACAGATGTATTG
TTAAGCAGAACCATCGTTTTGCCTACTGCCT
CGGA 
RASA2 RASA2.1884 TTGTTAAGCAGAACCATCGTTT TGCTGTTGACAGTGAGCGCAACGATGGTTCT
GCTTAACAATAGTGAAGCCACAGATGTATTG
TTAAGCAGAACCATCGTTTTGCCTACTGCCT
CGGA 
RASA2 RASA2.760 TTGTTCCACAAGTCGATCCTGA TGCTGTTGACAGTGAGCGCCAGGATCGACTT
GTGGAACAATAGTGAAGCCACAGATGTATT
GTTCCACAAGTCGATCCTGATGCCTACTGCC
TCGGA 
RASA2 RASA2.760 TTGTTCCACAAGTCGATCCTGA TGCTGTTGACAGTGAGCGCCAGGATCGACTT
GTGGAACAATAGTGAAGCCACAGATGTATT
GTTCCACAAGTCGATCCTGATGCCTACTGCC
TCGGA 
RASA2 RASA2.449 TTCAAGGTGAACTTTACCCTGA TGCTGTTGACAGTGAGCGCCAGGGTAAAGT
TCACCTTGAATAGTGAAGCCACAGATGTATT
CAAGGTGAACTTTACCCTGATGCCTACTGCC
TCGGA 
RASA2 RASA2.449 TTCAAGGTGAACTTTACCCTGA TGCTGTTGACAGTGAGCGCCAGGGTAAAGT
TCACCTTGAATAGTGAAGCCACAGATGTATT
CAAGGTGAACTTTACCCTGATGCCTACTGCC
TCGGA 
RASA2 RASA2.2057 TTCTACACAGTTATTTGCCTGG TGCTGTTGACAGTGAGCGACAGGCAAATAA
CTGTGTAGAATAGTGAAGCCACAGATGTATT
CTACACAGTTATTTGCCTGGTGCCTACTGCC
TCGGA 
RASA2 RASA2.2057 TTCTACACAGTTATTTGCCTGG TGCTGTTGACAGTGAGCGACAGGCAAATAA
CTGTGTAGAATAGTGAAGCCACAGATGTATT
CTACACAGTTATTTGCCTGGTGCCTACTGCC
TCGGA 
RASA3 RASA3.2532 TATTTCGTCTTCTTGAACTTGT TGCTGTTGACAGTGAGCGCCAAGTTCAAGA
AGACGAAATATAGTGAAGCCACAGATGTAT
ATTTCGTCTTCTTGAACTTGTTGCCTACTGC
CTCGGA 
RASA3 RASA3.3525 TTACTTTGTATCAAAGAGCTAA TGCTGTTGACAGTGAGCGCTAGCTCTTTGAT
ACAAAGTAATAGTGAAGCCACAGATGTATTA
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CTTTGTATCAAAGAGCTAATGCCTACTGCCT
CGGA 
RASA3 RASA3.276 TTTTCCACAATTTTGGTCCTGA TGCTGTTGACAGTGAGCGCCAGGACCAAAA
TTGTGGAAAATAGTGAAGCCACAGATGTATT
TTCCACAATTTTGGTCCTGATGCCTACTGCC
TCGGA 
RASA3 RASA3.4009 TTTGTGACAAGAAAGTTCCTAT TGCTGTTGACAGTGAGCGCTAGGAACTTTCT
TGTCACAAATAGTGAAGCCACAGATGTATTT
GTGACAAGAAAGTTCCTATTGCCTACTGCCT
CGGA 
RASA3 RASA3.707 TAAAACACTTCATCGAACTGGG TGCTGTTGACAGTGAGCGACCAGTTCGATGA
AGTGTTTTATAGTGAAGCCACAGATGTATAA
AACACTTCATCGAACTGGGTGCCTACTGCCT
CGGA 
RASA4 RASA4.4988 TTAATAATTCCAATCATCCTAT TGCTGTTGACAGTGAGCGCTAGGATGATTG
GAATTATTAATAGTGAAGCCACAGATGTATT
AATAATTCCAATCATCCTATTGCCTACTGCC
TCGGA 
RASA4 RASA4.4126 TTTCGTGATCTCTTCTTCCCTT TGCTGTTGACAGTGAGCGCAGGGAAGAAGA
GATCACGAAATAGTGAAGCCACAGATGTATT
TCGTGATCTCTTCTTCCCTTTGCCTACTGCC
TCGGA 
RASA4 RASA4.4422 TAAAAATACAAGAATTAGCTGG TGCTGTTGACAGTGAGCGACAGCTAATTCTT
GTATTTTTATAGTGAAGCCACAGATGTATAA
AAATACAAGAATTAGCTGGTGCCTACTGCCT
CGGA 
RASA4 RASA4.3049 TTTGAGGAGAGAACAGCTGGTT TGCTGTTGACAGTGAGCGCACCAGCTGTTCT
CTCCTCAAATAGTGAAGCCACAGATGTATTT
GAGGAGAGAACAGCTGGTTTGCCTACTGCC
TCGGA 
RASA4 RASA4.3459 TCAAGTTTTGCCAACCATCGGA TGCTGTTGACAGTGAGCGCCCGATGGTTGG
CAAAACTTGATAGTGAAGCCACAGATGTATC
AAGTTTTGCCAACCATCGGATGCCTACTGCC
TCGGA 
RASAL1 RASAL1.3203 TTCTAGCAGACATTCTAGCGGG TGCTGTTGACAGTGAGCGACCGCTAGAATGT
CTGCTAGAATAGTGAAGCCACAGATGTATTC
TAGCAGACATTCTAGCGGGTGCCTACTGCCT
CGGA 
RASAL1 RASAL1.3203 TTCTAGCAGACATTCTAGCGGG TGCTGTTGACAGTGAGCGACCGCTAGAATGT
CTGCTAGAATAGTGAAGCCACAGATGTATTC
TAGCAGACATTCTAGCGGGTGCCTACTGCCT
CGGA 
RASAL1 RASAL1.3202 TCTAGCAGACATTCTAGCGGGT TGCTGTTGACAGTGAGCGCCCCGCTAGAAT
GTCTGCTAGATAGTGAAGCCACAGATGTATC
TAGCAGACATTCTAGCGGGTTGCCTACTGCC
TCGGA 
RASAL1 RASAL1.3202 TCTAGCAGACATTCTAGCGGGT TGCTGTTGACAGTGAGCGCCCCGCTAGAAT
GTCTGCTAGATAGTGAAGCCACAGATGTATC
TAGCAGACATTCTAGCGGGTTGCCTACTGCC
TCGGA 
RASAL1 RASAL1.3144 TTCTTGAACTACCTCATTGGAA TGCTGTTGACAGTGAGCGCTCCAATGAGGTA
GTTCAAGAATAGTGAAGCCACAGATGTATTC
TTGAACTACCTCATTGGAATGCCTACTGCCT
CGGA 
RASAL1 RASAL1.3144 TTCTTGAACTACCTCATTGGAA TGCTGTTGACAGTGAGCGCTCCAATGAGGTA
GTTCAAGAATAGTGAAGCCACAGATGTATTC
TTGAACTACCTCATTGGAATGCCTACTGCCT
CGGA 
RASAL1 RASAL1.2886 TTAGCAGACATGAAAACAGGAA TGCTGTTGACAGTGAGCGCTCCTGTTTTCAT
GTCTGCTAATAGTGAAGCCACAGATGTATTA
GCAGACATGAAAACAGGAATGCCTACTGCC
TCGGA 
RASAL1 RASAL1.2886 TTAGCAGACATGAAAACAGGAA TGCTGTTGACAGTGAGCGCTCCTGTTTTCAT
GTCTGCTAATAGTGAAGCCACAGATGTATTA
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GCAGACATGAAAACAGGAATGCCTACTGCC
TCGGA 
RASAL1 RASAL1.1181 TAAACTGTTCCATCGACTTGGA TGCTGTTGACAGTGAGCGCCCAAGTCGATG
GAACAGTTTATAGTGAAGCCACAGATGTATA
AACTGTTCCATCGACTTGGATGCCTACTGCC
TCGGA 
RASAL1 RASAL1.1181 TAAACTGTTCCATCGACTTGGA TGCTGTTGACAGTGAGCGCCCAAGTCGATG
GAACAGTTTATAGTGAAGCCACAGATGTATA
AACTGTTCCATCGACTTGGATGCCTACTGCC
TCGGA 
RASAL2 RASAL2.9009 TATAGTAGCAACTTTAGTCTGA TGCTGTTGACAGTGAGCGCCAGACTAAAGTT
GCTACTATATAGTGAAGCCACAGATGTATAT
AGTAGCAACTTTAGTCTGATGCCTACTGCCT
CGGA 
RASAL2 RASAL2.9009 TATAGTAGCAACTTTAGTCTGA TGCTGTTGACAGTGAGCGCCAGACTAAAGTT
GCTACTATATAGTGAAGCCACAGATGTATAT
AGTAGCAACTTTAGTCTGATGCCTACTGCCT
CGGA 
RASAL2 RASAL2.6025 TAACTTAACATTTAACATCTAT TGCTGTTGACAGTGAGCGCTAGATGTTAAAT
GTTAAGTTATAGTGAAGCCACAGATGTATAA
CTTAACATTTAACATCTATTGCCTACTGCCT
CGGA 
RASAL2 RASAL2.6025 TAACTTAACATTTAACATCTAT TGCTGTTGACAGTGAGCGCTAGATGTTAAAT
GTTAAGTTATAGTGAAGCCACAGATGTATAA
CTTAACATTTAACATCTATTGCCTACTGCCT
CGGA 
RASAL2 RASAL2.3477 TTGTGAAGTAGCAACATTCTGT TGCTGTTGACAGTGAGCGCCAGAATGTTGCT
ACTTCACAATAGTGAAGCCACAGATGTATTG
TGAAGTAGCAACATTCTGTTGCCTACTGCCT
CGGA 
RASAL2 RASAL2.3477 TTGTGAAGTAGCAACATTCTGT TGCTGTTGACAGTGAGCGCCAGAATGTTGCT
ACTTCACAATAGTGAAGCCACAGATGTATTG
TGAAGTAGCAACATTCTGTTGCCTACTGCCT
CGGA 
RASAL2 RASAL2.8696 TATCATTGTAAAATAGTCGTGT TGCTGTTGACAGTGAGCGCCACGACTATTTT
ACAATGATATAGTGAAGCCACAGATGTATAT
CATTGTAAAATAGTCGTGTTGCCTACTGCCT
CGGA 
RASAL2 RASAL2.8696 TATCATTGTAAAATAGTCGTGT TGCTGTTGACAGTGAGCGCCACGACTATTTT
ACAATGATATAGTGAAGCCACAGATGTATAT
CATTGTAAAATAGTCGTGTTGCCTACTGCCT
CGGA 
RASAL2 RASAL2.459 TTAGGTTGAACTGTCCTGCGAA TGCTGTTGACAGTGAGCGCTCGCAGGACAG
TTCAACCTAATAGTGAAGCCACAGATGTATT
AGGTTGAACTGTCCTGCGAATGCCTACTGCC
TCGGA 
RASAL2 RASAL2.459 TTAGGTTGAACTGTCCTGCGAA TGCTGTTGACAGTGAGCGCTCGCAGGACAG
TTCAACCTAATAGTGAAGCCACAGATGTATT
AGGTTGAACTGTCCTGCGAATGCCTACTGCC
TCGGA 
RASGRF
1 
RASGRF1.265
8 
TACATTACTATATTCCTGCTAG TGCTGTTGACAGTGAGCGATAGCAGGAATAT
AGTAATGTATAGTGAAGCCACAGATGTATAC
ATTACTATATTCCTGCTAGTGCCTACTGCCT
CGGA 
RASGRF
1 
RASGRF1.302
9 
TATGGTGTCCTTGACACTCTGG TGCTGTTGACAGTGAGCGACAGAGTGTCAA
GGACACCATATAGTGAAGCCACAGATGTAT
ATGGTGTCCTTGACACTCTGGTGCCTACTGC
CTCGGA 
RASGRF
1 
RASGRF1.173
8 
TACAGTATCATCTAGCACATGT TGCTGTTGACAGTGAGCGCCATGTGCTAGAT
GATACTGTATAGTGAAGCCACAGATGTATAC
AGTATCATCTAGCACATGTTGCCTACTGCCT
CGGA 
RASGRF
1 
RASGRF1.234
2 
TAATCCTAGAGCAAGGAGCGAC TGCTGTTGACAGTGAGCGATCGCTCCTTGCT
CTAGGATTATAGTGAAGCCACAGATGTATAA
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TCCTAGAGCAAGGAGCGACTGCCTACTGCC
TCGGA 
RASGRF
1 
RASGRF1.277
1 
TTGTCTGTCTGTTGTAGTGGAG TGCTGTTGACAGTGAGCGATCCACTACAACA
GACAGACAATAGTGAAGCCACAGATGTATT
GTCTGTCTGTTGTAGTGGAGTGCCTACTGCC
TCGGA 
RBM14 RBM14.1421 TTTAGCTATCATGTCTTCCTGG TGCTGTTGACAGTGAGCGACAGGAAGACAT
GATAGCTAAATAGTGAAGCCACAGATGTATT
TAGCTATCATGTCTTCCTGGTGCCTACTGCC
TCGGA 
RBM14 RBM14.3781 TAAATCTAGACATAAAACCCAG TGCTGTTGACAGTGAGCGATGGGTTTTATGT
CTAGATTTATAGTGAAGCCACAGATGTATAA
ATCTAGACATAAAACCCAGTGCCTACTGCCT
CGGA 
RBM14 RBM14.1281 TTTTCTAACACCACCTACTTGG TGCTGTTGACAGTGAGCGACAAGTAGGTGG
TGTTAGAAAATAGTGAAGCCACAGATGTATT
TTCTAACACCACCTACTTGGTGCCTACTGCC
TCGGA 
RBM14 RBM14.1437 TTAGCTATCATGTCTTCCTGGA TGCTGTTGACAGTGAGCGCCCAGGAAGACA
TGATAGCTAATAGTGAAGCCACAGATGTATT
AGCTATCATGTCTTCCTGGATGCCTACTGCC
TCGGA 
RBM14 RBM14.1332 TTGTAGTCCATACAAAAGGGAA TGCTGTTGACAGTGAGCGCTCCCTTTTGTAT
GGACTACAATAGTGAAGCCACAGATGTATTG
TAGTCCATACAAAAGGGAATGCCTACTGCCT
CGGA 
RNF138 RNF138.759 TTACATTAGTGAAACATCTTTT TGCTGTTGACAGTGAGCGCAAAGATGTTTCA
CTAATGTAATAGTGAAGCCACAGATGTATTA
CATTAGTGAAACATCTTTTTGCCTACTGCCT
CGGA 
RNF138 RNF138.2339 TAACTTGACATATTGGATGTAT TGCTGTTGACAGTGAGCGCTACATCCAATAT
GTCAAGTTATAGTGAAGCCACAGATGTATAA
CTTGACATATTGGATGTATTGCCTACTGCCT
CGGA 
RNF138 RNF138.2861 TACATCTCAAATAAGACTCTGT TGCTGTTGACAGTGAGCGCCAGAGTCTTATT
TGAGATGTATAGTGAAGCCACAGATGTATAC
ATCTCAAATAAGACTCTGTTGCCTACTGCCT
CGGA 
RNF138 RNF138.481 TTGGGTTTCTTCATCTAGCTGA TGCTGTTGACAGTGAGCGCCAGCTAGATGA
AGAAACCCAATAGTGAAGCCACAGATGTATT
GGGTTTCTTCATCTAGCTGATGCCTACTGCC
TCGGA 
RNF138 RNF138.2166 TAAAATGACAGAACAAAGGCGT TGCTGTTGACAGTGAGCGCCGCCTTTGTTCT
GTCATTTTATAGTGAAGCCACAGATGTATAA
AATGACAGAACAAAGGCGTTGCCTACTGCC
TCGGA 
RUVBL1 RUVBL1.487 TTCACCTTCATAAACTTCCTTG TGCTGTTGACAGTGAGCGAAAGGAAGTTTAT
GAAGGTGAATAGTGAAGCCACAGATGTATT
CACCTTCATAAACTTCCTTGTGCCTACTGCC
TCGGA 
RUVBL1 RUVBL1.907 TTTGTCTGTGATTTCTGTCTTC TGCTGTTGACAGTGAGCGAAAGACAGAAAT
CACAGACAAATAGTGAAGCCACAGATGTATT
TGTCTGTGATTTCTGTCTTCTGCCTACTGCC
TCGGA 
RUVBL1 RUVBL1.1673 TTATAGAAAACACACCAGGTAA TGCTGTTGACAGTGAGCGCTACCTGGTGTGT
TTTCTATAATAGTGAAGCCACAGATGTATTA
TAGAAAACACACCAGGTAATGCCTACTGCCT
CGGA 
RUVBL1 RUVBL1.989 TCAACAAACAGCACACCCGGGA TGCTGTTGACAGTGAGCGCCCCGGGTGTGC
TGTTTGTTGATAGTGAAGCCACAGATGTATC
AACAAACAGCACACCCGGGATGCCTACTGC
CTCGGA 
RUVBL1 RUVBL1.1338 TTTAGCAAGCAAGTTGGCCGGG TGCTGTTGACAGTGAGCGACCGGCCAACTT
GCTTGCTAAATAGTGAAGCCACAGATGTATT
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TAGCAAGCAAGTTGGCCGGGTGCCTACTGC
CTCGGA 
SFPQ SFPQ.2323 TATTAGGTCAATAAACTGCTAA TGCTGTTGACAGTGAGCGCTAGCAGTTTATT
GACCTAATATAGTGAAGCCACAGATGTATAT
TAGGTCAATAAACTGCTAATGCCTACTGCCT
CGGA 
SFPQ SFPQ.1022 TAGTCTTTTGAATTCATCCTCC TGCTGTTGACAGTGAGCGAGAGGATGAATT
CAAAAGACTATAGTGAAGCCACAGATGTATA
GTCTTTTGAATTCATCCTCCTGCCTACTGCC
TCGGA 
SFPQ SFPQ.1062 TTGTTGATAAAAACTTCTCCTG TGCTGTTGACAGTGAGCGAAGGAGAAGTTTT
TATCAACAATAGTGAAGCCACAGATGTATTG
TTGATAAAAACTTCTCCTGTGCCTACTGCCT
CGGA 
SFPQ SFPQ.1734 TTGTGAAGTTCTTCCATGCGTC TGCTGTTGACAGTGAGCGAACGCATGGAAG
AACTTCACAATAGTGAAGCCACAGATGTATT
GTGAAGTTCTTCCATGCGTCTGCCTACTGCC
TCGGA 
SFPQ SFPQ.1059 TTGATAAAAACTTCTCCTGGTT TGCTGTTGACAGTGAGCGCACCAGGAGAAG
TTTTTATCAATAGTGAAGCCACAGATGTATT
GATAAAAACTTCTCCTGGTTTGCCTACTGCC
TCGGA 
SKI SKI.3286 TTGACTGCTCTATAAATCGGTA TGCTGTTGACAGTGAGCGCACCGATTTATAG
AGCAGTCAATAGTGAAGCCACAGATGTATTG
ACTGCTCTATAAATCGGTATGCCTACTGCCT
CGGA 
SKI SKI.4039 TTGCATAACAAAACCGACCCTT TGCTGTTGACAGTGAGCGCAGGGTCGGTTTT
GTTATGCAATAGTGAAGCCACAGATGTATTG
CATAACAAAACCGACCCTTTGCCTACTGCCT
CGGA 
SKI SKI.5673 TTATTGTACAATGTCATCTGTT TGCTGTTGACAGTGAGCGCACAGATGACATT
GTACAATAATAGTGAAGCCACAGATGTATTA
TTGTACAATGTCATCTGTTTGCCTACTGCCT
CGGA 
SKI SKI.4968 TACATGTATAATACAACGGTGA TGCTGTTGACAGTGAGCGCCACCGTTGTATT
ATACATGTATAGTGAAGCCACAGATGTATAC
ATGTATAATACAACGGTGATGCCTACTGCCT
CGGA 
SKI SKI.5667 TACAATGTCATCTGTTTCGGGG TGCTGTTGACAGTGAGCGACCCGAAACAGA
TGACATTGTATAGTGAAGCCACAGATGTATA
CAATGTCATCTGTTTCGGGGTGCCTACTGCC
TCGGA 
SMAD6 SMAD6.865 TACATTGTAAAAATGACTCCAT TGCTGTTGACAGTGAGCGCTGGAGTCATTTT
TACAATGTATAGTGAAGCCACAGATGTATAC
ATTGTAAAAATGACTCCATTGCCTACTGCCT
CGGA 
SMAD6 SMAD6.941 TATTGAAAGAATTATAAGCCAA TGCTGTTGACAGTGAGCGCTGGCTTATAATT
CTTTCAATATAGTGAAGCCACAGATGTATAT
TGAAAGAATTATAAGCCAATGCCTACTGCCT
CGGA 
SMAD6 SMAD6.82 TTTCAGTGTAAGACAATGTGGA TGCTGTTGACAGTGAGCGCCCACATTGTCTT
ACACTGAAATAGTGAAGCCACAGATGTATTT
CAGTGTAAGACAATGTGGATGCCTACTGCCT
CGGA 
SMAD6 SMAD6.81 TTCAGTGTAAGACAATGTGGAA TGCTGTTGACAGTGAGCGCTCCACATTGTCT
TACACTGAATAGTGAAGCCACAGATGTATTC
AGTGTAAGACAATGTGGAATGCCTACTGCCT
CGGA 
SMAD6 SMAD6.1061 TATCTCAAAAACCATACACCAA TGCTGTTGACAGTGAGCGCTGGTGTATGGTT
TTTGAGATATAGTGAAGCCACAGATGTATAT
CTCAAAAACCATACACCAATGCCTACTGCCT
CGGA 
SMAD7 SMAD7.390 TTGTGTACCAACAGCGTCCTGG TGCTGTTGACAGTGAGCGACAGGACGCTGT
TGGTACACAATAGTGAAGCCACAGATGTATT
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GTGTACCAACAGCGTCCTGGTGCCTACTGCC
TCGGA 
SMAD7 SMAD7.1703 TTGAGCTAAGAACAGTGTCGAA TGCTGTTGACAGTGAGCGCTCGACACTGTTC
TTAGCTCAATAGTGAAGCCACAGATGTATTG
AGCTAAGAACAGTGTCGAATGCCTACTGCCT
CGGA 
SMAD7 SMAD7.1953 TTCTTGTTTATACACATTGCAC TGCTGTTGACAGTGAGCGATGCAATGTGTAT
AAACAAGAATAGTGAAGCCACAGATGTATTC
TTGTTTATACACATTGCACTGCCTACTGCCT
CGGA 
SMAD7 SMAD7.2099 TTTAATGGAACATAAACTCCTT TGCTGTTGACAGTGAGCGCAGGAGTTTATGT
TCCATTAAATAGTGAAGCCACAGATGTATTT
AATGGAACATAAACTCCTTTGCCTACTGCCT
CGGA 
SMAD7 SMAD7.239 TTGTTGTCCGAATTGAGCTGTC TGCTGTTGACAGTGAGCGAACAGCTCAATTC
GGACAACAATAGTGAAGCCACAGATGTATT
GTTGTCCGAATTGAGCTGTCTGCCTACTGCC
TCGGA 
SMC3 SMC3.1337 TTTCTTGTCATTAATAGCCTGA TGCTGTTGACAGTGAGCGCCAGGCTATTAAT
GACAAGAAATAGTGAAGCCACAGATGTATTT
CTTGTCATTAATAGCCTGATGCCTACTGCCT
CGGA 
SMC3 SMC3.1442 TTTGACTTCATTAAGATCCTGG TGCTGTTGACAGTGAGCGACAGGATCTTAAT
GAAGTCAAATAGTGAAGCCACAGATGTATTT
GACTTCATTAAGATCCTGGTGCCTACTGCCT
CGGA 
SMC3 SMC3.860 TTCTCCACTAGTCTCTCGCTTA TGCTGTTGACAGTGAGCGCAAGCGAGAGAC
TAGTGGAGAATAGTGAAGCCACAGATGTATT
CTCCACTAGTCTCTCGCTTATGCCTACTGCC
TCGGA 
SMC3 SMC3.905 TTTATCTCTTGCATCCTGCTGA TGCTGTTGACAGTGAGCGCCAGCAGGATGC
AAGAGATAAATAGTGAAGCCACAGATGTATT
TATCTCTTGCATCCTGCTGATGCCTACTGCC
TCGGA 
SMC3 SMC3.3106 TAACTTTTCTTTCTGCTCGGAG TGCTGTTGACAGTGAGCGATCCGAGCAGAA
AGAAAAGTTATAGTGAAGCCACAGATGTATA
ACTTTTCTTTCTGCTCGGAGTGCCTACTGCC
TCGGA 
SMURF2 SMURF2.1967 TAAACTGTTGTGAAGATCCGGA TGCTGTTGACAGTGAGCGCCCGGATCTTCAC
AACAGTTTATAGTGAAGCCACAGATGTATAA
ACTGTTGTGAAGATCCGGATGCCTACTGCCT
CGGA 
SMURF2 SMURF2.1494 TTTCTGAACCAGGTCTCGCTTG TGCTGTTGACAGTGAGCGAAAGCGAGACCT
GGTTCAGAAATAGTGAAGCCACAGATGTATT
TCTGAACCAGGTCTCGCTTGTGCCTACTGCC
TCGGA 
SMURF2 SMURF2.3699 TTTAGAGCAAAATTCTTCCTTT TGCTGTTGACAGTGAGCGCAAGGAAGAATTT
TGCTCTAAATAGTGAAGCCACAGATGTATTT
AGAGCAAAATTCTTCCTTTTGCCTACTGCCT
CGGA 
SMURF2 SMURF2.3622 TTAATGGAAACTTACACTGTAG TGCTGTTGACAGTGAGCGATACAGTGTAAGT
TTCCATTAATAGTGAAGCCACAGATGTATTA
ATGGAAACTTACACTGTAGTGCCTACTGCCT
CGGA 
SMURF2 SMURF2.633 TTTCTTATGGATCTTCTTGTGA TGCTGTTGACAGTGAGCGCCACAAGAAGAT
CCATAAGAAATAGTGAAGCCACAGATGTATT
TCTTATGGATCTTCTTGTGATGCCTACTGCC
TCGGA 
SNRPB SNRPB.928 TAAAAGGACTATGTACAGCCTT TGCTGTTGACAGTGAGCGCAGGCTGTACATA
GTCCTTTTATAGTGAAGCCACAGATGTATAA
AAGGACTATGTACAGCCTTTGCCTACTGCCT
CGGA 
SNRPB SNRPB.20 TAGAAACCTACTTCCGGTCCAG TGCTGTTGACAGTGAGCGATGGACCGGAAG
TAGGTTTCTATAGTGAAGCCACAGATGTATA
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GAAACCTACTTCCGGTCCAGTGCCTACTGCC
TCGGA 
SNRPB SNRPB.391 TCTACTGTCATTGAGACCAGAT TGCTGTTGACAGTGAGCGCTCTGGTCTCAAT
GACAGTAGATAGTGAAGCCACAGATGTATCT
ACTGTCATTGAGACCAGATTGCCTACTGCCT
CGGA 
SNRPB SNRPB.292 TTTCTGAACTCATCACAGTCAC TGCTGTTGACAGTGAGCGATGACTGTGATGA
GTTCAGAAATAGTGAAGCCACAGATGTATTT
CTGAACTCATCACAGTCACTGCCTACTGCCT
CGGA 
SNRPB SNRPB.329 TTCCCTTTCTGCTTGTTTGGAG TGCTGTTGACAGTGAGCGATCCAAACAAGC
AGAAAGGGAATAGTGAAGCCACAGATGTAT
TCCCTTTCTGCTTGTTTGGAGTGCCTACTGC
CTCGGA 
SNRPD1 SNRPD1.1118 TATATTGTTAAGTTTAGCCTAA TGCTGTTGACAGTGAGCGCTAGGCTAAACTT
AACAATATATAGTGAAGCCACAGATGTATAT
ATTGTTAAGTTTAGCCTAATGCCTACTGCCT
CGGA 
SNRPD1 SNRPD1.1049 TAGAACTGTAGCCTAACTGGAC TGCTGTTGACAGTGAGCGATCCAGTTAGGCT
ACAGTTCTATAGTGAAGCCACAGATGTATAG
AACTGTAGCCTAACTGGACTGCCTACTGCCT
CGGA 
SNRPD1 SNRPD1.582 TAAATAGACAGCTCTGTCCCAC TGCTGTTGACAGTGAGCGATGGGACAGAGC
TGTCTATTTATAGTGAAGCCACAGATGTATA
AATAGACAGCTCTGTCCCACTGCCTACTGCC
TCGGA 
SNRPD1 SNRPD1.1061 TTTCTCAGTACATAGAACTGTA TGCTGTTGACAGTGAGCGCACAGTTCTATGT
ACTGAGAAATAGTGAAGCCACAGATGTATTT
CTCAGTACATAGAACTGTATGCCTACTGCCT
CGGA 
SNRPD1 SNRPD1.1469 TAACTGATAATCTAGTGACCAT TGCTGTTGACAGTGAGCGCTGGTCACTAGAT
TATCAGTTATAGTGAAGCCACAGATGTATAA
CTGATAATCTAGTGACCATTGCCTACTGCCT
CGGA 
SOWAHC SOWAHC.245
1 
TTAATGTACCTTAACACTGGTG TGCTGTTGACAGTGAGCGAACCAGTGTTAAG
GTACATTAATAGTGAAGCCACAGATGTATTA
ATGTACCTTAACACTGGTGTGCCTACTGCCT
CGGA 
SOWAHC SOWAHC.322
2 
TTAGGTTTCAGCAACTACGCGA TGCTGTTGACAGTGAGCGCCGCGTAGTTGCT
GAAACCTAATAGTGAAGCCACAGATGTATTA
GGTTTCAGCAACTACGCGATGCCTACTGCCT
CGGA 
SPRED1 SPRED1.5564 TTCAACACAAGAAATATCCTTA TGCTGTTGACAGTGAGCGCAAGGATATTTCT
TGTGTTGAATAGTGAAGCCACAGATGTATTC
AACACAAGAAATATCCTTATGCCTACTGCCT
CGGA 
SPRED1 SPRED1.5123 TAAAATACCAAAACTTAGCTGG TGCTGTTGACAGTGAGCGACAGCTAAGTTTT
GGTATTTTATAGTGAAGCCACAGATGTATAA
AATACCAAAACTTAGCTGGTGCCTACTGCCT
CGGA 
SPRED1 SPRED1.1060 TATTCTGACAATCTCATCCTCA TGCTGTTGACAGTGAGCGCGAGGATGAGAT
TGTCAGAATATAGTGAAGCCACAGATGTATA
TTCTGACAATCTCATCCTCATGCCTACTGCC
TCGGA 
SPRED1 SPRED1.6831 TATTACTGTCCTAATAACCTTT TGCTGTTGACAGTGAGCGCAAGGTTATTAGG
ACAGTAATATAGTGAAGCCACAGATGTATAT
TACTGTCCTAATAACCTTTTGCCTACTGCCT
CGGA 
SPRED1 SPRED1.5651 TACACTTGCTTAATGCACCTTT TGCTGTTGACAGTGAGCGCAAGGTGCATTAA
GCAAGTGTATAGTGAAGCCACAGATGTATAC
ACTTGCTTAATGCACCTTTTGCCTACTGCCT
CGGA 
SPRED2 SPRED2.418 TAGAAGAACTGTCTGTAGCTGT TGCTGTTGACAGTGAGCGCCAGCTACAGAC
AGTTCTTCTATAGTGAAGCCACAGATGTATA
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GAAGAACTGTCTGTAGCTGTTGCCTACTGCC
TCGGA 
SPRED2 SPRED2.1853 TAAAGATAGAAACTGCAGCTTA TGCTGTTGACAGTGAGCGCAAGCTGCAGTTT
CTATCTTTATAGTGAAGCCACAGATGTATAA
AGATAGAAACTGCAGCTTATGCCTACTGCCT
CGGA 
SPRED2 SPRED2.2948 TAATCTACTAAAGAAAATCGAT TGCTGTTGACAGTGAGCGCTCGATTTTCTTT
AGTAGATTATAGTGAAGCCACAGATGTATAA
TCTACTAAAGAAAATCGATTGCCTACTGCCT
CGGA 
SPRED2 SPRED2.1588 TTGCAGACTCCTTTGAACTGGA TGCTGTTGACAGTGAGCGCCCAGTTCAAAG
GAGTCTGCAATAGTGAAGCCACAGATGTATT
GCAGACTCCTTTGAACTGGATGCCTACTGCC
TCGGA 
SPRED2 SPRED2.1496 TAGTACAGGAGTCTGTGGCGAA TGCTGTTGACAGTGAGCGCTCGCCACAGAC
TCCTGTACTATAGTGAAGCCACAGATGTATA
GTACAGGAGTCTGTGGCGAATGCCTACTGC
CTCGGA 
SPRY1 SPRY1.2179 TAACATATGTACTTTCTTCGTG TGCTGTTGACAGTGAGCGAACGAAGAAAGT
ACATATGTTATAGTGAAGCCACAGATGTATA
ACATATGTACTTTCTTCGTGTGCCTACTGCC
TCGGA 
SPRY1 SPRY1.587 TTCACAAATGAACTTGTGCTGT TGCTGTTGACAGTGAGCGCCAGCACAAGTT
CATTTGTGAATAGTGAAGCCACAGATGTATT
CACAAATGAACTTGTGCTGTTGCCTACTGCC
TCGGA 
SPRY1 SPRY1.718 TTGACTAAGCACATGCAGGTTC TGCTGTTGACAGTGAGCGAAACCTGCATGTG
CTTAGTCAATAGTGAAGCCACAGATGTATTG
ACTAAGCACATGCAGGTTCTGCCTACTGCCT
CGGA 
SPRY1 SPRY1.311 TTATTATTCACATTAATTGGTA TGCTGTTGACAGTGAGCGCACCAATTAATGT
GAATAATAATAGTGAAGCCACAGATGTATTA
TTATTCACATTAATTGGTATGCCTACTGCCT
CGGA 
SPRY1 SPRY1.137 TCATAGTCTAATCTCTGACGGC TGCTGTTGACAGTGAGCGACCGTCAGAGATT
AGACTATGATAGTGAAGCCACAGATGTATCA
TAGTCTAATCTCTGACGGCTGCCTACTGCCT
CGGA 
SPRY2 SPRY2.328 TAGAACACATCTGAACTCCGTG TGCTGTTGACAGTGAGCGAACGGAGTTCAG
ATGTGTTCTATAGTGAAGCCACAGATGTATA
GAACACATCTGAACTCCGTGTGCCTACTGCC
TCGGA 
SPRY2 SPRY2.1747 TAGTATAATATTTTGTGTCTGT TGCTGTTGACAGTGAGCGCCAGACACAAAA
TATTATACTATAGTGAAGCCACAGATGTATA
GTATAATATTTTGTGTCTGTTGCCTACTGCC
TCGGA 
SPRY2 SPRY2.2060 TATATTGGACATATGCATCTGT TGCTGTTGACAGTGAGCGCCAGATGCATATG
TCCAATATATAGTGAAGCCACAGATGTATAT
ATTGGACATATGCATCTGTTGCCTACTGCCT
CGGA 
SPRY2 SPRY2.1553 TTAGCTTATGCAATACATGGGT TGCTGTTGACAGTGAGCGCCCCATGTATTGC
ATAAGCTAATAGTGAAGCCACAGATGTATTA
GCTTATGCAATACATGGGTTGCCTACTGCCT
CGGA 
SPRY2 SPRY2.329 TTAGAACACATCTGAACTCCGT TGCTGTTGACAGTGAGCGCCGGAGTTCAGA
TGTGTTCTAATAGTGAAGCCACAGATGTATT
AGAACACATCTGAACTCCGTTGCCTACTGCC
TCGGA 
SPRY3 SPRY3.6580 TTTAACAGCAGCAACACTGGTA TGCTGTTGACAGTGAGCGCACCAGTGTTGCT
GCTGTTAAATAGTGAAGCCACAGATGTATTT
AACAGCAGCAACACTGGTATGCCTACTGCCT
CGGA 
SPRY3 SPRY3.6604 TTCCTTATCTTGTCCATCCTGG TGCTGTTGACAGTGAGCGACAGGATGGACA
AGATAAGGAATAGTGAAGCCACAGATGTATT
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CCTTATCTTGTCCATCCTGGTGCCTACTGCC
TCGGA 
SPRY3 SPRY3.7990 TTGCATATTATAATCATCTGGG TGCTGTTGACAGTGAGCGACCAGATGATTAT
AATATGCAATAGTGAAGCCACAGATGTATTG
CATATTATAATCATCTGGGTGCCTACTGCCT
CGGA 
SPRY3 SPRY3.2842 TTCTTTTCCACACTTGAGCTTC TGCTGTTGACAGTGAGCGAAAGCTCAAGTGT
GGAAAAGAATAGTGAAGCCACAGATGTATT
CTTTTCCACACTTGAGCTTCTGCCTACTGCC
TCGGA 
SPRY3 SPRY3.7497 TTAGGTGAGAGAAACACACTGA TGCTGTTGACAGTGAGCGCCAGTGTGTTTCT
CTCACCTAATAGTGAAGCCACAGATGTATTA
GGTGAGAGAAACACACTGATGCCTACTGCC
TCGGA 
SPRY4 SPRY4.4393 TTCAAGGTGACAGTCATCCGGG TGCTGTTGACAGTGAGCGACCGGATGACTG
TCACCTTGAATAGTGAAGCCACAGATGTATT
CAAGGTGACAGTCATCCGGGTGCCTACTGC
CTCGGA 
SPRY4 SPRY4.2099 TAAAACACCGTTAGCATCCGGT TGCTGTTGACAGTGAGCGCCCGGATGCTAA
CGGTGTTTTATAGTGAAGCCACAGATGTATA
AAACACCGTTAGCATCCGGTTGCCTACTGCC
TCGGA 
SPRY4 SPRY4.2909 TAAGATGTTACTACTAGTCTTC TGCTGTTGACAGTGAGCGAAAGACTAGTAGT
AACATCTTATAGTGAAGCCACAGATGTATAA
GATGTTACTACTAGTCTTCTGCCTACTGCCT
CGGA 
SPRY4 SPRY4.4659 TTGTAACATGAAACCAAGCTGT TGCTGTTGACAGTGAGCGCCAGCTTGGTTTC
ATGTTACAATAGTGAAGCCACAGATGTATTG
TAACATGAAACCAAGCTGTTGCCTACTGCCT
CGGA 
SPRY4 SPRY4.2067 TATAAAAACATAATGACTGGAT TGCTGTTGACAGTGAGCGCTCCAGTCATTAT
GTTTTTATATAGTGAAGCCACAGATGTATAT
AAAAACATAATGACTGGATTGCCTACTGCCT
CGGA 
SRSF1 SRSF1.3300 TTAACATTTAATACTTACCTTT TGCTGTTGACAGTGAGCGCAAGGTAAGTATT
AAATGTTAATAGTGAAGCCACAGATGTATTA
ACATTTAATACTTACCTTTTGCCTACTGCCT
CGGA 
SRSF1 SRSF1.4112 TAAACTTACACTAAGTACTTAG TGCTGTTGACAGTGAGCGATAAGTACTTAGT
GTAAGTTTATAGTGAAGCCACAGATGTATAA
ACTTACACTAAGTACTTAGTGCCTACTGCCT
CGGA 
SRSF1 SRSF1.3678 TAATCTTGTGCACTCTTCCCTT TGCTGTTGACAGTGAGCGCAGGGAAGAGTG
CACAAGATTATAGTGAAGCCACAGATGTATA
ATCTTGTGCACTCTTCCCTTTGCCTACTGCC
TCGGA 
SRSF1 SRSF1.1216 TTACACAATATCACAGTCTGAA TGCTGTTGACAGTGAGCGCTCAGACTGTGAT
ATTGTGTAATAGTGAAGCCACAGATGTATTA
CACAATATCACAGTCTGAATGCCTACTGCCT
CGGA 
SRSF1 SRSF1.2656 TTTATCTCCAGGTCCTCGCTTT TGCTGTTGACAGTGAGCGCAAGCGAGGACC
TGGAGATAAATAGTGAAGCCACAGATGTATT
TATCTCCAGGTCCTCGCTTTTGCCTACTGCC
TCGGA 
SRSF10 SRSF10.613 TAGTTGTAATCAAAAGACCGAC TGCTGTTGACAGTGAGCGATCGGTCTTTTGA
TTACAACTATAGTGAAGCCACAGATGTATAG
TTGTAATCAAAAGACCGACTGCCTACTGCCT
CGGA 
SRSF10 SRSF10.371 TTGAACATAAGCAAATCCTCTT TGCTGTTGACAGTGAGCGCAGAGGATTTGCT
TATGTTCAATAGTGAAGCCACAGATGTATTG
AACATAAGCAAATCCTCTTTGCCTACTGCCT
CGGA 
SRSF10 SRSF10.567 TTCGGCTTCTAGAACGTCTGTA TGCTGTTGACAGTGAGCGCACAGACGTTCTA
GAAGCCGAATAGTGAAGCCACAGATGTATT
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CGGCTTCTAGAACGTCTGTATGCCTACTGCC
TCGGA 
SRSF10 SRSF10.319 TACACATCAACTATAGGACCAT TGCTGTTGACAGTGAGCGCTGGTCCTATAGT
TGATGTGTATAGTGAAGCCACAGATGTATAC
ACATCAACTATAGGACCATTGCCTACTGCCT
CGGA 
SRSF10 SRSF10.571 TAACTTCGGCTTCTAGAACGTC TGCTGTTGACAGTGAGCGAACGTTCTAGAAG
CCGAAGTTATAGTGAAGCCACAGATGTATAA
CTTCGGCTTCTAGAACGTCTGCCTACTGCCT
CGGA 
SRSF2 SRSF2.1937 TTAAACTACAGAAACAATGGTT TGCTGTTGACAGTGAGCGCACCATTGTTTCT
GTAGTTTAATAGTGAAGCCACAGATGTATTA
AACTACAGAAACAATGGTTTGCCTACTGCCT
CGGA 
SRSF2 SRSF2.1488 TTGTGTTTGATAAACAATCCTT TGCTGTTGACAGTGAGCGCAGGATTGTTTAT
CAAACACAATAGTGAAGCCACAGATGTATTG
TGTTTGATAAACAATCCTTTGCCTACTGCCT
CGGA 
SRSF2 SRSF2.1919 TAAACTACAGAAACAATGGTTA TGCTGTTGACAGTGAGCGCAACCATTGTTTC
TGTAGTTTATAGTGAAGCCACAGATGTATAA
ACTACAGAAACAATGGTTATGCCTACTGCCT
CGGA 
SRSF2 SRSF2.1545 TCAACTGCTACACAACTGCGCC TGCTGTTGACAGTGAGCGAGCGCAGTTGTGT
AGCAGTTGATAGTGAAGCCACAGATGTATCA
ACTGCTACACAACTGCGCCTGCCTACTGCCT
CGGA 
SRSF2 SRSF2.1723 TTATTTATATGCAAGGCCCGGG TGCTGTTGACAGTGAGCGACCGGGCCTTGC
ATATAAATAATAGTGAAGCCACAGATGTATT
ATTTATATGCAAGGCCCGGGTGCCTACTGCC
TCGGA 
SRSF3 SRSF3.2297 TTAACTTTAAGGCTGAACCTTC TGCTGTTGACAGTGAGCGAAAGGTTCAGCCT
TAAAGTTAATAGTGAAGCCACAGATGTATTA
ACTTTAAGGCTGAACCTTCTGCCTACTGCCT
CGGA 
SRSF3 SRSF3.1983 TTACATTTGAACCATATTGTGA TGCTGTTGACAGTGAGCGCCACAATATGGTT
CAAATGTAATAGTGAAGCCACAGATGTATTA
CATTTGAACCATATTGTGATGCCTACTGCCT
CGGA 
SRSF3 SRSF3.774 TTGAACAGCTAAAACATCTTAA TGCTGTTGACAGTGAGCGCTAAGATGTTTTA
GCTGTTCAATAGTGAAGCCACAGATGTATTG
AACAGCTAAAACATCTTAATGCCTACTGCCT
CGGA 
SRSF3 SRSF3.1204 TTCTTGAAACTTAACATTCTAT TGCTGTTGACAGTGAGCGCTAGAATGTTAAG
TTTCAAGAATAGTGAAGCCACAGATGTATTC
TTGAAACTTAACATTCTATTGCCTACTGCCT
CGGA 
SRSF3 SRSF3.941 TAGAGGTTTATTATCAGTCTGT TGCTGTTGACAGTGAGCGCCAGACTGATAAT
AAACCTCTATAGTGAAGCCACAGATGTATAG
AGGTTTATTATCAGTCTGTTGCCTACTGCCT
CGGA 
SSRP1 SSRP1.2236 TTGCTCTTGAAGCTCTCGCTTA TGCTGTTGACAGTGAGCGCAAGCGAGAGCT
TCAAGAGCAATAGTGAAGCCACAGATGTATT
GCTCTTGAAGCTCTCGCTTATGCCTACTGCC
TCGGA 
SSRP1 SSRP1.1950 TCTGACTTGATCTTCTCTCGGC TGCTGTTGACAGTGAGCGACCGAGAGAAGA
TCAAGTCAGATAGTGAAGCCACAGATGTATC
TGACTTGATCTTCTCTCGGCTGCCTACTGCC
TCGGA 
SSRP1 SSRP1.2168 TTTCTTTTCCATCTTTACCTTT TGCTGTTGACAGTGAGCGCAAGGTAAAGAT
GGAAAAGAAATAGTGAAGCCACAGATGTAT
TTCTTTTCCATCTTTACCTTTTGCCTACTGCC
TCGGA 
SSRP1 SSRP1.2149 TTTACTTTCTTCTTCTTCTTTG TGCTGTTGACAGTGAGCGAAAAGAAGAAGA
AGAAAGTAAATAGTGAAGCCACAGATGTATT
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TACTTTCTTCTTCTTCTTTGTGCCTACTGCCT
CGGA 
SSRP1 SSRP1.2143 TTCTTCTTCTTCTTTGACTTGT TGCTGTTGACAGTGAGCGCCAAGTCAAAGA
AGAAGAAGAATAGTGAAGCCACAGATGTAT
TCTTCTTCTTCTTTGACTTGTTGCCTACTGC
CTCGGA 
STRAP STRAP.683 TAACAAATAATTACTATCCTGC TGCTGTTGACAGTGAGCGACAGGATAGTAAT
TATTTGTTATAGTGAAGCCACAGATGTATAA
CAAATAATTACTATCCTGCTGCCTACTGCCT
CGGA 
STRAP STRAP.1693 TAAACAGCTACAAGAACCCTAA TGCTGTTGACAGTGAGCGCTAGGGTTCTTGT
AGCTGTTTATAGTGAAGCCACAGATGTATAA
ACAGCTACAAGAACCCTAATGCCTACTGCCT
CGGA 
STRAP STRAP.683 TTAACAAATAATTACTATCCTG TGCTGTTGACAGTGAGCGAAGGATAGTAATT
ATTTGTTAATAGTGAAGCCACAGATGTATTA
ACAAATAATTACTATCCTGTGCCTACTGCCT
CGGA 
STRAP STRAP.859 TGTCATAGTAGCATGATCCCAA TGCTGTTGACAGTGAGCGCTGGGATCATGCT
ACTATGACATAGTGAAGCCACAGATGTATGT
CATAGTAGCATGATCCCAATGCCTACTGCCT
CGGA 
STRAP STRAP.1476 TAAGCAGACAGTAACTCTGGAA TGCTGTTGACAGTGAGCGCTCCAGAGTTACT
GTCTGCTTATAGTGAAGCCACAGATGTATAA
GCAGACAGTAACTCTGGAATGCCTACTGCCT
CGGA 
TCERG1 TCERG1.2467 TTGATGAACTATCTACTGCTTT TGCTGTTGACAGTGAGCGCAAGCAGTAGAT
AGTTCATCAATAGTGAAGCCACAGATGTATT
GATGAACTATCTACTGCTTTTGCCTACTGCC
TCGGA 
TCERG1 TCERG1.1866 TTTATTATCGTCTCTCTTCCGT TGCTGTTGACAGTGAGCGCCGGAAGAGAGA
CGATAATAAATAGTGAAGCCACAGATGTATT
TATTATCGTCTCTCTTCCGTTGCCTACTGCC
TCGGA 
TCERG1 TCERG1.3848 TAAACAACAAGACTCGGTCTAT TGCTGTTGACAGTGAGCGCTAGACCGAGTCT
TGTTGTTTATAGTGAAGCCACAGATGTATAA
ACAACAAGACTCGGTCTATTGCCTACTGCCT
CGGA 
TCERG1 TCERG1.1882 TTATTATCGTCTCTCTTCCGTT TGCTGTTGACAGTGAGCGCACGGAAGAGAG
ACGATAATAATAGTGAAGCCACAGATGTATT
ATTATCGTCTCTCTTCCGTTTGCCTACTGCC
TCGGA 
TCERG1 TCERG1.2725 TATCAGACCATGACACATCTGA TGCTGTTGACAGTGAGCGCCAGATGTGTCAT
GGTCTGATATAGTGAAGCCACAGATGTATAT
CAGACCATGACACATCTGATGCCTACTGCCT
CGGA 
TCOF1 TCOF1.313 TTTCTTAGCTTGCAGTGCCGCA TGCTGTTGACAGTGAGCGCGCGGCACTGCA
AGCTAAGAAATAGTGAAGCCACAGATGTATT
TCTTAGCTTGCAGTGCCGCATGCCTACTGCC
TCGGA 
TCOF1 TCOF1.2214 TTTACTGAGGTTTTCACCTGTG TGCTGTTGACAGTGAGCGAACAGGTGAAAA
CCTCAGTAAATAGTGAAGCCACAGATGTATT
TACTGAGGTTTTCACCTGTGTGCCTACTGCC
TCGGA 
TCOF1 TCOF1.459 TTTTCTTTCATGCTTGATGGCA TGCTGTTGACAGTGAGCGCGCCATCAAGCA
TGAAAGAAAATAGTGAAGCCACAGATGTATT
TTCTTTCATGCTTGATGGCATGCCTACTGCC
TCGGA 
TCOF1 TCOF1.458 TTTCTTTCATGCTTGATGGCAA TGCTGTTGACAGTGAGCGCTGCCATCAAGC
ATGAAAGAAATAGTGAAGCCACAGATGTATT
TCTTTCATGCTTGATGGCAATGCCTACTGCC
TCGGA 
TCOF1 TCOF1.312 TTCTTAGCTTGCAGTGCCGCAT TGCTGTTGACAGTGAGCGCTGCGGCACTGC
AAGCTAAGAATAGTGAAGCCACAGATGTATT
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CTTAGCTTGCAGTGCCGCATTGCCTACTGCC
TCGGA 
TFAM TFAM.455 TATCTCTTCTTTATATACCTGC TGCTGTTGACAGTGAGCGACAGGTATATAAA
GAAGAGATATAGTGAAGCCACAGATGTATAT
CTCTTCTTTATATACCTGCTGCCTACTGCCT
CGGA 
TFAM TFAM.2312 TTCTAAAACAAGAACATCTGAA TGCTGTTGACAGTGAGCGCTCAGATGTTCTT
GTTTTAGAATAGTGAAGCCACAGATGTATTC
TAAAACAAGAACATCTGAATGCCTACTGCCT
CGGA 
TFAM TFAM.465 TAAATCTGCTTATCTCTTCTTT TGCTGTTGACAGTGAGCGCAAGAAGAGATA
AGCAGATTTATAGTGAAGCCACAGATGTATA
AATCTGCTTATCTCTTCTTTTGCCTACTGCC
TCGGA 
TFAM TFAM.674 TTCCTTTACAGTCTTCAGCTTT TGCTGTTGACAGTGAGCGCAAGCTGAAGAC
TGTAAAGGAATAGTGAAGCCACAGATGTATT
CCTTTACAGTCTTCAGCTTTTGCCTACTGCC
TCGGA 
TFAM TFAM.3304 TTAAGTATAAAATAATACGGGT TGCTGTTGACAGTGAGCGCCCCGTATTATTT
TATACTTAATAGTGAAGCCACAGATGTATTA
AGTATAAAATAATACGGGTTGCCTACTGCCT
CGGA 
TFDP1 TFDP1.1542 TAGCTTACCAATATCTTCTTGG TGCTGTTGACAGTGAGCGACAAGAAGATATT
GGTAAGCTATAGTGAAGCCACAGATGTATA
GCTTACCAATATCTTCTTGGTGCCTACTGCC
TCGGA 
TFDP1 TFDP1.865 TTGAAGTTGAGACTGTTTCTGT TGCTGTTGACAGTGAGCGCCAGAAACAGTC
TCAACTTCAATAGTGAAGCCACAGATGTATT
GAAGTTGAGACTGTTTCTGTTGCCTACTGCC
TCGGA 
TFDP1 TFDP1.2514 TTCAATAAAAAGACTATCGTTT TGCTGTTGACAGTGAGCGCAACGATAGTCTT
TTTATTGAATAGTGAAGCCACAGATGTATTC
AATAAAAAGACTATCGTTTTGCCTACTGCCT
CGGA 
TFDP1 TFDP1.841 TATTCTTTCAAGTCTCCTCTGT TGCTGTTGACAGTGAGCGCCAGAGGAGACT
TGAAAGAATATAGTGAAGCCACAGATGTATA
TTCTTTCAAGTCTCCTCTGTTGCCTACTGCC
TCGGA 
TFDP1 TFDP1.2064 TTTGTTGCTGCAAAACAGGGAG TGCTGTTGACAGTGAGCGATCCCTGTTTTGC
AGCAACAAATAGTGAAGCCACAGATGTATTT
GTTGCTGCAAAACAGGGAGTGCCTACTGCC
TCGGA 
TGIF1 TGIF1.787 TTAAGCTGTAAGTTTTGCCTGA TGCTGTTGACAGTGAGCGCCAGGCAAAACT
TACAGCTTAATAGTGAAGCCACAGATGTATT
AAGCTGTAAGTTTTGCCTGATGCCTACTGCC
TCGGA 
TGIF1 TGIF1.962 TTTAAGTTTATAGTTCTTGGAA TGCTGTTGACAGTGAGCGCTCCAAGAACTAT
AAACTTAAATAGTGAAGCCACAGATGTATTT
AAGTTTATAGTTCTTGGAATGCCTACTGCCT
CGGA 
TGIF1 TGIF1.954 TATAGTTCTTGGAATGACTGTA TGCTGTTGACAGTGAGCGCACAGTCATTCCA
AGAACTATATAGTGAAGCCACAGATGTATAT
AGTTCTTGGAATGACTGTATGCCTACTGCCT
CGGA 
TGIF1 TGIF1.199 TAGACAGGTGTGTTTGCTGGGA TGCTGTTGACAGTGAGCGCCCCAGCAAACA
CACCTGTCTATAGTGAAGCCACAGATGTATA
GACAGGTGTGTTTGCTGGGATGCCTACTGCC
TCGGA 
TGIF1 TGIF1.510 TTTCAATGCAGTCACAGTGGTA TGCTGTTGACAGTGAGCGCACCACTGTGACT
GCATTGAAATAGTGAAGCCACAGATGTATTT
CAATGCAGTCACAGTGGTATGCCTACTGCCT
CGGA 
TIMELES
S 
TIMELESS.401
2 
TAAATCTCCAGAGAGCTGCTGG TGCTGTTGACAGTGAGCGACAGCAGCTCTCT
GGAGATTTATAGTGAAGCCACAGATGTATAA
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ATCTCCAGAGAGCTGCTGGTGCCTACTGCCT
CGGA 
TIMELES
S 
TIMELESS.498
4 
TTGCAGTATTTATCCATCCTTT TGCTGTTGACAGTGAGCGCAAGGATGGATA
AATACTGCAATAGTGAAGCCACAGATGTATT
GCAGTATTTATCCATCCTTTTGCCTACTGCC
TCGGA 
TIMELES
S 
TIMELESS.939 TTTTCTGCCATCTCTCGCTGGC TGCTGTTGACAGTGAGCGACCAGCGAGAGA
TGGCAGAAAATAGTGAAGCCACAGATGTATT
TTCTGCCATCTCTCGCTGGCTGCCTACTGCC
TCGGA 
TIMELES
S 
TIMELESS.123
3 
TTTACTGATCCCATGAGCCGGT TGCTGTTGACAGTGAGCGCCCGGCTCATGG
GATCAGTAAATAGTGAAGCCACAGATGTATT
TACTGATCCCATGAGCCGGTTGCCTACTGCC
TCGGA 
TIMELES
S 
TIMELESS.290
0 
TATTCTTCATGATATGACCCAG TGCTGTTGACAGTGAGCGATGGGTCATATCA
TGAAGAATATAGTGAAGCCACAGATGTATAT
TCTTCATGATATGACCCAGTGCCTACTGCCT
CGGA 
TOP2B TOP2B.232 TACATCTTCATCATACACCCAC TGCTGTTGACAGTGAGCGATGGGTGTATGAT
GAAGATGTATAGTGAAGCCACAGATGTATAC
ATCTTCATCATACACCCACTGCCTACTGCCT
CGGA 
TOP2B TOP2B.849 TAAAGATCTACATAACTGCGAA TGCTGTTGACAGTGAGCGCTCGCAGTTATGT
AGATCTTTATAGTGAAGCCACAGATGTATAA
AGATCTACATAACTGCGAATGCCTACTGCCT
CGGA 
TOP2B TOP2B.1679 TTTTATGTGAGAACCATCTTGA TGCTGTTGACAGTGAGCGCCAAGATGGTTCT
CACATAAAATAGTGAAGCCACAGATGTATTT
TATGTGAGAACCATCTTGATGCCTACTGCCT
CGGA 
TOP2B TOP2B.4436 TTTACTTGGAACTTTATCTGTC TGCTGTTGACAGTGAGCGAACAGATAAAGTT
CCAAGTAAATAGTGAAGCCACAGATGTATTT
ACTTGGAACTTTATCTGTCTGCCTACTGCCT
CGGA 
TOP2B TOP2B.2861 TAGCATAGGTTCTAAAACCTGT TGCTGTTGACAGTGAGCGCCAGGTTTTAGAA
CCTATGCTATAGTGAAGCCACAGATGTATAG
CATAGGTTCTAAAACCTGTTGCCTACTGCCT
CGGA 
TRIP13 TRIP13.858 TTTATCATCAATCAAATCCTGA TGCTGTTGACAGTGAGCGCCAGGATTTGATT
GATGATAAATAGTGAAGCCACAGATGTATTT
ATCATCAATCAAATCCTGATGCCTACTGCCT
CGGA 
TRIP13 TRIP13.264 TAGCTTTCTAACACTCAGGTTT TGCTGTTGACAGTGAGCGCAACCTGAGTGTT
AGAAAGCTATAGTGAAGCCACAGATGTATA
GCTTTCTAACACTCAGGTTTTGCCTACTGCC
TCGGA 
TRIP13 TRIP13.839 TGAATCTTCTGAAACATCTTGG TGCTGTTGACAGTGAGCGACAAGATGTTTCA
GAAGATTCATAGTGAAGCCACAGATGTATGA
ATCTTCTGAAACATCTTGGTGCCTACTGCCT
CGGA 
TRIP13 TRIP13.989 TTTAATCTGATCAATTTGGGTC TGCTGTTGACAGTGAGCGAACCCAAATTGAT
CAGATTAAATAGTGAAGCCACAGATGTATTT
AATCTGATCAATTTGGGTCTGCCTACTGCCT
CGGA 
TRIP13 TRIP13.241 TTTATGTCTTCTTTCTTTGCAG TGCTGTTGACAGTGAGCGATGCAAAGAAAG
AAGACATAAATAGTGAAGCCACAGATGTATT
TATGTCTTCTTTCTTTGCAGTGCCTACTGCC
TCGGA 
WBP11 WBP11.2579 TAATTGTACATATTCTTCCCAC TGCTGTTGACAGTGAGCGATGGGAAGAATA
TGTACAATTATAGTGAAGCCACAGATGTATA
ATTGTACATATTCTTCCCACTGCCTACTGCC
TCGGA 
WBP11 WBP11.846 TAACATGTCTTCATCTCGCCTA TGCTGTTGACAGTGAGCGCAGGCGAGATGA
AGACATGTTATAGTGAAGCCACAGATGTATA
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ACATGTCTTCATCTCGCCTATGCCTACTGCC
TCGGA 
WBP11 WBP11.236 TTCTTTAATTCTCTCTTCCGGG TGCTGTTGACAGTGAGCGACCGGAAGAGAG
AATTAAAGAATAGTGAAGCCACAGATGTATT
CTTTAATTCTCTCTTCCGGGTGCCTACTGCC
TCGGA 
WBP11 WBP11.2271 TTCAATAACTGATCTATTCTGG TGCTGTTGACAGTGAGCGACAGAATAGATC
AGTTATTGAATAGTGAAGCCACAGATGTATT
CAATAACTGATCTATTCTGGTGCCTACTGCC
TCGGA 
WBP11 WBP11.1135 TTGAAGAGGAGTCAGTTCCTTC TGCTGTTGACAGTGAGCGAAAGGAACTGAC
TCCTCTTCAATAGTGAAGCCACAGATGTATT
GAAGAGGAGTCAGTTCCTTCTGCCTACTGCC
TCGGA 
WHSC1 WHSC1.1087 TTGAGGGTTGAGATGAAGCTGG TGCTGTTGACAGTGAGCGACAGCTTCATCTC
AACCCTCAATAGTGAAGCCACAGATGTATTG
AGGGTTGAGATGAAGCTGGTGCCTACTGCC
TCGGA 
WHSC1 WHSC1.767 TTAAGTTTGGTATAGCTGTGAA TGCTGTTGACAGTGAGCGCTCACAGCTATAC
CAAACTTAATAGTGAAGCCACAGATGTATTA
AGTTTGGTATAGCTGTGAATGCCTACTGCCT
CGGA 
WHSC1 WHSC1.67 TTATGCACTTTACAACACTCTG TGCTGTTGACAGTGAGCGAAGAGTGTTGTAA
AGTGCATAATAGTGAAGCCACAGATGTATTA
TGCACTTTACAACACTCTGTGCCTACTGCCT
CGGA 
WHSC1 WHSC1.777 TTTCTGACCTTTAAGTTTGGTA TGCTGTTGACAGTGAGCGCACCAAACTTAAA
GGTCAGAAATAGTGAAGCCACAGATGTATTT
CTGACCTTTAAGTTTGGTATGCCTACTGCCT
CGGA 
WHSC1 WHSC1.279 TTCTCCATTAAACACCCGGGAA TGCTGTTGACAGTGAGCGCTCCCGGGTGTTT
AATGGAGAATAGTGAAGCCACAGATGTATTC
TCCATTAAACACCCGGGAATGCCTACTGCCT
CGGA 
XRCC6 XRCC6.842 TTGAGCTTCAGCTTTAACCTGC TGCTGTTGACAGTGAGCGACAGGTTAAAGCT
GAAGCTCAATAGTGAAGCCACAGATGTATTG
AGCTTCAGCTTTAACCTGCTGCCTACTGCCT
CGGA 
XRCC6 XRCC6.1682 TTTCTCTTGGTAACTTTCCCTT TGCTGTTGACAGTGAGCGCAGGGAAAGTTA
CCAAGAGAAATAGTGAAGCCACAGATGTAT
TTCTCTTGGTAACTTTCCCTTTGCCTACTGC
CTCGGA 
XRCC6 XRCC6.480 TGAGTGAGTAGTCAGATCCGTG TGCTGTTGACAGTGAGCGAACGGATCTGACT
ACTCACTCATAGTGAAGCCACAGATGTATGA
GTGAGTAGTCAGATCCGTGTGCCTACTGCCT
CGGA 
XRCC6 XRCC6.828 TTAACCTGCTGAGTGCTCGCTT TGCTGTTGACAGTGAGCGCAGCGAGCACTC
AGCAGGTTAATAGTGAAGCCACAGATGTATT
AACCTGCTGAGTGCTCGCTTTGCCTACTGCC
TCGGA 
XRCC6 XRCC6.270 TACTGATGTACACACTTTGGAT TGCTGTTGACAGTGAGCGCTCCAAAGTGTGT
ACATCAGTATAGTGAAGCCACAGATGTATAC
TGATGTACACACTTTGGATTGCCTACTGCCT
CGGA 
ZNF207 ZNF207.1823 TAAGCTTACAGAACTTGCCTTT TGCTGTTGACAGTGAGCGCAAGGCAAGTTCT
GTAAGCTTATAGTGAAGCCACAGATGTATAA
GCTTACAGAACTTGCCTTTTGCCTACTGCCT
CGGA 
ZNF207 ZNF207.1051 TTGTACTAGTTGTTGAAGCTGT TGCTGTTGACAGTGAGCGCCAGCTTCAACAA
CTAGTACAATAGTGAAGCCACAGATGTATTG
TACTAGTTGTTGAAGCTGTTGCCTACTGCCT
CGGA 
ZNF207 ZNF207.318 TATTGTTTCTTTATGTACCTGC TGCTGTTGACAGTGAGCGACAGGTACATAA
AGAAACAATATAGTGAAGCCACAGATGTATA
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TTGTTTCTTTATGTACCTGCTGCCTACTGCC
TCGGA 
ZNF207 ZNF207.1042 TTGTTGAAGCTGTAGACTGTGT TGCTGTTGACAGTGAGCGCCACAGTCTACA
GCTTCAACAATAGTGAAGCCACAGATGTATT
GTTGAAGCTGTAGACTGTGTTGCCTACTGCC
TCGGA 
ZNF207 ZNF207.257 TTTCTTGTGACATATATGGCAT TGCTGTTGACAGTGAGCGCTGCCATATATGT
CACAAGAAATAGTGAAGCCACAGATGTATTT
CTTGTGACATATATGGCATTGCCTACTGCCT
CGGA 
 
 
 
 
Table A 2: Table of all screened shRNAs and their respective abundance after 14 and 
21 days with or without KRASG12V. Values indicate the log2 fold change of shRNA 
abundance after massive parallel sequencing compared to the control sample. 
(blue = depletion; red = enrichment; n.a. = not available) 
  14 days 21 days   
shRNA +KRASG12V -KRASG12V +KRASG12V -KRASG12V shRNA library pre-transduction 
AATF.1150 0.226 0.475 0.224 0.067 0.15 
AATF.1152 0.388 0.0319 0.621 0.0264 0.0852 
AATF.1223 -0.701 -0.171 -1.28 -0.785 -0.0732 
AATF.1732 -0.994 -0.114 -0.791 0.583 0.000896 
AATF.968 0.232 0.389 0.0751 0.123 0.0206 
ANKRD57.2246 -0.619 -0.203 -0.714 -0.229 -0.0732 
ANKRD57.2974 -0.183 -0.312 -0.0894 -0.522 0.436 
ANKRD57.3667 0.0606 0.463 -0.564 -0.128 -0.394 
AREG.460 0.375 0.686 -0.66 0.135 0.455 
AREG.517 -0.0539 -0.0704 -0.241 -0.335 -0.0823 
AREG.677 0.131 -0.0251 0.0594 -0.408 0.427 
AREG.850 0.424 -0.144 0.753 -0.188 -0.207 
AREG.868 -0.178 -1.77 -0.805 -1.48 -0.336 
ARNTL2.1018 0.066 0.0505 0.216 -0.168 0.00292 
ARNTL2.111 0.276 -0.344 0.383 0.317 -0.593 
ARNTL2.2192 -0.447 0.174 -0.536 0.142 -0.527 
ARNTL2.3342 0.219 -0.0256 -0.001 -0.0198 -0.268 
ARNTL2.674 -0.185 0.212 -0.48 -0.183 -0.466 
ATAD2.1342 0.458 -0.406 0.19 -0.225 -0.00205 
ATAD2.1599 0.232 0.322 0.531 0.651 -0.182 
ATAD2.3499 -0.432 -1.02 -0.929 -1.36 -0.0609 
ATAD2.4380 0.249 0.356 0.18 0.17 0.335 
ATAD2.569 -0.598 -0.466 -0.571 -0.402 -0.00413 
BARD1.1647 -0.346 -0.166 -1.46 0.722 0.356 
BARD1.1690 0.222 -0.327 -0.0201 0.193 0.251 
BARD1.543 n.a. n.a. -0.917 0.754 0.144 
BARD1.548 1.26 n.a. 0.868 n.a. 1.64 
BARD1.582 0.363 0.0779 -0.257 0.131 0.303 
BAZ1A.1434 -0.0826 0.000422 0.214 -0.531 -0.467 
BAZ1A.4218 0.604 0.031 0.227 0.136 -0.0858 
BAZ1A.4264 0.0116 -0.436 0.00433 0.593 -0.405 
BAZ1A.5297 0.102 -0.115 -0.0887 -0.818 0.267 
BAZ1A.5651 0.359 -0.0661 0.0158 0.0747 0.163 
BAZ1B.2041 -0.15 0.206 0.016 0.492 0.0413 
BAZ1B.2230 0.227 -0.314 -0.00934 -0.175 -0.235 
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BAZ1B.3381 -0.456 0.0329 -0.451 -0.0821 0.272 
BAZ1B.3695 -0.228 0.118 -0.373 -0.659 -0.193 
BAZ1B.5150 -0.323 0.108 -0.42 -0.109 0.123 
BRCA1.1108 0.0988 0.233 -0.174 0.702 0.0873 
BRCA1.190 0.502 -0.146 0.412 0.187 0.353 
BRCA1.2561 0.234 0.0768 0.266 -0.494 -0.037 
BRCA1.37 -0.872 -0.241 0.0793 -0.00707 -0.0614 
BRCA1.656 -0.258 -0.153 -0.396 -0.31 -0.172 
CBFB.2451 0.0201 -0.792 0.768 -0.746 0.00253 
CBFB.2457 0.69 -0.143 0.894 -0.341 -0.0581 
CBFB.3057 -0.403 -0.313 0.0876 0.186 -0.343 
CBFB.507 0.0893 -0.0212 0.859 -0.111 -0.143 
CBFB.665 0.367 0.0303 0.0406 0.556 -0.333 
CBX3.1081 -0.859 -0.205 -0.273 0.15 0.202 
CBX3.1278 -0.198 -0.162 -0.42 -0.134 -0.213 
CBX3.1941 -0.0129 -0.247 0.217 -0.0306 -0.158 
CBX3.560 -0.405 0.212 -0.845 0.124 0.0591 
CBX3.628 -0.324 -0.271 -0.815 -0.333 -0.149 
CHAF1A.1374 0.56 0.13 0.0381 0.547 0.0547 
CHAF1A.1387 0.248 0.484 0.32 -0.0841 -0.0612 
CHAF1A.182 -0.828 -0.00399 -0.491 0.273 0.123 
CHAF1A.3031 -0.873 -0.884 -0.198 -3.1 -0.446 
CHAF1A.3082 -0.524 -0.0135 -0.0331 -0.52 -0.461 
CTNNBL1.1495 -0.31 0.89 -1.63 1.38 0.0403 
CTNNBL1.1653 -0.4 -0.991 0.499 -1.46 -0.714 
CTNNBL1.1828 0.371 0.329 -0.122 0.0964 -0.276 
CTNNBL1.388 -0.0258 -0.0514 0.0519 -0.159 -0.572 
CTNNBL1.961 1.35 0.488 2.08 0.21 0.00168 
DAB2IP.2316 0.125 -0.0503 0.519 -0.909 -0.348 
DAB2IP.2670 -0.61 0.283 -0.272 0.818 -0.307 
DAB2IP.411 -0.0802 -0.266 -0.969 0.678 -0.823 
DAB2IP.468 -0.565 -0.555 -0.334 -0.488 -0.911 
DAB2IP.957 -0.112 1.23 -0.65 1.06 -0.159 
DDX54.1756 -0.3 -0.0433 0.38 0.564 0.152 
DDX54.2269 -0.639 -0.229 -0.543 -0.169 0.0177 
DDX54.2274 0.0659 -0.645 -0.0163 -0.727 0.377 
DDX54.301 0.0779 -0.147 0.184 -0.571 0.315 
DDX54.421 -0.539 -0.457 0.0965 -0.587 -0.541 
DEK.2225 -0.236 0.344 0.0927 -0.366 -0.0629 
DEK.398 -0.626 -0.118 -0.545 0.172 -0.16 
DEK.448 -0.0645 0.0921 -0.168 -0.701 -0.441 
DEK.508 0.348 0.347 0.22 0.0499 -0.0209 
DEK.829 -0.117 0.388 -0.00686 0.687 0.383 
DNAJC2.1157 -0.23 -0.592 0.284 -0.66 -0.375 
DNAJC2.1165 0.492 0.178 0.382 -0.359 0.00444 
DNAJC2.1455 0.067 -0.269 -0.147 0.0637 0.32 
DNAJC2.1466 0.0944 -0.094 -0.154 0.0276 0.165 
DNAJC2.429 -0.893 -0.449 -1.13 -0.468 -0.0269 
DNMT1.2410 0.231 0.182 0.135 0.529 0.294 
DNMT1.2839 -0.683 -0.218 -0.753 -0.243 -0.278 
DNMT1.3205 -0.279 0.0502 -0.704 0.214 -0.145 
DNMT1.3991 -1.1 -0.657 -0.52 -0.107 -0.31 
DNMT1.884 0.141 -0.116 0.00221 -0.353 0.149 
DR1.1454 0.69 1.19 1.25 1.6 0.615 
DR1.1779 0.44 0.32 0.184 0.224 0.312 
DR1.2574 -0.409 -0.291 -0.258 0.00295 0.0151 
DR1.2938 0.168 0.14 -0.0389 0.201 0.113 
DR1.766 -0.025 -0.000725 0.405 0.325 -0.074 
DUSP4.1193 -0.862 -1.07 -1.64 -1.26 -0.599 
DUSP4.1283 -0.81 0.19 -0.353 -0.145 -0.113 
DUSP4.1545 -0.129 0.218 0.615 0.0574 0.0684 
DUSP4.2934 -0.314 -0.411 0.358 -0.256 -0.0383 
DUSP6.1299 -0.0155 -0.189 -0.736 0.404 -0.837 
DUSP6.1330 -0.0233 0.344 -0.441 0.366 -0.128 
DUSP6.1382 0.0948 -0.254 -0.111 -0.105 -0.0269 
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DUSP6.1902 0.102 -0.198 -0.513 -0.14 -0.0435 
DUSP6.2099 0.777 0.282 1.05 0.449 0.341 
EGR1.2525 0.253 0.0255 -0.102 -0.053 -0.128 
EGR1.2815 0.224 0.0141 0.515 -0.797 -0.191 
EGR1.2822 0.306 0.401 -0.0206 0.473 0.19 
EGR1.2823 -0.0544 -0.0544 -0.114 -0.255 0.0558 
EGR1.2946 -0.613 -1.36 -0.199 -0.253 -0.649 
ELK1.1078 -0.0178 0.0451 0.132 0.448 0.00481 
ELK1.1488 -0.559 0.0786 -0.62 0.0387 -0.548 
ELK1.1708 -0.763 -0.143 -1.51 -0.13 -0.164 
ELK1.408 -0.781 0.476 -0.382 0.331 -0.315 
ELK1.447 -0.305 0.233 -8.09 -0.185 0.0912 
ENO1.1437 0.225 0.193 0.106 -0.159 -0.568 
ENO1.1440 -1.5 0.037 -1.18 0.118 -0.946 
ENO1.1441 -0.0211 -0.128 -0.215 -0.79 -0.437 
ENO1.261 -1.09 -2.05 -0.381 -1.21 -0.43 
ENO1.681 -1.72 -0.0155 -2.15 -1.49 -0.538 
EREG.1188 0.158 -0.224 -0.564 -0.583 -0.0708 
EREG.1324 0.75 0.128 0.638 0.224 0.249 
EREG.3002 -0.364 -0.464 0.268 -0.347 -0.255 
EREG.3718 0.296 0.348 0.162 0.213 0.425 
EREG.993 -0.29 0.399 -0.0705 0.614 -0.033 
ESPL1.1362 -0.449 -0.179 -0.552 -0.236 -0.451 
ESPL1.1771 0.345 0.425 -0.149 0.144 -0.323 
ESPL1.1897 0.25 -0.0337 -0.889 -0.0308 -0.281 
ESPL1.2669 -0.138 -0.336 -1.23 0.0821 -0.423 
ESPL1.267 -0.315 -0.594 0.136 -0.661 -0.549 
ETV4.380 -1.61 -0.562 -0.807 -1.96 -0.62 
ETV4.385 -1.02 -0.707 -0.411 -0.372 0.236 
ETV4.686 -0.0526 0.0198 -0.544 0.391 -0.0841 
ETV4.806 -0.0838 0.97 1.35 0.862 -0.446 
ETV4.816 0.558 0.518 0.344 0.18 0.169 
ETV5.2130 0.5 -0.0407 0.42 -0.633 -0.212 
ETV5.2355 -0.333 -0.604 0.123 -0.747 -0.0562 
ETV5.3085 -0.714 -0.507 -1.04 0.153 -0.47 
ETV5.3563 0.124 -0.291 0.32 0.0614 0.0228 
ETV5.390 -1.27 -1.55 -1.45 -1.28 -0.452 
EZH2.1100 0.704 -0.0898 0.0284 -0.492 -0.0177 
EZH2.1112 -0.261 0.282 0.153 0.00835 0.146 
EZH2.1700 -0.4 -0.295 -0.405 -0.432 -0.0952 
EZH2.292 0.321 0.0269 0.297 -0.372 0.105 
EZH2.578 -0.216 0.315 -0.0669 0.372 0.0628 
FOS.1690 0.34 0.0147 0.184 -0.245 0.352 
FOS.1804 0.655 -0.0715 0.498 0.00816 0.16 
FOS.1894 -0.407 0.0884 -0.647 0.269 0.197 
FOS.2115 0.128 0.153 0.222 -0.504 0.349 
FOS.703 0.765 0.415 1.31 -0.0119 -0.549 
FOSL1.1280 0.00899 -0.187 -0.334 0.231 -0.042 
FOSL1.1405 -0.415 0.0132 -0.949 0.355 -0.189 
FOSL1.1634 0.188 0.264 0.796 1.02 0.183 
FOSL1.90 -0.138 0.535 0.0878 -0.53 0.108 
FOSL1.91 -0.297 0.274 -0.39 0.587 0.106 
FOXM1.1277 -0.425 -0.933 -0.737 -1.71 -0.403 
FOXM1.1812 0.0653 0.476 0.385 0.22 -0.0828 
FOXM1.2496 -0.849 -0.186 -0.665 -0.389 -0.468 
FOXM1.463 -0.472 -0.615 0.04 -0.441 0.0231 
FOXM1.725 -0.8 -0.392 -0.474 -1.06 -0.298 
FUBP1.1846 0.0676 0.209 -0.194 -0.109 0.142 
FUBP1.1932 0.273 0.429 -0.125 0.148 -0.439 
FUBP1.236 n.a. n.a. n.a. n.a. n.a. 
FUBP1.2714 -0.164 0.297 -0.902 0.0172 -0.423 
FUBP1.521 -0.0598 -0.0598 0.243 0.069 -0.148 
FUS.1028 0.131 0.135 -0.42 0.597 0.139 
FUS.1050 0.142 -0.326 -0.167 -0.916 0.288 
FUS.212 0.156 -0.521 0.312 0.436 -0.222 
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FUS.2807 -0.438 -0.971 -0.547 -1.14 -0.524 
FUS.960 -0.606 0.0117 -0.403 0.0855 -0.205 
HMGA1.1061 0.00397 -0.212 0.668 -0.201 0.0622 
HMGA1.1391 -2.22 -0.985 -0.57 -0.835 -1.29 
HMGA1.155 n.a. n.a. n.a. n.a. n.a. 
HMGA1.211 0.0693 0.117 0.032 0.196 -0.562 
HMGA1.40 0.0619 -0.0113 0.716 -0.0214 0.188 
HMGB1.1534 -0.0584 -0.268 0.198 0.0379 0.287 
HMGB1.1726 0.472 0.844 -0.0148 0.751 -0.167 
HMGB1.2309 0.116 0.484 -0.496 0.396 0.113 
HMGB1.2683 -0.753 -0.189 -0.72 -0.475 0.257 
HMGB1.2936 -0.731 0.107 -0.427 -0.288 -0.22 
HMGB2.102 -0.897 -0.0749 -1.55 -1.3 -0.714 
HMGB2.1295 0.687 0.383 0.7 0.53 0.222 
HMGB2.635 0.264 -0.0549 0.15 0.235 0.165 
HMGB2.849 0.112 0.501 1.29 0.749 -0.105 
HMGB2.952 0.322 -0.197 0.6 0.345 0.269 
HMGB3.1249 0.347 -0.295 0.613 -1.06 -0.0948 
HMGB3.1909 -0.00944 0.707 -0.47 0.529 -0.421 
HMGB3.2264 0.1 0.113 0.704 0.0173 0.176 
HMGB3.2531 0.233 1.37 0.698 0.819 0.33 
HMGB3.628 -0.616 -0.13 -0.892 0.0718 -0.241 
HNRNPAB.1243 0.468 0.297 0.874 0.196 0.254 
HNRNPAB.1575 -0.0302 -0.0597 -0.0245 -0.0542 0.0366 
HNRNPAB.608 -0.89 -0.092 -0.271 -0.391 -0.243 
HNRNPAB.829 -0.411 -0.494 -0.048 -0.531 0.176 
HNRNPD.1060 0.471 0.0227 -0.274 0.46 0.0601 
HNRNPD.1275 -0.161 -0.421 0.19 0.144 0.0468 
HNRNPD.2045 0.507 0.184 -0.338 0.405 0.21 
HNRNPD.774 -0.235 0.356 0.0472 -0.0322 -0.0599 
HNRNPD.988 0.267 0.564 0.194 0.507 0.316 
HNRNPR.1892 -0.0762 0.243 0.283 -0.0343 0.000676 
HNRNPR.1919 -0.216 0.391 -0.247 0.348 -0.172 
HNRNPR.2400 0.095 0.32 0.339 0.639 0.152 
HNRNPR.510 -1.17 -0.251 -0.527 -1.33 -0.527 
HNRNPR.777 0.171 0.21 0.329 0.0708 0.554 
IL17RD.1052 0.179 0.215 0.145 0.0349 -0.0103 
IL17RD.4714 -0.316 -0.825 0.632 -0.129 -0.361 
IL17RD.493 -0.000402 -0.384 -0.0237 0.453 -0.223 
IL17RD.5166 -0.517 -0.0783 -1.59 -0.207 -0.299 
IL17RD.660 0.485 0.0212 0.0321 0.000448 -0.438 
ILF2.1584 0.0956 -0.336 0.348 -0.153 -0.301 
ILF2.1851 0.492 -2.15 -0.489 -2.29 -0.0742 
ILF2.45 -1.06 -0.67 -1.6 -0.205 -0.64 
ILF2.527 0.756 -0.161 0.612 -0.32 -0.252 
ILF2.785 -0.568 -0.354 -0.231 -0.0845 -0.167 
ILF3.1480 0.0201 0.292 -0.24 0.0445 0.316 
ILF3.2024 0.51 0.219 1.15 0.225 -0.156 
ILF3.299 -0.0203 0.422 -0.0316 0.481 0.27 
ILF3.534 0.0336 0.271 -0.0244 0.199 -0.295 
ILF3.724 0.056 0.00336 -0.107 -0.409 -0.483 
IQGAP1.3207 0.322 -0.0673 -0.277 -0.307 0.303 
IQGAP1.4793 -0.238 0.2 0.173 -0.26 0.136 
IQGAP1.5499 -0.333 0.459 0.25 0.895 0.226 
IQGAP1.622 -0.3 0.0521 -0.0295 0.511 -0.256 
IQGAP1.7193 -0.443 -1.14 -0.404 -0.942 -0.434 
JUNB.1241 0.226 -0.462 0.0315 -0.775 -0.172 
JUNB.1535 -0.181 -0.18 0.199 -0.107 -0.0863 
JUNB.273 -0.0734 0.0629 -0.0228 -0.00325 -0.631 
JUNB.308 -0.591 -0.565 -1.08 -0.93 -0.462 
JUNB.363 -0.262 0.138 -0.318 0.358 -0.51 
KLF10.1084 -3.08 -1.61 -2.71 -2.04 -1.15 
KLF10.1350 -0.28 -0.29 0.307 -0.219 0.0541 
KLF10.1413 -0.98 -0.704 -0.761 -1.16 -0.582 
KLF10.1822 -0.00357 -0.741 0.249 -0.694 -0.395 
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KLF10.622 -0.47 -0.0528 -0.282 0.0768 0.186 
LRRFIP1.259 0.213 0.155 -0.107 0.0903 0.339 
LRRFIP1.262 -0.0116 0.0419 -0.0613 0.336 0.343 
LRRFIP1.445 -0.569 -0.482 -0.627 -0.536 -0.273 
LRRFIP1.592 -0.692 -0.216 -0.476 -0.477 -0.33 
LRRFIP1.595 -0.104 -0.873 0.128 -0.454 0.176 
MAFF.1993 0.0277 -0.0627 -0.263 0.164 0.017 
MAFF.2 0.396 1.01 1.81 n.a. 0.376 
MAFF.708 -0.585 0.0734 -0.998 -1.04 -0.462 
MAFF.839 -0.0663 -0.535 -0.799 0.0485 -0.193 
MAFF.970 1.1 1.37 1.24 0.712 0.861 
MAPK1.1121 0.312 -0.541 -0.337 -0.548 -0.0632 
MAPK1.1233 -0.0432 -0.552 -0.249 -0.344 -0.356 
MAPK1.1316 0.114 0.138 0.112 0.0349 0.1 
MAPK1.528 -0.283 -0.338 0.338 0.0855 -0.56 
MAPK1.537 -0.00725 0.308 -0.347 0.595 0.268 
MAPK3.1200 0.537 -0.13 -0.0771 -0.554 -0.489 
MAPK3.1741 -0.0882 -0.77 0.289 -0.263 0.47 
MAPK3.616 0.583 0.294 0.222 0.136 -0.525 
MAPK3.751 0.18 -0.743 -0.693 -0.12 -0.215 
MAPK3.912 -0.81 -0.399 -0.643 -0.471 -0.292 
MCM2.1017 -0.189 0.15 0.444 0.178 -0.203 
MCM2.1302 0.244 -0.362 -0.943 0.258 -0.0612 
MCM2.1397 -0.168 -0.979 -0.415 0.081 -0.205 
MCM2.1427 -1.14 -0.134 0.153 0.0458 -0.143 
MCM2.715 -0.377 -0.185 0.161 -1.05 -0.116 
MCM3.246 -1.33 -0.625 0.192 -0.944 -0.804 
MCM3.2977 0.344 0.26 0.281 -0.0215 -0.204 
MCM3.3080 -1.14 -0.328 -0.437 -0.24 -0.0924 
MCM3.957 -0.177 -0.36 -0.438 -0.224 0.255 
MCM3.958 0.112 0.406 0.34 0.286 0.329 
MCM4.1641 0.0144 -0.46 -1.48 -0.647 -0.0547 
MCM4.216 -0.566 -0.586 -0.158 -0.427 -0.302 
MCM4.217 0.0334 -0.673 -0.236 -1.27 -0.0176 
MCM4.3163 -0.138 -0.307 -0.505 -0.157 -0.586 
MCM4.86 0.459 -0.271 0.28 -0.52 -0.194 
MCM5.1636 0.26 -0.0601 -0.143 -0.677 0.0603 
MCM5.240 0.194 -0.0636 1 -0.341 -0.165 
MCM5.2528 -0.0343 0.79 0.176 0.952 -0.22 
MCM5.2529 0.624 0.503 1.23 1.51 -0.318 
MCM5.343 -0.659 -3.57 0.648 -3.45 -1.91 
MCM6.1479 -0.201 -0.145 -0.999 0.215 -0.206 
MCM6.2096 -0.0123 -0.489 0.31 -0.939 -0.368 
MCM6.2172 -0.332 -0.296 -0.352 -0.253 0.135 
MCM6.2798 -0.294 -0.331 0.542 -0.15 -0.382 
MCM6.2807 -0.303 0.37 -0.483 -0.172 -0.036 
MCM7.1879 -1.07 0.219 -1.41 0.0575 0.0033 
MCM7.60 0.32 0.606 0.0715 -0.312 0.22 
MCM7.674 -0.0164 -0.3 -0.308 -0.248 0.0635 
MCM7.8 0.42 0.143 0.313 -0.523 -0.078 
MCM7.897 -0.469 -0.0828 -0.0407 -0.198 -0.163 
MED8.2 n.a. n.a. n.a. n.a. n.a. 
MED8.222 0.852 0.194 1.33 0.0639 -0.221 
MED8.405 -0.296 0.272 -0.11 -0.0826 0.00297 
MED8.474 -0.0875 -0.381 -1.75 -1.77 -0.219 
MED8.561 -1.07 0.168 -1.13 0.655 -0.286 
MYBL2.1535 0.586 -1.4 0.00922 -0.891 -0.456 
MYBL2.1874 -0.392 -0.491 -0.234 -0.296 -0.232 
MYBL2.2073 -0.485 -0.0732 -0.289 0.0479 -0.337 
MYBL2.2234 0.331 -0.515 -0.675 -1.04 -0.417 
MYBL2.875 -1.27 -1.12 -0.367 -1.27 -0.814 
NAP1L4.2472 0.575 -0.399 0.317 -0.177 0.253 
NAP1L4.362 -1 -0.665 -1.5 -0.245 -0.0507 
NAP1L4.740 0.33 -0.389 0.403 0.139 -0.392 
NAP1L4.885 0.148 0.395 0.135 0.15 -0.589 
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NAP1L4.909 0.00591 0.4 -0.104 0.25 -0.154 
NF1.1361 -0.153 -0.589 -1.46 0.624 0.0412 
NF1.1588 2.98 0.757 2.5 0.784 1.14 
NF1.1785 -0.238 0.226 -0.484 -0.829 -0.0802 
NF1.561 0.108 -0.119 0.812 -0.0635 -0.48 
NF1.898 0.0669 0.138 0.251 0.00658 0.294 
NFE2L3.1541 0.307 -0.214 0.625 -0.716 0.361 
NFE2L3.1962 0.453 0.389 0.308 0.839 0.162 
NFE2L3.350 -0.206 0.0351 -0.188 0.32 -0.0801 
NFE2L3.3599 -0.241 0.5 0.0387 0.174 -0.00575 
NFE2L3.943 -0.425 -0.753 -1.04 -0.25 0.0327 
NFKB1.1378 -0.0514 -0.146 -0.335 -0.288 0.149 
NFKB1.2367 0.146 0.67 1.61 -0.0531 0.247 
NFKB1.2920 0.21 -0.287 -0.71 0.124 -0.0427 
NFKB1.2926 0.228 0.782 0.389 0.202 0.00236 
NFKB1.3703 -0.00817 -0.0647 -0.142 -0.074 0.0921 
PA2G4.1492 -0.641 -0.00866 -0.726 -0.655 -0.288 
PA2G4.1809 0.0831 -0.67 0.661 0.117 0.102 
PA2G4.1812 0.438 -0.0881 0.273 -0.0877 0.184 
PA2G4.706 0.0289 0.384 0.378 0.253 0.112 
PA2G4.994 -0.0193 -0.625 0.166 -1.73 -0.128 
PHTF2.269 -0.583 0.354 -0.123 -0.0404 -0.304 
PHTF2.323 -0.472 -0.188 -1.04 -1.28 -0.375 
PHTF2.714 1.22 n.a. 3.51 n.a. 0.236 
PHTF2.808 0.448 0.896 0.526 0.459 0.123 
PHTF2.993 -0.435 0.372 -0.0717 0.0598 -0.142 
PMEPA1.2011 -0.146 0.00471 -0.0797 -0.106 0.129 
PMEPA1.2873 -0.235 -0.554 -0.678 -1.19 0.139 
PMEPA1.3541 0.165 0.206 0.271 0.203 -0.165 
PMEPA1.4018 0.189 -0.301 0.162 0.155 0.172 
PMEPA1.4210 -0.286 -0.0959 -0.307 0.0393 -0.326 
PML.105 0.283 0.217 0.211 -0.139 0.0419 
PML.109 0.125 0.124 0.698 -1.39 -0.395 
PML.111 -0.118 -0.167 0.167 -0.503 -0.0406 
PML.1148 -0.193 -0.751 -0.998 -0.611 -0.537 
PML.1271 -0.223 -0.558 -0.543 -0.0676 -0.466 
PNN.1071 0.104 0.0103 -0.0511 0.135 0.39 
PNN.2847 0.0194 -0.0442 -0.886 -0.298 0.371 
PNN.2904 0.299 -0.134 0.222 -0.0703 0.219 
PNN.400 -0.913 -1.13 0.851 -1.07 -0.713 
PNN.401 -0.102 0.405 -0.12 0.567 -0.167 
POLR1E.1199 -0.315 -0.565 -0.293 0.0709 -0.287 
POLR1E.1264 -0.0238 -0.0916 -0.101 -0.403 -0.0224 
POLR1E.467 0.368 0.934 -0.488 -0.14 -0.515 
POLR1E.501 -0.48 -0.161 -0.228 -0.746 -0.0659 
POLR1E.815 -0.581 -0.233 -0.376 -0.415 -0.0263 
POLR2F.112 0.326 -0.65 0.503 -2.45 -0.336 
POLR2F.1300 -0.61 -0.284 -0.759 0.453 0.044 
POLR2F.1305 -0.518 -1.23 -0.951 -1.39 0.00903 
POLR2F.1308 0.0413 -0.194 0.0779 -0.868 -0.211 
POLR2F.181 -0.331 -0.118 -0.845 -0.539 -0.157 
POLR3K.151 -0.327 -0.205 -0.267 0.058 -0.544 
POLR3K.166 0.397 0.357 0.555 0.728 -0.237 
POLR3K.313 0.000943 -0.0479 0.0584 -0.385 -0.594 
POLR3K.676 -0.809 -0.145 -0.391 -0.403 0.34 
POLR3K.726 0.0258 0.0767 -0.133 -0.155 0.398 
PPP1R15A.1494 -0.801 0.169 -1.03 0.593 -0.091 
PPP1R15A.2344 -0.216 0.348 0.000941 0.0223 0.258 
PPP1R15A.49 -0.108 0.0641 -0.0458 -0.333 -0.29 
PPP1R15A.963 0.122 -0.0326 -0.156 0.172 -0.0876 
PPP1R15A.964 0.0256 0.0679 -0.0437 -0.159 -0.24 
PPP2R5A.183 -3.62 1.04 -0.6 0.918 -0.414 
PPP2R5A.49 -0.257 0.0102 -0.399 0.116 -0.258 
PPP2R5A.694 -0.0119 -0.171 -0.387 0.336 -0.0845 
PPP2R5A.730 0.096 0.195 -0.505 -0.0951 0.0212 
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PPP2R5A.96 -0.279 0.305 -0.678 -0.13 0.0867 
PPP2R5B.1178 -0.256 0.148 0.128 0.0935 -0.221 
PPP2R5B.1181 0.296 0.433 -0.0671 0.0338 0.253 
PPP2R5B.1342 0.617 0.473 n.a. n.a. n.a. 
PPP2R5B.1879 0.349 -0.381 -0.405 -1.58 -0.241 
PPP2R5B.2733 0.208 -0.135 -0.0369 -0.11 0.219 
PPP2R5C.1159 -0.0393 0.0271 0.216 0.223 -0.075 
PPP2R5C.118 0.364 0.0847 1.05 -0.677 -0.198 
PPP2R5C.1208 -0.0997 -0.574 -0.778 -0.448 0.259 
PPP2R5C.362 -0.206 -0.649 -0.921 -1.01 -0.0903 
PPP2R5C.631 0.537 -0.122 0.621 0.0111 0.031 
PPP2R5E.1240 0.169 -0.301 -0.168 0.378 0.0815 
PPP2R5E.1269 -0.112 0.27 0.44 0.397 -0.387 
PPP2R5E.2031 -5.09 0.277 -1.66 0.552 0.344 
PPP2R5E.2683 0.0289 -0.359 0.497 -0.107 0.151 
PPP2R5E.679 -0.0973 -0.206 -0.0342 -0.243 -0.219 
PTTG1.18 -0.686 -0.548 -0.106 -0.336 -0.709 
PTTG1.236 0.506 -0.035 0.614 0.31 0.213 
PTTG1.327 0.347 -0.112 -0.0327 -0.125 0.0831 
PTTG1.670 -0.334 0.0894 0.652 -0.11 -0.166 
PTTG1.7 -0.691 -0.339 -0.874 -0.254 -0.517 
RASA1.1954 0.466 -0.124 0.349 0.253 0.439 
RASA1.2153 0.0723 -0.116 -0.0372 -0.168 0.0643 
RASA1.3593 -0.151 -0.0463 -0.1 0.193 0.298 
RASA1.396 -1.23 -0.248 -0.461 -0.0798 -0.559 
RASA1.573 -0.698 -0.129 -0.506 0.02 -0.1 
RASA2.1380 0.351 0.466 0.206 0.886 0.607 
RASA2.1884 0.0427 -0.101 0.126 -0.127 -0.322 
RASA2.2057 0.241 0.143 0.88 -0.546 -0.068 
RASA2.449 -0.0528 -0.267 0.26 -0.0456 -0.192 
RASA2.760 -0.268 -0.432 -0.769 -0.321 -0.367 
RASA3.2532 -0.00257 0.0672 0.4 0.0521 0.289 
RASA3.276 0.323 0.342 -0.0539 0.307 -0.0661 
RASA3.3525 0.0564 -0.305 -0.338 -0.403 -0.0793 
RASA3.4009 -0.438 -0.35 -0.49 -0.32 -0.489 
RASA3.707 0.182 -0.182 -0.00787 -0.374 -0.0776 
RASA4.3049 -0.463 -1.55 -0.0716 -1.31 -0.641 
RASA4.3459 -0.00874 -0.527 -0.0919 -0.663 -0.164 
RASA4.4126 0.172 0.929 0.235 0.427 0.292 
RASA4.4422 0.614 0.394 0.609 0.218 0.309 
RASA4.4988 -0.0094 -0.424 0.216 -0.0172 0.17 
RASAL1.1181 -0.681 -0.992 -0.0412 -0.116 -0.283 
RASAL1.2886 -0.975 -0.562 -0.583 -1.4 -0.392 
RASAL1.3144 -0.683 0.0195 -0.667 0.234 0.0188 
RASAL1.3202 -0.0169 -0.133 0.0843 -0.145 -0.651 
RASAL1.3203 -0.115 0.52 -0.0262 -0.36 -0.165 
RASAL2.3477 -0.613 -0.401 -0.656 -0.175 -0.403 
RASAL2.459 -0.222 -0.218 0.468 -0.0519 -0.167 
RASAL2.6025 0.222 -0.134 -0.0391 0.0412 0.243 
RASAL2.8696 -0.468 -0.344 -0.64 -0.199 -0.0108 
RASAL2.9009 -0.131 0.228 -0.152 0.314 0.234 
RASGRF1.1738 -0.348 -0.2 0.17 -0.364 0.0396 
RASGRF1.2342 -0.519 -0.227 -0.444 0.104 -0.249 
RASGRF1.2658 0.283 0.0622 0.275 0.117 0.248 
RASGRF1.2771 -0.299 0.0994 -0.765 0.734 -0.314 
RASGRF1.3029 -0.659 -0.216 -1.16 -0.159 -0.408 
RBM14.1281 0.229 0.436 0.524 0.357 -0.33 
RBM14.1332 -0.628 -0.774 -1.61 -0.601 -0.57 
RBM14.1421 0.625 0.288 0.686 0.74 0.158 
RBM14.1437 0.21 0.327 0.121 0.309 0.244 
RBM14.3781 -0.018 0.203 -0.294 -0.129 0.0616 
RNF138.2166 -0.345 0.326 0.0569 0.806 -0.13 
RNF138.2339 -0.136 -0.827 0.519 -1.09 0.0968 
RNF138.2861 0.061 -0.0722 1 -1.05 0.12 
RNF138.481 -0.33 -0.282 -0.295 -0.91 -0.355 
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RNF138.759 -0.0656 0.323 0.321 0.677 0.138 
RUVBL1.1338 0.331 -0.559 -0.142 -0.221 -0.741 
RUVBL1.1673 -0.558 -0.846 -0.213 -0.498 -0.39 
RUVBL1.487 0.00845 0.15 0.0843 0.0184 0.115 
RUVBL1.907 0.729 0.0865 0.179 0.173 -0.143 
RUVBL1.989 -1.17 -0.466 -0.944 -0.707 -0.293 
SFPQ.1022 0.714 n.a. n.a. n.a. 0.801 
SFPQ.1059 0.0733 0.144 0.328 0.0525 -0.128 
SFPQ.1062 -0.183 -0.294 -0.477 -0.0841 0.0189 
SFPQ.1734 -0.82 -0.464 -0.0801 -0.656 -0.413 
SFPQ.2323 0.325 -0.281 -0.501 0.64 0.386 
SKI.3286 -0.165 -0.186 0.691 0.151 -0.345 
SKI.4039 -0.513 0.0654 -0.6 0.307 -0.782 
SKI.4968 -0.389 -0.332 -0.377 -1.4 -0.116 
SKI.5667 -0.251 -0.595 -0.471 -0.147 -0.289 
SKI.5673 0.149 0.0627 -0.745 -0.184 -0.0513 
SMAD6.1061 -0.376 -0.483 -0.0728 -0.213 -0.324 
SMAD6.81 0.00159 0.301 -0.389 -0.221 0.169 
SMAD6.82 -0.542 -0.0556 -0.357 -0.226 -0.251 
SMAD6.865 -0.509 0.353 -1.01 0.425 0.415 
SMAD6.941 -0.244 -0.15 0.0196 -0.176 0.145 
SMAD7.1703 0.125 0.24 -0.385 0.547 -0.326 
SMAD7.1953 0.426 0.621 0.588 0.394 -0.15 
SMAD7.2099 0.68 0.186 0.146 0.237 -0.0589 
SMAD7.239 0.344 -0.809 -0.547 0.0786 -0.358 
SMAD7.390 -0.169 -0.0112 -0.615 0.335 -0.485 
SMC3.1337 -0.187 0.13 0.206 0.0966 -0.0154 
SMC3.1442 0.339 -0.211 0.894 -0.643 0.243 
SMC3.3106 0.205 0.408 0.612 0.456 0.009 
SMC3.860 -0.129 0.326 -0.245 0.214 -0.274 
SMC3.905 -0.107 -0.843 0.342 -0.353 -0.152 
SMURF2.1494 -0.372 0.0163 -0.248 0.216 -0.806 
SMURF2.1967 -0.112 -0.716 -0.387 -1.96 -0.137 
SMURF2.3622 0.0539 -0.0343 -0.33 -0.0196 0.0379 
SMURF2.3699 0.0255 0.513 -0.244 0.373 0.0466 
SMURF2.633 0.373 0.101 0.621 -0.314 0.424 
SNRPB.20 -1.51 -0.487 -0.807 -0.0835 -0.428 
SNRPB.292 0.00715 -0.317 0.155 0.163 -0.229 
SNRPB.329 0.957 -0.0675 0.557 0.283 0.377 
SNRPB.391 -0.533 -0.0236 -0.383 0.369 -0.132 
SNRPB.928 0.0489 0.632 -1.22 1.16 0.176 
SNRPD1.1049 0.503 -0.871 -0.123 -0.241 0.183 
SNRPD1.1061 0.0188 0.652 -0.0368 0.855 0.385 
SNRPD1.1118 0.657 0.0742 0.202 0.293 0.62 
SNRPD1.1469 -1.09 0.053 -0.259 0.3 -0.0915 
SNRPD1.582 -0.641 -0.288 -0.315 0.211 -0.217 
SOWAHC.2451 0.189 0.2 0.102 0.577 0.198 
SOWAHC.3222 -0.427 -0.708 -1.61 -0.474 -0.602 
SPRED1.1060 -0.136 -0.226 -0.113 -0.135 -0.00872 
SPRED1.5123 0.472 0.301 -0.25 0.244 0.0494 
SPRED1.5564 0.188 0.0817 -0.0776 0.244 0.148 
SPRED1.5651 -0.355 0.284 -0.0581 0.0581 -0.342 
SPRED1.6831 0.429 -0.0657 0.0995 -0.209 -0.074 
SPRED2.1496 -7.53 -1.44 -0.765 -1.85 -0.8 
SPRED2.1588 -0.606 -0.604 -0.713 -2.5 -0.636 
SPRED2.1853 0.151 0.263 0.294 0.384 -0.124 
SPRED2.2948 0.388 0.378 0.56 0.287 0.445 
SPRED2.418 -0.218 -0.648 -1.16 0.122 -0.291 
SPRY1.137 -0.464 0.0883 -0.146 0.657 -0.328 
SPRY1.2179 0.126 -1.08 -0.0635 -0.702 0.182 
SPRY1.311 0.15 0.14 0.0251 0.433 0.523 
SPRY1.587 -0.285 -0.0107 -1.18 0.0387 -0.609 
SPRY1.718 0.265 -0.117 -0.709 0.602 -0.0997 
SPRY2.1553 0.408 -0.243 0.0485 -0.391 0.0439 
SPRY2.1747 0.569 -0.577 0.696 -0.144 0.238 
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SPRY2.2060 -0.386 -0.0793 -0.461 -0.251 0.154 
SPRY2.328 -0.436 0.266 -0.663 0.9 -0.192 
SPRY2.329 2.01 0.953 n.a. -0.00226 0.177 
SPRY3.2842 0.0677 0.638 0.428 0.792 0.0793 
SPRY3.6580 -0.378 0.211 0.0651 0.267 -0.619 
SPRY3.6604 0.000808 -0.235 -0.579 -0.257 -0.377 
SPRY3.7497 -0.325 -0.382 -0.808 -0.109 -0.556 
SPRY3.7990 -0.169 0.0222 -0.558 0.307 -0.0676 
SPRY4.2067 -0.368 -1.73 -0.507 -0.189 0.184 
SPRY4.2099 0.0273 -1.24 0.698 -1.99 -0.524 
SPRY4.2909 -0.128 -0.444 0.13 -0.223 0.24 
SPRY4.4393 0.197 0.0905 0.387 -0.152 -0.699 
SPRY4.4659 -1.34 -1.88 -0.0425 -0.61 -0.301 
SRF.1868 -0.101 -0.513 -0.41 -0.556 -0.499 
SRF.2720 0.344 0.29 0.274 0.242 -0.111 
SRF.3603 0.185 0.365 -0.179 0.389 -0.263 
SRF.85 0.226 -0.17 -0.139 0.239 -0.082 
SRF.901 -1.34 -2.2 -1.73 -1.25 -0.423 
SRSF10.319 -0.268 -0.468 -0.836 -0.719 -0.23 
SRSF10.371 -0.409 -0.179 -0.638 -0.699 -0.643 
SRSF10.567 -0.632 -0.246 -0.362 0.0442 -0.323 
SRSF10.571 -0.615 0.443 -0.554 -0.0715 -0.0373 
SRSF10.613 0.0521 -0.229 0.544 -0.337 0.324 
SRSF1.1216 -0.0153 -0.769 -0.163 -0.247 -0.0808 
SRSF1.2656 -0.108 0.274 -0.347 0.134 -0.213 
SRSF1.3300 0.701 0.556 0.854 0.568 -0.236 
SRSF1.3678 0.0802 0.247 0.347 0.479 -0.28 
SRSF1.4112 0.333 0.411 0.344 0.441 0.179 
SRSF2.1488 -0.673 0.156 -0.479 0.0198 -0.327 
SRSF2.1545 -0.541 -0.0658 -0.499 -0.371 -0.111 
SRSF2.1723 -0.733 0.179 -0.567 0.436 -0.651 
SRSF2.1919 -0.353 -0.16 -0.155 -0.489 0.103 
SRSF2.1937 0.039 0.178 -0.088 -0.0715 -0.172 
SRSF3.1204 0.228 0.26 0.198 0.0689 0.0761 
SRSF3.1983 -0.199 0.0278 0.476 0.304 -0.0922 
SRSF3.2297 -0.559 -0.334 -0.898 -0.161 -0.347 
SRSF3.774 0.722 -0.707 0.517 0.122 0.192 
SRSF3.941 0.488 0.00526 0.197 -0.771 0.056 
SSRP1.1950 -1.34 -0.744 -0.253 -0.854 -0.381 
SSRP1.2143 -0.0386 0.125 -0.347 0.118 0.11 
SSRP1.2149 0.0816 0.0664 0.0287 -0.12 0.426 
SSRP1.2168 0.282 0.34 0.489 0.228 -0.138 
SSRP1.2236 0.377 0.417 -0.142 -0.339 -0.3 
STRAP.1476 0.905 -0.475 1.11 0.0534 0.0652 
STRAP.1693 0.29 -0.0996 0.112 0.0768 -0.0828 
STRAP.683_1 0.153 0.0614 0.00907 0.293 0.219 
STRAP.683_2 -0.0718 0.318 -0.184 0.62 0.259 
STRAP.859 0.0742 0.0987 -0.879 -0.0621 0.174 
TCERG1.1866 0.139 -0.142 0.425 0.067 0.0203 
TCERG1.1882 -0.361 0.158 -0.4 -0.517 -0.125 
TCERG1.2467 -0.441 -0.35 -0.942 -0.477 -0.161 
TCERG1.2725 0.337 0.396 -0.796 -0.538 0.134 
TCERG1.3848 -0.201 -0.0898 -0.299 -0.218 -0.0956 
TCOF1.2214 0.16 -0.23 -0.0645 -0.117 -0.21 
TCOF1.312 -0.107 0.567 -0.644 -0.159 -0.557 
TCOF1.313 0.186 0.473 -0.353 -0.138 -0.485 
TCOF1.458 -0.0282 -0.0851 0.319 -0.616 0.134 
TCOF1.459 -0.372 -0.324 -0.701 -0.801 -0.212 
TFAM.2312 -0.743 0.339 -0.0879 -0.727 0.172 
TFAM.3304 -0.0157 0.722 0.000104 0.783 0.231 
TFAM.455 0.28 -0.149 0.24 0.373 0.374 
TFAM.465 0.148 -0.192 0.163 -0.191 0.189 
TFAM.674 0.414 0.534 0.329 0.0737 -0.0479 
TFDP1.1542 0.0195 -0.253 0.167 0.062 0.064 
TFDP1.2064 -0.483 -0.487 -0.0806 -0.69 -0.371 
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TFDP1.2514 0.0915 -0.342 0.226 -0.679 0.264 
TFDP1.841 -0.0299 -0.373 -0.198 -0.572 -0.0903 
TFDP1.865 0.389 0.357 0.203 0.112 -0.245 
TGIF1.199 -0.166 -0.00507 0.217 -0.814 -0.727 
TGIF1.510 0.189 -0.278 -0.2 -0.185 -0.384 
TGIF1.787 -0.129 -0.92 -0.0483 0.0636 -0.00916 
TGIF1.954 -0.885 -0.667 -1.52 0.0947 0.252 
TGIF1.962 0.479 0.271 0.435 0.522 0.579 
TIMELESS.1233 0.888 -0.828 1.11 -0.452 -0.132 
TIMELESS.2900 -0.716 -0.335 -0.72 -0.458 0.338 
TIMELESS.4012 0.387 -0.046 -0.3 -0.0151 0.0697 
TIMELESS.4984 -0.0706 0.3 0.495 -0.0349 -0.00965 
TIMELESS.939 -0.359 0.395 -0.512 0.241 -0.524 
TOP2B.1679 0.608 0.401 -0.359 0.324 0.0379 
TOP2B.232 0.292 -0.259 0.458 0.138 0.00386 
TOP2B.2861 0.229 -0.838 1.42 -0.411 0.0661 
TOP2B.4436 0.29 -0.129 -0.0608 -0.26 -0.0407 
TOP2B.849 0.0802 -0.361 -0.12 -0.0664 0.0654 
TRIP13.241 0.135 0.383 0.304 -0.0511 0.43 
TRIP13.264 0.00446 0.962 0.301 1.05 0.0542 
TRIP13.839 -0.0535 -0.572 0.141 -0.933 0.158 
TRIP13.858 -0.285 -0.197 0.189 -0.569 0.0862 
TRIP13.989 0.145 0.0192 0.112 -0.513 0.0224 
WBP11.1135 -0.905 -0.195 -1.22 -0.668 -0.444 
WBP11.2271 -0.0697 0.173 0.128 0.404 0.246 
WBP11.236 0.143 0.203 0.0647 0.0368 -0.0456 
WBP11.2579 -0.138 -0.418 -0.246 -0.217 -0.00503 
WBP11.846 -0.0976 -0.0914 -0.0934 -0.274 0.134 
WHSC1.1087 -1.27 -0.598 -0.886 -0.847 -0.635 
WHSC1.279 -0.718 0.205 0.0387 -1.87 -0.234 
WHSC1.67 0.486 0.985 0.813 0.609 0.244 
WHSC1.767 -0.551 0.153 -0.601 0.109 0.107 
WHSC1.777 0.364 0.273 0.0673 -0.531 -0.241 
XRCC6.1682 -0.189 0.606 0.474 0.591 -0.144 
XRCC6.270 0.112 -0.865 0.388 -0.178 0.191 
XRCC6.480 0.525 0.481 -0.0262 0.0814 -0.724 
XRCC6.828 -1.64 -1.01 -2.39 -0.37 -1.28 
XRCC6.842 0.2 -0.0594 0.539 0.186 -0.29 
ZNF207.1042 0.201 -0.789 -0.177 -0.612 -0.456 
ZNF207.1051 -3.64 -2.64 -1.77 -1.13 -0.43 
ZNF207.1823 -0.306 -0.0173 0.103 0.0404 -0.171 
ZNF207.257 0.994 0.195 0.321 -0.789 -0.0439 
ZNF207.318 -0.174 0.231 -0.332 -0.0781 0.39 
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Figure A 1: CDC7 inhibition with PHA 767491in CaCo2 cells after MCM7 knockdown. 
KRASG12V expressing CaCo2 cells exhibited a higher resistance to CDC7 inhibition 
(IC50(vector MCM7.sh3)=0.5476 µM) after MCM7 knockdown than KRASwt CaCo2 cells 
(IC50(KRAS(G12V) MCM7.sh3)=2.833 µM). R²vector MCM7.sh3= 0.9486; R²KRAS(G12V) MCM7.sh3=0.9753. 
Mean relative confluency ± SEM is shown (n =4 per group). Nonlinear regression - 
extra sum-of-squares F test; **** = p < 0.0001. 
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Figure A 2: Cell cycle synchronization and release with nocodazole. CaCo2 cells were 
induced with doxycycline for 3 days and then treated with nocodazole for 21 h before 
they were released for the indicated time. Nocodazole untreated sample is indicated 
by “-“. (A) Cells of all samples entered G1 after mitotic arrest. Cells with knockdown of 
MCM7 showed a slower entry in G1 compared to the scrbl control. This was 
independent of KRASG12V expression. (B) Cells in all samples were equally well 
synchronized in the G2/M phase after 21 h of nocodazole treatment. 
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